id	sid	tid	token	lemma	pos
cord-324859-0yuhb5dl	1	1	key	key	JJ
cord-324859-0yuhb5dl	1	2	:	:	:
cord-324859-0yuhb5dl	1	3	cord-324859	cord-324859	NNP
cord-324859-0yuhb5dl	1	4	-	-	HYPH
cord-324859-0yuhb5dl	1	5	0yuhb5dl	0yuhb5dl	JJ
cord-324859-0yuhb5dl	1	6	authors	author	NNS
cord-324859-0yuhb5dl	1	7	:	:	:
cord-324859-0yuhb5dl	1	8	Mulchandani	Mulchandani	NNP
cord-324859-0yuhb5dl	1	9	,	,	,
cord-324859-0yuhb5dl	1	10	Rubina	Rubina	NNP
cord-324859-0yuhb5dl	1	11	;	;	:
cord-324859-0yuhb5dl	1	12	Lyngdoh	Lyngdoh	NNP
cord-324859-0yuhb5dl	1	13	,	,	,
cord-324859-0yuhb5dl	1	14	Tanica	Tanica	NNP
cord-324859-0yuhb5dl	1	15	;	;	:
cord-324859-0yuhb5dl	1	16	Kakkar	Kakkar	NNP
cord-324859-0yuhb5dl	1	17	,	,	,
cord-324859-0yuhb5dl	1	18	Ashish	Ashish	NNP
cord-324859-0yuhb5dl	1	19	Kumar	Kumar	NNP
cord-324859-0yuhb5dl	1	20	title	title	NN
cord-324859-0yuhb5dl	1	21	:	:	:
cord-324859-0yuhb5dl	1	22	Deciphering	decipher	VBG
cord-324859-0yuhb5dl	1	23	the	the	DT
cord-324859-0yuhb5dl	1	24	COVID‐19	COVID‐19	NNP
cord-324859-0yuhb5dl	1	25	cytokine	cytokine	NN
cord-324859-0yuhb5dl	1	26	storm	storm	NN
cord-324859-0yuhb5dl	1	27	:	:	:
cord-324859-0yuhb5dl	1	28	Systematic	systematic	JJ
cord-324859-0yuhb5dl	1	29	review	review	NN
cord-324859-0yuhb5dl	1	30	and	and	CC
cord-324859-0yuhb5dl	1	31	meta‐analysis	meta‐analysis	NN
cord-324859-0yuhb5dl	1	32	date	date	NN
cord-324859-0yuhb5dl	1	33	:	:	:
cord-324859-0yuhb5dl	1	34	2020	2020	CD
cord-324859-0yuhb5dl	1	35	-	-	HYPH
cord-324859-0yuhb5dl	1	36	11	11	CD
cord-324859-0yuhb5dl	1	37	-	-	HYPH
cord-324859-0yuhb5dl	1	38	02	02	CD
cord-324859-0yuhb5dl	1	39	journal	journal	NN
cord-324859-0yuhb5dl	1	40	:	:	:
cord-324859-0yuhb5dl	2	1	Eur	Eur	NNP
cord-324859-0yuhb5dl	2	2	J	J	NNP
cord-324859-0yuhb5dl	2	3	Clin	Clin	NNP
cord-324859-0yuhb5dl	2	4	Invest	Invest	NNP
cord-324859-0yuhb5dl	2	5	DOI	doi	NN
cord-324859-0yuhb5dl	2	6	:	:	:
cord-324859-0yuhb5dl	3	1	10.1111	10.1111	CD
cord-324859-0yuhb5dl	3	2	/	/	SYM
cord-324859-0yuhb5dl	3	3	eci.13429	eci.13429	NNP
cord-324859-0yuhb5dl	3	4	sha	sha	NNP
cord-324859-0yuhb5dl	3	5	:	:	:
cord-324859-0yuhb5dl	4	1	3d1371dbad38cd36a1054f60a87360bb8e8eba46	3d1371dbad38cd36a1054f60a87360bb8e8eba46	CD
cord-324859-0yuhb5dl	4	2	doc_id	doc_id	CD
cord-324859-0yuhb5dl	4	3	:	:	:
cord-324859-0yuhb5dl	4	4	324859	324859	CD
cord-324859-0yuhb5dl	4	5	cord_uid	cord_uid	NNS
cord-324859-0yuhb5dl	4	6	:	:	:
cord-324859-0yuhb5dl	5	1	0yuhb5dl	0yuhb5dl	CD
cord-324859-0yuhb5dl	5	2	INTRODUCTION	INTRODUCTION	NNP
cord-324859-0yuhb5dl	5	3	:	:	:
cord-324859-0yuhb5dl	6	1	The	the	DT
cord-324859-0yuhb5dl	6	2	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	6	3	pandemic	pandemic	NN
cord-324859-0yuhb5dl	6	4	has	have	VBZ
cord-324859-0yuhb5dl	6	5	affected	affect	VBN
cord-324859-0yuhb5dl	6	6	more	more	JJR
cord-324859-0yuhb5dl	6	7	than	than	IN
cord-324859-0yuhb5dl	6	8	20	20	CD
cord-324859-0yuhb5dl	6	9	million	million	CD
cord-324859-0yuhb5dl	6	10	people	people	NNS
cord-324859-0yuhb5dl	6	11	so	so	RB
cord-324859-0yuhb5dl	6	12	far	far	RB
cord-324859-0yuhb5dl	6	13	.	.	.
cord-324859-0yuhb5dl	7	1	Elevated	elevated	JJ
cord-324859-0yuhb5dl	7	2	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	7	3	and	and	CC
cord-324859-0yuhb5dl	7	4	suppressed	suppress	VBD
cord-324859-0yuhb5dl	7	5	immune	immune	JJ
cord-324859-0yuhb5dl	7	6	responses	response	NNS
cord-324859-0yuhb5dl	7	7	have	have	VBP
cord-324859-0yuhb5dl	7	8	been	be	VBN
cord-324859-0yuhb5dl	7	9	hypothesized	hypothesize	VBN
cord-324859-0yuhb5dl	7	10	to	to	TO
cord-324859-0yuhb5dl	7	11	set	set	VB
cord-324859-0yuhb5dl	7	12	off	off	RP
cord-324859-0yuhb5dl	7	13	a	a	DT
cord-324859-0yuhb5dl	7	14	cytokine	cytokine	NN
cord-324859-0yuhb5dl	7	15	storm	storm	NN
cord-324859-0yuhb5dl	7	16	,	,	,
cord-324859-0yuhb5dl	7	17	contributing	contribute	VBG
cord-324859-0yuhb5dl	7	18	to	to	IN
cord-324859-0yuhb5dl	7	19	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	7	20	,	,	,
cord-324859-0yuhb5dl	7	21	multiple‐organ	multiple‐organ	JJ
cord-324859-0yuhb5dl	7	22	failure	failure	NN
cord-324859-0yuhb5dl	7	23	and	and	CC
cord-324859-0yuhb5dl	7	24	,	,	,
cord-324859-0yuhb5dl	7	25	in	in	IN
cord-324859-0yuhb5dl	7	26	the	the	DT
cord-324859-0yuhb5dl	7	27	most	most	RBS
cord-324859-0yuhb5dl	7	28	severe	severe	JJ
cord-324859-0yuhb5dl	7	29	cases	case	NNS
cord-324859-0yuhb5dl	7	30	,	,	,
cord-324859-0yuhb5dl	7	31	death	death	NN
cord-324859-0yuhb5dl	7	32	.	.	.
cord-324859-0yuhb5dl	8	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	8	2	aimed	aim	VBD
cord-324859-0yuhb5dl	8	3	to	to	TO
cord-324859-0yuhb5dl	8	4	quantify	quantify	VB
cord-324859-0yuhb5dl	8	5	the	the	DT
cord-324859-0yuhb5dl	8	6	differences	difference	NNS
cord-324859-0yuhb5dl	8	7	in	in	IN
cord-324859-0yuhb5dl	8	8	the	the	DT
cord-324859-0yuhb5dl	8	9	circulating	circulate	VBG
cord-324859-0yuhb5dl	8	10	levels	level	NNS
cord-324859-0yuhb5dl	8	11	of	of	IN
cord-324859-0yuhb5dl	8	12	major	major	JJ
cord-324859-0yuhb5dl	8	13	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	8	14	and	and	CC
cord-324859-0yuhb5dl	8	15	immunological	immunological	JJ
cord-324859-0yuhb5dl	8	16	markers	marker	NNS
cord-324859-0yuhb5dl	8	17	between	between	IN
cord-324859-0yuhb5dl	8	18	severe	severe	JJ
cord-324859-0yuhb5dl	8	19	and	and	CC
cord-324859-0yuhb5dl	8	20	nonsevere	nonsevere	JJ
cord-324859-0yuhb5dl	8	21	COVID‐19	covid‐19	NN
cord-324859-0yuhb5dl	8	22	patients	patient	NNS
cord-324859-0yuhb5dl	8	23	.	.	.
cord-324859-0yuhb5dl	9	1	METHODS	methods	NN
cord-324859-0yuhb5dl	9	2	:	:	:
cord-324859-0yuhb5dl	10	1	Relevant	relevant	JJ
cord-324859-0yuhb5dl	10	2	studies	study	NNS
cord-324859-0yuhb5dl	10	3	were	be	VBD
cord-324859-0yuhb5dl	10	4	identified	identify	VBN
cord-324859-0yuhb5dl	10	5	from	from	IN
cord-324859-0yuhb5dl	10	6	PubMed	PubMed	NNP
cord-324859-0yuhb5dl	10	7	,	,	,
cord-324859-0yuhb5dl	10	8	EMBASE	EMBASE	NNP
cord-324859-0yuhb5dl	10	9	,	,	,
cord-324859-0yuhb5dl	10	10	Web	web	NN
cord-324859-0yuhb5dl	10	11	of	of	IN
cord-324859-0yuhb5dl	10	12	Science	Science	NNP
cord-324859-0yuhb5dl	10	13	,	,	,
cord-324859-0yuhb5dl	10	14	SCOPUS	SCOPUS	NNP
cord-324859-0yuhb5dl	10	15	and	and	CC
cord-324859-0yuhb5dl	10	16	preprint	preprint	NN
cord-324859-0yuhb5dl	10	17	servers	server	NNS
cord-324859-0yuhb5dl	10	18	.	.	.
cord-324859-0yuhb5dl	11	1	Risk	risk	NN
cord-324859-0yuhb5dl	11	2	of	of	IN
cord-324859-0yuhb5dl	11	3	bias	bias	NN
cord-324859-0yuhb5dl	11	4	was	be	VBD
cord-324859-0yuhb5dl	11	5	assessed	assess	VBN
cord-324859-0yuhb5dl	11	6	for	for	IN
cord-324859-0yuhb5dl	11	7	each	each	DT
cord-324859-0yuhb5dl	11	8	study	study	NN
cord-324859-0yuhb5dl	11	9	,	,	,
cord-324859-0yuhb5dl	11	10	using	use	VBG
cord-324859-0yuhb5dl	11	11	appropriate	appropriate	JJ
cord-324859-0yuhb5dl	11	12	checklists	checklist	NNS
cord-324859-0yuhb5dl	11	13	.	.	.
cord-324859-0yuhb5dl	12	1	All	all	DT
cord-324859-0yuhb5dl	12	2	studies	study	NNS
cord-324859-0yuhb5dl	12	3	were	be	VBD
cord-324859-0yuhb5dl	12	4	described	describe	VBN
cord-324859-0yuhb5dl	12	5	qualitatively	qualitatively	RB
cord-324859-0yuhb5dl	12	6	and	and	CC
cord-324859-0yuhb5dl	12	7	a	a	DT
cord-324859-0yuhb5dl	12	8	subset	subset	NN
cord-324859-0yuhb5dl	12	9	was	be	VBD
cord-324859-0yuhb5dl	12	10	included	include	VBN
cord-324859-0yuhb5dl	12	11	in	in	IN
cord-324859-0yuhb5dl	12	12	the	the	DT
cord-324859-0yuhb5dl	12	13	meta‐analysis	meta‐analysis	NNP
cord-324859-0yuhb5dl	12	14	,	,	,
cord-324859-0yuhb5dl	12	15	using	use	VBG
cord-324859-0yuhb5dl	12	16	forest	forest	NN
cord-324859-0yuhb5dl	12	17	plots	plot	NNS
cord-324859-0yuhb5dl	12	18	.	.	.
cord-324859-0yuhb5dl	13	1	RESULTS	result	NNS
cord-324859-0yuhb5dl	13	2	:	:	:
cord-324859-0yuhb5dl	14	1	Based	base	VBN
cord-324859-0yuhb5dl	14	2	on	on	IN
cord-324859-0yuhb5dl	14	3	23	23	CD
cord-324859-0yuhb5dl	14	4	studies	study	NNS
cord-324859-0yuhb5dl	14	5	,	,	,
cord-324859-0yuhb5dl	14	6	mean	mean	VB
cord-324859-0yuhb5dl	14	7	cytokine	cytokine	NN
cord-324859-0yuhb5dl	14	8	levels	level	NNS
cord-324859-0yuhb5dl	14	9	were	be	VBD
cord-324859-0yuhb5dl	14	10	significantly	significantly	RB
cord-324859-0yuhb5dl	14	11	higher	high	JJR
cord-324859-0yuhb5dl	14	12	(	(	-LRB-
cord-324859-0yuhb5dl	14	13	IL‐6	il‐6	NN
cord-324859-0yuhb5dl	14	14	:	:	:
cord-324859-0yuhb5dl	14	15	MD	MD	NNP
cord-324859-0yuhb5dl	14	16	,	,	,
cord-324859-0yuhb5dl	14	17	19.55	19.55	CD
cord-324859-0yuhb5dl	14	18	pg	pg	NN
cord-324859-0yuhb5dl	14	19	/	/	SYM
cord-324859-0yuhb5dl	14	20	mL	mL	NNP
cord-324859-0yuhb5dl	14	21	;	;	:
cord-324859-0yuhb5dl	14	22	CI	CI	NNP
cord-324859-0yuhb5dl	14	23	,	,	,
cord-324859-0yuhb5dl	14	24	14.80	14.80	CD
cord-324859-0yuhb5dl	14	25	,	,	,
cord-324859-0yuhb5dl	14	26	24.30	24.30	CD
cord-324859-0yuhb5dl	14	27	;	;	:
cord-324859-0yuhb5dl	14	28	IL‐8	IL‐8	NNP
cord-324859-0yuhb5dl	14	29	:	:	:
cord-324859-0yuhb5dl	14	30	MD	MD	NNP
cord-324859-0yuhb5dl	14	31	,	,	,
cord-324859-0yuhb5dl	14	32	19.18	19.18	CD
cord-324859-0yuhb5dl	14	33	pg	pg	NN
cord-324859-0yuhb5dl	14	34	/	/	SYM
cord-324859-0yuhb5dl	14	35	mL	mL	NNP
cord-324859-0yuhb5dl	14	36	;	;	:
cord-324859-0yuhb5dl	14	37	CI	CI	NNP
cord-324859-0yuhb5dl	14	38	,	,	,
cord-324859-0yuhb5dl	14	39	2.94	2.94	CD
cord-324859-0yuhb5dl	14	40	,	,	,
cord-324859-0yuhb5dl	14	41	35.43	35.43	CD
cord-324859-0yuhb5dl	14	42	;	;	:
cord-324859-0yuhb5dl	15	1	IL‐10	IL‐10	NNP
cord-324859-0yuhb5dl	15	2	:	:	:
cord-324859-0yuhb5dl	15	3	MD	MD	NNP
cord-324859-0yuhb5dl	15	4	,	,	,
cord-324859-0yuhb5dl	15	5	3.66	3.66	CD
cord-324859-0yuhb5dl	15	6	pg	pg	NN
cord-324859-0yuhb5dl	15	7	/	/	SYM
cord-324859-0yuhb5dl	15	8	mL	ml	NN
cord-324859-0yuhb5dl	15	9	;	;	:
cord-324859-0yuhb5dl	15	10	CI	CI	NNP
cord-324859-0yuhb5dl	15	11	,	,	,
cord-324859-0yuhb5dl	15	12	2.41	2.41	CD
cord-324859-0yuhb5dl	15	13	,	,	,
cord-324859-0yuhb5dl	15	14	4.92	4.92	CD
cord-324859-0yuhb5dl	15	15	;	;	:
cord-324859-0yuhb5dl	15	16	IL‐2R	il‐2r	NN
cord-324859-0yuhb5dl	15	17	:	:	:
cord-324859-0yuhb5dl	15	18	MD	MD	NNP
cord-324859-0yuhb5dl	15	19	,	,	,
cord-324859-0yuhb5dl	15	20	521.36	521.36	CD
cord-324859-0yuhb5dl	15	21	U	u	NN
cord-324859-0yuhb5dl	15	22	/	/	SYM
cord-324859-0yuhb5dl	15	23	mL	ml	NN
cord-324859-0yuhb5dl	15	24	;	;	:
cord-324859-0yuhb5dl	15	25	CI	CI	NNP
cord-324859-0yuhb5dl	15	26	,	,	,
cord-324859-0yuhb5dl	15	27	87.15	87.15	CD
cord-324859-0yuhb5dl	15	28	,	,	,
cord-324859-0yuhb5dl	15	29	955.57	955.57	CD
cord-324859-0yuhb5dl	15	30	;	;	:
cord-324859-0yuhb5dl	15	31	and	and	CC
cord-324859-0yuhb5dl	16	1	TNF‐alpha	tnf‐alpha	NN
cord-324859-0yuhb5dl	16	2	:	:	:
cord-324859-0yuhb5dl	16	3	MD	MD	NNP
cord-324859-0yuhb5dl	16	4	,	,	,
cord-324859-0yuhb5dl	16	5	1.11	1.11	CD
cord-324859-0yuhb5dl	16	6	pg	pg	NN
cord-324859-0yuhb5dl	16	7	/	/	SYM
cord-324859-0yuhb5dl	16	8	mL	ml	NN
cord-324859-0yuhb5dl	16	9	;	;	:
cord-324859-0yuhb5dl	16	10	CI	CI	NNP
cord-324859-0yuhb5dl	16	11	,	,	,
cord-324859-0yuhb5dl	16	12	0.07	0.07	CD
cord-324859-0yuhb5dl	16	13	,	,	,
cord-324859-0yuhb5dl	16	14	2.15	2.15	CD
cord-324859-0yuhb5dl	16	15	)	)	-RRB-
cord-324859-0yuhb5dl	16	16	and	and	CC
cord-324859-0yuhb5dl	16	17	T‐lymphocyte	T‐lymphocyte	NNP
cord-324859-0yuhb5dl	16	18	levels	level	NNS
cord-324859-0yuhb5dl	16	19	were	be	VBD
cord-324859-0yuhb5dl	16	20	significantly	significantly	RB
cord-324859-0yuhb5dl	16	21	lower	low	JJR
cord-324859-0yuhb5dl	16	22	(	(	-LRB-
cord-324859-0yuhb5dl	16	23	CD4	CD4	NNP
cord-324859-0yuhb5dl	16	24	+	+	CC
cord-324859-0yuhb5dl	16	25	T	T	NNP
cord-324859-0yuhb5dl	16	26	cells	cell	NNS
cord-324859-0yuhb5dl	16	27	:	:	:
cord-324859-0yuhb5dl	16	28	MD	MD	NNP
cord-324859-0yuhb5dl	16	29	,	,	,
cord-324859-0yuhb5dl	16	30	−165.28	−165.28	NNP
cord-324859-0yuhb5dl	16	31	cells/µL	cells/µL	NNP
cord-324859-0yuhb5dl	16	32	;	;	:
cord-324859-0yuhb5dl	16	33	CI	CI	NNP
cord-324859-0yuhb5dl	16	34	,	,	,
cord-324859-0yuhb5dl	16	35	−207.58	−207.58	NNP
cord-324859-0yuhb5dl	16	36	,	,	,
cord-324859-0yuhb5dl	16	37	−122.97	−122.97	NNP
cord-324859-0yuhb5dl	16	38	;	;	:
cord-324859-0yuhb5dl	16	39	CD8	CD8	NNP
cord-324859-0yuhb5dl	16	40	+	+	CC
cord-324859-0yuhb5dl	16	41	T	T	NNP
cord-324859-0yuhb5dl	16	42	cells	cell	NNS
cord-324859-0yuhb5dl	16	43	:	:	:
cord-324859-0yuhb5dl	16	44	MD	MD	NNP
cord-324859-0yuhb5dl	16	45	,	,	,
cord-324859-0yuhb5dl	16	46	−106.51	−106.51	NNP
cord-324859-0yuhb5dl	16	47	cells/µL	cells/µL	NNP
cord-324859-0yuhb5dl	16	48	;	;	:
cord-324859-0yuhb5dl	16	49	CI	CI	NNP
cord-324859-0yuhb5dl	16	50	,	,	,
cord-324859-0yuhb5dl	16	51	−128.59	−128.59	NNP
cord-324859-0yuhb5dl	16	52	,	,	,
cord-324859-0yuhb5dl	16	53	−84.43	−84.43	XX
cord-324859-0yuhb5dl	16	54	)	)	-RRB-
cord-324859-0yuhb5dl	16	55	among	among	IN
cord-324859-0yuhb5dl	16	56	severe	severe	JJ
cord-324859-0yuhb5dl	16	57	cases	case	NNS
cord-324859-0yuhb5dl	16	58	as	as	IN
cord-324859-0yuhb5dl	16	59	compared	compare	VBN
cord-324859-0yuhb5dl	16	60	to	to	IN
cord-324859-0yuhb5dl	16	61	nonsevere	nonsevere	JJ
cord-324859-0yuhb5dl	16	62	ones	one	NNS
cord-324859-0yuhb5dl	16	63	.	.	.
cord-324859-0yuhb5dl	17	1	There	there	EX
cord-324859-0yuhb5dl	17	2	was	be	VBD
cord-324859-0yuhb5dl	17	3	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	17	4	across	across	IN
cord-324859-0yuhb5dl	17	5	studies	study	NNS
cord-324859-0yuhb5dl	17	6	due	due	JJ
cord-324859-0yuhb5dl	17	7	to	to	IN
cord-324859-0yuhb5dl	17	8	small	small	JJ
cord-324859-0yuhb5dl	17	9	sample	sample	NN
cord-324859-0yuhb5dl	17	10	sizes	size	NNS
cord-324859-0yuhb5dl	17	11	and	and	CC
cord-324859-0yuhb5dl	17	12	nonuniformity	nonuniformity	NN
cord-324859-0yuhb5dl	17	13	in	in	IN
cord-324859-0yuhb5dl	17	14	outcome	outcome	NN
cord-324859-0yuhb5dl	17	15	assessment	assessment	NN
cord-324859-0yuhb5dl	17	16	and	and	CC
cord-324859-0yuhb5dl	17	17	varied	varied	JJ
cord-324859-0yuhb5dl	17	18	definitions	definition	NNS
cord-324859-0yuhb5dl	17	19	of	of	IN
cord-324859-0yuhb5dl	17	20	disease	disease	NN
cord-324859-0yuhb5dl	17	21	severity	severity	NN
cord-324859-0yuhb5dl	17	22	.	.	.
cord-324859-0yuhb5dl	18	1	The	the	DT
cord-324859-0yuhb5dl	18	2	overall	overall	JJ
cord-324859-0yuhb5dl	18	3	quality	quality	NN
cord-324859-0yuhb5dl	18	4	of	of	IN
cord-324859-0yuhb5dl	18	5	studies	study	NNS
cord-324859-0yuhb5dl	18	6	was	be	VBD
cord-324859-0yuhb5dl	18	7	sub‐optimal	sub‐optimal	VBN
cord-324859-0yuhb5dl	18	8	.	.	.
cord-324859-0yuhb5dl	19	1	CONCLUSION	conclusion	NN
cord-324859-0yuhb5dl	19	2	:	:	:
cord-324859-0yuhb5dl	20	1	Severe	severe	JJ
cord-324859-0yuhb5dl	20	2	COVID‐19	covid‐19	NN
cord-324859-0yuhb5dl	20	3	is	be	VBZ
cord-324859-0yuhb5dl	20	4	characterized	characterize	VBN
cord-324859-0yuhb5dl	20	5	by	by	IN
cord-324859-0yuhb5dl	20	6	significantly	significantly	RB
cord-324859-0yuhb5dl	20	7	increased	increase	VBN
cord-324859-0yuhb5dl	20	8	levels	level	NNS
cord-324859-0yuhb5dl	20	9	of	of	IN
cord-324859-0yuhb5dl	20	10	pro‐inflammatory	pro‐inflammatory	NN
cord-324859-0yuhb5dl	20	11	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	20	12	and	and	CC
cord-324859-0yuhb5dl	20	13	reduced	reduce	VBN
cord-324859-0yuhb5dl	20	14	T	t	NN
cord-324859-0yuhb5dl	20	15	lymphocytes	lymphocyte	NNS
cord-324859-0yuhb5dl	20	16	.	.	.
cord-324859-0yuhb5dl	21	1	Well‐designed	well‐designe	VBN
cord-324859-0yuhb5dl	21	2	and	and	CC
cord-324859-0yuhb5dl	21	3	adequately	adequately	RB
cord-324859-0yuhb5dl	21	4	powered	power	VBD
cord-324859-0yuhb5dl	21	5	prospective	prospective	JJ
cord-324859-0yuhb5dl	21	6	studies	study	NNS
cord-324859-0yuhb5dl	21	7	are	be	VBP
cord-324859-0yuhb5dl	21	8	needed	need	VBN
cord-324859-0yuhb5dl	21	9	to	to	TO
cord-324859-0yuhb5dl	21	10	amplify	amplify	VB
cord-324859-0yuhb5dl	21	11	the	the	DT
cord-324859-0yuhb5dl	21	12	current	current	JJ
cord-324859-0yuhb5dl	21	13	evidence	evidence	NN
cord-324859-0yuhb5dl	21	14	and	and	CC
cord-324859-0yuhb5dl	21	15	provide	provide	VB
cord-324859-0yuhb5dl	21	16	definitive	definitive	JJ
cord-324859-0yuhb5dl	21	17	answers	answer	NNS
cord-324859-0yuhb5dl	21	18	to	to	IN
cord-324859-0yuhb5dl	21	19	dilemmas	dilemma	NNS
cord-324859-0yuhb5dl	21	20	regarding	regard	VBG
cord-324859-0yuhb5dl	21	21	timing	timing	NN
cord-324859-0yuhb5dl	21	22	and	and	CC
cord-324859-0yuhb5dl	21	23	type	type	NN
cord-324859-0yuhb5dl	21	24	of	of	IN
cord-324859-0yuhb5dl	21	25	anti‐COVID‐19	anti‐covid‐19	CD
cord-324859-0yuhb5dl	21	26	therapy	therapy	NN
cord-324859-0yuhb5dl	21	27	particularly	particularly	RB
cord-324859-0yuhb5dl	21	28	in	in	IN
cord-324859-0yuhb5dl	21	29	severe	severe	JJ
cord-324859-0yuhb5dl	21	30	patients	patient	NNS
cord-324859-0yuhb5dl	21	31	.	.	.
cord-324859-0yuhb5dl	22	1	In	in	IN
cord-324859-0yuhb5dl	22	2	December	December	NNP
cord-324859-0yuhb5dl	22	3	of	of	IN
cord-324859-0yuhb5dl	22	4	2019	2019	CD
cord-324859-0yuhb5dl	22	5	,	,	,
cord-324859-0yuhb5dl	22	6	an	an	DT
cord-324859-0yuhb5dl	22	7	outbreak	outbreak	NN
cord-324859-0yuhb5dl	22	8	of	of	IN
cord-324859-0yuhb5dl	22	9	a	a	DT
cord-324859-0yuhb5dl	22	10	novel	novel	JJ
cord-324859-0yuhb5dl	22	11	strain	strain	NN
cord-324859-0yuhb5dl	22	12	of	of	IN
cord-324859-0yuhb5dl	22	13	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	22	14	named	name	VBN
cord-324859-0yuhb5dl	22	15	as	as	IN
cord-324859-0yuhb5dl	22	16	severe	severe	JJ
cord-324859-0yuhb5dl	22	17	acute	acute	JJ
cord-324859-0yuhb5dl	22	18	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	22	19	syndrome	syndrome	NN
cord-324859-0yuhb5dl	22	20	coronavirus-2	coronavirus-2	NNP
cord-324859-0yuhb5dl	22	21	(	(	-LRB-
cord-324859-0yuhb5dl	22	22	SARS	SARS	NNP
cord-324859-0yuhb5dl	22	23	-	-	HYPH
cord-324859-0yuhb5dl	22	24	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	22	25	)	)	-RRB-
cord-324859-0yuhb5dl	22	26	originated	originate	VBD
cord-324859-0yuhb5dl	22	27	in	in	IN
cord-324859-0yuhb5dl	22	28	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	22	29	,	,	,
cord-324859-0yuhb5dl	22	30	China	China	NNP
cord-324859-0yuhb5dl	22	31	,	,	,
cord-324859-0yuhb5dl	22	32	and	and	CC
cord-324859-0yuhb5dl	22	33	rapidly	rapidly	RB
cord-324859-0yuhb5dl	22	34	spread	spread	VBD
cord-324859-0yuhb5dl	22	35	across	across	IN
cord-324859-0yuhb5dl	22	36	the	the	DT
cord-324859-0yuhb5dl	22	37	globe	globe	NN
cord-324859-0yuhb5dl	22	38	.	.	.
cord-324859-0yuhb5dl	23	1	The	the	DT
cord-324859-0yuhb5dl	23	2	disease	disease	NN
cord-324859-0yuhb5dl	23	3	caused	cause	VBN
cord-324859-0yuhb5dl	23	4	by	by	IN
cord-324859-0yuhb5dl	23	5	the	the	DT
cord-324859-0yuhb5dl	23	6	virus	virus	NN
cord-324859-0yuhb5dl	23	7	is	be	VBZ
cord-324859-0yuhb5dl	23	8	officially	officially	RB
cord-324859-0yuhb5dl	23	9	called	call	VBN
cord-324859-0yuhb5dl	23	10	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	23	11	disease	disease	NN
cord-324859-0yuhb5dl	23	12	19	19	CD
cord-324859-0yuhb5dl	23	13	.	.	.
cord-324859-0yuhb5dl	24	1	The	the	DT
cord-324859-0yuhb5dl	24	2	outbreak	outbreak	NN
cord-324859-0yuhb5dl	24	3	was	be	VBD
cord-324859-0yuhb5dl	24	4	declared	declare	VBN
cord-324859-0yuhb5dl	24	5	a	a	DT
cord-324859-0yuhb5dl	24	6	Public	Public	NNP
cord-324859-0yuhb5dl	24	7	Health	Health	NNP
cord-324859-0yuhb5dl	24	8	Emergency	Emergency	NNP
cord-324859-0yuhb5dl	24	9	of	of	IN
cord-324859-0yuhb5dl	24	10	International	International	NNP
cord-324859-0yuhb5dl	24	11	Concern	Concern	NNP
cord-324859-0yuhb5dl	24	12	and	and	CC
cord-324859-0yuhb5dl	24	13	a	a	DT
cord-324859-0yuhb5dl	24	14	pandemic	pandemic	NN
cord-324859-0yuhb5dl	24	15	by	by	IN
cord-324859-0yuhb5dl	24	16	the	the	DT
cord-324859-0yuhb5dl	24	17	World	World	NNP
cord-324859-0yuhb5dl	24	18	Health	Health	NNP
cord-324859-0yuhb5dl	24	19	Organization	Organization	NNP
cord-324859-0yuhb5dl	24	20	(	(	-LRB-
cord-324859-0yuhb5dl	24	21	WHO	who	WP
cord-324859-0yuhb5dl	24	22	)	)	-RRB-
cord-324859-0yuhb5dl	24	23	in	in	IN
cord-324859-0yuhb5dl	24	24	January	January	NNP
cord-324859-0yuhb5dl	24	25	2020	2020	CD
cord-324859-0yuhb5dl	24	26	and	and	CC
cord-324859-0yuhb5dl	24	27	March	March	NNP
cord-324859-0yuhb5dl	24	28	2020	2020	CD
cord-324859-0yuhb5dl	24	29	,	,	,
cord-324859-0yuhb5dl	24	30	respectively	respectively	RB
cord-324859-0yuhb5dl	24	31	.	.	.
cord-324859-0yuhb5dl	25	1	As	as	IN
cord-324859-0yuhb5dl	25	2	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	25	3	is	be	VBZ
cord-324859-0yuhb5dl	25	4	raging	rage	VBG
cord-324859-0yuhb5dl	25	5	around	around	IN
cord-324859-0yuhb5dl	25	6	the	the	DT
cord-324859-0yuhb5dl	25	7	globe	globe	NN
cord-324859-0yuhb5dl	25	8	having	have	VBG
cord-324859-0yuhb5dl	25	9	affected	affect	VBN
cord-324859-0yuhb5dl	25	10	over	over	IN
cord-324859-0yuhb5dl	25	11	20	20	CD
cord-324859-0yuhb5dl	25	12	million	million	CD
cord-324859-0yuhb5dl	25	13	people	people	NNS
cord-324859-0yuhb5dl	25	14	across	across	IN
cord-324859-0yuhb5dl	25	15	more	more	JJR
cord-324859-0yuhb5dl	25	16	than	than	IN
cord-324859-0yuhb5dl	25	17	200	200	CD
cord-324859-0yuhb5dl	25	18	countries	country	NNS
cord-324859-0yuhb5dl	25	19	and	and	CC
cord-324859-0yuhb5dl	25	20	causing	cause	VBG
cord-324859-0yuhb5dl	25	21	more	more	JJR
cord-324859-0yuhb5dl	25	22	than	than	IN
cord-324859-0yuhb5dl	25	23	700	700	CD
cord-324859-0yuhb5dl	25	24	000	000	CD
cord-324859-0yuhb5dl	25	25	deaths	death	NNS
cord-324859-0yuhb5dl	25	26	,	,	,
cord-324859-0yuhb5dl	25	27	1	1	CD
cord-324859-0yuhb5dl	25	28	deciphering	decipher	VBG
cord-324859-0yuhb5dl	25	29	the	the	DT
cord-324859-0yuhb5dl	25	30	unique	unique	JJ
cord-324859-0yuhb5dl	25	31	infection	infection	NN
cord-324859-0yuhb5dl	25	32	mode	mode	NN
cord-324859-0yuhb5dl	25	33	of	of	IN
cord-324859-0yuhb5dl	25	34	this	this	DT
cord-324859-0yuhb5dl	25	35	novel	novel	JJ
cord-324859-0yuhb5dl	25	36	virus	virus	NN
cord-324859-0yuhb5dl	25	37	and	and	CC
cord-324859-0yuhb5dl	25	38	its	-PRON-	PRP$
cord-324859-0yuhb5dl	25	39	pathophysiology	pathophysiology	NN
cord-324859-0yuhb5dl	25	40	is	be	VBZ
cord-324859-0yuhb5dl	25	41	a	a	DT
cord-324859-0yuhb5dl	25	42	crucial	crucial	JJ
cord-324859-0yuhb5dl	25	43	step	step	NN
cord-324859-0yuhb5dl	25	44	towards	towards	IN
cord-324859-0yuhb5dl	25	45	arresting	arrest	VBG
cord-324859-0yuhb5dl	25	46	the	the	DT
cord-324859-0yuhb5dl	25	47	pandemic	pandemic	NN
cord-324859-0yuhb5dl	25	48	.	.	.
cord-324859-0yuhb5dl	26	1	The	the	DT
cord-324859-0yuhb5dl	26	2	current	current	JJ
cord-324859-0yuhb5dl	26	3	pandemic	pandemic	NN
cord-324859-0yuhb5dl	26	4	is	be	VBZ
cord-324859-0yuhb5dl	26	5	distinctive	distinctive	JJ
cord-324859-0yuhb5dl	26	6	in	in	IN
cord-324859-0yuhb5dl	26	7	that	that	IN
cord-324859-0yuhb5dl	26	8	the	the	DT
cord-324859-0yuhb5dl	26	9	range	range	NN
cord-324859-0yuhb5dl	26	10	of	of	IN
cord-324859-0yuhb5dl	26	11	innate	innate	JJ
cord-324859-0yuhb5dl	26	12	immune	immune	JJ
cord-324859-0yuhb5dl	26	13	responses	response	NNS
cord-324859-0yuhb5dl	26	14	is	be	VBZ
cord-324859-0yuhb5dl	26	15	unpredictable	unpredictable	JJ
cord-324859-0yuhb5dl	26	16	and	and	CC
cord-324859-0yuhb5dl	26	17	varies	vary	VBZ
cord-324859-0yuhb5dl	26	18	;	;	:
cord-324859-0yuhb5dl	26	19	it	-PRON-	PRP
cord-324859-0yuhb5dl	26	20	is	be	VBZ
cord-324859-0yuhb5dl	26	21	strong	strong	JJ
cord-324859-0yuhb5dl	26	22	enough	enough	RB
cord-324859-0yuhb5dl	26	23	to	to	TO
cord-324859-0yuhb5dl	26	24	kill	kill	VB
cord-324859-0yuhb5dl	26	25	in	in	RP
cord-324859-0yuhb5dl	26	26	some	some	DT
cord-324859-0yuhb5dl	26	27	,	,	,
cord-324859-0yuhb5dl	26	28	but	but	CC
cord-324859-0yuhb5dl	26	29	others	other	NNS
cord-324859-0yuhb5dl	26	30	escape	escape	VBP
cord-324859-0yuhb5dl	26	31	with	with	IN
cord-324859-0yuhb5dl	26	32	a	a	DT
cord-324859-0yuhb5dl	26	33	relatively	relatively	RB
cord-324859-0yuhb5dl	26	34	mild	mild	JJ
cord-324859-0yuhb5dl	26	35	infection	infection	NN
cord-324859-0yuhb5dl	26	36	.	.	.
cord-324859-0yuhb5dl	27	1	Infections	infection	NNS
cord-324859-0yuhb5dl	27	2	with	with	IN
cord-324859-0yuhb5dl	27	3	other	other	JJ
cord-324859-0yuhb5dl	27	4	subfamilies	subfamily	NNS
cord-324859-0yuhb5dl	27	5	of	of	IN
cord-324859-0yuhb5dl	27	6	the	the	DT
cord-324859-0yuhb5dl	27	7	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	27	8	are	be	VBP
cord-324859-0yuhb5dl	27	9	generally	generally	RB
cord-324859-0yuhb5dl	27	10	associated	associate	VBN
cord-324859-0yuhb5dl	27	11	with	with	IN
cord-324859-0yuhb5dl	27	12	upper	upper	JJ
cord-324859-0yuhb5dl	27	13	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	27	14	tract	tract	NN
cord-324859-0yuhb5dl	27	15	infections	infection	NNS
cord-324859-0yuhb5dl	27	16	(	(	-LRB-
cord-324859-0yuhb5dl	27	17	RTIs	rti	NNS
cord-324859-0yuhb5dl	27	18	)	)	-RRB-
cord-324859-0yuhb5dl	27	19	although	although	IN
cord-324859-0yuhb5dl	27	20	some	some	DT
cord-324859-0yuhb5dl	27	21	patients	patient	NNS
cord-324859-0yuhb5dl	27	22	may	may	MD
cord-324859-0yuhb5dl	27	23	present	present	VB
cord-324859-0yuhb5dl	27	24	with	with	IN
cord-324859-0yuhb5dl	27	25	lower	low	JJR
cord-324859-0yuhb5dl	27	26	RTIs	rti	NNS
cord-324859-0yuhb5dl	27	27	too	too	RB
cord-324859-0yuhb5dl	27	28	.	.	.
cord-324859-0yuhb5dl	28	1	In	in	IN
cord-324859-0yuhb5dl	28	2	contrast	contrast	NN
cord-324859-0yuhb5dl	28	3	,	,	,
cord-324859-0yuhb5dl	28	4	the	the	DT
cord-324859-0yuhb5dl	28	5	SARS	SARS	NNP
cord-324859-0yuhb5dl	28	6	-	-	HYPH
cord-324859-0yuhb5dl	28	7	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	28	8	infection	infection	NN
cord-324859-0yuhb5dl	28	9	may	may	MD
cord-324859-0yuhb5dl	28	10	remain	remain	VB
cord-324859-0yuhb5dl	28	11	asymptomatic	asymptomatic	JJ
cord-324859-0yuhb5dl	28	12	in	in	IN
cord-324859-0yuhb5dl	28	13	the	the	DT
cord-324859-0yuhb5dl	28	14	early	early	JJ
cord-324859-0yuhb5dl	28	15	stages	stage	NNS
cord-324859-0yuhb5dl	28	16	until	until	IN
cord-324859-0yuhb5dl	28	17	the	the	DT
cord-324859-0yuhb5dl	28	18	emergence	emergence	NN
cord-324859-0yuhb5dl	28	19	of	of	IN
cord-324859-0yuhb5dl	28	20	severe	severe	JJ
cord-324859-0yuhb5dl	28	21	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	28	22	,	,	,
cord-324859-0yuhb5dl	28	23	dyspnea	dyspnea	NN
cord-324859-0yuhb5dl	28	24	,	,	,
cord-324859-0yuhb5dl	28	25	organ	organ	NN
cord-324859-0yuhb5dl	28	26	dysfunction	dysfunction	NN
cord-324859-0yuhb5dl	28	27	and	and	CC
cord-324859-0yuhb5dl	28	28	even	even	RB
cord-324859-0yuhb5dl	28	29	death	death	NN
cord-324859-0yuhb5dl	28	30	.	.	.
cord-324859-0yuhb5dl	29	1	2	2	CD
cord-324859-0yuhb5dl	29	2	Pulmonary	pulmonary	JJ
cord-324859-0yuhb5dl	29	3	lesions	lesion	NNS
cord-324859-0yuhb5dl	29	4	in	in	IN
cord-324859-0yuhb5dl	29	5	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	29	6	show	show	NN
cord-324859-0yuhb5dl	29	7	pathological	pathological	JJ
cord-324859-0yuhb5dl	29	8	changes	change	NNS
cord-324859-0yuhb5dl	29	9	,	,	,
cord-324859-0yuhb5dl	29	10	degeneration	degeneration	NN
cord-324859-0yuhb5dl	29	11	,	,	,
cord-324859-0yuhb5dl	29	12	infiltration	infiltration	NN
cord-324859-0yuhb5dl	29	13	and	and	CC
cord-324859-0yuhb5dl	29	14	hyperplasia	hyperplasia	NN
cord-324859-0yuhb5dl	29	15	consistent	consistent	JJ
cord-324859-0yuhb5dl	29	16	with	with	IN
cord-324859-0yuhb5dl	29	17	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	29	18	response	response	NN
cord-324859-0yuhb5dl	29	19	throughout	throughout	IN
cord-324859-0yuhb5dl	29	20	the	the	DT
cord-324859-0yuhb5dl	29	21	course	course	NN
cord-324859-0yuhb5dl	29	22	of	of	IN
cord-324859-0yuhb5dl	29	23	the	the	DT
cord-324859-0yuhb5dl	29	24	disease	disease	NN
cord-324859-0yuhb5dl	29	25	.	.	.
cord-324859-0yuhb5dl	30	1	2	2	LS
cord-324859-0yuhb5dl	31	1	In	in	IN
cord-324859-0yuhb5dl	31	2	certain	certain	JJ
cord-324859-0yuhb5dl	31	3	cases	case	NNS
cord-324859-0yuhb5dl	31	4	,	,	,
cord-324859-0yuhb5dl	31	5	the	the	DT
cord-324859-0yuhb5dl	31	6	disease	disease	NN
cord-324859-0yuhb5dl	31	7	triggers	trigger	VBZ
cord-324859-0yuhb5dl	31	8	a	a	DT
cord-324859-0yuhb5dl	31	9	hyper	hyper	JJ
cord-324859-0yuhb5dl	31	10	-	-	JJ
cord-324859-0yuhb5dl	31	11	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	31	12	condition	condition	NN
cord-324859-0yuhb5dl	31	13	3	3	CD
cord-324859-0yuhb5dl	31	14	that	that	WDT
cord-324859-0yuhb5dl	31	15	is	be	VBZ
cord-324859-0yuhb5dl	31	16	potentially	potentially	RB
cord-324859-0yuhb5dl	31	17	life	life	NN
cord-324859-0yuhb5dl	31	18	-	-	HYPH
cord-324859-0yuhb5dl	31	19	threatening	threaten	VBG
cord-324859-0yuhb5dl	31	20	and	and	CC
cord-324859-0yuhb5dl	31	21	is	be	VBZ
cord-324859-0yuhb5dl	31	22	often	often	RB
cord-324859-0yuhb5dl	31	23	responsible	responsible	JJ
cord-324859-0yuhb5dl	31	24	for	for	IN
cord-324859-0yuhb5dl	31	25	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	31	26	fatality	fatality	NN
cord-324859-0yuhb5dl	31	27	.	.	.
cord-324859-0yuhb5dl	32	1	4	4	LS
cord-324859-0yuhb5dl	33	1	The	the	DT
cord-324859-0yuhb5dl	33	2	immune	immune	JJ
cord-324859-0yuhb5dl	33	3	pathogenesis	pathogenesis	NN
cord-324859-0yuhb5dl	33	4	associated	associate	VBN
cord-324859-0yuhb5dl	33	5	with	with	IN
cord-324859-0yuhb5dl	33	6	an	an	DT
cord-324859-0yuhb5dl	33	7	aberrant	aberrant	JJ
cord-324859-0yuhb5dl	33	8	immune	immune	JJ
cord-324859-0yuhb5dl	33	9	response	response	NN
cord-324859-0yuhb5dl	33	10	results	result	NNS
cord-324859-0yuhb5dl	33	11	in	in	IN
cord-324859-0yuhb5dl	33	12	lung	lung	NN
cord-324859-0yuhb5dl	33	13	damage	damage	NN
cord-324859-0yuhb5dl	33	14	,	,	,
cord-324859-0yuhb5dl	33	15	functional	functional	JJ
cord-324859-0yuhb5dl	33	16	impairment	impairment	NN
cord-324859-0yuhb5dl	33	17	,	,	,
cord-324859-0yuhb5dl	33	18	reduced	reduce	VBN
cord-324859-0yuhb5dl	33	19	pulmonary	pulmonary	JJ
cord-324859-0yuhb5dl	33	20	capacity	capacity	NN
cord-324859-0yuhb5dl	33	21	and	and	CC
cord-324859-0yuhb5dl	33	22	eventually	eventually	RB
cord-324859-0yuhb5dl	33	23	death	death	NN
cord-324859-0yuhb5dl	33	24	.	.	.
cord-324859-0yuhb5dl	34	1	2	2	LS
cord-324859-0yuhb5dl	35	1	Such	such	JJ
cord-324859-0yuhb5dl	35	2	'	'	``
cord-324859-0yuhb5dl	35	3	cytokine	cytokine	NN
cord-324859-0yuhb5dl	35	4	storm	storm	NN
cord-324859-0yuhb5dl	35	5	'	'	''
cord-324859-0yuhb5dl	35	6	syndromes	syndrome	NNS
cord-324859-0yuhb5dl	35	7	are	be	VBP
cord-324859-0yuhb5dl	35	8	described	describe	VBN
cord-324859-0yuhb5dl	35	9	by	by	IN
cord-324859-0yuhb5dl	35	10	inappropriately	inappropriately	RB
cord-324859-0yuhb5dl	35	11	elevated	elevate	VBN
cord-324859-0yuhb5dl	35	12	pro	pro	JJ
cord-324859-0yuhb5dl	35	13	-	-	JJ
cord-324859-0yuhb5dl	35	14	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	35	15	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	35	16	and	and	CC
cord-324859-0yuhb5dl	35	17	chemokines	chemokine	NNS
cord-324859-0yuhb5dl	35	18	produced	produce	VBN
cord-324859-0yuhb5dl	35	19	by	by	IN
cord-324859-0yuhb5dl	35	20	a	a	DT
cord-324859-0yuhb5dl	35	21	dysregulated	dysregulate	VBN
cord-324859-0yuhb5dl	35	22	immune	immune	JJ
cord-324859-0yuhb5dl	35	23	response	response	NN
cord-324859-0yuhb5dl	35	24	with	with	IN
cord-324859-0yuhb5dl	35	25	subsequent	subsequent	JJ
cord-324859-0yuhb5dl	35	26	multi	multi	JJ
cord-324859-0yuhb5dl	35	27	-	-	JJ
cord-324859-0yuhb5dl	35	28	organ	organ	JJ
cord-324859-0yuhb5dl	35	29	failure	failure	NN
cord-324859-0yuhb5dl	35	30	.	.	.
cord-324859-0yuhb5dl	36	1	Interestingly	interestingly	RB
cord-324859-0yuhb5dl	36	2	,	,	,
cord-324859-0yuhb5dl	36	3	the	the	DT
cord-324859-0yuhb5dl	36	4	COVID-19-associated	covid-19-associated	JJ
cord-324859-0yuhb5dl	36	5	cytokine	cytokine	NN
cord-324859-0yuhb5dl	36	6	storm	storm	NN
cord-324859-0yuhb5dl	36	7	is	be	VBZ
cord-324859-0yuhb5dl	36	8	distinctive	distinctive	JJ
cord-324859-0yuhb5dl	36	9	in	in	IN
cord-324859-0yuhb5dl	36	10	being	be	VBG
cord-324859-0yuhb5dl	36	11	associated	associate	VBN
cord-324859-0yuhb5dl	36	12	with	with	IN
cord-324859-0yuhb5dl	36	13	early	early	JJ
cord-324859-0yuhb5dl	36	14	acute	acute	JJ
cord-324859-0yuhb5dl	36	15	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	36	16	distress	distress	NN
cord-324859-0yuhb5dl	36	17	syndrome	syndrome	NN
cord-324859-0yuhb5dl	36	18	(	(	-LRB-
cord-324859-0yuhb5dl	36	19	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	36	20	)	)	-RRB-
cord-324859-0yuhb5dl	36	21	and	and	CC
cord-324859-0yuhb5dl	36	22	coagulopathy	coagulopathy	NN
cord-324859-0yuhb5dl	36	23	,	,	,
cord-324859-0yuhb5dl	36	24	and	and	CC
cord-324859-0yuhb5dl	36	25	biochemical	biochemical	JJ
cord-324859-0yuhb5dl	36	26	parameters	parameter	NNS
cord-324859-0yuhb5dl	36	27	include	include	VBP
cord-324859-0yuhb5dl	36	28	elevated	elevate	VBN
cord-324859-0yuhb5dl	36	29	but	but	CC
cord-324859-0yuhb5dl	36	30	lower	low	JJR
cord-324859-0yuhb5dl	36	31	serum	serum	NN
cord-324859-0yuhb5dl	36	32	ferritin	ferritin	NNS
cord-324859-0yuhb5dl	36	33	and	and	CC
cord-324859-0yuhb5dl	36	34	lower	low	JJR
cord-324859-0yuhb5dl	36	35	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	36	36	levels	level	NNS
cord-324859-0yuhb5dl	36	37	as	as	IN
cord-324859-0yuhb5dl	36	38	compared	compare	VBN
cord-324859-0yuhb5dl	36	39	to	to	IN
cord-324859-0yuhb5dl	36	40	those	those	DT
cord-324859-0yuhb5dl	36	41	encountered	encounter	VBN
cord-324859-0yuhb5dl	36	42	in	in	IN
cord-324859-0yuhb5dl	36	43	other	other	JJ
cord-324859-0yuhb5dl	36	44	cytokine	cytokine	NN
cord-324859-0yuhb5dl	36	45	storm	storm	NN
cord-324859-0yuhb5dl	36	46	syndromes	syndrome	NNS
cord-324859-0yuhb5dl	36	47	.	.	.
cord-324859-0yuhb5dl	37	1	5	5	CD
cord-324859-0yuhb5dl	37	2	,	,	,
cord-324859-0yuhb5dl	37	3	6	6	CD
cord-324859-0yuhb5dl	38	1	Given	give	VBN
cord-324859-0yuhb5dl	38	2	the	the	DT
cord-324859-0yuhb5dl	38	3	novelty	novelty	NN
cord-324859-0yuhb5dl	38	4	of	of	IN
cord-324859-0yuhb5dl	38	5	the	the	DT
cord-324859-0yuhb5dl	38	6	disease	disease	NN
cord-324859-0yuhb5dl	38	7	,	,	,
cord-324859-0yuhb5dl	38	8	definitive	definitive	JJ
cord-324859-0yuhb5dl	38	9	insights	insight	NNS
cord-324859-0yuhb5dl	38	10	into	into	IN
cord-324859-0yuhb5dl	38	11	the	the	DT
cord-324859-0yuhb5dl	38	12	dynamics	dynamic	NNS
cord-324859-0yuhb5dl	38	13	of	of	IN
cord-324859-0yuhb5dl	38	14	the	the	DT
cord-324859-0yuhb5dl	38	15	dysfunctional	dysfunctional	JJ
cord-324859-0yuhb5dl	38	16	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	38	17	reaction	reaction	NN
cord-324859-0yuhb5dl	38	18	in	in	IN
cord-324859-0yuhb5dl	38	19	the	the	DT
cord-324859-0yuhb5dl	38	20	context	context	NN
cord-324859-0yuhb5dl	38	21	of	of	IN
cord-324859-0yuhb5dl	38	22	cellular	cellular	JJ
cord-324859-0yuhb5dl	38	23	immune	immune	JJ
cord-324859-0yuhb5dl	38	24	responses	response	NNS
cord-324859-0yuhb5dl	38	25	in	in	IN
cord-324859-0yuhb5dl	38	26	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	38	27	are	be	VBP
cord-324859-0yuhb5dl	38	28	much	much	RB
cord-324859-0yuhb5dl	38	29	awaited	await	VBN
cord-324859-0yuhb5dl	38	30	and	and	CC
cord-324859-0yuhb5dl	38	31	anticipated	anticipate	VBN
cord-324859-0yuhb5dl	38	32	.	.	.
cord-324859-0yuhb5dl	39	1	Understanding	understand	VBG
cord-324859-0yuhb5dl	39	2	the	the	DT
cord-324859-0yuhb5dl	39	3	biological	biological	JJ
cord-324859-0yuhb5dl	39	4	and	and	CC
cord-324859-0yuhb5dl	39	5	clinical	clinical	JJ
cord-324859-0yuhb5dl	39	6	consequences	consequence	NNS
cord-324859-0yuhb5dl	39	7	of	of	IN
cord-324859-0yuhb5dl	39	8	the	the	DT
cord-324859-0yuhb5dl	39	9	role	role	NN
cord-324859-0yuhb5dl	39	10	of	of	IN
cord-324859-0yuhb5dl	39	11	pro	pro	JJ
cord-324859-0yuhb5dl	39	12	-	-	JJ
cord-324859-0yuhb5dl	39	13	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	39	14	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	39	15	in	in	IN
cord-324859-0yuhb5dl	39	16	the	the	DT
cord-324859-0yuhb5dl	39	17	pathogenesis	pathogenesis	NN
cord-324859-0yuhb5dl	39	18	of	of	IN
cord-324859-0yuhb5dl	39	19	the	the	DT
cord-324859-0yuhb5dl	39	20	disease	disease	NN
cord-324859-0yuhb5dl	39	21	is	be	VBZ
cord-324859-0yuhb5dl	39	22	important	important	JJ
cord-324859-0yuhb5dl	39	23	for	for	IN
cord-324859-0yuhb5dl	39	24	the	the	DT
cord-324859-0yuhb5dl	39	25	scientific	scientific	JJ
cord-324859-0yuhb5dl	39	26	community	community	NN
cord-324859-0yuhb5dl	39	27	as	as	IN
cord-324859-0yuhb5dl	39	28	they	-PRON-	PRP
cord-324859-0yuhb5dl	39	29	are	be	VBP
cord-324859-0yuhb5dl	39	30	racing	race	VBG
cord-324859-0yuhb5dl	39	31	against	against	IN
cord-324859-0yuhb5dl	39	32	time	time	NN
cord-324859-0yuhb5dl	39	33	to	to	TO
cord-324859-0yuhb5dl	39	34	develop	develop	VB
cord-324859-0yuhb5dl	39	35	therapeutics	therapeutic	NNS
cord-324859-0yuhb5dl	39	36	to	to	TO
cord-324859-0yuhb5dl	39	37	treat	treat	VB
cord-324859-0yuhb5dl	39	38	patients	patient	NNS
cord-324859-0yuhb5dl	39	39	.	.	.
cord-324859-0yuhb5dl	40	1	There	there	EX
cord-324859-0yuhb5dl	40	2	has	have	VBZ
cord-324859-0yuhb5dl	40	3	been	be	VBN
cord-324859-0yuhb5dl	40	4	some	some	DT
cord-324859-0yuhb5dl	40	5	sporadic	sporadic	JJ
cord-324859-0yuhb5dl	40	6	evidence	evidence	NN
cord-324859-0yuhb5dl	40	7	to	to	TO
cord-324859-0yuhb5dl	40	8	suggest	suggest	VB
cord-324859-0yuhb5dl	40	9	that	that	IN
cord-324859-0yuhb5dl	40	10	the	the	DT
cord-324859-0yuhb5dl	40	11	level	level	NN
cord-324859-0yuhb5dl	40	12	of	of	IN
cord-324859-0yuhb5dl	40	13	immune	immune	JJ
cord-324859-0yuhb5dl	40	14	response	response	NN
cord-324859-0yuhb5dl	40	15	hyperactivity	hyperactivity	NN
cord-324859-0yuhb5dl	40	16	is	be	VBZ
cord-324859-0yuhb5dl	40	17	significantly	significantly	RB
cord-324859-0yuhb5dl	40	18	higher	high	JJR
cord-324859-0yuhb5dl	40	19	in	in	IN
cord-324859-0yuhb5dl	40	20	patients	patient	NNS
cord-324859-0yuhb5dl	40	21	with	with	IN
cord-324859-0yuhb5dl	40	22	severe	severe	JJ
cord-324859-0yuhb5dl	40	23	disease	disease	NN
cord-324859-0yuhb5dl	40	24	,	,	,
cord-324859-0yuhb5dl	40	25	as	as	IN
cord-324859-0yuhb5dl	40	26	compared	compare	VBN
cord-324859-0yuhb5dl	40	27	to	to	IN
cord-324859-0yuhb5dl	40	28	patients	patient	NNS
cord-324859-0yuhb5dl	40	29	with	with	IN
cord-324859-0yuhb5dl	40	30	a	a	DT
cord-324859-0yuhb5dl	40	31	mild	mild	JJ
cord-324859-0yuhb5dl	40	32	infection	infection	NN
cord-324859-0yuhb5dl	40	33	.	.	.
cord-324859-0yuhb5dl	41	1	[	[	-LRB-
cord-324859-0yuhb5dl	41	2	7	7	CD
cord-324859-0yuhb5dl	41	3	]	]	-RRB-
cord-324859-0yuhb5dl	41	4	[	[	-LRB-
cord-324859-0yuhb5dl	41	5	8	8	CD
cord-324859-0yuhb5dl	41	6	]	]	-RRB-
cord-324859-0yuhb5dl	41	7	[	[	-LRB-
cord-324859-0yuhb5dl	41	8	9	9	CD
cord-324859-0yuhb5dl	41	9	]	]	-RRB-
cord-324859-0yuhb5dl	42	1	However	however	RB
cord-324859-0yuhb5dl	42	2	,	,	,
cord-324859-0yuhb5dl	42	3	it	-PRON-	PRP
cord-324859-0yuhb5dl	42	4	is	be	VBZ
cord-324859-0yuhb5dl	42	5	crucial	crucial	JJ
cord-324859-0yuhb5dl	42	6	to	to	TO
cord-324859-0yuhb5dl	42	7	generate	generate	VB
cord-324859-0yuhb5dl	42	8	systematic	systematic	JJ
cord-324859-0yuhb5dl	42	9	evidence	evidence	NN
cord-324859-0yuhb5dl	42	10	from	from	IN
cord-324859-0yuhb5dl	42	11	research	research	NN
cord-324859-0yuhb5dl	42	12	that	that	WDT
cord-324859-0yuhb5dl	42	13	is	be	VBZ
cord-324859-0yuhb5dl	42	14	adequately	adequately	RB
cord-324859-0yuhb5dl	42	15	powered	power	VBN
cord-324859-0yuhb5dl	42	16	,	,	,
cord-324859-0yuhb5dl	42	17	to	to	TO
cord-324859-0yuhb5dl	42	18	statistically	statistically	RB
cord-324859-0yuhb5dl	42	19	compare	compare	VB
cord-324859-0yuhb5dl	42	20	the	the	DT
cord-324859-0yuhb5dl	42	21	cytokine	cytokine	NN
cord-324859-0yuhb5dl	42	22	levels	level	NNS
cord-324859-0yuhb5dl	42	23	in	in	IN
cord-324859-0yuhb5dl	42	24	patients	patient	NNS
cord-324859-0yuhb5dl	42	25	at	at	IN
cord-324859-0yuhb5dl	42	26	various	various	JJ
cord-324859-0yuhb5dl	42	27	stages	stage	NNS
cord-324859-0yuhb5dl	42	28	of	of	IN
cord-324859-0yuhb5dl	42	29	the	the	DT
cord-324859-0yuhb5dl	42	30	illness	illness	NN
cord-324859-0yuhb5dl	42	31	.	.	.
cord-324859-0yuhb5dl	43	1	In	in	IN
cord-324859-0yuhb5dl	43	2	this	this	DT
cord-324859-0yuhb5dl	43	3	context	context	NN
cord-324859-0yuhb5dl	43	4	,	,	,
cord-324859-0yuhb5dl	43	5	we	-PRON-	PRP
cord-324859-0yuhb5dl	43	6	sought	seek	VBD
cord-324859-0yuhb5dl	43	7	to	to	TO
cord-324859-0yuhb5dl	43	8	undertake	undertake	VB
cord-324859-0yuhb5dl	43	9	a	a	DT
cord-324859-0yuhb5dl	43	10	systematic	systematic	JJ
cord-324859-0yuhb5dl	43	11	review	review	NN
cord-324859-0yuhb5dl	43	12	and	and	CC
cord-324859-0yuhb5dl	43	13	meta	meta	NNP
cord-324859-0yuhb5dl	43	14	-	-	HYPH
cord-324859-0yuhb5dl	43	15	analysis	analysis	NN
cord-324859-0yuhb5dl	43	16	of	of	IN
cord-324859-0yuhb5dl	43	17	available	available	JJ
cord-324859-0yuhb5dl	43	18	evidence	evidence	NN
cord-324859-0yuhb5dl	43	19	to	to	TO
cord-324859-0yuhb5dl	43	20	understand	understand	VB
cord-324859-0yuhb5dl	43	21	the	the	DT
cord-324859-0yuhb5dl	43	22	pattern	pattern	NN
cord-324859-0yuhb5dl	43	23	of	of	IN
cord-324859-0yuhb5dl	43	24	host	host	NN
cord-324859-0yuhb5dl	43	25	immune	immune	JJ
cord-324859-0yuhb5dl	43	26	response	response	NN
cord-324859-0yuhb5dl	43	27	in	in	IN
cord-324859-0yuhb5dl	43	28	patients	patient	NNS
cord-324859-0yuhb5dl	43	29	diagnosed	diagnose	VBN
cord-324859-0yuhb5dl	43	30	with	with	IN
cord-324859-0yuhb5dl	43	31	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	43	32	and	and	CC
cord-324859-0yuhb5dl	43	33	how	how	WRB
cord-324859-0yuhb5dl	43	34	the	the	DT
cord-324859-0yuhb5dl	43	35	levels	level	NNS
cord-324859-0yuhb5dl	43	36	of	of	IN
cord-324859-0yuhb5dl	43	37	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	43	38	and	and	CC
cord-324859-0yuhb5dl	43	39	immunological	immunological	JJ
cord-324859-0yuhb5dl	43	40	markers	marker	NNS
cord-324859-0yuhb5dl	43	41	vary	vary	VBP
cord-324859-0yuhb5dl	43	42	according	accord	VBG
cord-324859-0yuhb5dl	43	43	to	to	IN
cord-324859-0yuhb5dl	43	44	the	the	DT
cord-324859-0yuhb5dl	43	45	severity	severity	NN
cord-324859-0yuhb5dl	43	46	or	or	CC
cord-324859-0yuhb5dl	43	47	stage	stage	NN
cord-324859-0yuhb5dl	43	48	of	of	IN
cord-324859-0yuhb5dl	43	49	the	the	DT
cord-324859-0yuhb5dl	43	50	disease	disease	NN
cord-324859-0yuhb5dl	43	51	.	.	.
cord-324859-0yuhb5dl	44	1	Systematic	systematic	JJ
cord-324859-0yuhb5dl	44	2	reviews	review	NNS
cord-324859-0yuhb5dl	44	3	and	and	CC
cord-324859-0yuhb5dl	44	4	meta	meta	NNP
cord-324859-0yuhb5dl	44	5	-	-	HYPH
cord-324859-0yuhb5dl	44	6	analyses	analysis	NNS
cord-324859-0yuhb5dl	44	7	provide	provide	VBP
cord-324859-0yuhb5dl	44	8	the	the	DT
cord-324859-0yuhb5dl	44	9	highest	high	JJS
cord-324859-0yuhb5dl	44	10	level	level	NN
cord-324859-0yuhb5dl	44	11	of	of	IN
cord-324859-0yuhb5dl	44	12	evidence	evidence	NN
cord-324859-0yuhb5dl	44	13	that	that	WDT
cord-324859-0yuhb5dl	44	14	is	be	VBZ
cord-324859-0yuhb5dl	44	15	statistically	statistically	RB
cord-324859-0yuhb5dl	44	16	meaningful	meaningful	JJ
cord-324859-0yuhb5dl	44	17	and	and	CC
cord-324859-0yuhb5dl	44	18	thus	thus	RB
cord-324859-0yuhb5dl	44	19	considered	consider	VBN
cord-324859-0yuhb5dl	44	20	a	a	DT
cord-324859-0yuhb5dl	44	21	gold	gold	JJ
cord-324859-0yuhb5dl	44	22	standard	standard	NN
cord-324859-0yuhb5dl	44	23	.	.	.
cord-324859-0yuhb5dl	45	1	A	a	DT
cord-324859-0yuhb5dl	45	2	few	few	JJ
cord-324859-0yuhb5dl	45	3	systematic	systematic	JJ
cord-324859-0yuhb5dl	45	4	reviews	review	NNS
cord-324859-0yuhb5dl	45	5	and	and	CC
cord-324859-0yuhb5dl	45	6	meta	meta	NNP
cord-324859-0yuhb5dl	45	7	-	-	HYPH
cord-324859-0yuhb5dl	45	8	analyses	analysis	NNS
cord-324859-0yuhb5dl	45	9	have	have	VBP
cord-324859-0yuhb5dl	45	10	been	be	VBN
cord-324859-0yuhb5dl	45	11	conducted	conduct	VBN
cord-324859-0yuhb5dl	45	12	in	in	IN
cord-324859-0yuhb5dl	45	13	the	the	DT
cord-324859-0yuhb5dl	45	14	last	last	JJ
cord-324859-0yuhb5dl	45	15	few	few	JJ
cord-324859-0yuhb5dl	45	16	months	month	NNS
cord-324859-0yuhb5dl	45	17	,	,	,
cord-324859-0yuhb5dl	45	18	to	to	TO
cord-324859-0yuhb5dl	45	19	understand	understand	VB
cord-324859-0yuhb5dl	45	20	the	the	DT
cord-324859-0yuhb5dl	45	21	relationship	relationship	NN
cord-324859-0yuhb5dl	45	22	between	between	IN
cord-324859-0yuhb5dl	45	23	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	45	24	and	and	CC
cord-324859-0yuhb5dl	45	25	the	the	DT
cord-324859-0yuhb5dl	45	26	novel	novel	JJ
cord-324859-0yuhb5dl	45	27	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	45	28	disease	disease	NN
cord-324859-0yuhb5dl	45	29	2019	2019	CD
cord-324859-0yuhb5dl	45	30	.	.	.
cord-324859-0yuhb5dl	46	1	However	however	RB
cord-324859-0yuhb5dl	46	2	,	,	,
cord-324859-0yuhb5dl	46	3	they	-PRON-	PRP
cord-324859-0yuhb5dl	46	4	have	have	VBP
cord-324859-0yuhb5dl	46	5	been	be	VBN
cord-324859-0yuhb5dl	46	6	majorly	majorly	RB
cord-324859-0yuhb5dl	46	7	centred	centre	VBN
cord-324859-0yuhb5dl	46	8	on	on	IN
cord-324859-0yuhb5dl	46	9	exploring	explore	VBG
cord-324859-0yuhb5dl	46	10	the	the	DT
cord-324859-0yuhb5dl	46	11	correlation	correlation	NN
cord-324859-0yuhb5dl	46	12	between	between	IN
cord-324859-0yuhb5dl	46	13	varying	vary	VBG
cord-324859-0yuhb5dl	46	14	levels	level	NNS
cord-324859-0yuhb5dl	46	15	of	of	IN
cord-324859-0yuhb5dl	46	16	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	46	17	(	(	-LRB-
cord-324859-0yuhb5dl	46	18	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	46	19	)	)	-RRB-
cord-324859-0yuhb5dl	46	20	and	and	CC
cord-324859-0yuhb5dl	46	21	the	the	DT
cord-324859-0yuhb5dl	46	22	degree	degree	NN
cord-324859-0yuhb5dl	46	23	of	of	IN
cord-324859-0yuhb5dl	46	24	severity	severity	NN
cord-324859-0yuhb5dl	46	25	of	of	IN
cord-324859-0yuhb5dl	46	26	the	the	DT
cord-324859-0yuhb5dl	46	27	illness	illness	NN
cord-324859-0yuhb5dl	46	28	.	.	.
cord-324859-0yuhb5dl	47	1	[	[	-LRB-
cord-324859-0yuhb5dl	47	2	10	10	CD
cord-324859-0yuhb5dl	47	3	]	]	-RRB-
cord-324859-0yuhb5dl	47	4	[	[	-LRB-
cord-324859-0yuhb5dl	47	5	11	11	CD
cord-324859-0yuhb5dl	47	6	]	]	-RRB-
cord-324859-0yuhb5dl	47	7	[	[	-LRB-
cord-324859-0yuhb5dl	47	8	12	12	CD
cord-324859-0yuhb5dl	47	9	]	]	-RRB-
cord-324859-0yuhb5dl	48	1	A	a	DT
cord-324859-0yuhb5dl	48	2	few	few	JJ
cord-324859-0yuhb5dl	48	3	others	other	NNS
cord-324859-0yuhb5dl	48	4	have	have	VBP
cord-324859-0yuhb5dl	48	5	provided	provide	VBN
cord-324859-0yuhb5dl	48	6	a	a	DT
cord-324859-0yuhb5dl	48	7	broader	broad	JJR
cord-324859-0yuhb5dl	48	8	overview	overview	NN
cord-324859-0yuhb5dl	48	9	,	,	,
cord-324859-0yuhb5dl	48	10	albeit	albeit	IN
cord-324859-0yuhb5dl	48	11	utilizing	utilize	VBG
cord-324859-0yuhb5dl	48	12	data	datum	NNS
cord-324859-0yuhb5dl	48	13	from	from	IN
cord-324859-0yuhb5dl	48	14	a	a	DT
cord-324859-0yuhb5dl	48	15	very	very	RB
cord-324859-0yuhb5dl	48	16	small	small	JJ
cord-324859-0yuhb5dl	48	17	number	number	NN
cord-324859-0yuhb5dl	48	18	of	of	IN
cord-324859-0yuhb5dl	48	19	studies	study	NNS
cord-324859-0yuhb5dl	48	20	for	for	IN
cord-324859-0yuhb5dl	48	21	each	each	DT
cord-324859-0yuhb5dl	48	22	outcome	outcome	NN
cord-324859-0yuhb5dl	48	23	.	.	.
cord-324859-0yuhb5dl	49	1	13	13	CD
cord-324859-0yuhb5dl	49	2	,	,	,
cord-324859-0yuhb5dl	49	3	14	14	CD
cord-324859-0yuhb5dl	49	4	Moreover	moreover	RB
cord-324859-0yuhb5dl	49	5	,	,	,
cord-324859-0yuhb5dl	49	6	individual	individual	JJ
cord-324859-0yuhb5dl	49	7	studies	study	NNS
cord-324859-0yuhb5dl	49	8	with	with	IN
cord-324859-0yuhb5dl	49	9	inadequate	inadequate	JJ
cord-324859-0yuhb5dl	49	10	sample	sample	NN
cord-324859-0yuhb5dl	49	11	sizes	size	NNS
cord-324859-0yuhb5dl	49	12	have	have	VBP
cord-324859-0yuhb5dl	49	13	produced	produce	VBN
cord-324859-0yuhb5dl	49	14	conflicting	conflicting	JJ
cord-324859-0yuhb5dl	49	15	findings	finding	NNS
cord-324859-0yuhb5dl	49	16	possibly	possibly	RB
cord-324859-0yuhb5dl	49	17	due	due	JJ
cord-324859-0yuhb5dl	49	18	to	to	IN
cord-324859-0yuhb5dl	49	19	a	a	DT
cord-324859-0yuhb5dl	49	20	lack	lack	NN
cord-324859-0yuhb5dl	49	21	of	of	IN
cord-324859-0yuhb5dl	49	22	statistical	statistical	JJ
cord-324859-0yuhb5dl	49	23	power	power	NN
cord-324859-0yuhb5dl	49	24	.	.	.
cord-324859-0yuhb5dl	50	1	As	as	IN
cord-324859-0yuhb5dl	50	2	we	-PRON-	PRP
cord-324859-0yuhb5dl	50	3	grapple	grapple	VBP
cord-324859-0yuhb5dl	50	4	with	with	IN
cord-324859-0yuhb5dl	50	5	a	a	DT
cord-324859-0yuhb5dl	50	6	pandemic	pandemic	NN
cord-324859-0yuhb5dl	50	7	and	and	CC
cord-324859-0yuhb5dl	50	8	continue	continue	VBP
cord-324859-0yuhb5dl	50	9	to	to	TO
cord-324859-0yuhb5dl	50	10	get	get	VB
cord-324859-0yuhb5dl	50	11	inundated	inundate	VBN
cord-324859-0yuhb5dl	50	12	with	with	IN
cord-324859-0yuhb5dl	50	13	clinical	clinical	JJ
cord-324859-0yuhb5dl	50	14	data	datum	NNS
cord-324859-0yuhb5dl	50	15	from	from	IN
cord-324859-0yuhb5dl	50	16	numerous	numerous	JJ
cord-324859-0yuhb5dl	50	17	disease	disease	NN
cord-324859-0yuhb5dl	50	18	cohorts	cohort	NNS
cord-324859-0yuhb5dl	50	19	,	,	,
cord-324859-0yuhb5dl	50	20	it	-PRON-	PRP
cord-324859-0yuhb5dl	50	21	becomes	become	VBZ
cord-324859-0yuhb5dl	50	22	imperative	imperative	JJ
cord-324859-0yuhb5dl	50	23	to	to	TO
cord-324859-0yuhb5dl	50	24	collate	collate	VB
cord-324859-0yuhb5dl	50	25	existing	exist	VBG
cord-324859-0yuhb5dl	50	26	data	datum	NNS
cord-324859-0yuhb5dl	50	27	and	and	CC
cord-324859-0yuhb5dl	50	28	provide	provide	VB
cord-324859-0yuhb5dl	50	29	the	the	DT
cord-324859-0yuhb5dl	50	30	latest	late	JJS
cord-324859-0yuhb5dl	50	31	scientific	scientific	JJ
cord-324859-0yuhb5dl	50	32	evidence	evidence	NN
cord-324859-0yuhb5dl	50	33	,	,	,
cord-324859-0yuhb5dl	50	34	which	which	WDT
cord-324859-0yuhb5dl	50	35	could	could	MD
cord-324859-0yuhb5dl	50	36	be	be	VB
cord-324859-0yuhb5dl	50	37	instrumental	instrumental	JJ
cord-324859-0yuhb5dl	50	38	in	in	IN
cord-324859-0yuhb5dl	50	39	informing	inform	VBG
cord-324859-0yuhb5dl	50	40	healthcare	healthcare	NN
cord-324859-0yuhb5dl	50	41	professionals	professional	NNS
cord-324859-0yuhb5dl	50	42	and	and	CC
cord-324859-0yuhb5dl	50	43	devising	devise	VBG
cord-324859-0yuhb5dl	50	44	appropriate	appropriate	JJ
cord-324859-0yuhb5dl	50	45	treatment	treatment	NN
cord-324859-0yuhb5dl	50	46	strategies	strategy	NNS
cord-324859-0yuhb5dl	50	47	.	.	.
cord-324859-0yuhb5dl	51	1	Therefore	therefore	RB
cord-324859-0yuhb5dl	51	2	,	,	,
cord-324859-0yuhb5dl	51	3	our	-PRON-	PRP$
cord-324859-0yuhb5dl	51	4	review	review	NN
cord-324859-0yuhb5dl	51	5	was	be	VBD
cord-324859-0yuhb5dl	51	6	aimed	aim	VBN
cord-324859-0yuhb5dl	51	7	to	to	TO
cord-324859-0yuhb5dl	51	8	summarize	summarize	VB
cord-324859-0yuhb5dl	51	9	the	the	DT
cord-324859-0yuhb5dl	51	10	relationship	relationship	NN
cord-324859-0yuhb5dl	51	11	between	between	IN
cord-324859-0yuhb5dl	51	12	circulating	circulate	VBG
cord-324859-0yuhb5dl	51	13	cytokine	cytokine	NN
cord-324859-0yuhb5dl	51	14	levels	level	NNS
cord-324859-0yuhb5dl	51	15	and	and	CC
cord-324859-0yuhb5dl	51	16	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	51	17	,	,	,
cord-324859-0yuhb5dl	51	18	and	and	CC
cord-324859-0yuhb5dl	51	19	more	more	RBR
cord-324859-0yuhb5dl	51	20	specifically	specifically	RB
cord-324859-0yuhb5dl	51	21	focusing	focus	VBG
cord-324859-0yuhb5dl	51	22	on	on	IN
cord-324859-0yuhb5dl	51	23	important	important	JJ
cord-324859-0yuhb5dl	51	24	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	51	25	and	and	CC
cord-324859-0yuhb5dl	51	26	immunological	immunological	JJ
cord-324859-0yuhb5dl	51	27	markers	marker	NNS
cord-324859-0yuhb5dl	51	28	that	that	WDT
cord-324859-0yuhb5dl	51	29	are	be	VBP
cord-324859-0yuhb5dl	51	30	shown	show	VBN
cord-324859-0yuhb5dl	51	31	to	to	TO
cord-324859-0yuhb5dl	51	32	be	be	VB
cord-324859-0yuhb5dl	51	33	responsible	responsible	JJ
cord-324859-0yuhb5dl	51	34	for	for	IN
cord-324859-0yuhb5dl	51	35	an	an	DT
cord-324859-0yuhb5dl	51	36	exaggerated	exaggerated	JJ
cord-324859-0yuhb5dl	51	37	immune	immune	JJ
cord-324859-0yuhb5dl	51	38	response	response	NN
cord-324859-0yuhb5dl	51	39	that	that	WDT
cord-324859-0yuhb5dl	51	40	triggers	trigger	VBZ
cord-324859-0yuhb5dl	51	41	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	51	42	distress	distress	NN
cord-324859-0yuhb5dl	51	43	,	,	,
cord-324859-0yuhb5dl	51	44	multi	multi	JJ
cord-324859-0yuhb5dl	51	45	-	-	JJ
cord-324859-0yuhb5dl	51	46	organ	organ	JJ
cord-324859-0yuhb5dl	51	47	failure	failure	NN
cord-324859-0yuhb5dl	51	48	and	and	CC
cord-324859-0yuhb5dl	51	49	,	,	,
cord-324859-0yuhb5dl	51	50	in	in	IN
cord-324859-0yuhb5dl	51	51	the	the	DT
cord-324859-0yuhb5dl	51	52	worst	bad	JJS
cord-324859-0yuhb5dl	51	53	cases	case	NNS
cord-324859-0yuhb5dl	51	54	,	,	,
cord-324859-0yuhb5dl	51	55	death	death	NN
cord-324859-0yuhb5dl	51	56	.	.	.
cord-324859-0yuhb5dl	52	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	52	2	undertook	undertake	VBD
cord-324859-0yuhb5dl	52	3	a	a	DT
cord-324859-0yuhb5dl	52	4	systematic	systematic	JJ
cord-324859-0yuhb5dl	52	5	and	and	CC
cord-324859-0yuhb5dl	52	6	comprehensive	comprehensive	JJ
cord-324859-0yuhb5dl	52	7	synthesis	synthesis	NN
cord-324859-0yuhb5dl	52	8	of	of	IN
cord-324859-0yuhb5dl	52	9	the	the	DT
cord-324859-0yuhb5dl	52	10	currently	currently	RB
cord-324859-0yuhb5dl	52	11	available	available	JJ
cord-324859-0yuhb5dl	52	12	literature	literature	NN
cord-324859-0yuhb5dl	52	13	,	,	,
cord-324859-0yuhb5dl	52	14	to	to	TO
cord-324859-0yuhb5dl	52	15	obtain	obtain	VB
cord-324859-0yuhb5dl	52	16	a	a	DT
cord-324859-0yuhb5dl	52	17	detailed	detailed	JJ
cord-324859-0yuhb5dl	52	18	and	and	CC
cord-324859-0yuhb5dl	52	19	holistic	holistic	JJ
cord-324859-0yuhb5dl	52	20	view	view	NN
cord-324859-0yuhb5dl	52	21	of	of	IN
cord-324859-0yuhb5dl	52	22	the	the	DT
cord-324859-0yuhb5dl	52	23	dynamics	dynamic	NNS
cord-324859-0yuhb5dl	52	24	between	between	IN
cord-324859-0yuhb5dl	52	25	the	the	DT
cord-324859-0yuhb5dl	52	26	host	host	NN
cord-324859-0yuhb5dl	52	27	immune	immune	JJ
cord-324859-0yuhb5dl	52	28	response	response	NN
cord-324859-0yuhb5dl	52	29	and	and	CC
cord-324859-0yuhb5dl	52	30	levels	level	NNS
cord-324859-0yuhb5dl	52	31	of	of	IN
cord-324859-0yuhb5dl	52	32	disease	disease	NN
cord-324859-0yuhb5dl	52	33	severity	severity	NN
cord-324859-0yuhb5dl	52	34	among	among	IN
cord-324859-0yuhb5dl	52	35	clinically	clinically	RB
cord-324859-0yuhb5dl	52	36	confirmed	confirm	VBN
cord-324859-0yuhb5dl	52	37	patients	patient	NNS
cord-324859-0yuhb5dl	52	38	of	of	IN
cord-324859-0yuhb5dl	52	39	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	52	40	.	.	.
cord-324859-0yuhb5dl	53	1	To	to	TO
cord-324859-0yuhb5dl	53	2	understand	understand	VB
cord-324859-0yuhb5dl	53	3	the	the	DT
cord-324859-0yuhb5dl	53	4	pattern	pattern	NN
cord-324859-0yuhb5dl	53	5	of	of	IN
cord-324859-0yuhb5dl	53	6	host	host	NN
cord-324859-0yuhb5dl	53	7	immune	immune	JJ
cord-324859-0yuhb5dl	53	8	response	response	NN
cord-324859-0yuhb5dl	53	9	and	and	CC
cord-324859-0yuhb5dl	53	10	summarize	summarize	VB
cord-324859-0yuhb5dl	53	11	evidence	evidence	NN
cord-324859-0yuhb5dl	53	12	for	for	IN
cord-324859-0yuhb5dl	53	13	the	the	DT
cord-324859-0yuhb5dl	53	14	difference	difference	NN
cord-324859-0yuhb5dl	53	15	in	in	IN
cord-324859-0yuhb5dl	53	16	the	the	DT
cord-324859-0yuhb5dl	53	17	levels	level	NNS
cord-324859-0yuhb5dl	53	18	of	of	IN
cord-324859-0yuhb5dl	53	19	immunological	immunological	JJ
cord-324859-0yuhb5dl	53	20	and	and	CC
cord-324859-0yuhb5dl	53	21	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	53	22	biomarkers	biomarker	NNS
cord-324859-0yuhb5dl	53	23	associated	associate	VBN
cord-324859-0yuhb5dl	53	24	with	with	IN
cord-324859-0yuhb5dl	53	25	cytokine	cytokine	NN
cord-324859-0yuhb5dl	53	26	storm	storm	NN
cord-324859-0yuhb5dl	53	27	,	,	,
cord-324859-0yuhb5dl	53	28	between	between	IN
cord-324859-0yuhb5dl	53	29	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	53	30	patient	patient	JJ
cord-324859-0yuhb5dl	53	31	groups	group	NNS
cord-324859-0yuhb5dl	53	32	of	of	IN
cord-324859-0yuhb5dl	53	33	varying	vary	VBG
cord-324859-0yuhb5dl	53	34	disease	disease	NN
cord-324859-0yuhb5dl	53	35	severity	severity	NN
cord-324859-0yuhb5dl	53	36	.	.	.
cord-324859-0yuhb5dl	53	37	 	 	_SP
cord-324859-0yuhb5dl	54	1	The	the	DT
cord-324859-0yuhb5dl	54	2	systematic	systematic	JJ
cord-324859-0yuhb5dl	54	3	review	review	NN
cord-324859-0yuhb5dl	54	4	methodology	methodology	NN
cord-324859-0yuhb5dl	54	5	has	have	VBZ
cord-324859-0yuhb5dl	54	6	been	be	VBN
cord-324859-0yuhb5dl	54	7	described	describe	VBN
cord-324859-0yuhb5dl	54	8	in	in	IN
cord-324859-0yuhb5dl	54	9	detail	detail	NN
cord-324859-0yuhb5dl	54	10	,	,	,
cord-324859-0yuhb5dl	54	11	in	in	IN
cord-324859-0yuhb5dl	54	12	the	the	DT
cord-324859-0yuhb5dl	54	13	protocol	protocol	NN
cord-324859-0yuhb5dl	54	14	registered	register	VBN
cord-324859-0yuhb5dl	54	15	with	with	IN
cord-324859-0yuhb5dl	54	16	PROSPERO	PROSPERO	NNP
cord-324859-0yuhb5dl	54	17	(	(	-LRB-
cord-324859-0yuhb5dl	54	18	registration	registration	NN
cord-324859-0yuhb5dl	54	19	number	number	NN
cord-324859-0yuhb5dl	54	20	:	:	:
cord-324859-0yuhb5dl	54	21	CRD42020183246	CRD42020183246	NNP
cord-324859-0yuhb5dl	54	22	)	)	-RRB-
cord-324859-0yuhb5dl	54	23	.	.	.
cord-324859-0yuhb5dl	55	1	15	15	CD
cord-324859-0yuhb5dl	56	1	The	the	DT
cord-324859-0yuhb5dl	56	2	reporting	reporting	NN
cord-324859-0yuhb5dl	56	3	of	of	IN
cord-324859-0yuhb5dl	56	4	this	this	DT
cord-324859-0yuhb5dl	56	5	review	review	NN
cord-324859-0yuhb5dl	56	6	is	be	VBZ
cord-324859-0yuhb5dl	56	7	consistent	consistent	JJ
cord-324859-0yuhb5dl	56	8	with	with	IN
cord-324859-0yuhb5dl	56	9	the	the	DT
cord-324859-0yuhb5dl	56	10	Preferred	Preferred	NNP
cord-324859-0yuhb5dl	56	11	Reporting	Reporting	NNP
cord-324859-0yuhb5dl	56	12	of	of	IN
cord-324859-0yuhb5dl	56	13	Items	Items	NNPS
cord-324859-0yuhb5dl	56	14	for	for	IN
cord-324859-0yuhb5dl	56	15	Systematic	Systematic	NNP
cord-324859-0yuhb5dl	56	16	Reviews	Reviews	NNPS
cord-324859-0yuhb5dl	56	17	and	and	CC
cord-324859-0yuhb5dl	56	18	Meta	Meta	NNP
cord-324859-0yuhb5dl	56	19	-	-	HYPH
cord-324859-0yuhb5dl	56	20	Analyses	Analyses	NNP
cord-324859-0yuhb5dl	56	21	(	(	-LRB-
cord-324859-0yuhb5dl	56	22	PRISMA	PRISMA	NNP
cord-324859-0yuhb5dl	56	23	)	)	-RRB-
cord-324859-0yuhb5dl	56	24	guidelines	guideline	VBZ
cord-324859-0yuhb5dl	56	25	16	16	CD
cord-324859-0yuhb5dl	56	26	as	as	RB
cord-324859-0yuhb5dl	56	27	well	well	RB
cord-324859-0yuhb5dl	56	28	as	as	IN
cord-324859-0yuhb5dl	56	29	the	the	DT
cord-324859-0yuhb5dl	56	30	Meta	Meta	NNP
cord-324859-0yuhb5dl	56	31	-	-	HYPH
cord-324859-0yuhb5dl	56	32	Analysis	Analysis	NNP
cord-324859-0yuhb5dl	56	33	of	of	IN
cord-324859-0yuhb5dl	56	34	Observational	Observational	NNP
cord-324859-0yuhb5dl	56	35	Studies	Studies	NNPS
cord-324859-0yuhb5dl	56	36	in	in	IN
cord-324859-0yuhb5dl	56	37	Epidemiology	Epidemiology	NNP
cord-324859-0yuhb5dl	56	38	(	(	-LRB-
cord-324859-0yuhb5dl	56	39	MOOSE	MOOSE	NNP
cord-324859-0yuhb5dl	56	40	)	)	-RRB-
cord-324859-0yuhb5dl	56	41	recommendations	recommendation	NNS
cord-324859-0yuhb5dl	56	42	.	.	.
cord-324859-0yuhb5dl	57	1	17	17	CD
cord-324859-0yuhb5dl	57	2	 	 	_SP
cord-324859-0yuhb5dl	58	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	58	2	searched	search	VBD
cord-324859-0yuhb5dl	58	3	PubMed	PubMed	NNP
cord-324859-0yuhb5dl	58	4	,	,	,
cord-324859-0yuhb5dl	58	5	EMBASE	EMBASE	NNP
cord-324859-0yuhb5dl	58	6	,	,	,
cord-324859-0yuhb5dl	58	7	Web	web	NN
cord-324859-0yuhb5dl	58	8	of	of	IN
cord-324859-0yuhb5dl	58	9	Science	Science	NNP
cord-324859-0yuhb5dl	58	10	,	,	,
cord-324859-0yuhb5dl	58	11	SCOPUS	SCOPUS	NNP
cord-324859-0yuhb5dl	58	12	,	,	,
cord-324859-0yuhb5dl	58	13	Cochrane	Cochrane	NNP
cord-324859-0yuhb5dl	58	14	Central	Central	NNP
cord-324859-0yuhb5dl	58	15	,	,	,
cord-324859-0yuhb5dl	58	16	clinicaltrials.gov	clinicaltrials.gov	NNP
cord-324859-0yuhb5dl	58	17	and	and	CC
cord-324859-0yuhb5dl	58	18	the	the	DT
cord-324859-0yuhb5dl	58	19	preprint	preprint	NN
cord-324859-0yuhb5dl	58	20	server	server	NN
cord-324859-0yuhb5dl	58	21	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	58	22	,	,	,
cord-324859-0yuhb5dl	58	23	to	to	TO
cord-324859-0yuhb5dl	58	24	obtain	obtain	VB
cord-324859-0yuhb5dl	58	25	relevant	relevant	JJ
cord-324859-0yuhb5dl	58	26	articles	article	NNS
cord-324859-0yuhb5dl	58	27	on	on	IN
cord-324859-0yuhb5dl	58	28	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	58	29	patient	patient	JJ
cord-324859-0yuhb5dl	58	30	outcomes	outcome	NNS
cord-324859-0yuhb5dl	58	31	,	,	,
cord-324859-0yuhb5dl	58	32	published	publish	VBN
cord-324859-0yuhb5dl	58	33	till	till	IN
cord-324859-0yuhb5dl	58	34	April	April	NNP
cord-324859-0yuhb5dl	58	35	2020	2020	CD
cord-324859-0yuhb5dl	58	36	.	.	.
cord-324859-0yuhb5dl	59	1	A	a	DT
cord-324859-0yuhb5dl	59	2	sensitive	sensitive	JJ
cord-324859-0yuhb5dl	59	3	search	search	NN
cord-324859-0yuhb5dl	59	4	was	be	VBD
cord-324859-0yuhb5dl	59	5	designed	design	VBN
cord-324859-0yuhb5dl	59	6	using	use	VBG
cord-324859-0yuhb5dl	59	7	synonyms	synonyms	NN
cord-324859-0yuhb5dl	59	8	for	for	IN
cord-324859-0yuhb5dl	59	9	the	the	DT
cord-324859-0yuhb5dl	59	10	novel	novel	JJ
cord-324859-0yuhb5dl	59	11	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	59	12	2019	2019	CD
cord-324859-0yuhb5dl	59	13	,	,	,
cord-324859-0yuhb5dl	59	14	along	along	IN
cord-324859-0yuhb5dl	59	15	with	with	IN
cord-324859-0yuhb5dl	59	16	keywords	keyword	NNS
cord-324859-0yuhb5dl	59	17	such	such	JJ
cord-324859-0yuhb5dl	59	18	as	as	IN
cord-324859-0yuhb5dl	59	19	'	'	``
cord-324859-0yuhb5dl	59	20	interleukins	interleukin	NNS
cord-324859-0yuhb5dl	59	21	'	'	''
cord-324859-0yuhb5dl	59	22	,	,	,
cord-324859-0yuhb5dl	59	23	'	'	``
cord-324859-0yuhb5dl	59	24	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	59	25	'	'	''
cord-324859-0yuhb5dl	59	26	,	,	,
cord-324859-0yuhb5dl	59	27	'	'	''
cord-324859-0yuhb5dl	59	28	inflammation	inflammation	NN
cord-324859-0yuhb5dl	59	29	markers	marker	NNS
cord-324859-0yuhb5dl	59	30	'	'	''
cord-324859-0yuhb5dl	59	31	,	,	,
cord-324859-0yuhb5dl	59	32	'	'	``
cord-324859-0yuhb5dl	59	33	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	59	34	'	'	''
cord-324859-0yuhb5dl	59	35	,	,	,
cord-324859-0yuhb5dl	59	36	'	'	``
cord-324859-0yuhb5dl	59	37	immunomodulatory	immunomodulatory	NNP
cord-324859-0yuhb5dl	59	38	'	'	''
cord-324859-0yuhb5dl	59	39	,	,	,
cord-324859-0yuhb5dl	59	40	'	'	''
cord-324859-0yuhb5dl	59	41	clinical	clinical	JJ
cord-324859-0yuhb5dl	59	42	features	feature	NNS
cord-324859-0yuhb5dl	59	43	'	'	''
cord-324859-0yuhb5dl	59	44	,	,	,
cord-324859-0yuhb5dl	59	45	'	'	``
cord-324859-0yuhb5dl	59	46	patient	patient	JJ
cord-324859-0yuhb5dl	59	47	outcomes	outcome	NNS
cord-324859-0yuhb5dl	59	48	'	'	''
cord-324859-0yuhb5dl	59	49	,	,	,
cord-324859-0yuhb5dl	59	50	combined	combine	VBN
cord-324859-0yuhb5dl	59	51	using	use	VBG
cord-324859-0yuhb5dl	59	52	boolean	boolean	JJ
cord-324859-0yuhb5dl	59	53	operators	operator	NNS
cord-324859-0yuhb5dl	59	54	as	as	IN
cord-324859-0yuhb5dl	59	55	appropriate	appropriate	JJ
cord-324859-0yuhb5dl	59	56	.	.	.
cord-324859-0yuhb5dl	60	1	The	the	DT
cord-324859-0yuhb5dl	60	2	strategies	strategy	NNS
cord-324859-0yuhb5dl	60	3	were	be	VBD
cord-324859-0yuhb5dl	60	4	prepared	prepare	VBN
cord-324859-0yuhb5dl	60	5	by	by	IN
cord-324859-0yuhb5dl	60	6	one	one	CD
cord-324859-0yuhb5dl	60	7	investigator	investigator	NN
cord-324859-0yuhb5dl	60	8	(	(	-LRB-
cord-324859-0yuhb5dl	60	9	RM	RM	NNP
cord-324859-0yuhb5dl	60	10	)	)	-RRB-
cord-324859-0yuhb5dl	60	11	and	and	CC
cord-324859-0yuhb5dl	60	12	reviewed	review	VBN
cord-324859-0yuhb5dl	60	13	by	by	IN
cord-324859-0yuhb5dl	60	14	the	the	DT
cord-324859-0yuhb5dl	60	15	other	other	JJ
cord-324859-0yuhb5dl	60	16	two	two	CD
cord-324859-0yuhb5dl	60	17	investigators	investigator	NNS
cord-324859-0yuhb5dl	60	18	(	(	-LRB-
cord-324859-0yuhb5dl	60	19	AK	AK	NNP
cord-324859-0yuhb5dl	60	20	and	and	CC
cord-324859-0yuhb5dl	60	21	TL	TL	NNP
cord-324859-0yuhb5dl	60	22	)	)	-RRB-
cord-324859-0yuhb5dl	60	23	to	to	TO
cord-324859-0yuhb5dl	60	24	ensure	ensure	VB
cord-324859-0yuhb5dl	60	25	comprehensiveness	comprehensiveness	NN
cord-324859-0yuhb5dl	60	26	.	.	.
cord-324859-0yuhb5dl	61	1	The	the	DT
cord-324859-0yuhb5dl	61	2	complete	complete	JJ
cord-324859-0yuhb5dl	61	3	search	search	NN
cord-324859-0yuhb5dl	61	4	strategy	strategy	NN
cord-324859-0yuhb5dl	61	5	prepared	prepare	VBN
cord-324859-0yuhb5dl	61	6	for	for	IN
cord-324859-0yuhb5dl	61	7	PubMed	PubMed	NNP
cord-324859-0yuhb5dl	61	8	is	be	VBZ
cord-324859-0yuhb5dl	61	9	given	give	VBN
cord-324859-0yuhb5dl	61	10	in	in	IN
cord-324859-0yuhb5dl	61	11	the	the	DT
cord-324859-0yuhb5dl	61	12	File	File	NNP
cord-324859-0yuhb5dl	61	13	S1	S1	NNP
cord-324859-0yuhb5dl	61	14	.	.	.
cord-324859-0yuhb5dl	62	1	It	-PRON-	PRP
cord-324859-0yuhb5dl	62	2	was	be	VBD
cord-324859-0yuhb5dl	62	3	modified	modify	VBN
cord-324859-0yuhb5dl	62	4	for	for	IN
cord-324859-0yuhb5dl	62	5	use	use	NN
cord-324859-0yuhb5dl	62	6	according	accord	VBG
cord-324859-0yuhb5dl	62	7	to	to	IN
cord-324859-0yuhb5dl	62	8	the	the	DT
cord-324859-0yuhb5dl	62	9	indexing	indexing	NN
cord-324859-0yuhb5dl	62	10	style	style	NN
cord-324859-0yuhb5dl	62	11	of	of	IN
cord-324859-0yuhb5dl	62	12	the	the	DT
cord-324859-0yuhb5dl	62	13	other	other	JJ
cord-324859-0yuhb5dl	62	14	databases	database	NNS
cord-324859-0yuhb5dl	62	15	.	.	.
cord-324859-0yuhb5dl	63	1	The	the	DT
cord-324859-0yuhb5dl	63	2	reference	reference	NN
cord-324859-0yuhb5dl	63	3	list	list	NN
cord-324859-0yuhb5dl	63	4	of	of	IN
cord-324859-0yuhb5dl	63	5	the	the	DT
cord-324859-0yuhb5dl	63	6	relevant	relevant	JJ
cord-324859-0yuhb5dl	63	7	papers	paper	NNS
cord-324859-0yuhb5dl	63	8	was	be	VBD
cord-324859-0yuhb5dl	63	9	also	also	RB
cord-324859-0yuhb5dl	63	10	hand	hand	NN
cord-324859-0yuhb5dl	63	11	-	-	HYPH
cord-324859-0yuhb5dl	63	12	searched	search	VBN
cord-324859-0yuhb5dl	63	13	to	to	TO
cord-324859-0yuhb5dl	63	14	obtain	obtain	VB
cord-324859-0yuhb5dl	63	15	any	any	DT
cord-324859-0yuhb5dl	63	16	additional	additional	JJ
cord-324859-0yuhb5dl	63	17	articles	article	NNS
cord-324859-0yuhb5dl	63	18	.	.	.
cord-324859-0yuhb5dl	64	1	Articles	article	NNS
cord-324859-0yuhb5dl	64	2	eligible	eligible	JJ
cord-324859-0yuhb5dl	64	3	for	for	IN
cord-324859-0yuhb5dl	64	4	inclusion	inclusion	NN
cord-324859-0yuhb5dl	64	5	in	in	IN
cord-324859-0yuhb5dl	64	6	our	-PRON-	PRP$
cord-324859-0yuhb5dl	64	7	review	review	NN
cord-324859-0yuhb5dl	64	8	were	be	VBD
cord-324859-0yuhb5dl	64	9	observational	observational	JJ
cord-324859-0yuhb5dl	64	10	studies	study	NNS
cord-324859-0yuhb5dl	64	11	(	(	-LRB-
cord-324859-0yuhb5dl	64	12	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	64	13	cohorts	cohort	NNS
cord-324859-0yuhb5dl	64	14	,	,	,
cord-324859-0yuhb5dl	64	15	prospective	prospective	JJ
cord-324859-0yuhb5dl	64	16	cohorts	cohort	NNS
cord-324859-0yuhb5dl	64	17	,	,	,
cord-324859-0yuhb5dl	64	18	case	case	NN
cord-324859-0yuhb5dl	64	19	-	-	HYPH
cord-324859-0yuhb5dl	64	20	control	control	NN
cord-324859-0yuhb5dl	64	21	studies	study	NNS
cord-324859-0yuhb5dl	64	22	,	,	,
cord-324859-0yuhb5dl	64	23	and	and	CC
cord-324859-0yuhb5dl	64	24	case	case	NN
cord-324859-0yuhb5dl	64	25	series	series	NN
cord-324859-0yuhb5dl	64	26	)	)	-RRB-
cord-324859-0yuhb5dl	64	27	or	or	CC
cord-324859-0yuhb5dl	64	28	randomized	randomize	VBN
cord-324859-0yuhb5dl	64	29	controlled	control	VBN
cord-324859-0yuhb5dl	64	30	trials	trial	NNS
cord-324859-0yuhb5dl	64	31	,	,	,
cord-324859-0yuhb5dl	64	32	characterizing	characterize	VBG
cord-324859-0yuhb5dl	64	33	and	and	CC
cord-324859-0yuhb5dl	64	34	comparing	compare	VBG
cord-324859-0yuhb5dl	64	35	severe	severe	JJ
cord-324859-0yuhb5dl	64	36	and	and	CC
cord-324859-0yuhb5dl	64	37	nonsevere	nonsevere	JJ
cord-324859-0yuhb5dl	64	38	groups	group	NNS
cord-324859-0yuhb5dl	64	39	of	of	IN
cord-324859-0yuhb5dl	64	40	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	64	41	patients	patient	NNS
cord-324859-0yuhb5dl	64	42	.	.	.
cord-324859-0yuhb5dl	65	1	Studies	study	NNS
cord-324859-0yuhb5dl	65	2	measuring	measure	VBG
cord-324859-0yuhb5dl	65	3	the	the	DT
cord-324859-0yuhb5dl	65	4	immunological	immunological	JJ
cord-324859-0yuhb5dl	65	5	and	and	CC
cord-324859-0yuhb5dl	65	6	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	65	7	indicators	indicator	NNS
cord-324859-0yuhb5dl	65	8	of	of	IN
cord-324859-0yuhb5dl	65	9	cytokine	cytokine	NN
cord-324859-0yuhb5dl	65	10	storm	storm	NN
cord-324859-0yuhb5dl	65	11	in	in	IN
cord-324859-0yuhb5dl	65	12	adult	adult	NN
cord-324859-0yuhb5dl	65	13	patients	patient	NNS
cord-324859-0yuhb5dl	65	14	with	with	IN
cord-324859-0yuhb5dl	65	15	a	a	DT
cord-324859-0yuhb5dl	65	16	confirmed	confirm	VBN
cord-324859-0yuhb5dl	65	17	diagnosis	diagnosis	NN
cord-324859-0yuhb5dl	65	18	of	of	IN
cord-324859-0yuhb5dl	65	19	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	65	20	,	,	,
cord-324859-0yuhb5dl	65	21	and	and	CC
cord-324859-0yuhb5dl	65	22	comparing	compare	VBG
cord-324859-0yuhb5dl	65	23	them	-PRON-	PRP
cord-324859-0yuhb5dl	65	24	between	between	IN
cord-324859-0yuhb5dl	65	25	severe	severe	JJ
cord-324859-0yuhb5dl	65	26	and	and	CC
cord-324859-0yuhb5dl	65	27	non	non	JJ
cord-324859-0yuhb5dl	65	28	-	-	JJ
cord-324859-0yuhb5dl	65	29	severe	severe	JJ
cord-324859-0yuhb5dl	65	30	(	(	-LRB-
cord-324859-0yuhb5dl	65	31	mild	mild	JJ
cord-324859-0yuhb5dl	65	32	-	-	HYPH
cord-324859-0yuhb5dl	65	33	moderate	moderate	JJ
cord-324859-0yuhb5dl	65	34	)	)	-RRB-
cord-324859-0yuhb5dl	65	35	cases	case	NNS
cord-324859-0yuhb5dl	65	36	,	,	,
cord-324859-0yuhb5dl	65	37	were	be	VBD
cord-324859-0yuhb5dl	65	38	eligible	eligible	JJ
cord-324859-0yuhb5dl	65	39	to	to	TO
cord-324859-0yuhb5dl	65	40	be	be	VB
cord-324859-0yuhb5dl	65	41	included	include	VBN
cord-324859-0yuhb5dl	65	42	in	in	IN
cord-324859-0yuhb5dl	65	43	our	-PRON-	PRP$
cord-324859-0yuhb5dl	65	44	review	review	NN
cord-324859-0yuhb5dl	65	45	.	.	.
cord-324859-0yuhb5dl	66	1	Disease	disease	NN
cord-324859-0yuhb5dl	66	2	assessment	assessment	NN
cord-324859-0yuhb5dl	66	3	and	and	CC
cord-324859-0yuhb5dl	66	4	clinical	clinical	JJ
cord-324859-0yuhb5dl	66	5	classification	classification	NN
cord-324859-0yuhb5dl	66	6	in	in	IN
cord-324859-0yuhb5dl	66	7	each	each	DT
cord-324859-0yuhb5dl	66	8	study	study	NN
cord-324859-0yuhb5dl	66	9	were	be	VBD
cord-324859-0yuhb5dl	66	10	based	base	VBN
cord-324859-0yuhb5dl	66	11	on	on	IN
cord-324859-0yuhb5dl	66	12	evaluation	evaluation	NN
cord-324859-0yuhb5dl	66	13	of	of	IN
cord-324859-0yuhb5dl	66	14	symptoms	symptom	NNS
cord-324859-0yuhb5dl	66	15	by	by	IN
cord-324859-0yuhb5dl	66	16	the	the	DT
cord-324859-0yuhb5dl	66	17	study	study	NN
cord-324859-0yuhb5dl	66	18	investigators	investigator	NNS
cord-324859-0yuhb5dl	66	19	as	as	IN
cord-324859-0yuhb5dl	66	20	per	per	IN
cord-324859-0yuhb5dl	66	21	the	the	DT
cord-324859-0yuhb5dl	66	22	standard	standard	JJ
cord-324859-0yuhb5dl	66	23	protocols	protocol	NNS
cord-324859-0yuhb5dl	66	24	for	for	IN
cord-324859-0yuhb5dl	66	25	the	the	DT
cord-324859-0yuhb5dl	66	26	diagnosis	diagnosis	NN
cord-324859-0yuhb5dl	66	27	and	and	CC
cord-324859-0yuhb5dl	66	28	clinical	clinical	JJ
cord-324859-0yuhb5dl	66	29	management	management	NN
cord-324859-0yuhb5dl	66	30	of	of	IN
cord-324859-0yuhb5dl	66	31	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	66	32	.	.	.
cord-324859-0yuhb5dl	66	33	18	18	CD
cord-324859-0yuhb5dl	66	34	,	,	,
cord-324859-0yuhb5dl	66	35	19	19	CD
cord-324859-0yuhb5dl	66	36	Severe	severe	JJ
cord-324859-0yuhb5dl	66	37	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	66	38	according	accord	VBG
cord-324859-0yuhb5dl	66	39	to	to	IN
cord-324859-0yuhb5dl	66	40	both	both	CC
cord-324859-0yuhb5dl	66	41	the	the	DT
cord-324859-0yuhb5dl	66	42	protocols	protocol	NNS
cord-324859-0yuhb5dl	66	43	was	be	VBD
cord-324859-0yuhb5dl	66	44	defined	define	VBN
cord-324859-0yuhb5dl	66	45	as	as	IN
cord-324859-0yuhb5dl	66	46	having	have	VBG
cord-324859-0yuhb5dl	66	47	one	one	CD
cord-324859-0yuhb5dl	66	48	of	of	IN
cord-324859-0yuhb5dl	66	49	the	the	DT
cord-324859-0yuhb5dl	66	50	following	follow	VBG
cord-324859-0yuhb5dl	66	51	:	:	:
cord-324859-0yuhb5dl	66	52	a	a	DT
cord-324859-0yuhb5dl	66	53	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	66	54	frequency	frequency	NN
cord-324859-0yuhb5dl	66	55	≥30	≥30	NNS
cord-324859-0yuhb5dl	66	56	/	/	SYM
cord-324859-0yuhb5dl	66	57	min	min	NN
cord-324859-0yuhb5dl	66	58	;	;	:
cord-324859-0yuhb5dl	66	59	oxygen	oxygen	NN
cord-324859-0yuhb5dl	66	60	saturation	saturation	NN
cord-324859-0yuhb5dl	66	61	≤	≤	NN
cord-324859-0yuhb5dl	66	62	93	93	CD
cord-324859-0yuhb5dl	66	63	%	%	NN
cord-324859-0yuhb5dl	66	64	;	;	,
cord-324859-0yuhb5dl	66	65	and	and	CC
cord-324859-0yuhb5dl	66	66	oxygenation	oxygenation	NN
cord-324859-0yuhb5dl	66	67	index	index	NN
cord-324859-0yuhb5dl	66	68	(	(	-LRB-
cord-324859-0yuhb5dl	66	69	PaO2	PaO2	NNS
cord-324859-0yuhb5dl	66	70	/	/	SYM
cord-324859-0yuhb5dl	66	71	FiO2	FiO2	NNS
cord-324859-0yuhb5dl	66	72	)	)	-RRB-
cord-324859-0yuhb5dl	67	1	≤300	≤300	NNP
cord-324859-0yuhb5dl	67	2	mm	mm	NNP
cord-324859-0yuhb5dl	67	3	Hg	Hg	NNP
cord-324859-0yuhb5dl	67	4	.	.	.
cord-324859-0yuhb5dl	68	1	The	the	DT
cord-324859-0yuhb5dl	68	2	disease	disease	NN
cord-324859-0yuhb5dl	68	3	severity	severity	NN
cord-324859-0yuhb5dl	68	4	groups	group	NNS
cord-324859-0yuhb5dl	68	5	created	create	VBN
cord-324859-0yuhb5dl	68	6	in	in	IN
cord-324859-0yuhb5dl	68	7	every	every	DT
cord-324859-0yuhb5dl	68	8	individual	individual	JJ
cord-324859-0yuhb5dl	68	9	study	study	NN
cord-324859-0yuhb5dl	68	10	were	be	VBD
cord-324859-0yuhb5dl	68	11	used	use	VBN
cord-324859-0yuhb5dl	68	12	as	as	IN
cord-324859-0yuhb5dl	68	13	is	be	VBZ
cord-324859-0yuhb5dl	68	14	,	,	,
cord-324859-0yuhb5dl	68	15	for	for	IN
cord-324859-0yuhb5dl	68	16	our	-PRON-	PRP$
cord-324859-0yuhb5dl	68	17	review	review	NN
cord-324859-0yuhb5dl	68	18	.	.	.
cord-324859-0yuhb5dl	69	1	Additionally	additionally	RB
cord-324859-0yuhb5dl	69	2	,	,	,
cord-324859-0yuhb5dl	69	3	for	for	IN
cord-324859-0yuhb5dl	69	4	studies	study	NNS
cord-324859-0yuhb5dl	69	5	comparing	compare	VBG
cord-324859-0yuhb5dl	69	6	outcomes	outcome	NNS
cord-324859-0yuhb5dl	69	7	of	of	IN
cord-324859-0yuhb5dl	69	8	patients	patient	NNS
cord-324859-0yuhb5dl	69	9	who	who	WP
cord-324859-0yuhb5dl	69	10	had	have	VBD
cord-324859-0yuhb5dl	69	11	died	die	VBN
cord-324859-0yuhb5dl	69	12	and	and	CC
cord-324859-0yuhb5dl	69	13	those	those	DT
cord-324859-0yuhb5dl	69	14	who	who	WP
cord-324859-0yuhb5dl	69	15	were	be	VBD
cord-324859-0yuhb5dl	69	16	alive	alive	JJ
cord-324859-0yuhb5dl	69	17	,	,	,
cord-324859-0yuhb5dl	69	18	we	-PRON-	PRP
cord-324859-0yuhb5dl	69	19	considered	consider	VBD
cord-324859-0yuhb5dl	69	20	dead	dead	JJ
cord-324859-0yuhb5dl	69	21	as	as	IN
cord-324859-0yuhb5dl	69	22	severe	severe	JJ
cord-324859-0yuhb5dl	69	23	and	and	CC
cord-324859-0yuhb5dl	69	24	alive	alive	JJ
cord-324859-0yuhb5dl	69	25	as	as	IN
cord-324859-0yuhb5dl	69	26	the	the	DT
cord-324859-0yuhb5dl	69	27	non	non	JJ
cord-324859-0yuhb5dl	69	28	-	-	JJ
cord-324859-0yuhb5dl	69	29	severe	severe	JJ
cord-324859-0yuhb5dl	69	30	category	category	NN
cord-324859-0yuhb5dl	69	31	.	.	.
cord-324859-0yuhb5dl	70	1	Outcomes	outcome	NNS
cord-324859-0yuhb5dl	70	2	included	include	VBD
cord-324859-0yuhb5dl	70	3	circulating	circulate	VBG
cord-324859-0yuhb5dl	70	4	levels	level	NNS
cord-324859-0yuhb5dl	70	5	of	of	IN
cord-324859-0yuhb5dl	70	6	interleukins	interleukin	NNS
cord-324859-0yuhb5dl	70	7	(	(	-LRB-
cord-324859-0yuhb5dl	70	8	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	70	9	,	,	,
cord-324859-0yuhb5dl	70	10	IL-8	IL-8	NNP
cord-324859-0yuhb5dl	70	11	,	,	,
cord-324859-0yuhb5dl	70	12	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	70	13	and	and	CC
cord-324859-0yuhb5dl	70	14	others	other	NNS
cord-324859-0yuhb5dl	70	15	depending	depend	VBG
cord-324859-0yuhb5dl	70	16	on	on	IN
cord-324859-0yuhb5dl	70	17	availability	availability	NN
cord-324859-0yuhb5dl	70	18	of	of	IN
cord-324859-0yuhb5dl	70	19	estimates	estimate	NNS
cord-324859-0yuhb5dl	70	20	)	)	-RRB-
cord-324859-0yuhb5dl	70	21	,	,	,
cord-324859-0yuhb5dl	70	22	tumour	tumour	NN
cord-324859-0yuhb5dl	70	23	necrosis	necrosis	NN
cord-324859-0yuhb5dl	70	24	factor	factor	NN
cord-324859-0yuhb5dl	70	25	-	-	HYPH
cord-324859-0yuhb5dl	70	26	alpha	alpha	NN
cord-324859-0yuhb5dl	70	27	and	and	CC
cord-324859-0yuhb5dl	70	28	T	t	NN
cord-324859-0yuhb5dl	70	29	-	-	HYPH
cord-324859-0yuhb5dl	70	30	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	70	31	counts	count	NNS
cord-324859-0yuhb5dl	70	32	(	(	-LRB-
cord-324859-0yuhb5dl	70	33	CD4	CD4	NNP
cord-324859-0yuhb5dl	70	34	+	+	CC
cord-324859-0yuhb5dl	70	35	T	T	NNP
cord-324859-0yuhb5dl	70	36	cells	cell	NNS
cord-324859-0yuhb5dl	70	37	and	and	CC
cord-324859-0yuhb5dl	70	38	CD8	CD8	NNP
cord-324859-0yuhb5dl	70	39	+	+	CC
cord-324859-0yuhb5dl	70	40	T	T	NNP
cord-324859-0yuhb5dl	70	41	cells	cell	NNS
cord-324859-0yuhb5dl	70	42	)	)	-RRB-
cord-324859-0yuhb5dl	70	43	that	that	WDT
cord-324859-0yuhb5dl	70	44	have	have	VBP
cord-324859-0yuhb5dl	70	45	been	be	VBN
cord-324859-0yuhb5dl	70	46	widely	widely	RB
cord-324859-0yuhb5dl	70	47	reported	report	VBN
cord-324859-0yuhb5dl	70	48	in	in	IN
cord-324859-0yuhb5dl	70	49	relation	relation	NN
cord-324859-0yuhb5dl	70	50	to	to	IN
cord-324859-0yuhb5dl	70	51	the	the	DT
cord-324859-0yuhb5dl	70	52	cytokine	cytokine	NN
cord-324859-0yuhb5dl	70	53	storm	storm	NN
cord-324859-0yuhb5dl	70	54	in	in	IN
cord-324859-0yuhb5dl	70	55	patients	patient	NNS
cord-324859-0yuhb5dl	70	56	having	have	VBG
cord-324859-0yuhb5dl	70	57	severe	severe	JJ
cord-324859-0yuhb5dl	70	58	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	70	59	.	.	.
cord-324859-0yuhb5dl	71	1	Studies	study	NNS
cord-324859-0yuhb5dl	71	2	published	publish	VBN
cord-324859-0yuhb5dl	71	3	in	in	IN
cord-324859-0yuhb5dl	71	4	non	non	JJ
cord-324859-0yuhb5dl	71	5	-	-	JJ
cord-324859-0yuhb5dl	71	6	English	english	JJ
cord-324859-0yuhb5dl	71	7	languages	language	NNS
cord-324859-0yuhb5dl	71	8	,	,	,
cord-324859-0yuhb5dl	71	9	those	those	DT
cord-324859-0yuhb5dl	71	10	without	without	IN
cord-324859-0yuhb5dl	71	11	a	a	DT
cord-324859-0yuhb5dl	71	12	comparator	comparator	NN
cord-324859-0yuhb5dl	71	13	group	group	NN
cord-324859-0yuhb5dl	71	14	,	,	,
cord-324859-0yuhb5dl	71	15	clinical	clinical	JJ
cord-324859-0yuhb5dl	71	16	trials	trial	NNS
cord-324859-0yuhb5dl	71	17	with	with	IN
cord-324859-0yuhb5dl	71	18	a	a	DT
cord-324859-0yuhb5dl	71	19	pre	pre	JJ
cord-324859-0yuhb5dl	71	20	-	-	JJ
cord-324859-0yuhb5dl	71	21	post	post	JJ
cord-324859-0yuhb5dl	71	22	design	design	NN
cord-324859-0yuhb5dl	71	23	,	,	,
cord-324859-0yuhb5dl	71	24	case	case	NN
cord-324859-0yuhb5dl	71	25	reports	report	NNS
cord-324859-0yuhb5dl	71	26	and	and	CC
cord-324859-0yuhb5dl	71	27	systematic	systematic	JJ
cord-324859-0yuhb5dl	71	28	and	and	CC
cord-324859-0yuhb5dl	71	29	narrative	narrative	NN
cord-324859-0yuhb5dl	71	30	reviews	review	NNS
cord-324859-0yuhb5dl	71	31	were	be	VBD
cord-324859-0yuhb5dl	71	32	not	not	RB
cord-324859-0yuhb5dl	71	33	eligible	eligible	JJ
cord-324859-0yuhb5dl	71	34	for	for	IN
cord-324859-0yuhb5dl	71	35	inclusion	inclusion	NN
cord-324859-0yuhb5dl	71	36	.	.	.
cord-324859-0yuhb5dl	72	1	Small	small	JJ
cord-324859-0yuhb5dl	72	2	case	case	NN
cord-324859-0yuhb5dl	72	3	series	series	NN
cord-324859-0yuhb5dl	72	4	and	and	CC
cord-324859-0yuhb5dl	72	5	case	case	NN
cord-324859-0yuhb5dl	72	6	reports	report	NNS
cord-324859-0yuhb5dl	72	7	involving	involve	VBG
cord-324859-0yuhb5dl	72	8	less	less	JJR
cord-324859-0yuhb5dl	72	9	than	than	IN
cord-324859-0yuhb5dl	72	10	10	10	CD
cord-324859-0yuhb5dl	72	11	patients	patient	NNS
cord-324859-0yuhb5dl	72	12	were	be	VBD
cord-324859-0yuhb5dl	72	13	excluded	exclude	VBN
cord-324859-0yuhb5dl	72	14	to	to	TO
cord-324859-0yuhb5dl	72	15	minimize	minimize	VB
cord-324859-0yuhb5dl	72	16	bias	bias	NN
cord-324859-0yuhb5dl	72	17	.	.	.
cord-324859-0yuhb5dl	73	1	Eligible	eligible	JJ
cord-324859-0yuhb5dl	73	2	studies	study	NNS
cord-324859-0yuhb5dl	73	3	were	be	VBD
cord-324859-0yuhb5dl	73	4	imported	import	VBN
cord-324859-0yuhb5dl	73	5	into	into	IN
cord-324859-0yuhb5dl	73	6	a	a	DT
cord-324859-0yuhb5dl	73	7	reference	reference	NN
cord-324859-0yuhb5dl	73	8	manager	manager	NN
cord-324859-0yuhb5dl	73	9	(	(	-LRB-
cord-324859-0yuhb5dl	73	10	Zotero	Zotero	NNP
cord-324859-0yuhb5dl	73	11	version	version	NN
cord-324859-0yuhb5dl	73	12	5.0	5.0	CD
cord-324859-0yuhb5dl	73	13	)	)	-RRB-
cord-324859-0yuhb5dl	73	14	for	for	IN
cord-324859-0yuhb5dl	73	15	sorting	sorting	NN
cord-324859-0yuhb5dl	73	16	and	and	CC
cord-324859-0yuhb5dl	73	17	removal	removal	NN
cord-324859-0yuhb5dl	73	18	of	of	IN
cord-324859-0yuhb5dl	73	19	duplicates	duplicate	NNS
cord-324859-0yuhb5dl	73	20	.	.	.
cord-324859-0yuhb5dl	74	1	At	at	IN
cord-324859-0yuhb5dl	74	2	level	level	NN
cord-324859-0yuhb5dl	74	3	1	1	CD
cord-324859-0yuhb5dl	74	4	,	,	,
cord-324859-0yuhb5dl	74	5	titles	title	NNS
cord-324859-0yuhb5dl	74	6	and	and	CC
cord-324859-0yuhb5dl	74	7	abstracts	abstract	NNS
cord-324859-0yuhb5dl	74	8	of	of	IN
cord-324859-0yuhb5dl	74	9	all	all	PDT
cord-324859-0yuhb5dl	74	10	the	the	DT
cord-324859-0yuhb5dl	74	11	retrieved	retrieve	VBN
cord-324859-0yuhb5dl	74	12	articles	article	NNS
cord-324859-0yuhb5dl	74	13	were	be	VBD
cord-324859-0yuhb5dl	74	14	individually	individually	RB
cord-324859-0yuhb5dl	74	15	screened	screen	VBN
cord-324859-0yuhb5dl	74	16	by	by	IN
cord-324859-0yuhb5dl	74	17	two	two	CD
cord-324859-0yuhb5dl	74	18	reviewers	reviewer	NNS
cord-324859-0yuhb5dl	74	19	(	(	-LRB-
cord-324859-0yuhb5dl	74	20	RM	RM	NNP
cord-324859-0yuhb5dl	74	21	and	and	CC
cord-324859-0yuhb5dl	74	22	AK	AK	NNP
cord-324859-0yuhb5dl	74	23	;	;	:
cord-324859-0yuhb5dl	74	24	RM	RM	NNP
cord-324859-0yuhb5dl	74	25	and	and	CC
cord-324859-0yuhb5dl	74	26	TL	TL	NNP
cord-324859-0yuhb5dl	74	27	)	)	-RRB-
cord-324859-0yuhb5dl	74	28	.	.	.
cord-324859-0yuhb5dl	75	1	Full	full	JJ
cord-324859-0yuhb5dl	75	2	texts	text	NNS
cord-324859-0yuhb5dl	75	3	of	of	IN
cord-324859-0yuhb5dl	75	4	studies	study	NNS
cord-324859-0yuhb5dl	75	5	eligible	eligible	JJ
cord-324859-0yuhb5dl	75	6	for	for	IN
cord-324859-0yuhb5dl	75	7	inclusion	inclusion	NN
cord-324859-0yuhb5dl	75	8	were	be	VBD
cord-324859-0yuhb5dl	75	9	examined	examine	VBN
cord-324859-0yuhb5dl	75	10	by	by	IN
cord-324859-0yuhb5dl	75	11	two	two	CD
cord-324859-0yuhb5dl	75	12	reviewers	reviewer	NNS
cord-324859-0yuhb5dl	75	13	at	at	IN
cord-324859-0yuhb5dl	75	14	level	level	NN
cord-324859-0yuhb5dl	75	15	2	2	CD
cord-324859-0yuhb5dl	75	16	,	,	,
cord-324859-0yuhb5dl	75	17	and	and	CC
cord-324859-0yuhb5dl	75	18	discrepancies	discrepancy	NNS
cord-324859-0yuhb5dl	75	19	were	be	VBD
cord-324859-0yuhb5dl	75	20	resolved	resolve	VBN
cord-324859-0yuhb5dl	75	21	through	through	IN
cord-324859-0yuhb5dl	75	22	mutual	mutual	JJ
cord-324859-0yuhb5dl	75	23	consensus	consensus	NN
cord-324859-0yuhb5dl	75	24	among	among	IN
cord-324859-0yuhb5dl	75	25	the	the	DT
cord-324859-0yuhb5dl	75	26	team	team	NN
cord-324859-0yuhb5dl	75	27	members	member	NNS
cord-324859-0yuhb5dl	75	28	.	.	.
cord-324859-0yuhb5dl	76	1	In	in	IN
cord-324859-0yuhb5dl	76	2	case	case	NN
cord-324859-0yuhb5dl	76	3	of	of	IN
cord-324859-0yuhb5dl	76	4	a	a	DT
cord-324859-0yuhb5dl	76	5	suspected	suspect	VBN
cord-324859-0yuhb5dl	76	6	patient	patient	NN
cord-324859-0yuhb5dl	76	7	overlap	overlap	NN
cord-324859-0yuhb5dl	76	8	across	across	IN
cord-324859-0yuhb5dl	76	9	studies	study	NNS
cord-324859-0yuhb5dl	76	10	,	,	,
cord-324859-0yuhb5dl	76	11	the	the	DT
cord-324859-0yuhb5dl	76	12	respective	respective	JJ
cord-324859-0yuhb5dl	76	13	authors	author	NNS
cord-324859-0yuhb5dl	76	14	were	be	VBD
cord-324859-0yuhb5dl	76	15	contacted	contact	VBN
cord-324859-0yuhb5dl	76	16	and	and	CC
cord-324859-0yuhb5dl	76	17	requested	request	VBN
cord-324859-0yuhb5dl	76	18	for	for	IN
cord-324859-0yuhb5dl	76	19	clarification	clarification	NN
cord-324859-0yuhb5dl	76	20	.	.	.
cord-324859-0yuhb5dl	77	1	Two	two	CD
cord-324859-0yuhb5dl	77	2	further	further	JJ
cord-324859-0yuhb5dl	77	3	reminders	reminder	NNS
cord-324859-0yuhb5dl	77	4	were	be	VBD
cord-324859-0yuhb5dl	77	5	sent	send	VBN
cord-324859-0yuhb5dl	77	6	in	in	IN
cord-324859-0yuhb5dl	77	7	case	case	NN
cord-324859-0yuhb5dl	77	8	no	no	DT
cord-324859-0yuhb5dl	77	9	reply	reply	NN
cord-324859-0yuhb5dl	77	10	was	be	VBD
cord-324859-0yuhb5dl	77	11	received	receive	VBN
cord-324859-0yuhb5dl	77	12	to	to	IN
cord-324859-0yuhb5dl	77	13	the	the	DT
cord-324859-0yuhb5dl	77	14	initial	initial	JJ
cord-324859-0yuhb5dl	77	15	queries	query	NNS
cord-324859-0yuhb5dl	77	16	.	.	.
cord-324859-0yuhb5dl	78	1	Data	data	NN
cord-324859-0yuhb5dl	78	2	extraction	extraction	NN
cord-324859-0yuhb5dl	78	3	was	be	VBD
cord-324859-0yuhb5dl	78	4	undertaken	undertake	VBN
cord-324859-0yuhb5dl	78	5	independently	independently	RB
cord-324859-0yuhb5dl	78	6	by	by	IN
cord-324859-0yuhb5dl	78	7	RM	RM	NNP
cord-324859-0yuhb5dl	78	8	and	and	CC
cord-324859-0yuhb5dl	78	9	AK	AK	NNP
cord-324859-0yuhb5dl	78	10	,	,	,
cord-324859-0yuhb5dl	78	11	and	and	CC
cord-324859-0yuhb5dl	78	12	a	a	DT
cord-324859-0yuhb5dl	78	13	data	data	NN
cord-324859-0yuhb5dl	78	14	extraction	extraction	NN
cord-324859-0yuhb5dl	78	15	form	form	NN
cord-324859-0yuhb5dl	78	16	was	be	VBD
cord-324859-0yuhb5dl	78	17	prepared	prepare	VBN
cord-324859-0yuhb5dl	78	18	in	in	IN
cord-324859-0yuhb5dl	78	19	Microsoft	Microsoft	NNP
cord-324859-0yuhb5dl	78	20	Excel	Excel	NNP
cord-324859-0yuhb5dl	78	21	based	base	VBN
cord-324859-0yuhb5dl	78	22	on	on	IN
cord-324859-0yuhb5dl	78	23	the	the	DT
cord-324859-0yuhb5dl	78	24	Cochrane	Cochrane	NNP
cord-324859-0yuhb5dl	78	25	Handbook	Handbook	NNP
cord-324859-0yuhb5dl	78	26	of	of	IN
cord-324859-0yuhb5dl	78	27	Recommendations	Recommendations	NNPS
cord-324859-0yuhb5dl	78	28	.	.	.
cord-324859-0yuhb5dl	79	1	Information	information	NN
cord-324859-0yuhb5dl	79	2	on	on	IN
cord-324859-0yuhb5dl	79	3	author	author	NN
cord-324859-0yuhb5dl	79	4	names	name	NNS
cord-324859-0yuhb5dl	79	5	,	,	,
cord-324859-0yuhb5dl	79	6	month	month	NN
cord-324859-0yuhb5dl	79	7	of	of	IN
cord-324859-0yuhb5dl	79	8	publication	publication	NN
cord-324859-0yuhb5dl	79	9	,	,	,
cord-324859-0yuhb5dl	79	10	country	country	NN
cord-324859-0yuhb5dl	79	11	,	,	,
cord-324859-0yuhb5dl	79	12	study	study	NN
cord-324859-0yuhb5dl	79	13	site	site	NN
cord-324859-0yuhb5dl	79	14	,	,	,
cord-324859-0yuhb5dl	79	15	study	study	NN
cord-324859-0yuhb5dl	79	16	design	design	NN
cord-324859-0yuhb5dl	79	17	,	,	,
cord-324859-0yuhb5dl	79	18	enrolment	enrolment	NN
cord-324859-0yuhb5dl	79	19	duration	duration	NN
cord-324859-0yuhb5dl	79	20	,	,	,
cord-324859-0yuhb5dl	79	21	patient	patient	JJ
cord-324859-0yuhb5dl	79	22	demographics	demographic	NNS
cord-324859-0yuhb5dl	79	23	(	(	-LRB-
cord-324859-0yuhb5dl	79	24	age	age	NN
cord-324859-0yuhb5dl	79	25	and	and	CC
cord-324859-0yuhb5dl	79	26	sex	sex	NN
cord-324859-0yuhb5dl	79	27	)	)	-RRB-
cord-324859-0yuhb5dl	79	28	,	,	,
cord-324859-0yuhb5dl	79	29	comorbidities	comorbiditie	NNS
cord-324859-0yuhb5dl	79	30	,	,	,
cord-324859-0yuhb5dl	79	31	sample	sample	NN
cord-324859-0yuhb5dl	79	32	size	size	NN
cord-324859-0yuhb5dl	79	33	,	,	,
cord-324859-0yuhb5dl	79	34	levels	level	NNS
cord-324859-0yuhb5dl	79	35	of	of	IN
cord-324859-0yuhb5dl	79	36	the	the	DT
cord-324859-0yuhb5dl	79	37	requisite	requisite	JJ
cord-324859-0yuhb5dl	79	38	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	79	39	and	and	CC
cord-324859-0yuhb5dl	79	40	immunological	immunological	JJ
cord-324859-0yuhb5dl	79	41	markers	marker	NNS
cord-324859-0yuhb5dl	79	42	and	and	CC
cord-324859-0yuhb5dl	79	43	major	major	JJ
cord-324859-0yuhb5dl	79	44	study	study	NN
cord-324859-0yuhb5dl	79	45	findings	finding	NNS
cord-324859-0yuhb5dl	79	46	were	be	VBD
cord-324859-0yuhb5dl	79	47	recorded	record	VBN
cord-324859-0yuhb5dl	79	48	for	for	IN
cord-324859-0yuhb5dl	79	49	each	each	DT
cord-324859-0yuhb5dl	79	50	study	study	NN
cord-324859-0yuhb5dl	79	51	.	.	.
cord-324859-0yuhb5dl	80	1	All	all	PDT
cord-324859-0yuhb5dl	80	2	the	the	DT
cord-324859-0yuhb5dl	80	3	eligible	eligible	JJ
cord-324859-0yuhb5dl	80	4	studies	study	NNS
cord-324859-0yuhb5dl	80	5	were	be	VBD
cord-324859-0yuhb5dl	80	6	included	include	VBN
cord-324859-0yuhb5dl	80	7	in	in	IN
cord-324859-0yuhb5dl	80	8	the	the	DT
cord-324859-0yuhb5dl	80	9	narrative	narrative	NN
cord-324859-0yuhb5dl	80	10	synthesis	synthesis	NN
cord-324859-0yuhb5dl	80	11	;	;	:
cord-324859-0yuhb5dl	80	12	and	and	CC
cord-324859-0yuhb5dl	80	13	studies	study	NNS
cord-324859-0yuhb5dl	80	14	reporting	report	VBG
cord-324859-0yuhb5dl	80	15	appropriate	appropriate	JJ
cord-324859-0yuhb5dl	80	16	numeric	numeric	JJ
cord-324859-0yuhb5dl	80	17	estimates	estimate	NNS
cord-324859-0yuhb5dl	80	18	of	of	IN
cord-324859-0yuhb5dl	80	19	the	the	DT
cord-324859-0yuhb5dl	80	20	required	require	VBN
cord-324859-0yuhb5dl	80	21	markers	marker	NNS
cord-324859-0yuhb5dl	80	22	were	be	VBD
cord-324859-0yuhb5dl	80	23	included	include	VBN
cord-324859-0yuhb5dl	80	24	in	in	IN
cord-324859-0yuhb5dl	80	25	the	the	DT
cord-324859-0yuhb5dl	80	26	quantitative	quantitative	JJ
cord-324859-0yuhb5dl	80	27	synthesis	synthesis	NN
cord-324859-0yuhb5dl	80	28	.	.	.
cord-324859-0yuhb5dl	81	1	Review	Review	NNP
cord-324859-0yuhb5dl	81	2	Manager	Manager	NNP
cord-324859-0yuhb5dl	81	3	software	software	NN
cord-324859-0yuhb5dl	81	4	(	(	-LRB-
cord-324859-0yuhb5dl	81	5	RevMan	RevMan	NNP
cord-324859-0yuhb5dl	81	6	version	version	NN
cord-324859-0yuhb5dl	81	7	5.3	5.3	CD
cord-324859-0yuhb5dl	81	8	)	)	-RRB-
cord-324859-0yuhb5dl	81	9	was	be	VBD
cord-324859-0yuhb5dl	81	10	used	use	VBN
cord-324859-0yuhb5dl	81	11	for	for	IN
cord-324859-0yuhb5dl	81	12	a	a	DT
cord-324859-0yuhb5dl	81	13	statistical	statistical	JJ
cord-324859-0yuhb5dl	81	14	pooling	pooling	NN
cord-324859-0yuhb5dl	81	15	of	of	IN
cord-324859-0yuhb5dl	81	16	estimates	estimate	NNS
cord-324859-0yuhb5dl	81	17	through	through	IN
cord-324859-0yuhb5dl	81	18	a	a	DT
cord-324859-0yuhb5dl	81	19	meta	meta	JJ
cord-324859-0yuhb5dl	81	20	-	-	HYPH
cord-324859-0yuhb5dl	81	21	analysis	analysis	NN
cord-324859-0yuhb5dl	81	22	.	.	.
cord-324859-0yuhb5dl	82	1	Outcomes	outcome	NNS
cord-324859-0yuhb5dl	82	2	reported	report	VBD
cord-324859-0yuhb5dl	82	3	as	as	IN
cord-324859-0yuhb5dl	82	4	medians	median	NNS
cord-324859-0yuhb5dl	82	5	and	and	CC
cord-324859-0yuhb5dl	82	6	interquartile	interquartile	JJ
cord-324859-0yuhb5dl	82	7	ranges	range	NNS
cord-324859-0yuhb5dl	82	8	(	(	-LRB-
cord-324859-0yuhb5dl	82	9	IQRs	iqr	NNS
cord-324859-0yuhb5dl	82	10	)	)	-RRB-
cord-324859-0yuhb5dl	82	11	were	be	VBD
cord-324859-0yuhb5dl	82	12	converted	convert	VBN
cord-324859-0yuhb5dl	82	13	to	to	IN
cord-324859-0yuhb5dl	82	14	means	mean	NNS
cord-324859-0yuhb5dl	82	15	and	and	CC
cord-324859-0yuhb5dl	82	16	standard	standard	JJ
cord-324859-0yuhb5dl	82	17	deviations	deviation	NNS
cord-324859-0yuhb5dl	82	18	using	use	VBG
cord-324859-0yuhb5dl	82	19	standard	standard	JJ
cord-324859-0yuhb5dl	82	20	methods	method	NNS
cord-324859-0yuhb5dl	82	21	,	,	,
cord-324859-0yuhb5dl	82	22	20	20	CD
cord-324859-0yuhb5dl	82	23	for	for	IN
cord-324859-0yuhb5dl	82	24	statistical	statistical	JJ
cord-324859-0yuhb5dl	82	25	uniformity	uniformity	NN
cord-324859-0yuhb5dl	82	26	across	across	IN
cord-324859-0yuhb5dl	82	27	study	study	NN
cord-324859-0yuhb5dl	82	28	data	datum	NNS
cord-324859-0yuhb5dl	82	29	.	.	.
cord-324859-0yuhb5dl	83	1	The	the	DT
cord-324859-0yuhb5dl	83	2	overall	overall	JJ
cord-324859-0yuhb5dl	83	3	difference	difference	NN
cord-324859-0yuhb5dl	83	4	in	in	IN
cord-324859-0yuhb5dl	83	5	the	the	DT
cord-324859-0yuhb5dl	83	6	average	average	JJ
cord-324859-0yuhb5dl	83	7	value	value	NN
cord-324859-0yuhb5dl	83	8	of	of	IN
cord-324859-0yuhb5dl	83	9	each	each	DT
cord-324859-0yuhb5dl	83	10	outcome	outcome	NN
cord-324859-0yuhb5dl	83	11	between	between	IN
cord-324859-0yuhb5dl	83	12	severe	severe	JJ
cord-324859-0yuhb5dl	83	13	and	and	CC
cord-324859-0yuhb5dl	83	14	non	non	JJ
cord-324859-0yuhb5dl	83	15	-	-	JJ
cord-324859-0yuhb5dl	83	16	severe	severe	JJ
cord-324859-0yuhb5dl	83	17	groups	group	NNS
cord-324859-0yuhb5dl	83	18	was	be	VBD
cord-324859-0yuhb5dl	83	19	reported	report	VBN
cord-324859-0yuhb5dl	83	20	as	as	IN
cord-324859-0yuhb5dl	83	21	mean	mean	JJ
cord-324859-0yuhb5dl	83	22	difference	difference	NN
cord-324859-0yuhb5dl	83	23	(	(	-LRB-
cord-324859-0yuhb5dl	83	24	MD	MD	NNP
cord-324859-0yuhb5dl	83	25	)	)	-RRB-
cord-324859-0yuhb5dl	83	26	along	along	IN
cord-324859-0yuhb5dl	83	27	with	with	IN
cord-324859-0yuhb5dl	83	28	95	95	CD
cord-324859-0yuhb5dl	83	29	%	%	NN
cord-324859-0yuhb5dl	83	30	confidence	confidence	NN
cord-324859-0yuhb5dl	83	31	intervals	interval	NNS
cord-324859-0yuhb5dl	83	32	(	(	-LRB-
cord-324859-0yuhb5dl	83	33	CIs	CIs	NNP
cord-324859-0yuhb5dl	83	34	)	)	-RRB-
cord-324859-0yuhb5dl	83	35	.	.	.
cord-324859-0yuhb5dl	84	1	Confidence	confidence	NN
cord-324859-0yuhb5dl	84	2	intervals	interval	NNS
cord-324859-0yuhb5dl	84	3	excluding	exclude	VBG
cord-324859-0yuhb5dl	84	4	the	the	DT
cord-324859-0yuhb5dl	84	5	null	null	JJ
cord-324859-0yuhb5dl	84	6	value	value	NN
cord-324859-0yuhb5dl	84	7	of	of	IN
cord-324859-0yuhb5dl	84	8	0	0	CD
cord-324859-0yuhb5dl	84	9	were	be	VBD
cord-324859-0yuhb5dl	84	10	considered	consider	VBN
cord-324859-0yuhb5dl	84	11	to	to	TO
cord-324859-0yuhb5dl	84	12	be	be	VB
cord-324859-0yuhb5dl	84	13	significant	significant	JJ
cord-324859-0yuhb5dl	84	14	.	.	.
cord-324859-0yuhb5dl	85	1	The	the	DT
cord-324859-0yuhb5dl	85	2	pooled	pool	VBN
cord-324859-0yuhb5dl	85	3	values	value	NNS
cord-324859-0yuhb5dl	85	4	were	be	VBD
cord-324859-0yuhb5dl	85	5	computed	compute	VBN
cord-324859-0yuhb5dl	85	6	through	through	IN
cord-324859-0yuhb5dl	85	7	random	random	JJ
cord-324859-0yuhb5dl	85	8	-	-	HYPH
cord-324859-0yuhb5dl	85	9	effect	effect	NN
cord-324859-0yuhb5dl	85	10	models	model	NNS
cord-324859-0yuhb5dl	85	11	(	(	-LRB-
cord-324859-0yuhb5dl	85	12	REMs	REMs	NNP
cord-324859-0yuhb5dl	85	13	)	)	-RRB-
cord-324859-0yuhb5dl	85	14	,	,	,
cord-324859-0yuhb5dl	85	15	using	use	VBG
cord-324859-0yuhb5dl	85	16	the	the	DT
cord-324859-0yuhb5dl	85	17	inverse	inverse	JJ
cord-324859-0yuhb5dl	85	18	variance	variance	NN
cord-324859-0yuhb5dl	85	19	method	method	NN
cord-324859-0yuhb5dl	85	20	by	by	IN
cord-324859-0yuhb5dl	85	21	DerSimonian	DerSimonian	NNP
cord-324859-0yuhb5dl	85	22	and	and	CC
cord-324859-0yuhb5dl	85	23	Laird	Laird	NNP
cord-324859-0yuhb5dl	85	24	.	.	.
cord-324859-0yuhb5dl	86	1	21	21	CD
cord-324859-0yuhb5dl	87	1	Forest	forest	NN
cord-324859-0yuhb5dl	87	2	plots	plot	NNS
cord-324859-0yuhb5dl	87	3	were	be	VBD
cord-324859-0yuhb5dl	87	4	generated	generate	VBN
cord-324859-0yuhb5dl	87	5	to	to	TO
cord-324859-0yuhb5dl	87	6	compare	compare	VB
cord-324859-0yuhb5dl	87	7	the	the	DT
cord-324859-0yuhb5dl	87	8	levels	level	NNS
cord-324859-0yuhb5dl	87	9	of	of	IN
cord-324859-0yuhb5dl	87	10	and	and	CC
cord-324859-0yuhb5dl	87	11	quantify	quantify	VB
cord-324859-0yuhb5dl	87	12	the	the	DT
cord-324859-0yuhb5dl	87	13	difference	difference	NN
cord-324859-0yuhb5dl	87	14	in	in	IN
cord-324859-0yuhb5dl	87	15	each	each	DT
cord-324859-0yuhb5dl	87	16	outcome	outcome	NN
cord-324859-0yuhb5dl	87	17	,	,	,
cord-324859-0yuhb5dl	87	18	between	between	IN
cord-324859-0yuhb5dl	87	19	the	the	DT
cord-324859-0yuhb5dl	87	20	two	two	CD
cord-324859-0yuhb5dl	87	21	patient	patient	JJ
cord-324859-0yuhb5dl	87	22	groups	group	NNS
cord-324859-0yuhb5dl	87	23	.	.	.
cord-324859-0yuhb5dl	88	1	Articles	article	NNS
cord-324859-0yuhb5dl	88	2	that	that	WDT
cord-324859-0yuhb5dl	88	3	did	do	VBD
cord-324859-0yuhb5dl	88	4	not	not	RB
cord-324859-0yuhb5dl	88	5	provide	provide	VB
cord-324859-0yuhb5dl	88	6	numeric	numeric	JJ
cord-324859-0yuhb5dl	88	7	estimates	estimate	NNS
cord-324859-0yuhb5dl	88	8	were	be	VBD
cord-324859-0yuhb5dl	88	9	excluded	exclude	VBN
cord-324859-0yuhb5dl	88	10	from	from	IN
cord-324859-0yuhb5dl	88	11	this	this	DT
cord-324859-0yuhb5dl	88	12	meta	meta	NN
cord-324859-0yuhb5dl	88	13	-	-	HYPH
cord-324859-0yuhb5dl	88	14	analysis	analysis	NN
cord-324859-0yuhb5dl	88	15	.	.	.
cord-324859-0yuhb5dl	89	1	The	the	DT
cord-324859-0yuhb5dl	89	2	confidence	confidence	NN
cord-324859-0yuhb5dl	89	3	intervals	interval	NNS
cord-324859-0yuhb5dl	89	4	of	of	IN
cord-324859-0yuhb5dl	89	5	each	each	DT
cord-324859-0yuhb5dl	89	6	study	study	NN
cord-324859-0yuhb5dl	89	7	of	of	IN
cord-324859-0yuhb5dl	89	8	each	each	DT
cord-324859-0yuhb5dl	89	9	outcome	outcome	NN
cord-324859-0yuhb5dl	89	10	were	be	VBD
cord-324859-0yuhb5dl	89	11	visually	visually	RB
cord-324859-0yuhb5dl	89	12	observed	observe	VBN
cord-324859-0yuhb5dl	89	13	for	for	IN
cord-324859-0yuhb5dl	89	14	the	the	DT
cord-324859-0yuhb5dl	89	15	presence	presence	NN
cord-324859-0yuhb5dl	89	16	of	of	IN
cord-324859-0yuhb5dl	89	17	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	89	18	,	,	,
cord-324859-0yuhb5dl	89	19	indicated	indicate	VBN
cord-324859-0yuhb5dl	89	20	by	by	IN
cord-324859-0yuhb5dl	89	21	an	an	DT
cord-324859-0yuhb5dl	89	22	overlap	overlap	NN
cord-324859-0yuhb5dl	89	23	.	.	.
cord-324859-0yuhb5dl	90	1	The	the	DT
cord-324859-0yuhb5dl	90	2	magnitude	magnitude	NN
cord-324859-0yuhb5dl	90	3	of	of	IN
cord-324859-0yuhb5dl	90	4	variation	variation	NN
cord-324859-0yuhb5dl	90	5	beyond	beyond	IN
cord-324859-0yuhb5dl	90	6	chance	chance	NN
cord-324859-0yuhb5dl	90	7	was	be	VBD
cord-324859-0yuhb5dl	90	8	also	also	RB
cord-324859-0yuhb5dl	90	9	objectively	objectively	RB
cord-324859-0yuhb5dl	90	10	assessed	assess	VBN
cord-324859-0yuhb5dl	90	11	using	use	VBG
cord-324859-0yuhb5dl	90	12	the	the	DT
cord-324859-0yuhb5dl	90	13	Cochran	Cochran	NNP
cord-324859-0yuhb5dl	90	14	's	's	POS
cord-324859-0yuhb5dl	90	15	Q	Q	NNP
cord-324859-0yuhb5dl	90	16	test	test	NN
cord-324859-0yuhb5dl	90	17	,	,	,
cord-324859-0yuhb5dl	90	18	22	22	CD
cord-324859-0yuhb5dl	90	19	to	to	TO
cord-324859-0yuhb5dl	90	20	ascertain	ascertain	VB
cord-324859-0yuhb5dl	90	21	the	the	DT
cord-324859-0yuhb5dl	90	22	level	level	NN
cord-324859-0yuhb5dl	90	23	of	of	IN
cord-324859-0yuhb5dl	90	24	overlap	overlap	NN
cord-324859-0yuhb5dl	90	25	among	among	IN
cord-324859-0yuhb5dl	90	26	the	the	DT
cord-324859-0yuhb5dl	90	27	CIs	ci	NNS
cord-324859-0yuhb5dl	90	28	of	of	IN
cord-324859-0yuhb5dl	90	29	different	different	JJ
cord-324859-0yuhb5dl	90	30	studies	study	NNS
cord-324859-0yuhb5dl	90	31	.	.	.
cord-324859-0yuhb5dl	91	1	Variability	variability	NN
cord-324859-0yuhb5dl	91	2	in	in	IN
cord-324859-0yuhb5dl	91	3	estimates	estimate	NNS
cord-324859-0yuhb5dl	91	4	was	be	VBD
cord-324859-0yuhb5dl	91	5	estimated	estimate	VBN
cord-324859-0yuhb5dl	91	6	by	by	IN
cord-324859-0yuhb5dl	91	7	the	the	DT
cord-324859-0yuhb5dl	91	8	Higgins	Higgins	NNP
cord-324859-0yuhb5dl	91	9	I	i	CD
cord-324859-0yuhb5dl	91	10	2	2	CD
cord-324859-0yuhb5dl	91	11	statistic	statistic	NN
cord-324859-0yuhb5dl	91	12	,	,	,
cord-324859-0yuhb5dl	91	13	used	use	VBN
cord-324859-0yuhb5dl	91	14	to	to	TO
cord-324859-0yuhb5dl	91	15	determine	determine	VB
cord-324859-0yuhb5dl	91	16	the	the	DT
cord-324859-0yuhb5dl	91	17	magnitude	magnitude	NN
cord-324859-0yuhb5dl	91	18	of	of	IN
cord-324859-0yuhb5dl	91	19	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	91	20	across	across	IN
cord-324859-0yuhb5dl	91	21	studies	study	NNS
cord-324859-0yuhb5dl	91	22	.	.	.
cord-324859-0yuhb5dl	92	1	A	a	DT
cord-324859-0yuhb5dl	92	2	chi	chi	JJ
cord-324859-0yuhb5dl	92	3	-	-	HYPH
cord-324859-0yuhb5dl	92	4	square	square	JJ
cord-324859-0yuhb5dl	92	5	P	p	NN
cord-324859-0yuhb5dl	92	6	-	-	HYPH
cord-324859-0yuhb5dl	92	7	value	value	NN
cord-324859-0yuhb5dl	92	8	smaller	small	JJR
cord-324859-0yuhb5dl	92	9	than	than	IN
cord-324859-0yuhb5dl	92	10	.05	.05	NNP
cord-324859-0yuhb5dl	92	11	was	be	VBD
cord-324859-0yuhb5dl	92	12	considered	consider	VBN
cord-324859-0yuhb5dl	92	13	statistically	statistically	RB
cord-324859-0yuhb5dl	92	14	significant	significant	JJ
cord-324859-0yuhb5dl	92	15	.	.	.
cord-324859-0yuhb5dl	93	1	The	the	DT
cord-324859-0yuhb5dl	93	2	Cochrane	Cochrane	NNP
cord-324859-0yuhb5dl	93	3	Handbook	Handbook	NNP
cord-324859-0yuhb5dl	93	4	cut	cut	NN
cord-324859-0yuhb5dl	93	5	-	-	HYPH
cord-324859-0yuhb5dl	93	6	offs	off	NNS
cord-324859-0yuhb5dl	93	7	were	be	VBD
cord-324859-0yuhb5dl	93	8	used	use	VBN
cord-324859-0yuhb5dl	93	9	to	to	TO
cord-324859-0yuhb5dl	93	10	ascertain	ascertain	VB
cord-324859-0yuhb5dl	93	11	the	the	DT
cord-324859-0yuhb5dl	93	12	degree	degree	NN
cord-324859-0yuhb5dl	93	13	of	of	IN
cord-324859-0yuhb5dl	93	14	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	93	15	.	.	.
cord-324859-0yuhb5dl	94	1	A	a	DT
cord-324859-0yuhb5dl	94	2	sensitivity	sensitivity	NN
cord-324859-0yuhb5dl	94	3	analysis	analysis	NN
cord-324859-0yuhb5dl	94	4	was	be	VBD
cord-324859-0yuhb5dl	94	5	also	also	RB
cord-324859-0yuhb5dl	94	6	undertaken	undertake	VBN
cord-324859-0yuhb5dl	94	7	to	to	TO
cord-324859-0yuhb5dl	94	8	obtain	obtain	VB
cord-324859-0yuhb5dl	94	9	pooled	pool	VBN
cord-324859-0yuhb5dl	94	10	estimates	estimate	NNS
cord-324859-0yuhb5dl	94	11	where	where	WRB
cord-324859-0yuhb5dl	94	12	preprints	preprint	NNS
cord-324859-0yuhb5dl	94	13	were	be	VBD
cord-324859-0yuhb5dl	94	14	excluded	exclude	VBN
cord-324859-0yuhb5dl	94	15	,	,	,
cord-324859-0yuhb5dl	94	16	and	and	CC
cord-324859-0yuhb5dl	94	17	only	only	RB
cord-324859-0yuhb5dl	94	18	published	publish	VBN
cord-324859-0yuhb5dl	94	19	studies	study	NNS
cord-324859-0yuhb5dl	94	20	were	be	VBD
cord-324859-0yuhb5dl	94	21	considered	consider	VBN
cord-324859-0yuhb5dl	94	22	.	.	.
cord-324859-0yuhb5dl	95	1	The	the	DT
cord-324859-0yuhb5dl	95	2	Newcastle	Newcastle	NNP
cord-324859-0yuhb5dl	95	3	-	-	HYPH
cord-324859-0yuhb5dl	95	4	Ottawa	Ottawa	NNP
cord-324859-0yuhb5dl	95	5	Scale	Scale	NNP
cord-324859-0yuhb5dl	95	6	(	(	-LRB-
cord-324859-0yuhb5dl	95	7	NOS	NOS	NNP
cord-324859-0yuhb5dl	95	8	)	)	-RRB-
cord-324859-0yuhb5dl	95	9	for	for	IN
cord-324859-0yuhb5dl	95	10	cohort	cohort	NN
cord-324859-0yuhb5dl	95	11	studies	study	NNS
cord-324859-0yuhb5dl	95	12	,	,	,
cord-324859-0yuhb5dl	95	13	as	as	IN
cord-324859-0yuhb5dl	95	14	recommended	recommend	VBN
cord-324859-0yuhb5dl	95	15	by	by	IN
cord-324859-0yuhb5dl	95	16	Cochrane	Cochrane	NNP
cord-324859-0yuhb5dl	95	17	,	,	,
cord-324859-0yuhb5dl	95	18	23	23	CD
cord-324859-0yuhb5dl	95	19	and	and	CC
cord-324859-0yuhb5dl	95	20	the	the	DT
cord-324859-0yuhb5dl	95	21	Joanna	Joanna	NNP
cord-324859-0yuhb5dl	95	22	Briggs	Briggs	NNP
cord-324859-0yuhb5dl	95	23	Institute	Institute	NNP
cord-324859-0yuhb5dl	95	24	(	(	-LRB-
cord-324859-0yuhb5dl	95	25	JBI	JBI	NNP
cord-324859-0yuhb5dl	95	26	)	)	-RRB-
cord-324859-0yuhb5dl	95	27	checklist	checklist	NN
cord-324859-0yuhb5dl	95	28	24	24	CD
cord-324859-0yuhb5dl	95	29	were	be	VBD
cord-324859-0yuhb5dl	95	30	used	use	VBN
cord-324859-0yuhb5dl	95	31	to	to	TO
cord-324859-0yuhb5dl	95	32	assess	assess	VB
cord-324859-0yuhb5dl	95	33	the	the	DT
cord-324859-0yuhb5dl	95	34	level	level	NN
cord-324859-0yuhb5dl	95	35	of	of	IN
cord-324859-0yuhb5dl	95	36	bias	bias	NN
cord-324859-0yuhb5dl	95	37	in	in	IN
cord-324859-0yuhb5dl	95	38	the	the	DT
cord-324859-0yuhb5dl	95	39	included	include	VBN
cord-324859-0yuhb5dl	95	40	observational	observational	JJ
cord-324859-0yuhb5dl	95	41	studies	study	NNS
cord-324859-0yuhb5dl	95	42	.	.	.
cord-324859-0yuhb5dl	96	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	96	2	used	use	VBD
cord-324859-0yuhb5dl	96	3	a	a	DT
cord-324859-0yuhb5dl	96	4	modified	modify	VBN
cord-324859-0yuhb5dl	96	5	version	version	NN
cord-324859-0yuhb5dl	96	6	of	of	IN
cord-324859-0yuhb5dl	96	7	the	the	DT
cord-324859-0yuhb5dl	96	8	NOS	NOS	NNP
cord-324859-0yuhb5dl	96	9	for	for	IN
cord-324859-0yuhb5dl	96	10	cohort	cohort	NN
cord-324859-0yuhb5dl	96	11	studies	study	NNS
cord-324859-0yuhb5dl	96	12	and	and	CC
cord-324859-0yuhb5dl	96	13	removed	remove	VBD
cord-324859-0yuhb5dl	96	14	two	two	CD
cord-324859-0yuhb5dl	96	15	questions	question	NNS
cord-324859-0yuhb5dl	96	16	on	on	IN
cord-324859-0yuhb5dl	96	17	comparability	comparability	NN
cord-324859-0yuhb5dl	96	18	of	of	IN
cord-324859-0yuhb5dl	96	19	groups	group	NNS
cord-324859-0yuhb5dl	96	20	and	and	CC
cord-324859-0yuhb5dl	96	21	selection	selection	NN
cord-324859-0yuhb5dl	96	22	of	of	IN
cord-324859-0yuhb5dl	96	23	the	the	DT
cord-324859-0yuhb5dl	96	24	non	non	JJ
cord-324859-0yuhb5dl	96	25	-	-	JJ
cord-324859-0yuhb5dl	96	26	exposed	exposed	JJ
cord-324859-0yuhb5dl	96	27	cohort	cohort	NN
cord-324859-0yuhb5dl	96	28	based	base	VBN
cord-324859-0yuhb5dl	96	29	on	on	IN
cord-324859-0yuhb5dl	96	30	relevance	relevance	NN
cord-324859-0yuhb5dl	96	31	and	and	CC
cord-324859-0yuhb5dl	96	32	to	to	TO
cord-324859-0yuhb5dl	96	33	meet	meet	VB
cord-324859-0yuhb5dl	96	34	our	-PRON-	PRP$
cord-324859-0yuhb5dl	96	35	study	study	NN
cord-324859-0yuhb5dl	96	36	requirements	requirement	NNS
cord-324859-0yuhb5dl	96	37	.	.	.
cord-324859-0yuhb5dl	97	1	Two	two	CD
cord-324859-0yuhb5dl	97	2	reviewers	reviewer	NNS
cord-324859-0yuhb5dl	97	3	(	(	-LRB-
cord-324859-0yuhb5dl	97	4	RM	RM	NNP
cord-324859-0yuhb5dl	97	5	and	and	CC
cord-324859-0yuhb5dl	97	6	AK	AK	NNP
cord-324859-0yuhb5dl	97	7	)	)	-RRB-
cord-324859-0yuhb5dl	97	8	independently	independently	RB
cord-324859-0yuhb5dl	97	9	graded	grade	VBD
cord-324859-0yuhb5dl	97	10	each	each	DT
cord-324859-0yuhb5dl	97	11	study	study	NN
cord-324859-0yuhb5dl	97	12	,	,	,
cord-324859-0yuhb5dl	97	13	and	and	CC
cord-324859-0yuhb5dl	97	14	disagreements	disagreement	NNS
cord-324859-0yuhb5dl	97	15	were	be	VBD
cord-324859-0yuhb5dl	97	16	resolved	resolve	VBN
cord-324859-0yuhb5dl	97	17	by	by	IN
cord-324859-0yuhb5dl	97	18	consensus	consensus	NN
cord-324859-0yuhb5dl	97	19	.	.	.
cord-324859-0yuhb5dl	98	1	Further	further	RB
cord-324859-0yuhb5dl	98	2	,	,	,
cord-324859-0yuhb5dl	98	3	funnel	funnel	VB
cord-324859-0yuhb5dl	98	4	plots	plot	NNS
cord-324859-0yuhb5dl	98	5	were	be	VBD
cord-324859-0yuhb5dl	98	6	generated	generate	VBN
cord-324859-0yuhb5dl	98	7	to	to	TO
cord-324859-0yuhb5dl	98	8	visually	visually	RB
cord-324859-0yuhb5dl	98	9	assess	assess	VB
cord-324859-0yuhb5dl	98	10	the	the	DT
cord-324859-0yuhb5dl	98	11	presence	presence	NN
cord-324859-0yuhb5dl	98	12	of	of	IN
cord-324859-0yuhb5dl	98	13	a	a	DT
cord-324859-0yuhb5dl	98	14	publication	publication	NN
cord-324859-0yuhb5dl	98	15	bias	bias	NN
cord-324859-0yuhb5dl	98	16	among	among	IN
cord-324859-0yuhb5dl	98	17	studies	study	NNS
cord-324859-0yuhb5dl	98	18	.	.	.
cord-324859-0yuhb5dl	99	1	Bias	Bias	NNP
cord-324859-0yuhb5dl	99	2	was	be	VBD
cord-324859-0yuhb5dl	99	3	also	also	RB
cord-324859-0yuhb5dl	99	4	detected	detect	VBN
cord-324859-0yuhb5dl	99	5	statistically	statistically	RB
cord-324859-0yuhb5dl	99	6	by	by	IN
cord-324859-0yuhb5dl	99	7	Egger	Egger	NNP
cord-324859-0yuhb5dl	99	8	's	's	POS
cord-324859-0yuhb5dl	99	9	test	test	NN
cord-324859-0yuhb5dl	99	10	,	,	,
cord-324859-0yuhb5dl	99	11	25	25	CD
cord-324859-0yuhb5dl	99	12	using	use	VBG
cord-324859-0yuhb5dl	99	13	Stata	Stata	NNP
cord-324859-0yuhb5dl	99	14	version	version	NN
cord-324859-0yuhb5dl	99	15	15.1	15.1	CD
cord-324859-0yuhb5dl	99	16	.	.	.
cord-324859-0yuhb5dl	100	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	100	2	database	database	NN
cord-324859-0yuhb5dl	100	3	search	search	NN
cord-324859-0yuhb5dl	100	4	identified	identify	VBD
cord-324859-0yuhb5dl	100	5	a	a	DT
cord-324859-0yuhb5dl	100	6	total	total	NN
cord-324859-0yuhb5dl	100	7	of	of	IN
cord-324859-0yuhb5dl	100	8	893	893	CD
cord-324859-0yuhb5dl	100	9	records	record	NNS
cord-324859-0yuhb5dl	100	10	(	(	-LRB-
cord-324859-0yuhb5dl	100	11	Figure	figure	NN
cord-324859-0yuhb5dl	100	12	1	1	CD
cord-324859-0yuhb5dl	100	13	)	)	-RRB-
cord-324859-0yuhb5dl	100	14	.	.	.
cord-324859-0yuhb5dl	101	1	After	after	IN
cord-324859-0yuhb5dl	101	2	removal	removal	NN
cord-324859-0yuhb5dl	101	3	of	of	IN
cord-324859-0yuhb5dl	101	4	duplicates	duplicate	NNS
cord-324859-0yuhb5dl	101	5	,	,	,
cord-324859-0yuhb5dl	101	6	861	861	CD
cord-324859-0yuhb5dl	101	7	articles	article	NNS
cord-324859-0yuhb5dl	101	8	were	be	VBD
cord-324859-0yuhb5dl	101	9	screened	screen	VBN
cord-324859-0yuhb5dl	101	10	on	on	IN
cord-324859-0yuhb5dl	101	11	the	the	DT
cord-324859-0yuhb5dl	101	12	basis	basis	NN
cord-324859-0yuhb5dl	101	13	of	of	IN
cord-324859-0yuhb5dl	101	14	their	-PRON-	PRP$
cord-324859-0yuhb5dl	101	15	titles	title	NNS
cord-324859-0yuhb5dl	101	16	and	and	CC
cord-324859-0yuhb5dl	101	17	abstracts	abstract	NNS
cord-324859-0yuhb5dl	101	18	,	,	,
cord-324859-0yuhb5dl	101	19	following	follow	VBG
cord-324859-0yuhb5dl	101	20	which	which	WDT
cord-324859-0yuhb5dl	101	21	full	full	JJ
cord-324859-0yuhb5dl	101	22	texts	text	NNS
cord-324859-0yuhb5dl	101	23	of	of	IN
cord-324859-0yuhb5dl	101	24	209	209	CD
cord-324859-0yuhb5dl	101	25	studies	study	NNS
cord-324859-0yuhb5dl	101	26	were	be	VBD
cord-324859-0yuhb5dl	101	27	assessed	assess	VBN
cord-324859-0yuhb5dl	101	28	for	for	IN
cord-324859-0yuhb5dl	101	29	eligibility	eligibility	NN
cord-324859-0yuhb5dl	101	30	in	in	IN
cord-324859-0yuhb5dl	101	31	the	the	DT
cord-324859-0yuhb5dl	101	32	review	review	NN
cord-324859-0yuhb5dl	101	33	.	.	.
cord-324859-0yuhb5dl	102	1	A	a	DT
cord-324859-0yuhb5dl	102	2	total	total	NN
cord-324859-0yuhb5dl	102	3	of	of	IN
cord-324859-0yuhb5dl	102	4	40	40	CD
cord-324859-0yuhb5dl	102	5	studies	study	NNS
cord-324859-0yuhb5dl	102	6	were	be	VBD
cord-324859-0yuhb5dl	102	7	included	include	VBN
cord-324859-0yuhb5dl	102	8	in	in	IN
cord-324859-0yuhb5dl	102	9	the	the	DT
cord-324859-0yuhb5dl	102	10	narrative	narrative	NN
cord-324859-0yuhb5dl	102	11	synthesis	synthesis	NN
cord-324859-0yuhb5dl	102	12	,	,	,
cord-324859-0yuhb5dl	102	13	and	and	CC
cord-324859-0yuhb5dl	102	14	25	25	CD
cord-324859-0yuhb5dl	102	15	of	of	IN
cord-324859-0yuhb5dl	102	16	them	-PRON-	PRP
cord-324859-0yuhb5dl	102	17	contributed	contribute	VBD
cord-324859-0yuhb5dl	102	18	to	to	IN
cord-324859-0yuhb5dl	102	19	the	the	DT
cord-324859-0yuhb5dl	102	20	metaanalysis	metaanalysis	NN
cord-324859-0yuhb5dl	102	21	.	.	.
cord-324859-0yuhb5dl	103	1	A	a	DT
cord-324859-0yuhb5dl	103	2	few	few	JJ
cord-324859-0yuhb5dl	103	3	studies	study	NNS
cord-324859-0yuhb5dl	103	4	with	with	IN
cord-324859-0yuhb5dl	103	5	three	three	CD
cord-324859-0yuhb5dl	103	6	different	different	JJ
cord-324859-0yuhb5dl	103	7	severity	severity	NN
cord-324859-0yuhb5dl	103	8	groups	group	NNS
cord-324859-0yuhb5dl	103	9	instead	instead	RB
cord-324859-0yuhb5dl	103	10	of	of	IN
cord-324859-0yuhb5dl	103	11	two	two	CD
cord-324859-0yuhb5dl	103	12	,	,	,
cord-324859-0yuhb5dl	103	13	as	as	RB
cord-324859-0yuhb5dl	103	14	well	well	RB
cord-324859-0yuhb5dl	103	15	as	as	IN
cord-324859-0yuhb5dl	103	16	those	those	DT
cord-324859-0yuhb5dl	103	17	that	that	WDT
cord-324859-0yuhb5dl	103	18	did	do	VBD
cord-324859-0yuhb5dl	103	19	not	not	RB
cord-324859-0yuhb5dl	103	20	provide	provide	VB
cord-324859-0yuhb5dl	103	21	appropriate	appropriate	JJ
cord-324859-0yuhb5dl	103	22	numeric	numeric	JJ
cord-324859-0yuhb5dl	103	23	estimates	estimate	NNS
cord-324859-0yuhb5dl	103	24	,	,	,
cord-324859-0yuhb5dl	103	25	were	be	VBD
cord-324859-0yuhb5dl	103	26	excluded	exclude	VBN
cord-324859-0yuhb5dl	103	27	from	from	IN
cord-324859-0yuhb5dl	103	28	the	the	DT
cord-324859-0yuhb5dl	103	29	quantitative	quantitative	JJ
cord-324859-0yuhb5dl	103	30	synthesis	synthesis	NN
cord-324859-0yuhb5dl	103	31	.	.	.
cord-324859-0yuhb5dl	104	1	The	the	DT
cord-324859-0yuhb5dl	104	2	following	follow	VBG
cord-324859-0yuhb5dl	104	3	PRISMA	PRISMA	NNP
cord-324859-0yuhb5dl	104	4	diagram	diagram	NN
cord-324859-0yuhb5dl	104	5	lists	list	VBZ
cord-324859-0yuhb5dl	104	6	the	the	DT
cord-324859-0yuhb5dl	104	7	common	common	JJ
cord-324859-0yuhb5dl	104	8	reasons	reason	NNS
cord-324859-0yuhb5dl	104	9	for	for	IN
cord-324859-0yuhb5dl	104	10	excluding	exclude	VBG
cord-324859-0yuhb5dl	104	11	studies	study	NNS
cord-324859-0yuhb5dl	104	12	and	and	CC
cord-324859-0yuhb5dl	104	13	demonstrates	demonstrate	VBZ
cord-324859-0yuhb5dl	104	14	the	the	DT
cord-324859-0yuhb5dl	104	15	study	study	NN
cord-324859-0yuhb5dl	104	16	selection	selection	NN
cord-324859-0yuhb5dl	104	17	process	process	NN
cord-324859-0yuhb5dl	104	18	for	for	IN
cord-324859-0yuhb5dl	104	19	this	this	DT
cord-324859-0yuhb5dl	104	20	review	review	NN
cord-324859-0yuhb5dl	104	21	.	.	.
cord-324859-0yuhb5dl	105	1	The	the	DT
cord-324859-0yuhb5dl	105	2	descriptive	descriptive	JJ
cord-324859-0yuhb5dl	105	3	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	105	4	of	of	IN
cord-324859-0yuhb5dl	105	5	the	the	DT
cord-324859-0yuhb5dl	105	6	included	include	VBN
cord-324859-0yuhb5dl	105	7	studies	study	NNS
cord-324859-0yuhb5dl	105	8	are	be	VBP
cord-324859-0yuhb5dl	105	9	presented	present	VBN
cord-324859-0yuhb5dl	105	10	in	in	IN
cord-324859-0yuhb5dl	105	11	Table	Table	NNP
cord-324859-0yuhb5dl	105	12	1	1	CD
cord-324859-0yuhb5dl	105	13	.	.	.
cord-324859-0yuhb5dl	106	1	The	the	DT
cord-324859-0yuhb5dl	106	2	sample	sample	NN
cord-324859-0yuhb5dl	106	3	size	size	NN
cord-324859-0yuhb5dl	106	4	across	across	IN
cord-324859-0yuhb5dl	106	5	all	all	PDT
cord-324859-0yuhb5dl	106	6	the	the	DT
cord-324859-0yuhb5dl	106	7	studies	study	NNS
cord-324859-0yuhb5dl	106	8	ranged	range	VBD
cord-324859-0yuhb5dl	106	9	from	from	IN
cord-324859-0yuhb5dl	106	10	10	10	CD
cord-324859-0yuhb5dl	106	11	patients	patient	NNS
cord-324859-0yuhb5dl	106	12	to	to	IN
cord-324859-0yuhb5dl	106	13	548	548	CD
cord-324859-0yuhb5dl	106	14	patients	patient	NNS
cord-324859-0yuhb5dl	106	15	,	,	,
cord-324859-0yuhb5dl	106	16	and	and	CC
cord-324859-0yuhb5dl	106	17	a	a	DT
cord-324859-0yuhb5dl	106	18	total	total	NN
cord-324859-0yuhb5dl	106	19	of	of	IN
cord-324859-0yuhb5dl	106	20	5209	5209	CD
cord-324859-0yuhb5dl	106	21	males	male	NNS
cord-324859-0yuhb5dl	106	22	and	and	CC
cord-324859-0yuhb5dl	106	23	females	female	NNS
cord-324859-0yuhb5dl	106	24	participated	participate	VBD
cord-324859-0yuhb5dl	106	25	in	in	IN
cord-324859-0yuhb5dl	106	26	the	the	DT
cord-324859-0yuhb5dl	106	27	40	40	CD
cord-324859-0yuhb5dl	106	28	studies	study	NNS
cord-324859-0yuhb5dl	106	29	included	include	VBN
cord-324859-0yuhb5dl	106	30	in	in	IN
cord-324859-0yuhb5dl	106	31	our	-PRON-	PRP$
cord-324859-0yuhb5dl	106	32	review	review	NN
cord-324859-0yuhb5dl	106	33	.	.	.
cord-324859-0yuhb5dl	107	1	Of	of	IN
cord-324859-0yuhb5dl	107	2	the	the	DT
cord-324859-0yuhb5dl	107	3	total	total	JJ
cord-324859-0yuhb5dl	107	4	studies	study	NNS
cord-324859-0yuhb5dl	107	5	,	,	,
cord-324859-0yuhb5dl	107	6	35	35	CD
cord-324859-0yuhb5dl	107	7	were	be	VBD
cord-324859-0yuhb5dl	107	8	case	case	NN
cord-324859-0yuhb5dl	107	9	series	series	NNP
cord-324859-0yuhb5dl	107	10	7,26	7,26	NNP
cord-324859-0yuhb5dl	107	11	-	-	HYPH
cord-324859-0yuhb5dl	107	12	59	59	CD
cord-324859-0yuhb5dl	107	13	and	and	CC
cord-324859-0yuhb5dl	107	14	five	five	CD
cord-324859-0yuhb5dl	107	15	were	be	VBD
cord-324859-0yuhb5dl	107	16	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	107	17	cohorts	cohort	NNS
cord-324859-0yuhb5dl	107	18	,	,	,
cord-324859-0yuhb5dl	107	19	60	60	CD
cord-324859-0yuhb5dl	107	20	-	-	SYM
cord-324859-0yuhb5dl	107	21	64	64	CD
cord-324859-0yuhb5dl	107	22	based	base	VBN
cord-324859-0yuhb5dl	107	23	in	in	IN
cord-324859-0yuhb5dl	107	24	hospitals	hospital	NNS
cord-324859-0yuhb5dl	107	25	in	in	IN
cord-324859-0yuhb5dl	107	26	different	different	JJ
cord-324859-0yuhb5dl	107	27	parts	part	NNS
cord-324859-0yuhb5dl	107	28	of	of	IN
cord-324859-0yuhb5dl	107	29	China	China	NNP
cord-324859-0yuhb5dl	107	30	.	.	.
cord-324859-0yuhb5dl	108	1	The	the	DT
cord-324859-0yuhb5dl	108	2	participants	participant	NNS
cord-324859-0yuhb5dl	108	3	were	be	VBD
cord-324859-0yuhb5dl	108	4	patients	patient	NNS
cord-324859-0yuhb5dl	108	5	with	with	IN
cord-324859-0yuhb5dl	108	6	a	a	DT
cord-324859-0yuhb5dl	108	7	reverse	reverse	JJ
cord-324859-0yuhb5dl	108	8	transcription	transcription	NN
cord-324859-0yuhb5dl	108	9	-	-	HYPH
cord-324859-0yuhb5dl	108	10	polymerase	polymerase	NN
cord-324859-0yuhb5dl	108	11	chain	chain	NN
cord-324859-0yuhb5dl	108	12	reaction	reaction	NN
cord-324859-0yuhb5dl	108	13	(	(	-LRB-
cord-324859-0yuhb5dl	108	14	RT	RT	NNP
cord-324859-0yuhb5dl	108	15	-	-	HYPH
cord-324859-0yuhb5dl	108	16	PCR)-confirmed	pcr)-confirmed	JJ
cord-324859-0yuhb5dl	108	17	diagnosis	diagnosis	NN
cord-324859-0yuhb5dl	108	18	of	of	IN
cord-324859-0yuhb5dl	108	19	the	the	DT
cord-324859-0yuhb5dl	108	20	novel	novel	JJ
cord-324859-0yuhb5dl	108	21	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	108	22	2019	2019	CD
cord-324859-0yuhb5dl	108	23	,	,	,
cord-324859-0yuhb5dl	108	24	enrolled	enrol	VBN
cord-324859-0yuhb5dl	108	25	in	in	IN
cord-324859-0yuhb5dl	108	26	the	the	DT
cord-324859-0yuhb5dl	108	27	hospital	hospital	NN
cord-324859-0yuhb5dl	108	28	within	within	IN
cord-324859-0yuhb5dl	108	29	the	the	DT
cord-324859-0yuhb5dl	108	30	four	four	CD
cord-324859-0yuhb5dl	108	31	-	-	HYPH
cord-324859-0yuhb5dl	108	32	month	month	NN
cord-324859-0yuhb5dl	108	33	duration	duration	NN
cord-324859-0yuhb5dl	108	34	of	of	IN
cord-324859-0yuhb5dl	108	35	December	December	NNP
cord-324859-0yuhb5dl	108	36	2019	2019	CD
cord-324859-0yuhb5dl	108	37	to	to	IN
cord-324859-0yuhb5dl	108	38	March	March	NNP
cord-324859-0yuhb5dl	108	39	2020	2020	CD
cord-324859-0yuhb5dl	108	40	.	.	.
cord-324859-0yuhb5dl	109	1	Laboratory	laboratory	NN
cord-324859-0yuhb5dl	109	2	assessments	assessment	NNS
cord-324859-0yuhb5dl	109	3	of	of	IN
cord-324859-0yuhb5dl	109	4	all	all	DT
cord-324859-0yuhb5dl	109	5	confirmed	confirm	VBN
cord-324859-0yuhb5dl	109	6	COVID-19	covid-19	CD
cord-324859-0yuhb5dl	109	7	cases	case	NNS
cord-324859-0yuhb5dl	109	8	were	be	VBD
cord-324859-0yuhb5dl	109	9	baseline	baseline	JJ
cord-324859-0yuhb5dl	109	10	measurements	measurement	NNS
cord-324859-0yuhb5dl	109	11	undertaken	undertake	VBN
cord-324859-0yuhb5dl	109	12	at	at	IN
cord-324859-0yuhb5dl	109	13	the	the	DT
cord-324859-0yuhb5dl	109	14	time	time	NN
cord-324859-0yuhb5dl	109	15	of	of	IN
cord-324859-0yuhb5dl	109	16	their	-PRON-	PRP$
cord-324859-0yuhb5dl	109	17	hospitalization	hospitalization	NN
cord-324859-0yuhb5dl	109	18	.	.	.
cord-324859-0yuhb5dl	110	1	The	the	DT
cord-324859-0yuhb5dl	110	2	average	average	JJ
cord-324859-0yuhb5dl	110	3	age	age	NN
cord-324859-0yuhb5dl	110	4	of	of	IN
cord-324859-0yuhb5dl	110	5	the	the	DT
cord-324859-0yuhb5dl	110	6	patients	patient	NNS
cord-324859-0yuhb5dl	110	7	ranged	range	VBD
cord-324859-0yuhb5dl	110	8	from	from	IN
cord-324859-0yuhb5dl	110	9	about	about	RB
cord-324859-0yuhb5dl	110	10	40	40	CD
cord-324859-0yuhb5dl	110	11	-	-	SYM
cord-324859-0yuhb5dl	110	12	55	55	CD
cord-324859-0yuhb5dl	110	13	years	year	NNS
cord-324859-0yuhb5dl	110	14	in	in	IN
cord-324859-0yuhb5dl	110	15	nearly	nearly	RB
cord-324859-0yuhb5dl	110	16	three	three	CD
cord-324859-0yuhb5dl	110	17	-	-	HYPH
cord-324859-0yuhb5dl	110	18	quarters	quarter	NNS
cord-324859-0yuhb5dl	110	19	of	of	IN
cord-324859-0yuhb5dl	110	20	the	the	DT
cord-324859-0yuhb5dl	110	21	studies	study	NNS
cord-324859-0yuhb5dl	110	22	,	,	,
cord-324859-0yuhb5dl	110	23	to	to	IN
cord-324859-0yuhb5dl	110	24	over	over	IN
cord-324859-0yuhb5dl	110	25	60	60	CD
cord-324859-0yuhb5dl	110	26	years	year	NNS
cord-324859-0yuhb5dl	110	27	in	in	IN
cord-324859-0yuhb5dl	110	28	the	the	DT
cord-324859-0yuhb5dl	110	29	remaining	remain	VBG
cord-324859-0yuhb5dl	110	30	.	.	.
cord-324859-0yuhb5dl	111	1	Almost	almost	RB
cord-324859-0yuhb5dl	111	2	one	one	CD
cord-324859-0yuhb5dl	111	3	-	-	HYPH
cord-324859-0yuhb5dl	111	4	third	third	NN
cord-324859-0yuhb5dl	111	5	of	of	IN
cord-324859-0yuhb5dl	111	6	the	the	DT
cord-324859-0yuhb5dl	111	7	patients	patient	NNS
cord-324859-0yuhb5dl	111	8	in	in	IN
cord-324859-0yuhb5dl	111	9	each	each	DT
cord-324859-0yuhb5dl	111	10	study	study	NN
cord-324859-0yuhb5dl	111	11	had	have	VBD
cord-324859-0yuhb5dl	111	12	a	a	DT
cord-324859-0yuhb5dl	111	13	comorbid	comorbid	JJ
cord-324859-0yuhb5dl	111	14	condition	condition	NN
cord-324859-0yuhb5dl	111	15	with	with	IN
cord-324859-0yuhb5dl	111	16	heart	heart	NN
cord-324859-0yuhb5dl	111	17	disease	disease	NN
cord-324859-0yuhb5dl	111	18	,	,	,
cord-324859-0yuhb5dl	111	19	diabetes	diabetes	NN
cord-324859-0yuhb5dl	111	20	,	,	,
cord-324859-0yuhb5dl	111	21	hypertension	hypertension	NN
cord-324859-0yuhb5dl	111	22	,	,	,
cord-324859-0yuhb5dl	111	23	and	and	CC
cord-324859-0yuhb5dl	111	24	kidney	kidney	NN
cord-324859-0yuhb5dl	111	25	disease	disease	NN
cord-324859-0yuhb5dl	111	26	being	be	VBG
cord-324859-0yuhb5dl	111	27	the	the	DT
cord-324859-0yuhb5dl	111	28	most	most	RBS
cord-324859-0yuhb5dl	111	29	prevalent	prevalent	JJ
cord-324859-0yuhb5dl	111	30	ones	one	NNS
cord-324859-0yuhb5dl	111	31	.	.	.
cord-324859-0yuhb5dl	112	1	The	the	DT
cord-324859-0yuhb5dl	112	2	most	most	RBS
cord-324859-0yuhb5dl	112	3	common	common	JJ
cord-324859-0yuhb5dl	112	4	symptoms	symptom	NNS
cord-324859-0yuhb5dl	112	5	across	across	IN
cord-324859-0yuhb5dl	112	6	studies	study	NNS
cord-324859-0yuhb5dl	112	7	were	be	VBD
cord-324859-0yuhb5dl	112	8	fever	fever	NN
cord-324859-0yuhb5dl	112	9	,	,	,
cord-324859-0yuhb5dl	112	10	cough	cough	NN
cord-324859-0yuhb5dl	112	11	,	,	,
cord-324859-0yuhb5dl	112	12	fatigue	fatigue	NN
cord-324859-0yuhb5dl	112	13	,	,	,
cord-324859-0yuhb5dl	112	14	dyspnea	dyspnea	NN
cord-324859-0yuhb5dl	112	15	,	,	,
cord-324859-0yuhb5dl	112	16	myalgia	myalgia	NN
cord-324859-0yuhb5dl	112	17	and	and	CC
cord-324859-0yuhb5dl	112	18	headache	headache	NN
cord-324859-0yuhb5dl	112	19	.	.	.
cord-324859-0yuhb5dl	113	1	A	a	DT
cord-324859-0yuhb5dl	113	2	summary	summary	NN
cord-324859-0yuhb5dl	113	3	of	of	IN
cord-324859-0yuhb5dl	113	4	major	major	JJ
cord-324859-0yuhb5dl	113	5	findings	finding	NNS
cord-324859-0yuhb5dl	113	6	of	of	IN
cord-324859-0yuhb5dl	113	7	each	each	DT
cord-324859-0yuhb5dl	113	8	of	of	IN
cord-324859-0yuhb5dl	113	9	the	the	DT
cord-324859-0yuhb5dl	113	10	included	include	VBN
cord-324859-0yuhb5dl	113	11	studies	study	NNS
cord-324859-0yuhb5dl	113	12	is	be	VBZ
cord-324859-0yuhb5dl	113	13	presented	present	VBN
cord-324859-0yuhb5dl	113	14	in	in	IN
cord-324859-0yuhb5dl	113	15	Table	Table	NNP
cord-324859-0yuhb5dl	113	16	1	1	CD
cord-324859-0yuhb5dl	113	17	.	.	.
cord-324859-0yuhb5dl	114	1	Older	old	JJR
cord-324859-0yuhb5dl	114	2	age	age	NN
cord-324859-0yuhb5dl	114	3	,	,	,
cord-324859-0yuhb5dl	114	4	presence	presence	NN
cord-324859-0yuhb5dl	114	5	of	of	IN
cord-324859-0yuhb5dl	114	6	comorbidities	comorbiditie	NNS
cord-324859-0yuhb5dl	114	7	such	such	JJ
cord-324859-0yuhb5dl	114	8	as	as	IN
cord-324859-0yuhb5dl	114	9	cardiovascular	cardiovascular	JJ
cord-324859-0yuhb5dl	114	10	disease	disease	NN
cord-324859-0yuhb5dl	114	11	,	,	,
cord-324859-0yuhb5dl	114	12	hypertension	hypertension	NN
cord-324859-0yuhb5dl	114	13	and	and	CC
cord-324859-0yuhb5dl	114	14	chronic	chronic	JJ
cord-324859-0yuhb5dl	114	15	obstructive	obstructive	JJ
cord-324859-0yuhb5dl	114	16	pulmonary	pulmonary	JJ
cord-324859-0yuhb5dl	114	17	disease	disease	NN
cord-324859-0yuhb5dl	114	18	,	,	,
cord-324859-0yuhb5dl	114	19	and	and	CC
cord-324859-0yuhb5dl	114	20	being	be	VBG
cord-324859-0yuhb5dl	114	21	male	male	JJ
cord-324859-0yuhb5dl	114	22	were	be	VBD
cord-324859-0yuhb5dl	114	23	found	find	VBN
cord-324859-0yuhb5dl	114	24	to	to	TO
cord-324859-0yuhb5dl	114	25	be	be	VB
cord-324859-0yuhb5dl	114	26	major	major	JJ
cord-324859-0yuhb5dl	114	27	risk	risk	NN
cord-324859-0yuhb5dl	114	28	factors	factor	NNS
cord-324859-0yuhb5dl	114	29	for	for	IN
cord-324859-0yuhb5dl	114	30	disease	disease	NN
cord-324859-0yuhb5dl	114	31	severity	severity	NN
cord-324859-0yuhb5dl	114	32	,	,	,
cord-324859-0yuhb5dl	114	33	higher	high	JJR
cord-324859-0yuhb5dl	114	34	complications	complication	NNS
cord-324859-0yuhb5dl	114	35	and	and	CC
cord-324859-0yuhb5dl	114	36	a	a	DT
cord-324859-0yuhb5dl	114	37	greater	great	JJR
cord-324859-0yuhb5dl	114	38	likelihood	likelihood	NN
cord-324859-0yuhb5dl	114	39	of	of	IN
cord-324859-0yuhb5dl	114	40	death	death	NN
cord-324859-0yuhb5dl	114	41	.	.	.
cord-324859-0yuhb5dl	115	1	Additionally	additionally	RB
cord-324859-0yuhb5dl	115	2	,	,	,
cord-324859-0yuhb5dl	115	3	patients	patient	NNS
cord-324859-0yuhb5dl	115	4	in	in	IN
cord-324859-0yuhb5dl	115	5	the	the	DT
cord-324859-0yuhb5dl	115	6	severe	severe	JJ
cord-324859-0yuhb5dl	115	7	groups	group	NNS
cord-324859-0yuhb5dl	115	8	were	be	VBD
cord-324859-0yuhb5dl	115	9	characterized	characterize	VBN
cord-324859-0yuhb5dl	115	10	by	by	IN
cord-324859-0yuhb5dl	115	11	lymphocytopenia	lymphocytopenia	NNP
cord-324859-0yuhb5dl	115	12	(	(	-LRB-
cord-324859-0yuhb5dl	115	13	low	low	JJ
cord-324859-0yuhb5dl	115	14	CD3	CD3	NNP
cord-324859-0yuhb5dl	115	15	+	+	CC
cord-324859-0yuhb5dl	115	16	,	,	,
cord-324859-0yuhb5dl	115	17	CD4	CD4	NNP
cord-324859-0yuhb5dl	115	18	+	+	CC
cord-324859-0yuhb5dl	115	19	and	and	CC
cord-324859-0yuhb5dl	115	20	CD8	CD8	NNP
cord-324859-0yuhb5dl	115	21	+	+	CC
cord-324859-0yuhb5dl	115	22	T	t	NN
cord-324859-0yuhb5dl	115	23	-	-	HYPH
cord-324859-0yuhb5dl	115	24	cell	cell	NN
cord-324859-0yuhb5dl	115	25	counts	count	NNS
cord-324859-0yuhb5dl	115	26	)	)	-RRB-
cord-324859-0yuhb5dl	115	27	,	,	,
cord-324859-0yuhb5dl	115	28	leucocytosis	leucocytosis	NNP
cord-324859-0yuhb5dl	115	29	,	,	,
cord-324859-0yuhb5dl	115	30	higher	high	JJR
cord-324859-0yuhb5dl	115	31	plasma	plasma	NN
cord-324859-0yuhb5dl	115	32	levels	level	NNS
cord-324859-0yuhb5dl	115	33	of	of	IN
cord-324859-0yuhb5dl	115	34	infection	infection	NN
cord-324859-0yuhb5dl	115	35	-	-	HYPH
cord-324859-0yuhb5dl	115	36	related	relate	VBN
cord-324859-0yuhb5dl	115	37	biomarkers	biomarker	NNS
cord-324859-0yuhb5dl	115	38	such	such	JJ
cord-324859-0yuhb5dl	115	39	as	as	IN
cord-324859-0yuhb5dl	115	40	erythrocyte	erythrocyte	NN
cord-324859-0yuhb5dl	115	41	sedimentation	sedimentation	NN
cord-324859-0yuhb5dl	115	42	rate	rate	NN
cord-324859-0yuhb5dl	115	43	(	(	-LRB-
cord-324859-0yuhb5dl	115	44	ESR	ESR	NNP
cord-324859-0yuhb5dl	115	45	)	)	-RRB-
cord-324859-0yuhb5dl	115	46	,	,	,
cord-324859-0yuhb5dl	115	47	C	C	NNP
cord-324859-0yuhb5dl	115	48	-	-	HYPH
cord-324859-0yuhb5dl	115	49	reactive	reactive	JJ
cord-324859-0yuhb5dl	115	50	protein	protein	NN
cord-324859-0yuhb5dl	115	51	and	and	CC
cord-324859-0yuhb5dl	115	52	procalcitonin	procalcitonin	NNS
cord-324859-0yuhb5dl	115	53	,	,	,
cord-324859-0yuhb5dl	115	54	and	and	CC
cord-324859-0yuhb5dl	115	55	enzymes	enzyme	NNS
cord-324859-0yuhb5dl	115	56	such	such	JJ
cord-324859-0yuhb5dl	115	57	as	as	IN
cord-324859-0yuhb5dl	115	58	lactate	lactate	NN
cord-324859-0yuhb5dl	115	59	dehydrogenase	dehydrogenase	NN
cord-324859-0yuhb5dl	115	60	(	(	-LRB-
cord-324859-0yuhb5dl	115	61	LDH	LDH	NNP
cord-324859-0yuhb5dl	115	62	)	)	-RRB-
cord-324859-0yuhb5dl	115	63	and	and	CC
cord-324859-0yuhb5dl	115	64	alanine	alanine	JJ
cord-324859-0yuhb5dl	115	65	aminotransferase	aminotransferase	NN
cord-324859-0yuhb5dl	115	66	(	(	-LRB-
cord-324859-0yuhb5dl	115	67	ALT	ALT	NNP
cord-324859-0yuhb5dl	115	68	)	)	-RRB-
cord-324859-0yuhb5dl	115	69	.	.	.
cord-324859-0yuhb5dl	116	1	The	the	DT
cord-324859-0yuhb5dl	116	2	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	116	3	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	116	4	,	,	,
cord-324859-0yuhb5dl	116	5	especially	especially	RB
cord-324859-0yuhb5dl	116	6	circulating	circulate	VBG
cord-324859-0yuhb5dl	116	7	interleukins	interleukin	NNS
cord-324859-0yuhb5dl	116	8	6	6	CD
cord-324859-0yuhb5dl	116	9	,	,	,
cord-324859-0yuhb5dl	116	10	8	8	CD
cord-324859-0yuhb5dl	116	11	,	,	,
cord-324859-0yuhb5dl	116	12	10	10	CD
cord-324859-0yuhb5dl	116	13	,	,	,
cord-324859-0yuhb5dl	116	14	2R	2R	NNP
cord-324859-0yuhb5dl	116	15	and	and	CC
cord-324859-0yuhb5dl	116	16	TNF	tnf	NN
cord-324859-0yuhb5dl	116	17	-	-	HYPH
cord-324859-0yuhb5dl	116	18	alpha	alpha	NN
cord-324859-0yuhb5dl	116	19	levels	level	NNS
cord-324859-0yuhb5dl	116	20	were	be	VBD
cord-324859-0yuhb5dl	116	21	significantly	significantly	RB
cord-324859-0yuhb5dl	116	22	elevated	elevate	VBN
cord-324859-0yuhb5dl	116	23	among	among	IN
cord-324859-0yuhb5dl	116	24	severe	severe	JJ
cord-324859-0yuhb5dl	116	25	/	/	SYM
cord-324859-0yuhb5dl	116	26	critical	critical	JJ
cord-324859-0yuhb5dl	116	27	cases	case	NNS
cord-324859-0yuhb5dl	116	28	,	,	,
cord-324859-0yuhb5dl	116	29	as	as	IN
cord-324859-0yuhb5dl	116	30	compared	compare	VBN
cord-324859-0yuhb5dl	116	31	to	to	IN
cord-324859-0yuhb5dl	116	32	the	the	DT
cord-324859-0yuhb5dl	116	33	mild	mild	JJ
cord-324859-0yuhb5dl	116	34	-	-	HYPH
cord-324859-0yuhb5dl	116	35	to	to	IN
cord-324859-0yuhb5dl	116	36	-	-	HYPH
cord-324859-0yuhb5dl	116	37	moderate	moderate	JJ
cord-324859-0yuhb5dl	116	38	patients	patient	NNS
cord-324859-0yuhb5dl	116	39	.	.	.
cord-324859-0yuhb5dl	117	1	Lymphocytopenia	Lymphocytopenia	NNP
cord-324859-0yuhb5dl	117	2	and	and	CC
cord-324859-0yuhb5dl	117	3	a	a	DT
cord-324859-0yuhb5dl	117	4	pro	pro	JJ
cord-324859-0yuhb5dl	117	5	-	-	JJ
cord-324859-0yuhb5dl	117	6	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	117	7	cytokine	cytokine	NN
cord-324859-0yuhb5dl	117	8	storm	storm	NN
cord-324859-0yuhb5dl	117	9	were	be	VBD
cord-324859-0yuhb5dl	117	10	therefore	therefore	RB
cord-324859-0yuhb5dl	117	11	considered	consider	VBN
cord-324859-0yuhb5dl	117	12	to	to	TO
cord-324859-0yuhb5dl	117	13	be	be	VB
cord-324859-0yuhb5dl	117	14	the	the	DT
cord-324859-0yuhb5dl	117	15	most	most	RBS
cord-324859-0yuhb5dl	117	16	critical	critical	JJ
cord-324859-0yuhb5dl	117	17	contributors	contributor	NNS
cord-324859-0yuhb5dl	117	18	to	to	IN
cord-324859-0yuhb5dl	117	19	adverse	adverse	JJ
cord-324859-0yuhb5dl	117	20	clinical	clinical	JJ
cord-324859-0yuhb5dl	117	21	outcomes	outcome	NNS
cord-324859-0yuhb5dl	117	22	in	in	IN
cord-324859-0yuhb5dl	117	23	patients	patient	NNS
cord-324859-0yuhb5dl	117	24	of	of	IN
cord-324859-0yuhb5dl	117	25	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	117	26	.	.	.
cord-324859-0yuhb5dl	118	1	The	the	DT
cord-324859-0yuhb5dl	118	2	studies	study	NNS
cord-324859-0yuhb5dl	118	3	included	include	VBD
cord-324859-0yuhb5dl	118	4	in	in	IN
cord-324859-0yuhb5dl	118	5	the	the	DT
cord-324859-0yuhb5dl	118	6	meta	meta	NNP
cord-324859-0yuhb5dl	118	7	-	-	HYPH
cord-324859-0yuhb5dl	118	8	analysis	analysis	NN
cord-324859-0yuhb5dl	118	9	reported	report	VBD
cord-324859-0yuhb5dl	118	10	various	various	JJ
cord-324859-0yuhb5dl	118	11	outcomes	outcome	NNS
cord-324859-0yuhb5dl	118	12	:	:	:
cord-324859-0yuhb5dl	118	13	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	118	14	(	(	-LRB-
cord-324859-0yuhb5dl	118	15	n	n	NN
cord-324859-0yuhb5dl	118	16	=	=	SYM
cord-324859-0yuhb5dl	118	17	21	21	CD
cord-324859-0yuhb5dl	118	18	)	)	-RRB-
cord-324859-0yuhb5dl	118	19	,	,	,
cord-324859-0yuhb5dl	118	20	7	7	CD
cord-324859-0yuhb5dl	118	21	 	 	_SP
cord-324859-0yuhb5dl	118	22	The	the	DT
cord-324859-0yuhb5dl	118	23	methodological	methodological	JJ
cord-324859-0yuhb5dl	118	24	quality	quality	NN
cord-324859-0yuhb5dl	118	25	of	of	IN
cord-324859-0yuhb5dl	118	26	and	and	CC
cord-324859-0yuhb5dl	118	27	the	the	DT
cord-324859-0yuhb5dl	118	28	presence	presence	NN
cord-324859-0yuhb5dl	118	29	of	of	IN
cord-324859-0yuhb5dl	118	30	bias	bias	NN
cord-324859-0yuhb5dl	118	31	among	among	IN
cord-324859-0yuhb5dl	118	32	the	the	DT
cord-324859-0yuhb5dl	118	33	studies	study	NNS
cord-324859-0yuhb5dl	118	34	was	be	VBD
cord-324859-0yuhb5dl	118	35	assessed	assess	VBN
cord-324859-0yuhb5dl	118	36	using	use	VBG
cord-324859-0yuhb5dl	118	37	the	the	DT
cord-324859-0yuhb5dl	118	38	JBI	JBI	NNP
cord-324859-0yuhb5dl	118	39	checklist	checklist	NN
cord-324859-0yuhb5dl	118	40	for	for	IN
cord-324859-0yuhb5dl	118	41	case	case	NN
cord-324859-0yuhb5dl	118	42	series	series	NNP
cord-324859-0yuhb5dl	118	43	and	and	CC
cord-324859-0yuhb5dl	118	44	the	the	DT
cord-324859-0yuhb5dl	118	45	NOS	NOS	NNP
cord-324859-0yuhb5dl	118	46	for	for	IN
cord-324859-0yuhb5dl	118	47	cohort	cohort	NN
cord-324859-0yuhb5dl	118	48	studies	study	NNS
cord-324859-0yuhb5dl	118	49	in	in	IN
cord-324859-0yuhb5dl	118	50	our	-PRON-	PRP$
cord-324859-0yuhb5dl	118	51	review	review	NN
cord-324859-0yuhb5dl	118	52	.	.	.
cord-324859-0yuhb5dl	119	1	Out	out	IN
cord-324859-0yuhb5dl	119	2	of	of	IN
cord-324859-0yuhb5dl	119	3	the	the	DT
cord-324859-0yuhb5dl	119	4	35	35	CD
cord-324859-0yuhb5dl	119	5	case	case	NN
cord-324859-0yuhb5dl	119	6	series	series	NN
cord-324859-0yuhb5dl	119	7	,	,	,
cord-324859-0yuhb5dl	119	8	29	29	CD
cord-324859-0yuhb5dl	119	9	studies	study	NNS
cord-324859-0yuhb5dl	119	10	showed	show	VBD
cord-324859-0yuhb5dl	119	11	a	a	DT
cord-324859-0yuhb5dl	119	12	low	low	JJ
cord-324859-0yuhb5dl	119	13	-	-	HYPH
cord-324859-0yuhb5dl	119	14	moderate	moderate	JJ
cord-324859-0yuhb5dl	119	15	bias	bias	NN
cord-324859-0yuhb5dl	119	16	and	and	CC
cord-324859-0yuhb5dl	119	17	six	six	CD
cord-324859-0yuhb5dl	119	18	studies	study	NNS
cord-324859-0yuhb5dl	119	19	had	have	VBD
cord-324859-0yuhb5dl	119	20	a	a	DT
cord-324859-0yuhb5dl	119	21	high	high	JJ
cord-324859-0yuhb5dl	119	22	risk	risk	NN
cord-324859-0yuhb5dl	119	23	of	of	IN
cord-324859-0yuhb5dl	119	24	bias	bias	NN
cord-324859-0yuhb5dl	119	25	.	.	.
cord-324859-0yuhb5dl	120	1	Major	major	JJ
cord-324859-0yuhb5dl	120	2	factors	factor	NNS
cord-324859-0yuhb5dl	120	3	contributing	contribute	VBG
cord-324859-0yuhb5dl	120	4	to	to	IN
cord-324859-0yuhb5dl	120	5	the	the	DT
cord-324859-0yuhb5dl	120	6	sub	sub	JJ
cord-324859-0yuhb5dl	120	7	-	-	JJ
cord-324859-0yuhb5dl	120	8	optimal	optimal	JJ
cord-324859-0yuhb5dl	120	9	study	study	NN
cord-324859-0yuhb5dl	120	10	quality	quality	NN
cord-324859-0yuhb5dl	120	11	were	be	VBD
cord-324859-0yuhb5dl	120	12	a	a	DT
cord-324859-0yuhb5dl	120	13	lack	lack	NN
cord-324859-0yuhb5dl	120	14	of	of	IN
cord-324859-0yuhb5dl	120	15	consecutive	consecutive	JJ
cord-324859-0yuhb5dl	120	16	and	and	CC
cord-324859-0yuhb5dl	120	17	complete	complete	JJ
cord-324859-0yuhb5dl	120	18	inclusion	inclusion	NN
cord-324859-0yuhb5dl	120	19	of	of	IN
cord-324859-0yuhb5dl	120	20	participants	participant	NNS
cord-324859-0yuhb5dl	120	21	or	or	CC
cord-324859-0yuhb5dl	120	22	unclear	unclear	JJ
cord-324859-0yuhb5dl	120	23	reporting	reporting	NN
cord-324859-0yuhb5dl	120	24	of	of	IN
cord-324859-0yuhb5dl	120	25	the	the	DT
cord-324859-0yuhb5dl	120	26	same	same	JJ
cord-324859-0yuhb5dl	120	27	,	,	,
cord-324859-0yuhb5dl	120	28	inadequate	inadequate	JJ
cord-324859-0yuhb5dl	120	29	description	description	NN
cord-324859-0yuhb5dl	120	30	of	of	IN
cord-324859-0yuhb5dl	120	31	the	the	DT
cord-324859-0yuhb5dl	120	32	socio	socio	JJ
cord-324859-0yuhb5dl	120	33	-	-	HYPH
cord-324859-0yuhb5dl	120	34	demographic	demographic	JJ
cord-324859-0yuhb5dl	120	35	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	120	36	of	of	IN
cord-324859-0yuhb5dl	120	37	patients	patient	NNS
cord-324859-0yuhb5dl	120	38	and	and	CC
cord-324859-0yuhb5dl	120	39	paucity	paucity	NN
cord-324859-0yuhb5dl	120	40	of	of	IN
cord-324859-0yuhb5dl	120	41	information	information	NN
cord-324859-0yuhb5dl	120	42	about	about	IN
cord-324859-0yuhb5dl	120	43	the	the	DT
cord-324859-0yuhb5dl	120	44	study	study	NN
cord-324859-0yuhb5dl	120	45	sites	site	NNS
cord-324859-0yuhb5dl	120	46	/	/	SYM
cord-324859-0yuhb5dl	120	47	hospitals	hospital	NNS
cord-324859-0yuhb5dl	120	48	.	.	.
cord-324859-0yuhb5dl	121	1	A	a	DT
cord-324859-0yuhb5dl	121	2	high	high	JJ
cord-324859-0yuhb5dl	121	3	risk	risk	NN
cord-324859-0yuhb5dl	121	4	of	of	IN
cord-324859-0yuhb5dl	121	5	bias	bias	NN
cord-324859-0yuhb5dl	121	6	emanated	emanate	VBD
cord-324859-0yuhb5dl	121	7	from	from	IN
cord-324859-0yuhb5dl	121	8	the	the	DT
cord-324859-0yuhb5dl	121	9	recruitment	recruitment	NN
cord-324859-0yuhb5dl	121	10	and	and	CC
cord-324859-0yuhb5dl	121	11	selection	selection	NN
cord-324859-0yuhb5dl	121	12	process	process	NN
cord-324859-0yuhb5dl	121	13	as	as	RB
cord-324859-0yuhb5dl	121	14	well	well	RB
cord-324859-0yuhb5dl	121	15	as	as	IN
cord-324859-0yuhb5dl	121	16	ambiguity	ambiguity	NN
cord-324859-0yuhb5dl	121	17	in	in	IN
cord-324859-0yuhb5dl	121	18	reporting	report	VBG
cord-324859-0yuhb5dl	121	19	the	the	DT
cord-324859-0yuhb5dl	121	20	same	same	JJ
cord-324859-0yuhb5dl	121	21	,	,	,
cord-324859-0yuhb5dl	121	22	across	across	IN
cord-324859-0yuhb5dl	121	23	various	various	JJ
cord-324859-0yuhb5dl	121	24	studies	study	NNS
cord-324859-0yuhb5dl	121	25	.	.	.
cord-324859-0yuhb5dl	122	1	Since	since	IN
cord-324859-0yuhb5dl	122	2	a	a	DT
cord-324859-0yuhb5dl	122	3	majority	majority	NN
cord-324859-0yuhb5dl	122	4	of	of	IN
cord-324859-0yuhb5dl	122	5	the	the	DT
cord-324859-0yuhb5dl	122	6	studies	study	NNS
cord-324859-0yuhb5dl	122	7	included	include	VBN
cord-324859-0yuhb5dl	122	8	in	in	IN
cord-324859-0yuhb5dl	122	9	this	this	DT
cord-324859-0yuhb5dl	122	10	review	review	NN
cord-324859-0yuhb5dl	122	11	were	be	VBD
cord-324859-0yuhb5dl	122	12	case	case	NN
cord-324859-0yuhb5dl	122	13	series	series	NN
cord-324859-0yuhb5dl	122	14	,	,	,
cord-324859-0yuhb5dl	122	15	the	the	DT
cord-324859-0yuhb5dl	122	16	overall	overall	JJ
cord-324859-0yuhb5dl	122	17	quality	quality	NN
cord-324859-0yuhb5dl	122	18	of	of	IN
cord-324859-0yuhb5dl	122	19	evidence	evidence	NN
cord-324859-0yuhb5dl	122	20	was	be	VBD
cord-324859-0yuhb5dl	122	21	not	not	RB
cord-324859-0yuhb5dl	122	22	satisfactory	satisfactory	JJ
cord-324859-0yuhb5dl	122	23	.	.	.
cord-324859-0yuhb5dl	123	1	Out	out	IN
cord-324859-0yuhb5dl	123	2	of	of	IN
cord-324859-0yuhb5dl	123	3	the	the	DT
cord-324859-0yuhb5dl	123	4	five	five	CD
cord-324859-0yuhb5dl	123	5	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	123	6	cohorts	cohort	NNS
cord-324859-0yuhb5dl	123	7	,	,	,
cord-324859-0yuhb5dl	123	8	three	three	CD
cord-324859-0yuhb5dl	123	9	studies	study	NNS
cord-324859-0yuhb5dl	123	10	had	have	VBD
cord-324859-0yuhb5dl	123	11	a	a	DT
cord-324859-0yuhb5dl	123	12	moderate	moderate	JJ
cord-324859-0yuhb5dl	123	13	level	level	NN
cord-324859-0yuhb5dl	123	14	of	of	IN
cord-324859-0yuhb5dl	123	15	bias	bias	NN
cord-324859-0yuhb5dl	123	16	,	,	,
cord-324859-0yuhb5dl	123	17	one	one	PRP
cord-324859-0yuhb5dl	123	18	had	have	VBD
cord-324859-0yuhb5dl	123	19	a	a	DT
cord-324859-0yuhb5dl	123	20	high	high	JJ
cord-324859-0yuhb5dl	123	21	risk	risk	NN
cord-324859-0yuhb5dl	123	22	of	of	IN
cord-324859-0yuhb5dl	123	23	bias	bias	NN
cord-324859-0yuhb5dl	123	24	,	,	,
cord-324859-0yuhb5dl	123	25	and	and	CC
cord-324859-0yuhb5dl	123	26	one	one	CD
cord-324859-0yuhb5dl	123	27	study	study	NN
cord-324859-0yuhb5dl	123	28	had	have	VBD
cord-324859-0yuhb5dl	123	29	a	a	DT
cord-324859-0yuhb5dl	123	30	low	low	JJ
cord-324859-0yuhb5dl	123	31	risk	risk	NN
cord-324859-0yuhb5dl	123	32	of	of	IN
cord-324859-0yuhb5dl	123	33	bias	bias	NN
cord-324859-0yuhb5dl	123	34	.	.	.
cord-324859-0yuhb5dl	124	1	The	the	DT
cord-324859-0yuhb5dl	124	2	major	major	JJ
cord-324859-0yuhb5dl	124	3	risk	risk	NN
cord-324859-0yuhb5dl	124	4	of	of	IN
cord-324859-0yuhb5dl	124	5	bias	bias	NN
cord-324859-0yuhb5dl	124	6	in	in	IN
cord-324859-0yuhb5dl	124	7	these	these	DT
cord-324859-0yuhb5dl	124	8	resulted	result	VBD
cord-324859-0yuhb5dl	124	9	from	from	IN
cord-324859-0yuhb5dl	124	10	the	the	DT
cord-324859-0yuhb5dl	124	11	non	non	JJ
cord-324859-0yuhb5dl	124	12	-	-	JJ
cord-324859-0yuhb5dl	124	13	representativeness	representativeness	NN
cord-324859-0yuhb5dl	124	14	of	of	IN
cord-324859-0yuhb5dl	124	15	the	the	DT
cord-324859-0yuhb5dl	124	16	study	study	NN
cord-324859-0yuhb5dl	124	17	cohorts	cohort	NNS
cord-324859-0yuhb5dl	124	18	and	and	CC
cord-324859-0yuhb5dl	124	19	gaps	gap	NNS
cord-324859-0yuhb5dl	124	20	in	in	IN
cord-324859-0yuhb5dl	124	21	reporting	reporting	NN
cord-324859-0yuhb5dl	124	22	of	of	IN
cord-324859-0yuhb5dl	124	23	study	study	NN
cord-324859-0yuhb5dl	124	24	outcomes	outcome	NNS
cord-324859-0yuhb5dl	124	25	,	,	,
cord-324859-0yuhb5dl	124	26	in	in	IN
cord-324859-0yuhb5dl	124	27	terms	term	NNS
cord-324859-0yuhb5dl	124	28	of	of	IN
cord-324859-0yuhb5dl	124	29	timing	timing	NN
cord-324859-0yuhb5dl	124	30	,	,	,
cord-324859-0yuhb5dl	124	31	assessment	assessment	NN
cord-324859-0yuhb5dl	124	32	and	and	CC
cord-324859-0yuhb5dl	124	33	follow	follow	NN
cord-324859-0yuhb5dl	124	34	-	-	HYPH
cord-324859-0yuhb5dl	124	35	up	up	RP
cord-324859-0yuhb5dl	124	36	duration	duration	NN
cord-324859-0yuhb5dl	124	37	.	.	.
cord-324859-0yuhb5dl	125	1	The	the	DT
cord-324859-0yuhb5dl	125	2	detailed	detailed	JJ
cord-324859-0yuhb5dl	125	3	assessment	assessment	NN
cord-324859-0yuhb5dl	125	4	of	of	IN
cord-324859-0yuhb5dl	125	5	bias	bias	NN
cord-324859-0yuhb5dl	125	6	is	be	VBZ
cord-324859-0yuhb5dl	125	7	provided	provide	VBN
cord-324859-0yuhb5dl	125	8	in	in	IN
cord-324859-0yuhb5dl	125	9	File	File	NNP
cord-324859-0yuhb5dl	125	10	S2	S2	NNP
cord-324859-0yuhb5dl	125	11	.	.	.
cord-324859-0yuhb5dl	126	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	126	2	undertook	undertake	VBD
cord-324859-0yuhb5dl	126	3	a	a	DT
cord-324859-0yuhb5dl	126	4	statistical	statistical	JJ
cord-324859-0yuhb5dl	126	5	pooling	pooling	NN
cord-324859-0yuhb5dl	126	6	of	of	IN
cord-324859-0yuhb5dl	126	7	estimates	estimate	NNS
cord-324859-0yuhb5dl	126	8	across	across	IN
cord-324859-0yuhb5dl	126	9	23	23	CD
cord-324859-0yuhb5dl	126	10	studies	study	NNS
cord-324859-0yuhb5dl	126	11	,	,	,
cord-324859-0yuhb5dl	126	12	to	to	TO
cord-324859-0yuhb5dl	126	13	quantify	quantify	VB
cord-324859-0yuhb5dl	126	14	the	the	DT
cord-324859-0yuhb5dl	126	15	difference	difference	NN
cord-324859-0yuhb5dl	126	16	in	in	IN
cord-324859-0yuhb5dl	126	17	the	the	DT
cord-324859-0yuhb5dl	126	18	levels	level	NNS
cord-324859-0yuhb5dl	126	19	of	of	IN
cord-324859-0yuhb5dl	126	20	various	various	JJ
cord-324859-0yuhb5dl	126	21	COVID-19-related	covid-19-related	JJ
cord-324859-0yuhb5dl	126	22	inflammatory	inflammatory	NN
cord-324859-0yuhb5dl	126	23	(	(	-LRB-
cord-324859-0yuhb5dl	126	24	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	126	25	,	,	,
cord-324859-0yuhb5dl	126	26	IL-8	IL-8	NNP
cord-324859-0yuhb5dl	126	27	,	,	,
cord-324859-0yuhb5dl	126	28	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	126	29	,	,	,
cord-324859-0yuhb5dl	126	30	IL-2R	IL-2R	NNP
cord-324859-0yuhb5dl	126	31	and	and	CC
cord-324859-0yuhb5dl	126	32	TNF	TNF	NNP
cord-324859-0yuhb5dl	126	33	-	-	HYPH
cord-324859-0yuhb5dl	126	34	alpha	alpha	NN
cord-324859-0yuhb5dl	126	35	)	)	-RRB-
cord-324859-0yuhb5dl	126	36	and	and	CC
cord-324859-0yuhb5dl	126	37	immunological	immunological	JJ
cord-324859-0yuhb5dl	126	38	markers	marker	NNS
cord-324859-0yuhb5dl	126	39	(	(	-LRB-
cord-324859-0yuhb5dl	126	40	CD4	CD4	NNP
cord-324859-0yuhb5dl	126	41	+	+	CC
cord-324859-0yuhb5dl	126	42	T	T	NNP
cord-324859-0yuhb5dl	126	43	and	and	CC
cord-324859-0yuhb5dl	126	44	Deceased	Deceased	NNP
cord-324859-0yuhb5dl	126	45	were	be	VBD
cord-324859-0yuhb5dl	126	46	older	old	JJR
cord-324859-0yuhb5dl	126	47	males	male	NNS
cord-324859-0yuhb5dl	126	48	with	with	IN
cord-324859-0yuhb5dl	126	49	comorbidities	comorbiditie	NNS
cord-324859-0yuhb5dl	126	50	,	,	,
cord-324859-0yuhb5dl	126	51	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	126	52	,	,	,
cord-324859-0yuhb5dl	126	53	sepsis	sepsis	NN
cord-324859-0yuhb5dl	126	54	,	,	,
cord-324859-0yuhb5dl	126	55	cardiac	cardiac	JJ
cord-324859-0yuhb5dl	126	56	injury	injury	NN
cord-324859-0yuhb5dl	126	57	,	,	,
cord-324859-0yuhb5dl	126	58	heart	heart	NN
cord-324859-0yuhb5dl	126	59	failure	failure	NN
cord-324859-0yuhb5dl	126	60	and	and	CC
cord-324859-0yuhb5dl	126	61	kidney	kidney	NN
cord-324859-0yuhb5dl	126	62	injury	injury	NN
cord-324859-0yuhb5dl	126	63	.	.	.
cord-324859-0yuhb5dl	127	1	30	30	CD
cord-324859-0yuhb5dl	127	2	55.5	55.5	CD
cord-324859-0yuhb5dl	127	3	M	M	NNP
cord-324859-0yuhb5dl	127	4	10	10	CD
cord-324859-0yuhb5dl	127	5	%	%	NN
cord-324859-0yuhb5dl	127	6	diabetes	diabetes	NN
cord-324859-0yuhb5dl	127	7	and	and	CC
cord-324859-0yuhb5dl	127	8	CVD	CVD	NNP
cord-324859-0yuhb5dl	127	9	,	,	,
cord-324859-0yuhb5dl	127	10	and	and	CC
cord-324859-0yuhb5dl	127	11	23	23	CD
cord-324859-0yuhb5dl	127	12	%	%	NN
cord-324859-0yuhb5dl	127	13	hypertension	hypertension	NN
cord-324859-0yuhb5dl	128	1	85	85	CD
cord-324859-0yuhb5dl	128	2	70	70	CD
cord-324859-0yuhb5dl	128	3	Refractory	refractory	JJ
cord-324859-0yuhb5dl	128	4	patients	patient	NNS
cord-324859-0yuhb5dl	128	5	had	have	VBD
cord-324859-0yuhb5dl	128	6	an	an	DT
cord-324859-0yuhb5dl	128	7	older	old	JJR
cord-324859-0yuhb5dl	128	8	age	age	NN
cord-324859-0yuhb5dl	128	9	;	;	:
cord-324859-0yuhb5dl	128	10	male	male	JJ
cord-324859-0yuhb5dl	128	11	sex	sex	NN
cord-324859-0yuhb5dl	128	12	;	;	,
cord-324859-0yuhb5dl	128	13	more	more	JJR
cord-324859-0yuhb5dl	128	14	underlying	underlying	JJ
cord-324859-0yuhb5dl	128	15	comorbidities	comorbiditie	NNS
cord-324859-0yuhb5dl	128	16	;	;	:
cord-324859-0yuhb5dl	128	17	lower	low	JJR
cord-324859-0yuhb5dl	128	18	fever	fever	NN
cord-324859-0yuhb5dl	128	19	incidence	incidence	NN
cord-324859-0yuhb5dl	128	20	;	;	:
cord-324859-0yuhb5dl	128	21	higher	high	JJR
cord-324859-0yuhb5dl	128	22	incidence	incidence	NN
cord-324859-0yuhb5dl	128	23	of	of	IN
cord-324859-0yuhb5dl	128	24	breath	breath	NN
cord-324859-0yuhb5dl	128	25	shortness	shortness	NN
cord-324859-0yuhb5dl	128	26	;	;	:
cord-324859-0yuhb5dl	128	27	high	high	JJ
cord-324859-0yuhb5dl	128	28	levels	level	NNS
cord-324859-0yuhb5dl	128	29	of	of	IN
cord-324859-0yuhb5dl	128	30	neutrophil	neutrophil	NN
cord-324859-0yuhb5dl	128	31	(	(	-LRB-
cord-324859-0yuhb5dl	128	32	AST	AST	NNP
cord-324859-0yuhb5dl	128	33	)	)	-RRB-
cord-324859-0yuhb5dl	128	34	,	,	,
cord-324859-0yuhb5dl	128	35	LDH	LDH	NNP
cord-324859-0yuhb5dl	128	36	and	and	CC
cord-324859-0yuhb5dl	128	37	C	C	NNP
cord-324859-0yuhb5dl	128	38	-	-	HYPH
cord-324859-0yuhb5dl	128	39	reactive	reactive	JJ
cord-324859-0yuhb5dl	128	40	protein	protein	NN
cord-324859-0yuhb5dl	128	41	;	;	:
cord-324859-0yuhb5dl	128	42	and	and	CC
cord-324859-0yuhb5dl	128	43	higher	high	JJR
cord-324859-0yuhb5dl	128	44	incidence	incidence	NN
cord-324859-0yuhb5dl	128	45	of	of	IN
cord-324859-0yuhb5dl	128	46	bilateral	bilateral	JJ
cord-324859-0yuhb5dl	128	47	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	128	48	and	and	CC
cord-324859-0yuhb5dl	128	49	pleural	pleural	JJ
cord-324859-0yuhb5dl	128	50	effusion	effusion	NN
cord-324859-0yuhb5dl	128	51	.	.	.
cord-324859-0yuhb5dl	129	1	31	31	CD
cord-324859-0yuhb5dl	129	2	63.7	63.7	CD
cord-324859-0yuhb5dl	129	3	%	%	NN
cord-324859-0yuhb5dl	129	4	M	M	NNP
cord-324859-0yuhb5dl	129	5	4	4	CD
cord-324859-0yuhb5dl	129	6	%	%	NN
cord-324859-0yuhb5dl	129	7	diabetes	diabete	NNS
cord-324859-0yuhb5dl	129	8	,	,	,
cord-324859-0yuhb5dl	129	9	10	10	CD
cord-324859-0yuhb5dl	129	10	%	%	NN
cord-324859-0yuhb5dl	129	11	CVD	CVD	NNP
cord-324859-0yuhb5dl	129	12	and	and	CC
cord-324859-0yuhb5dl	129	13	20	20	CD
cord-324859-0yuhb5dl	129	14	%	%	NN
cord-324859-0yuhb5dl	129	15	hypertension	hypertension	NN
cord-324859-0yuhb5dl	129	16	84	84	CD
cord-324859-0yuhb5dl	129	17	117	117	CD
cord-324859-0yuhb5dl	129	18	Older	old	JJR
cord-324859-0yuhb5dl	129	19	age	age	NN
cord-324859-0yuhb5dl	129	20	was	be	VBD
cord-324859-0yuhb5dl	129	21	associated	associate	VBN
cord-324859-0yuhb5dl	129	22	with	with	IN
cord-324859-0yuhb5dl	129	23	greater	great	JJR
cord-324859-0yuhb5dl	129	24	risk	risk	NN
cord-324859-0yuhb5dl	129	25	of	of	IN
cord-324859-0yuhb5dl	129	26	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	129	27	and	and	CC
cord-324859-0yuhb5dl	129	28	death	death	NN
cord-324859-0yuhb5dl	129	29	.	.	.
cord-324859-0yuhb5dl	130	1	High	high	JJ
cord-324859-0yuhb5dl	130	2	fever	fever	NN
cord-324859-0yuhb5dl	130	3	was	be	VBD
cord-324859-0yuhb5dl	130	4	associated	associate	VBN
cord-324859-0yuhb5dl	130	5	with	with	IN
cord-324859-0yuhb5dl	130	6	better	well	JJR
cord-324859-0yuhb5dl	130	7	outcomes	outcome	NNS
cord-324859-0yuhb5dl	130	8	.	.	.
cord-324859-0yuhb5dl	131	1	60	60	CD
cord-324859-0yuhb5dl	131	2	65.9	65.9	CD
cord-324859-0yuhb5dl	131	3	%	%	NN
cord-324859-0yuhb5dl	131	4	M	M	NNP
cord-324859-0yuhb5dl	131	5	76.20	76.20	CD
cord-324859-0yuhb5dl	131	6	%	%	NN
cord-324859-0yuhb5dl	131	7	13	13	CD
cord-324859-0yuhb5dl	131	8	8	8	CD
cord-324859-0yuhb5dl	132	1	The	the	DT
cord-324859-0yuhb5dl	132	2	most	most	RBS
cord-324859-0yuhb5dl	132	3	common	common	JJ
cord-324859-0yuhb5dl	132	4	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	132	5	on	on	IN
cord-324859-0yuhb5dl	132	6	chest	chest	NN
cord-324859-0yuhb5dl	132	7	CT	CT	NNP
cord-324859-0yuhb5dl	132	8	were	be	VBD
cord-324859-0yuhb5dl	132	9	ground	ground	NN
cord-324859-0yuhb5dl	132	10	-	-	HYPH
cord-324859-0yuhb5dl	132	11	glass	glass	NN
cord-324859-0yuhb5dl	132	12	opacity	opacity	NN
cord-324859-0yuhb5dl	132	13	and	and	CC
cord-324859-0yuhb5dl	132	14	bilateral	bilateral	JJ
cord-324859-0yuhb5dl	132	15	patchy	patchy	JJ
cord-324859-0yuhb5dl	132	16	shadowing	shadowing	NN
cord-324859-0yuhb5dl	132	17	.	.	.
cord-324859-0yuhb5dl	133	1	The	the	DT
cord-324859-0yuhb5dl	133	2	most	most	RBS
cord-324859-0yuhb5dl	133	3	common	common	JJ
cord-324859-0yuhb5dl	133	4	findings	finding	NNS
cord-324859-0yuhb5dl	133	5	on	on	IN
cord-324859-0yuhb5dl	133	6	laboratory	laboratory	NN
cord-324859-0yuhb5dl	133	7	measurements	measurement	NNS
cord-324859-0yuhb5dl	133	8	were	be	VBD
cord-324859-0yuhb5dl	133	9	lymphocytopenia	lymphocytopenia	NNP
cord-324859-0yuhb5dl	133	10	,	,	,
cord-324859-0yuhb5dl	133	11	elevated	elevated	JJ
cord-324859-0yuhb5dl	133	12	levels	level	NNS
cord-324859-0yuhb5dl	133	13	of	of	IN
cord-324859-0yuhb5dl	133	14	C	c	NN
cord-324859-0yuhb5dl	133	15	-	-	HYPH
cord-324859-0yuhb5dl	133	16	reactive	reactive	JJ
cord-324859-0yuhb5dl	133	17	protein	protein	NN
cord-324859-0yuhb5dl	133	18	and	and	CC
cord-324859-0yuhb5dl	133	19	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	133	20	.	.	.
cord-324859-0yuhb5dl	134	1	32	32	CD
cord-324859-0yuhb5dl	134	2	53.6	53.6	CD
cord-324859-0yuhb5dl	134	3	%	%	NN
cord-324859-0yuhb5dl	134	4	M	M	NNP
cord-324859-0yuhb5dl	134	5	13	13	CD
cord-324859-0yuhb5dl	134	6	%	%	NN
cord-324859-0yuhb5dl	134	7	21	21	CD
cord-324859-0yuhb5dl	134	8	102	102	CD
cord-324859-0yuhb5dl	134	9	Significant	significant	JJ
cord-324859-0yuhb5dl	134	10	positive	positive	JJ
cord-324859-0yuhb5dl	134	11	correlations	correlation	NNS
cord-324859-0yuhb5dl	134	12	between	between	IN
cord-324859-0yuhb5dl	134	13	CD4	CD4	NNP
cord-324859-0yuhb5dl	134	14	+	+	CC
cord-324859-0yuhb5dl	134	15	T	T	NNP
cord-324859-0yuhb5dl	134	16	and	and	CC
cord-324859-0yuhb5dl	134	17	CD8	CD8	NNP
cord-324859-0yuhb5dl	134	18	+	+	CC
cord-324859-0yuhb5dl	134	19	T	T	NNP
cord-324859-0yuhb5dl	134	20	,	,	,
cord-324859-0yuhb5dl	134	21	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	134	22	and	and	CC
cord-324859-0yuhb5dl	134	23	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	134	24	in	in	IN
cord-324859-0yuhb5dl	134	25	the	the	DT
cord-324859-0yuhb5dl	134	26	mild	mild	JJ
cord-324859-0yuhb5dl	134	27	group	group	NN
cord-324859-0yuhb5dl	134	28	.	.	.
cord-324859-0yuhb5dl	135	1	33	33	CD
cord-324859-0yuhb5dl	135	2	Older	old	JJR
cord-324859-0yuhb5dl	135	3	age	age	NN
cord-324859-0yuhb5dl	135	4	,	,	,
cord-324859-0yuhb5dl	135	5	higher	high	JJR
cord-324859-0yuhb5dl	135	6	neutrophils	neutrophil	NNS
cord-324859-0yuhb5dl	135	7	,	,	,
cord-324859-0yuhb5dl	135	8	high	high	JJ
cord-324859-0yuhb5dl	135	9	CRP	crp	NN
cord-324859-0yuhb5dl	135	10	and	and	CC
cord-324859-0yuhb5dl	135	11	decreased	decrease	VBD
cord-324859-0yuhb5dl	135	12	T	T	NNP
cord-324859-0yuhb5dl	135	13	cell	cell	NN
cord-324859-0yuhb5dl	135	14	found	find	VBN
cord-324859-0yuhb5dl	135	15	in	in	IN
cord-324859-0yuhb5dl	135	16	severe	severe	JJ
cord-324859-0yuhb5dl	135	17	cases	case	NNS
cord-324859-0yuhb5dl	135	18	;	;	:
cord-324859-0yuhb5dl	135	19	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	135	20	level	level	NN
cord-324859-0yuhb5dl	135	21	was	be	VBD
cord-324859-0yuhb5dl	135	22	significantly	significantly	RB
cord-324859-0yuhb5dl	135	23	varied	varied	JJ
cord-324859-0yuhb5dl	135	24	with	with	IN
cord-324859-0yuhb5dl	135	25	disease	disease	NN
cord-324859-0yuhb5dl	135	26	progression	progression	NN
cord-324859-0yuhb5dl	135	27	and	and	CC
cord-324859-0yuhb5dl	135	28	treatment	treatment	NN
cord-324859-0yuhb5dl	135	29	.	.	.
cord-324859-0yuhb5dl	136	1	52	52	CD
cord-324859-0yuhb5dl	136	2	37.5	37.5	CD
cord-324859-0yuhb5dl	136	3	%	%	NN
cord-324859-0yuhb5dl	136	4	M	M	NNP
cord-324859-0yuhb5dl	136	5	35	35	CD
cord-324859-0yuhb5dl	136	6	%	%	NN
cord-324859-0yuhb5dl	136	7	13	13	CD
cord-324859-0yuhb5dl	136	8	27	27	CD
cord-324859-0yuhb5dl	136	9	Severe	severe	JJ
cord-324859-0yuhb5dl	136	10	cases	case	NNS
cord-324859-0yuhb5dl	136	11	showed	show	VBD
cord-324859-0yuhb5dl	136	12	significant	significant	JJ
cord-324859-0yuhb5dl	136	13	and	and	CC
cord-324859-0yuhb5dl	136	14	sustained	sustained	JJ
cord-324859-0yuhb5dl	136	15	decreases	decrease	NNS
cord-324859-0yuhb5dl	136	16	in	in	IN
cord-324859-0yuhb5dl	136	17	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	136	18	counts	count	NNS
cord-324859-0yuhb5dl	136	19	,	,	,
cord-324859-0yuhb5dl	136	20	CD8	CD8	NNP
cord-324859-0yuhb5dl	136	21	cells	cell	NNS
cord-324859-0yuhb5dl	136	22	,	,	,
cord-324859-0yuhb5dl	136	23	increase	increase	VBP
cord-324859-0yuhb5dl	136	24	in	in	IN
cord-324859-0yuhb5dl	136	25	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	136	26	,	,	,
cord-324859-0yuhb5dl	136	27	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	136	28	,	,	,
cord-324859-0yuhb5dl	136	29	IL-2	IL-2	NNP
cord-324859-0yuhb5dl	136	30	and	and	CC
cord-324859-0yuhb5dl	136	31	IFN	IFN	NNP
cord-324859-0yuhb5dl	136	32	-	-	HYPH
cord-324859-0yuhb5dl	136	33	γ	γ	NN
cord-324859-0yuhb5dl	136	34	levels	level	NNS
cord-324859-0yuhb5dl	136	35	compared	compare	VBN
cord-324859-0yuhb5dl	136	36	to	to	IN
cord-324859-0yuhb5dl	136	37	mild	mild	JJ
cord-324859-0yuhb5dl	136	38	cases	case	NNS
cord-324859-0yuhb5dl	136	39	.	.	.
cord-324859-0yuhb5dl	137	1	The	the	DT
cord-324859-0yuhb5dl	137	2	degree	degree	NN
cord-324859-0yuhb5dl	137	3	of	of	IN
cord-324859-0yuhb5dl	137	4	lymphopenia	lymphopenia	NNP
cord-324859-0yuhb5dl	137	5	and	and	CC
cord-324859-0yuhb5dl	137	6	a	a	DT
cord-324859-0yuhb5dl	137	7	pro	pro	JJ
cord-324859-0yuhb5dl	137	8	-	-	JJ
cord-324859-0yuhb5dl	137	9	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	137	10	cytokine	cytokine	NN
cord-324859-0yuhb5dl	137	11	storm	storm	NN
cord-324859-0yuhb5dl	137	12	is	be	VBZ
cord-324859-0yuhb5dl	137	13	higher	high	JJR
cord-324859-0yuhb5dl	137	14	in	in	IN
cord-324859-0yuhb5dl	137	15	severe	severe	JJ
cord-324859-0yuhb5dl	137	16	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	137	17	patients	patient	NNS
cord-324859-0yuhb5dl	137	18	than	than	IN
cord-324859-0yuhb5dl	137	19	in	in	IN
cord-324859-0yuhb5dl	137	20	mild	mild	JJ
cord-324859-0yuhb5dl	137	21	cases	case	NNS
cord-324859-0yuhb5dl	137	22	and	and	CC
cord-324859-0yuhb5dl	137	23	is	be	VBZ
cord-324859-0yuhb5dl	137	24	associated	associate	VBN
cord-324859-0yuhb5dl	137	25	with	with	IN
cord-324859-0yuhb5dl	137	26	the	the	DT
cord-324859-0yuhb5dl	137	27	disease	disease	NN
cord-324859-0yuhb5dl	137	28	severity	severity	NN
cord-324859-0yuhb5dl	137	29	.	.	.
cord-324859-0yuhb5dl	138	1	53	53	CD
cord-324859-0yuhb5dl	138	2	64.4	64.4	CD
cord-324859-0yuhb5dl	138	3	%	%	NN
cord-324859-0yuhb5dl	138	4	M	M	NNP
cord-324859-0yuhb5dl	138	5	34.20	34.20	CD
cord-324859-0yuhb5dl	138	6	%	%	NN
cord-324859-0yuhb5dl	138	7	30	30	CD
cord-324859-0yuhb5dl	138	8	46	46	CD
cord-324859-0yuhb5dl	139	1	The	the	DT
cord-324859-0yuhb5dl	139	2	CD4	CD4	NNP
cord-324859-0yuhb5dl	139	3	+	+	CC
cord-324859-0yuhb5dl	139	4	T	T	NNP
cord-324859-0yuhb5dl	139	5	and	and	CC
cord-324859-0yuhb5dl	139	6	CD8	CD8	NNP
cord-324859-0yuhb5dl	139	7	+	+	CC
cord-324859-0yuhb5dl	139	8	T	t	NN
cord-324859-0yuhb5dl	139	9	-	-	HYPH
cord-324859-0yuhb5dl	139	10	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	139	11	counts	count	NNS
cord-324859-0yuhb5dl	139	12	differed	differ	VBD
cord-324859-0yuhb5dl	139	13	significantly	significantly	RB
cord-324859-0yuhb5dl	139	14	between	between	IN
cord-324859-0yuhb5dl	139	15	the	the	DT
cord-324859-0yuhb5dl	139	16	two	two	CD
cord-324859-0yuhb5dl	139	17	groups	group	NNS
cord-324859-0yuhb5dl	139	18	,	,	,
cord-324859-0yuhb5dl	139	19	as	as	IN
cord-324859-0yuhb5dl	139	20	did	do	VBD
cord-324859-0yuhb5dl	139	21	differences	difference	NNS
cord-324859-0yuhb5dl	139	22	in	in	IN
cord-324859-0yuhb5dl	139	23	interleukin	interleukin	NN
cord-324859-0yuhb5dl	139	24	IL-2R	IL-2R	NNP
cord-324859-0yuhb5dl	139	25	,	,	,
cord-324859-0yuhb5dl	139	26	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	139	27	and	and	CC
cord-324859-0yuhb5dl	139	28	IL-8	IL-8	NNP
cord-324859-0yuhb5dl	139	29	levels	level	NNS
cord-324859-0yuhb5dl	139	30	.	.	.
cord-324859-0yuhb5dl	140	1	SARS	SARS	NNP
cord-324859-0yuhb5dl	140	2	-	-	HYPH
cord-324859-0yuhb5dl	140	3	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	140	4	RNA	RNA	NNP
cord-324859-0yuhb5dl	140	5	load	load	NN
cord-324859-0yuhb5dl	140	6	and	and	CC
cord-324859-0yuhb5dl	140	7	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	140	8	count	count	NN
cord-324859-0yuhb5dl	140	9	,	,	,
cord-324859-0yuhb5dl	140	10	CD4	CD4	NNP
cord-324859-0yuhb5dl	140	11	+	+	CC
cord-324859-0yuhb5dl	140	12	T	t	NN
cord-324859-0yuhb5dl	140	13	-	-	HYPH
cord-324859-0yuhb5dl	140	14	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	140	15	count	count	NN
cord-324859-0yuhb5dl	140	16	and	and	CC
cord-324859-0yuhb5dl	140	17	CD8	CD8	NNP
cord-324859-0yuhb5dl	140	18	+	+	CC
cord-324859-0yuhb5dl	140	19	T	t	NN
cord-324859-0yuhb5dl	140	20	-	-	HYPH
cord-324859-0yuhb5dl	140	21	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	140	22	count	count	NN
cord-324859-0yuhb5dl	140	23	were	be	VBD
cord-324859-0yuhb5dl	140	24	linearly	linearly	RB
cord-324859-0yuhb5dl	140	25	negatively	negatively	RB
cord-324859-0yuhb5dl	140	26	correlated	correlate	VBN
cord-324859-0yuhb5dl	140	27	.	.	.
cord-324859-0yuhb5dl	141	1	54	54	CD
cord-324859-0yuhb5dl	141	2	35	35	CD
cord-324859-0yuhb5dl	141	3	%	%	NN
cord-324859-0yuhb5dl	141	4	M	M	NNP
cord-324859-0yuhb5dl	141	5	24	24	CD
cord-324859-0yuhb5dl	141	6	%	%	NN
cord-324859-0yuhb5dl	141	7	diabetes	diabete	NNS
cord-324859-0yuhb5dl	141	8	,	,	,
cord-324859-0yuhb5dl	141	9	25	25	CD
cord-324859-0yuhb5dl	141	10	%	%	NN
cord-324859-0yuhb5dl	141	11	cardiopathy	cardiopathy	NN
cord-324859-0yuhb5dl	141	12	and	and	CC
cord-324859-0yuhb5dl	141	13	45	45	CD
cord-324859-0yuhb5dl	141	14	%	%	NN
cord-324859-0yuhb5dl	141	15	hypertension	hypertension	NN
cord-324859-0yuhb5dl	141	16	33	33	CD
cord-324859-0yuhb5dl	141	17	107	107	CD
cord-324859-0yuhb5dl	142	1	The	the	DT
cord-324859-0yuhb5dl	142	2	proportion	proportion	NN
cord-324859-0yuhb5dl	142	3	of	of	IN
cord-324859-0yuhb5dl	142	4	patients	patient	NNS
cord-324859-0yuhb5dl	142	5	with	with	IN
cord-324859-0yuhb5dl	142	6	increased	increase	VBN
cord-324859-0yuhb5dl	142	7	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	142	8	and	and	CC
cord-324859-0yuhb5dl	142	9	CRP	CRP	NNP
cord-324859-0yuhb5dl	142	10	levels	level	NNS
cord-324859-0yuhb5dl	142	11	was	be	VBD
cord-324859-0yuhb5dl	142	12	significantly	significantly	RB
cord-324859-0yuhb5dl	142	13	higher	high	JJR
cord-324859-0yuhb5dl	142	14	in	in	IN
cord-324859-0yuhb5dl	142	15	the	the	DT
cord-324859-0yuhb5dl	142	16	severe	severe	JJ
cord-324859-0yuhb5dl	142	17	group	group	NN
cord-324859-0yuhb5dl	142	18	compared	compare	VBN
cord-324859-0yuhb5dl	142	19	to	to	IN
cord-324859-0yuhb5dl	142	20	mild	mild	JJ
cord-324859-0yuhb5dl	142	21	group	group	NN
cord-324859-0yuhb5dl	142	22	.	.	.
cord-324859-0yuhb5dl	143	1	Cox	Cox	NNP
cord-324859-0yuhb5dl	143	2	proportional	proportional	JJ
cord-324859-0yuhb5dl	143	3	hazard	hazard	NN
cord-324859-0yuhb5dl	143	4	model	model	NN
cord-324859-0yuhb5dl	143	5	showed	show	VBD
cord-324859-0yuhb5dl	143	6	that	that	IN
cord-324859-0yuhb5dl	143	7	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	143	8	and	and	CC
cord-324859-0yuhb5dl	143	9	CRP	CRP	NNP
cord-324859-0yuhb5dl	143	10	could	could	MD
cord-324859-0yuhb5dl	143	11	be	be	VB
cord-324859-0yuhb5dl	143	12	used	use	VBN
cord-324859-0yuhb5dl	143	13	as	as	IN
cord-324859-0yuhb5dl	143	14	independent	independent	JJ
cord-324859-0yuhb5dl	143	15	factors	factor	NNS
cord-324859-0yuhb5dl	143	16	to	to	TO
cord-324859-0yuhb5dl	143	17	predict	predict	VB
cord-324859-0yuhb5dl	143	18	the	the	DT
cord-324859-0yuhb5dl	143	19	severity	severity	NN
cord-324859-0yuhb5dl	143	20	of	of	IN
cord-324859-0yuhb5dl	143	21	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	143	22	.	.	.
cord-324859-0yuhb5dl	143	23	64	64	CD
cord-324859-0yuhb5dl	143	24	63	63	CD
cord-324859-0yuhb5dl	143	25	%	%	NN
cord-324859-0yuhb5dl	143	26	M	M	NNP
cord-324859-0yuhb5dl	143	27	55.50	55.50	CD
cord-324859-0yuhb5dl	143	28	%	%	NN
cord-324859-0yuhb5dl	143	29	31	31	CD
cord-324859-0yuhb5dl	143	30	23	23	CD
cord-324859-0yuhb5dl	143	31	Lymphocytes	lymphocyte	NNS
cord-324859-0yuhb5dl	143	32	lower	low	JJR
cord-324859-0yuhb5dl	143	33	,	,	,
cord-324859-0yuhb5dl	143	34	IL-2R	IL-2R	NNP
cord-324859-0yuhb5dl	143	35	and	and	CC
cord-324859-0yuhb5dl	143	36	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	143	37	higher	high	JJR
cord-324859-0yuhb5dl	143	38	,	,	,
cord-324859-0yuhb5dl	143	39	and	and	CC
cord-324859-0yuhb5dl	143	40	prolonged	prolong	VBN
cord-324859-0yuhb5dl	143	41	PT	pt	NN
cord-324859-0yuhb5dl	143	42	in	in	IN
cord-324859-0yuhb5dl	143	43	more	more	RBR
cord-324859-0yuhb5dl	143	44	critical	critical	JJ
cord-324859-0yuhb5dl	143	45	patients	patient	NNS
cord-324859-0yuhb5dl	143	46	.	.	.
cord-324859-0yuhb5dl	144	1	55	55	CD
cord-324859-0yuhb5dl	144	2	55	55	CD
cord-324859-0yuhb5dl	144	3	%	%	NN
cord-324859-0yuhb5dl	144	4	M	M	NNP
cord-324859-0yuhb5dl	144	5	50.80	50.80	CD
cord-324859-0yuhb5dl	144	6	%	%	NN
cord-324859-0yuhb5dl	144	7	28	28	CD
cord-324859-0yuhb5dl	144	8	died	die	VBD
cord-324859-0yuhb5dl	144	9	,	,	,
cord-324859-0yuhb5dl	144	10	42	42	CD
cord-324859-0yuhb5dl	144	11	in	in	IN
cord-324859-0yuhb5dl	144	12	-	-	HYPH
cord-324859-0yuhb5dl	144	13	hospital	hospital	NN
cord-324859-0yuhb5dl	144	14	and	and	CC
cord-324859-0yuhb5dl	144	15	117	117	CD
cord-324859-0yuhb5dl	144	16	discharged	discharge	VBN
cord-324859-0yuhb5dl	145	1	All	all	DT
cord-324859-0yuhb5dl	145	2	patients	patient	NNS
cord-324859-0yuhb5dl	145	3	exhibited	exhibit	VBD
cord-324859-0yuhb5dl	145	4	a	a	DT
cord-324859-0yuhb5dl	145	5	significant	significant	JJ
cord-324859-0yuhb5dl	145	6	drop	drop	NN
cord-324859-0yuhb5dl	145	7	of	of	IN
cord-324859-0yuhb5dl	145	8	T	t	NN
cord-324859-0yuhb5dl	145	9	-	-	HYPH
cord-324859-0yuhb5dl	145	10	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	145	11	subset	subset	NN
cord-324859-0yuhb5dl	145	12	counts	count	VBZ
cord-324859-0yuhb5dl	145	13	with	with	IN
cord-324859-0yuhb5dl	145	14	remarkably	remarkably	RB
cord-324859-0yuhb5dl	145	15	increasing	increase	VBG
cord-324859-0yuhb5dl	145	16	concentrations	concentration	NNS
cord-324859-0yuhb5dl	145	17	of	of	IN
cord-324859-0yuhb5dl	145	18	CRP	CRP	NNP
cord-324859-0yuhb5dl	145	19	,	,	,
cord-324859-0yuhb5dl	145	20	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	145	21	and	and	CC
cord-324859-0yuhb5dl	145	22	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	145	23	compared	compare	VBD
cord-324859-0yuhb5dl	145	24	to	to	IN
cord-324859-0yuhb5dl	145	25	normal	normal	JJ
cord-324859-0yuhb5dl	145	26	values	value	NNS
cord-324859-0yuhb5dl	145	27	.	.	.
cord-324859-0yuhb5dl	146	1	The	the	DT
cord-324859-0yuhb5dl	146	2	median	median	JJ
cord-324859-0yuhb5dl	146	3	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	146	4	,	,	,
cord-324859-0yuhb5dl	146	5	CD3	CD3	NNP
cord-324859-0yuhb5dl	146	6	+	+	CC
cord-324859-0yuhb5dl	146	7	T	T	NNP
cord-324859-0yuhb5dl	146	8	cell	cell	NN
cord-324859-0yuhb5dl	146	9	,	,	,
cord-324859-0yuhb5dl	146	10	CD4	CD4	NNP
cord-324859-0yuhb5dl	146	11	+	+	CC
cord-324859-0yuhb5dl	146	12	T	T	NNP
cord-324859-0yuhb5dl	146	13	cell	cell	NN
cord-324859-0yuhb5dl	146	14	,	,	,
cord-324859-0yuhb5dl	146	15	CD8	CD8	NNP
cord-324859-0yuhb5dl	146	16	+	+	CC
cord-324859-0yuhb5dl	146	17	T	T	NNP
cord-324859-0yuhb5dl	146	18	cell	cell	NN
cord-324859-0yuhb5dl	146	19	and	and	CC
cord-324859-0yuhb5dl	146	20	B	b	NN
cord-324859-0yuhb5dl	146	21	cell	cell	NN
cord-324859-0yuhb5dl	146	22	were	be	VBD
cord-324859-0yuhb5dl	146	23	significantly	significantly	RB
cord-324859-0yuhb5dl	146	24	lower	low	JJR
cord-324859-0yuhb5dl	146	25	in	in	IN
cord-324859-0yuhb5dl	146	26	patients	patient	NNS
cord-324859-0yuhb5dl	146	27	who	who	WP
cord-324859-0yuhb5dl	146	28	died	die	VBD
cord-324859-0yuhb5dl	146	29	.	.	.
cord-324859-0yuhb5dl	147	1	Lower	low	JJR
cord-324859-0yuhb5dl	147	2	counts	count	NNS
cord-324859-0yuhb5dl	147	3	(	(	-LRB-
cord-324859-0yuhb5dl	147	4	/uL	/uL	NFP
cord-324859-0yuhb5dl	147	5	)	)	-RRB-
cord-324859-0yuhb5dl	147	6	of	of	IN
cord-324859-0yuhb5dl	147	7	T	t	NN
cord-324859-0yuhb5dl	147	8	-	-	HYPH
cord-324859-0yuhb5dl	147	9	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	147	10	subsets	subset	NNS
cord-324859-0yuhb5dl	147	11	were	be	VBD
cord-324859-0yuhb5dl	147	12	associated	associate	VBN
cord-324859-0yuhb5dl	147	13	with	with	IN
cord-324859-0yuhb5dl	147	14	higher	high	JJR
cord-324859-0yuhb5dl	147	15	risks	risk	NNS
cord-324859-0yuhb5dl	147	16	of	of	IN
cord-324859-0yuhb5dl	147	17	in	in	IN
cord-324859-0yuhb5dl	147	18	-	-	HYPH
cord-324859-0yuhb5dl	147	19	hospital	hospital	NN
cord-324859-0yuhb5dl	147	20	death	death	NN
cord-324859-0yuhb5dl	147	21	.	.	.
cord-324859-0yuhb5dl	148	1	54	54	CD
cord-324859-0yuhb5dl	148	2	43.6	43.6	CD
cord-324859-0yuhb5dl	148	3	%	%	NN
cord-324859-0yuhb5dl	148	4	M	M	NNP
cord-324859-0yuhb5dl	148	5	Not	not	RB
cord-324859-0yuhb5dl	148	6	given	give	VBN
cord-324859-0yuhb5dl	148	7	21	21	CD
cord-324859-0yuhb5dl	148	8	34	34	CD
cord-324859-0yuhb5dl	148	9	Patients	patient	NNS
cord-324859-0yuhb5dl	148	10	in	in	IN
cord-324859-0yuhb5dl	148	11	the	the	DT
cord-324859-0yuhb5dl	148	12	severe	severe	JJ
cord-324859-0yuhb5dl	148	13	group	group	NN
cord-324859-0yuhb5dl	148	14	had	have	VBD
cord-324859-0yuhb5dl	148	15	a	a	DT
cord-324859-0yuhb5dl	148	16	lower	low	JJR
cord-324859-0yuhb5dl	148	17	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	148	18	count	count	NN
cord-324859-0yuhb5dl	148	19	and	and	CC
cord-324859-0yuhb5dl	148	20	CD3-T	CD3-T	NNP
cord-324859-0yuhb5dl	148	21	cells	cell	NNS
cord-324859-0yuhb5dl	148	22	percentage	percentage	NN
cord-324859-0yuhb5dl	148	23	than	than	IN
cord-324859-0yuhb5dl	148	24	the	the	DT
cord-324859-0yuhb5dl	148	25	nonsevere	nonsevere	JJ
cord-324859-0yuhb5dl	148	26	group	group	NN
cord-324859-0yuhb5dl	148	27	.	.	.
cord-324859-0yuhb5dl	149	1	The	the	DT
cord-324859-0yuhb5dl	149	2	severe	severe	JJ
cord-324859-0yuhb5dl	149	3	group	group	NN
cord-324859-0yuhb5dl	149	4	also	also	RB
cord-324859-0yuhb5dl	149	5	had	have	VBD
cord-324859-0yuhb5dl	149	6	a	a	DT
cord-324859-0yuhb5dl	149	7	higher	high	JJR
cord-324859-0yuhb5dl	149	8	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	149	9	level	level	NN
cord-324859-0yuhb5dl	149	10	than	than	IN
cord-324859-0yuhb5dl	149	11	the	the	DT
cord-324859-0yuhb5dl	149	12	nonsevere	nonsevere	JJ
cord-324859-0yuhb5dl	149	13	group	group	NN
cord-324859-0yuhb5dl	149	14	.	.	.
cord-324859-0yuhb5dl	150	1	57	57	CD
cord-324859-0yuhb5dl	150	2	Not	not	RB
cord-324859-0yuhb5dl	150	3	given	give	VBN
cord-324859-0yuhb5dl	150	4	37.50	37.50	CD
cord-324859-0yuhb5dl	150	5	%	%	NN
cord-324859-0yuhb5dl	150	6	6	6	CD
cord-324859-0yuhb5dl	150	7	10	10	CD
cord-324859-0yuhb5dl	150	8	Among	among	IN
cord-324859-0yuhb5dl	150	9	the	the	DT
cord-324859-0yuhb5dl	150	10	differentially	differentially	RB
cord-324859-0yuhb5dl	150	11	expressed	express	VBN
cord-324859-0yuhb5dl	150	12	functional	functional	JJ
cord-324859-0yuhb5dl	150	13	molecules	molecule	NNS
cord-324859-0yuhb5dl	150	14	,	,	,
cord-324859-0yuhb5dl	150	15	the	the	DT
cord-324859-0yuhb5dl	150	16	levels	level	NNS
cord-324859-0yuhb5dl	150	17	of	of	IN
cord-324859-0yuhb5dl	150	18	interferon	interferon	NN
cord-324859-0yuhb5dl	150	19	-	-	HYPH
cord-324859-0yuhb5dl	150	20	γ	γ	NN
cord-324859-0yuhb5dl	150	21	and	and	CC
cord-324859-0yuhb5dl	150	22	TNF	TNF	NNP
cord-324859-0yuhb5dl	150	23	-	-	HYPH
cord-324859-0yuhb5dl	150	24	α	α	NNP
cord-324859-0yuhb5dl	150	25	in	in	IN
cord-324859-0yuhb5dl	150	26	CD4	CD4	NNP
cord-324859-0yuhb5dl	150	27	+	+	CC
cord-324859-0yuhb5dl	150	28	T	t	NN
cord-324859-0yuhb5dl	150	29	cells	cell	NNS
cord-324859-0yuhb5dl	150	30	were	be	VBD
cord-324859-0yuhb5dl	150	31	lower	low	JJR
cord-324859-0yuhb5dl	150	32	in	in	IN
cord-324859-0yuhb5dl	150	33	the	the	DT
cord-324859-0yuhb5dl	150	34	severe	severe	JJ
cord-324859-0yuhb5dl	150	35	group	group	NN
cord-324859-0yuhb5dl	150	36	than	than	IN
cord-324859-0yuhb5dl	150	37	in	in	IN
cord-324859-0yuhb5dl	150	38	the	the	DT
cord-324859-0yuhb5dl	150	39	mild	mild	JJ
cord-324859-0yuhb5dl	150	40	group	group	NN
cord-324859-0yuhb5dl	150	41	,	,	,
cord-324859-0yuhb5dl	150	42	whereas	whereas	IN
cord-324859-0yuhb5dl	150	43	the	the	DT
cord-324859-0yuhb5dl	150	44	levels	level	NNS
cord-324859-0yuhb5dl	150	45	of	of	IN
cord-324859-0yuhb5dl	150	46	granzyme	granzyme	NNS
cord-324859-0yuhb5dl	150	47	B	b	NN
cord-324859-0yuhb5dl	150	48	and	and	CC
cord-324859-0yuhb5dl	150	49	perforin	perforin	NNP
cord-324859-0yuhb5dl	150	50	in	in	IN
cord-324859-0yuhb5dl	150	51	CD8	CD8	NNP
cord-324859-0yuhb5dl	150	52	+	+	CC
cord-324859-0yuhb5dl	150	53	T	T	NNP
cord-324859-0yuhb5dl	150	54	cells	cell	NNS
cord-324859-0yuhb5dl	150	55	were	be	VBD
cord-324859-0yuhb5dl	150	56	higher	high	JJR
cord-324859-0yuhb5dl	150	57	in	in	IN
cord-324859-0yuhb5dl	150	58	the	the	DT
cord-324859-0yuhb5dl	150	59	severe	severe	JJ
cord-324859-0yuhb5dl	150	60	group	group	NN
cord-324859-0yuhb5dl	150	61	.	.	.
cord-324859-0yuhb5dl	151	1	58	58	CD
cord-324859-0yuhb5dl	151	2	53	53	CD
cord-324859-0yuhb5dl	151	3	%	%	NN
cord-324859-0yuhb5dl	151	4	M	m	NN
cord-324859-0yuhb5dl	151	5	Not	not	RB
cord-324859-0yuhb5dl	151	6	given	give	VBN
cord-324859-0yuhb5dl	151	7	13	13	CD
cord-324859-0yuhb5dl	151	8	55	55	CD
cord-324859-0yuhb5dl	152	1	The	the	DT
cord-324859-0yuhb5dl	152	2	number	number	NN
cord-324859-0yuhb5dl	152	3	of	of	IN
cord-324859-0yuhb5dl	152	4	T	t	NN
cord-324859-0yuhb5dl	152	5	cells	cell	NNS
cord-324859-0yuhb5dl	152	6	and	and	CC
cord-324859-0yuhb5dl	152	7	CD8	CD8	NNP
cord-324859-0yuhb5dl	152	8	+	+	CC
cord-324859-0yuhb5dl	152	9	T	T	NNP
cord-324859-0yuhb5dl	152	10	cells	cell	NNS
cord-324859-0yuhb5dl	152	11	was	be	VBD
cord-324859-0yuhb5dl	152	12	significantly	significantly	RB
cord-324859-0yuhb5dl	152	13	lower	low	JJR
cord-324859-0yuhb5dl	152	14	in	in	IN
cord-324859-0yuhb5dl	152	15	severe	severe	JJ
cord-324859-0yuhb5dl	152	16	patients	patient	NNS
cord-324859-0yuhb5dl	152	17	than	than	IN
cord-324859-0yuhb5dl	152	18	that	that	DT
cord-324859-0yuhb5dl	152	19	in	in	IN
cord-324859-0yuhb5dl	152	20	the	the	DT
cord-324859-0yuhb5dl	152	21	mild	mild	JJ
cord-324859-0yuhb5dl	152	22	cases	case	NNS
cord-324859-0yuhb5dl	152	23	.	.	.
cord-324859-0yuhb5dl	153	1	59	59	CD
cord-324859-0yuhb5dl	153	2	CD8	CD8	NNS
cord-324859-0yuhb5dl	153	3	+	+	CC
cord-324859-0yuhb5dl	153	4	T	T	NNP
cord-324859-0yuhb5dl	153	5	)	)	-RRB-
cord-324859-0yuhb5dl	153	6	in	in	IN
cord-324859-0yuhb5dl	153	7	severely	severely	RB
cord-324859-0yuhb5dl	153	8	diseased	diseased	JJ
cord-324859-0yuhb5dl	153	9	patients	patient	NNS
cord-324859-0yuhb5dl	153	10	,	,	,
cord-324859-0yuhb5dl	153	11	compared	compare	VBN
cord-324859-0yuhb5dl	153	12	to	to	IN
cord-324859-0yuhb5dl	153	13	the	the	DT
cord-324859-0yuhb5dl	153	14	nonsevere	nonsevere	JJ
cord-324859-0yuhb5dl	153	15	ones	one	NNS
cord-324859-0yuhb5dl	153	16	,	,	,
cord-324859-0yuhb5dl	153	17	through	through	IN
cord-324859-0yuhb5dl	153	18	a	a	DT
cord-324859-0yuhb5dl	153	19	meta	meta	JJ
cord-324859-0yuhb5dl	153	20	-	-	HYPH
cord-324859-0yuhb5dl	153	21	analysis	analysis	NN
cord-324859-0yuhb5dl	153	22	.	.	.
cord-324859-0yuhb5dl	154	1	Severity	severity	NN
cord-324859-0yuhb5dl	154	2	was	be	VBD
cord-324859-0yuhb5dl	154	3	defined	define	VBN
cord-324859-0yuhb5dl	154	4	according	accord	VBG
cord-324859-0yuhb5dl	154	5	to	to	IN
cord-324859-0yuhb5dl	154	6	the	the	DT
cord-324859-0yuhb5dl	154	7	WHO	WHO	NNP
cord-324859-0yuhb5dl	154	8	interim	interim	JJ
cord-324859-0yuhb5dl	154	9	guidance	guidance	NN
cord-324859-0yuhb5dl	154	10	or	or	CC
cord-324859-0yuhb5dl	154	11	the	the	DT
cord-324859-0yuhb5dl	154	12	Chinese	chinese	JJ
cord-324859-0yuhb5dl	154	13	protocol	protocol	NN
cord-324859-0yuhb5dl	154	14	in	in	IN
cord-324859-0yuhb5dl	154	15	a	a	DT
cord-324859-0yuhb5dl	154	16	majority	majority	NN
cord-324859-0yuhb5dl	154	17	(	(	-LRB-
cord-324859-0yuhb5dl	154	18	78	78	CD
cord-324859-0yuhb5dl	154	19	%	%	NN
cord-324859-0yuhb5dl	154	20	)	)	-RRB-
cord-324859-0yuhb5dl	154	21	of	of	IN
cord-324859-0yuhb5dl	154	22	the	the	DT
cord-324859-0yuhb5dl	154	23	meta	meta	NNP
cord-324859-0yuhb5dl	154	24	-	-	HYPH
cord-324859-0yuhb5dl	154	25	analysed	analyse	VBN
cord-324859-0yuhb5dl	154	26	studies	study	NNS
cord-324859-0yuhb5dl	154	27	.	.	.
cord-324859-0yuhb5dl	155	1	One	one	CD
cord-324859-0yuhb5dl	155	2	study	study	NN
cord-324859-0yuhb5dl	155	3	defined	define	VBD
cord-324859-0yuhb5dl	155	4	an	an	DT
cord-324859-0yuhb5dl	155	5	oxygen	oxygen	NN
cord-324859-0yuhb5dl	155	6	saturation	saturation	NN
cord-324859-0yuhb5dl	155	7	of	of	IN
cord-324859-0yuhb5dl	155	8	≤90	≤90	NNP
cord-324859-0yuhb5dl	155	9	%	%	NN
cord-324859-0yuhb5dl	155	10	as	as	IN
cord-324859-0yuhb5dl	155	11	the	the	DT
cord-324859-0yuhb5dl	155	12	severe	severe	JJ
cord-324859-0yuhb5dl	155	13	group	group	NN
cord-324859-0yuhb5dl	155	14	,	,	,
cord-324859-0yuhb5dl	155	15	while	while	IN
cord-324859-0yuhb5dl	155	16	another	another	DT
cord-324859-0yuhb5dl	155	17	used	use	VBN
cord-324859-0yuhb5dl	155	18	categories	category	NNS
cord-324859-0yuhb5dl	155	19	of	of	IN
cord-324859-0yuhb5dl	155	20	dead	dead	JJ
cord-324859-0yuhb5dl	155	21	and	and	CC
cord-324859-0yuhb5dl	155	22	discharged	discharge	VBN
cord-324859-0yuhb5dl	155	23	.	.	.
cord-324859-0yuhb5dl	156	1	For	for	IN
cord-324859-0yuhb5dl	156	2	three	three	CD
cord-324859-0yuhb5dl	156	3	studies	study	NNS
cord-324859-0yuhb5dl	156	4	,	,	,
cord-324859-0yuhb5dl	156	5	categorization	categorization	NN
cord-324859-0yuhb5dl	156	6	into	into	IN
cord-324859-0yuhb5dl	156	7	severe	severe	JJ
cord-324859-0yuhb5dl	156	8	and	and	CC
cord-324859-0yuhb5dl	156	9	non	non	JJ
cord-324859-0yuhb5dl	156	10	-	-	JJ
cord-324859-0yuhb5dl	156	11	severe	severe	JJ
cord-324859-0yuhb5dl	156	12	groups	group	NNS
cord-324859-0yuhb5dl	156	13	was	be	VBD
cord-324859-0yuhb5dl	156	14	not	not	RB
cord-324859-0yuhb5dl	156	15	described	describe	VBN
cord-324859-0yuhb5dl	156	16	.	.	.
cord-324859-0yuhb5dl	157	1	Forest	forest	NN
cord-324859-0yuhb5dl	157	2	plots	plot	NNS
cord-324859-0yuhb5dl	157	3	were	be	VBD
cord-324859-0yuhb5dl	157	4	generated	generate	VBN
cord-324859-0yuhb5dl	157	5	,	,	,
cord-324859-0yuhb5dl	157	6	and	and	CC
cord-324859-0yuhb5dl	157	7	mean	mean	VB
cord-324859-0yuhb5dl	157	8	difference	difference	NN
cord-324859-0yuhb5dl	157	9	was	be	VBD
cord-324859-0yuhb5dl	157	10	calculated	calculate	VBN
cord-324859-0yuhb5dl	157	11	using	use	VBG
cord-324859-0yuhb5dl	157	12	the	the	DT
cord-324859-0yuhb5dl	157	13	random	random	JJ
cord-324859-0yuhb5dl	157	14	-	-	HYPH
cord-324859-0yuhb5dl	157	15	effects	effect	NNS
cord-324859-0yuhb5dl	157	16	model	model	NN
cord-324859-0yuhb5dl	157	17	.	.	.
cord-324859-0yuhb5dl	158	1	Results	result	NNS
cord-324859-0yuhb5dl	158	2	from	from	IN
cord-324859-0yuhb5dl	158	3	the	the	DT
cord-324859-0yuhb5dl	158	4	meta	meta	NNP
cord-324859-0yuhb5dl	158	5	-	-	HYPH
cord-324859-0yuhb5dl	158	6	analysis	analysis	NN
cord-324859-0yuhb5dl	158	7	showed	show	VBD
cord-324859-0yuhb5dl	158	8	significantly	significantly	RB
cord-324859-0yuhb5dl	158	9	higher	high	JJR
cord-324859-0yuhb5dl	158	10	mean	mean	JJ
cord-324859-0yuhb5dl	158	11	levels	level	NNS
cord-324859-0yuhb5dl	158	12	of	of	IN
cord-324859-0yuhb5dl	158	13	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	158	14	(	(	-LRB-
cord-324859-0yuhb5dl	158	15	21	21	CD
cord-324859-0yuhb5dl	158	16	studies	study	NNS
cord-324859-0yuhb5dl	158	17	(	(	-LRB-
cord-324859-0yuhb5dl	158	18	n	n	NN
cord-324859-0yuhb5dl	158	19	=	=	SYM
cord-324859-0yuhb5dl	158	20	2477	2477	CD
cord-324859-0yuhb5dl	158	21	)	)	-RRB-
cord-324859-0yuhb5dl	159	1	;	;	:
cord-324859-0yuhb5dl	159	2	mean	mean	VB
cord-324859-0yuhb5dl	159	3	difference	difference	NN
cord-324859-0yuhb5dl	159	4	:	:	:
cord-324859-0yuhb5dl	159	5	19.55	19.55	CD
cord-324859-0yuhb5dl	159	6	pg	pg	NN
cord-324859-0yuhb5dl	159	7	/	/	SYM
cord-324859-0yuhb5dl	159	8	mL	ml	NN
cord-324859-0yuhb5dl	159	9	;	;	:
cord-324859-0yuhb5dl	159	10	CI	CI	NNP
cord-324859-0yuhb5dl	159	11	:	:	:
cord-324859-0yuhb5dl	159	12	14	14	CD
cord-324859-0yuhb5dl	159	13	.	.	.
cord-324859-0yuhb5dl	160	1	However	however	RB
cord-324859-0yuhb5dl	160	2	,	,	,
cord-324859-0yuhb5dl	160	3	there	there	EX
cord-324859-0yuhb5dl	160	4	was	be	VBD
cord-324859-0yuhb5dl	160	5	substantial	substantial	JJ
cord-324859-0yuhb5dl	160	6	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	160	7	across	across	IN
cord-324859-0yuhb5dl	160	8	estimates	estimate	NNS
cord-324859-0yuhb5dl	160	9	of	of	IN
cord-324859-0yuhb5dl	160	10	all	all	PDT
cord-324859-0yuhb5dl	160	11	the	the	DT
cord-324859-0yuhb5dl	160	12	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	160	13	cytokine	cytokine	NN
cord-324859-0yuhb5dl	160	14	markers	marker	NNS
cord-324859-0yuhb5dl	160	15	(	(	-LRB-
cord-324859-0yuhb5dl	160	16	I	i	NN
cord-324859-0yuhb5dl	160	17	2	2	CD
cord-324859-0yuhb5dl	160	18	values	value	NNS
cord-324859-0yuhb5dl	160	19	ranging	range	VBG
cord-324859-0yuhb5dl	160	20	from	from	IN
cord-324859-0yuhb5dl	160	21	92	92	CD
cord-324859-0yuhb5dl	160	22	%	%	NN
cord-324859-0yuhb5dl	160	23	to	to	IN
cord-324859-0yuhb5dl	160	24	97	97	CD
cord-324859-0yuhb5dl	160	25	%	%	NN
cord-324859-0yuhb5dl	160	26	;	;	:
cord-324859-0yuhb5dl	160	27	P	p	NN
cord-324859-0yuhb5dl	160	28	-	-	HYPH
cord-324859-0yuhb5dl	160	29	value	value	NN
cord-324859-0yuhb5dl	160	30	<	<	XX
cord-324859-0yuhb5dl	160	31	.05	.05	XX
cord-324859-0yuhb5dl	160	32	;	;	:
cord-324859-0yuhb5dl	160	33	Table	table	NN
cord-324859-0yuhb5dl	160	34	2	2	CD
cord-324859-0yuhb5dl	160	35	)	)	-RRB-
cord-324859-0yuhb5dl	160	36	.	.	.
cord-324859-0yuhb5dl	161	1	A	a	DT
cord-324859-0yuhb5dl	161	2	sensitivity	sensitivity	NN
cord-324859-0yuhb5dl	161	3	analysis	analysis	NN
cord-324859-0yuhb5dl	161	4	was	be	VBD
cord-324859-0yuhb5dl	161	5	undertaken	undertake	VBN
cord-324859-0yuhb5dl	161	6	to	to	TO
cord-324859-0yuhb5dl	161	7	obtain	obtain	VB
cord-324859-0yuhb5dl	161	8	pooled	pool	VBN
cord-324859-0yuhb5dl	161	9	estimates	estimate	NNS
cord-324859-0yuhb5dl	161	10	for	for	IN
cord-324859-0yuhb5dl	161	11	each	each	DT
cord-324859-0yuhb5dl	161	12	outcome	outcome	NN
cord-324859-0yuhb5dl	161	13	after	after	IN
cord-324859-0yuhb5dl	161	14	excluding	exclude	VBG
cord-324859-0yuhb5dl	161	15	preprint	preprint	NN
cord-324859-0yuhb5dl	161	16	articles	article	NNS
cord-324859-0yuhb5dl	161	17	.	.	.
cord-324859-0yuhb5dl	162	1	The	the	DT
cord-324859-0yuhb5dl	162	2	results	result	NNS
cord-324859-0yuhb5dl	162	3	from	from	IN
cord-324859-0yuhb5dl	162	4	this	this	DT
cord-324859-0yuhb5dl	162	5	group	group	NN
cord-324859-0yuhb5dl	162	6	of	of	IN
cord-324859-0yuhb5dl	162	7	peer	peer	NN
cord-324859-0yuhb5dl	162	8	-	-	HYPH
cord-324859-0yuhb5dl	162	9	reviewed	review	VBN
cord-324859-0yuhb5dl	162	10	studies	study	NNS
cord-324859-0yuhb5dl	162	11	were	be	VBD
cord-324859-0yuhb5dl	162	12	consistent	consistent	JJ
cord-324859-0yuhb5dl	162	13	with	with	IN
cord-324859-0yuhb5dl	162	14	the	the	DT
cord-324859-0yuhb5dl	162	15	overall	overall	JJ
cord-324859-0yuhb5dl	162	16	analyses	analysis	NNS
cord-324859-0yuhb5dl	162	17	.	.	.
cord-324859-0yuhb5dl	163	1	The	the	DT
cord-324859-0yuhb5dl	163	2	level	level	NN
cord-324859-0yuhb5dl	163	3	of	of	IN
cord-324859-0yuhb5dl	163	4	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	163	5	in	in	IN
cord-324859-0yuhb5dl	163	6	these	these	DT
cord-324859-0yuhb5dl	163	7	two	two	CD
cord-324859-0yuhb5dl	163	8	groups	group	NNS
cord-324859-0yuhb5dl	163	9	was	be	VBD
cord-324859-0yuhb5dl	163	10	also	also	RB
cord-324859-0yuhb5dl	163	11	comparable	comparable	JJ
cord-324859-0yuhb5dl	163	12	.	.	.
cord-324859-0yuhb5dl	164	1	The	the	DT
cord-324859-0yuhb5dl	164	2	forest	forest	NN
cord-324859-0yuhb5dl	164	3	plots	plot	NNS
cord-324859-0yuhb5dl	164	4	for	for	IN
cord-324859-0yuhb5dl	164	5	each	each	DT
cord-324859-0yuhb5dl	164	6	of	of	IN
cord-324859-0yuhb5dl	164	7	the	the	DT
cord-324859-0yuhb5dl	164	8	individual	individual	JJ
cord-324859-0yuhb5dl	164	9	outcomes	outcome	NNS
cord-324859-0yuhb5dl	164	10	included	include	VBN
cord-324859-0yuhb5dl	164	11	in	in	IN
cord-324859-0yuhb5dl	164	12	the	the	DT
cord-324859-0yuhb5dl	164	13	meta	meta	NNP
cord-324859-0yuhb5dl	164	14	-	-	HYPH
cord-324859-0yuhb5dl	164	15	analysis	analysis	NN
cord-324859-0yuhb5dl	164	16	are	be	VBP
cord-324859-0yuhb5dl	164	17	depicted	depict	VBN
cord-324859-0yuhb5dl	164	18	in	in	IN
cord-324859-0yuhb5dl	164	19	Figures	figure	NNS
cord-324859-0yuhb5dl	164	20	2	2	CD
cord-324859-0yuhb5dl	164	21	-	-	SYM
cord-324859-0yuhb5dl	164	22	8	8	CD
cord-324859-0yuhb5dl	164	23	.	.	.
cord-324859-0yuhb5dl	165	1	Every	every	DT
cord-324859-0yuhb5dl	165	2	plot	plot	NN
cord-324859-0yuhb5dl	165	3	depicts	depict	VBZ
cord-324859-0yuhb5dl	165	4	the	the	DT
cord-324859-0yuhb5dl	165	5	mean	mean	JJ
cord-324859-0yuhb5dl	165	6	values	value	NNS
cord-324859-0yuhb5dl	165	7	of	of	IN
cord-324859-0yuhb5dl	165	8	the	the	DT
cord-324859-0yuhb5dl	165	9	biomarker	biomarker	NN
cord-324859-0yuhb5dl	165	10	in	in	IN
cord-324859-0yuhb5dl	165	11	the	the	DT
cord-324859-0yuhb5dl	165	12	severe	severe	JJ
cord-324859-0yuhb5dl	165	13	and	and	CC
cord-324859-0yuhb5dl	165	14	moderate	moderate	JJ
cord-324859-0yuhb5dl	165	15	groups	group	NNS
cord-324859-0yuhb5dl	165	16	as	as	RB
cord-324859-0yuhb5dl	165	17	well	well	RB
cord-324859-0yuhb5dl	165	18	as	as	IN
cord-324859-0yuhb5dl	165	19	the	the	DT
cord-324859-0yuhb5dl	165	20	mean	mean	JJ
cord-324859-0yuhb5dl	165	21	difference	difference	NN
cord-324859-0yuhb5dl	165	22	in	in	IN
cord-324859-0yuhb5dl	165	23	each	each	DT
cord-324859-0yuhb5dl	165	24	study	study	NN
cord-324859-0yuhb5dl	165	25	,	,	,
cord-324859-0yuhb5dl	165	26	along	along	IN
cord-324859-0yuhb5dl	165	27	with	with	IN
cord-324859-0yuhb5dl	165	28	the	the	DT
cord-324859-0yuhb5dl	165	29	sample	sample	NN
cord-324859-0yuhb5dl	165	30	sizes	size	NNS
cord-324859-0yuhb5dl	165	31	(	(	-LRB-
cord-324859-0yuhb5dl	165	32	study	study	NN
cord-324859-0yuhb5dl	165	33	-	-	HYPH
cord-324859-0yuhb5dl	165	34	wise	wise	JJ
cord-324859-0yuhb5dl	165	35	and	and	CC
cord-324859-0yuhb5dl	165	36	cumulative	cumulative	JJ
cord-324859-0yuhb5dl	165	37	)	)	-RRB-
cord-324859-0yuhb5dl	165	38	,	,	,
cord-324859-0yuhb5dl	165	39	the	the	DT
cord-324859-0yuhb5dl	165	40	pooled	pool	VBN
cord-324859-0yuhb5dl	165	41	mean	mean	JJ
cord-324859-0yuhb5dl	165	42	difference	difference	NN
cord-324859-0yuhb5dl	165	43	and	and	CC
cord-324859-0yuhb5dl	165	44	the	the	DT
cord-324859-0yuhb5dl	165	45	corresponding	correspond	VBG
cord-324859-0yuhb5dl	165	46	confidence	confidence	NN
cord-324859-0yuhb5dl	165	47	intervals	interval	NNS
cord-324859-0yuhb5dl	165	48	.	.	.
cord-324859-0yuhb5dl	166	1	Funnel	funnel	NN
cord-324859-0yuhb5dl	166	2	plots	plot	NNS
cord-324859-0yuhb5dl	166	3	were	be	VBD
cord-324859-0yuhb5dl	166	4	created	create	VBN
cord-324859-0yuhb5dl	166	5	using	use	VBG
cord-324859-0yuhb5dl	166	6	RevMan	RevMan	NNP
cord-324859-0yuhb5dl	166	7	,	,	,
cord-324859-0yuhb5dl	166	8	for	for	IN
cord-324859-0yuhb5dl	166	9	a	a	DT
cord-324859-0yuhb5dl	166	10	visual	visual	JJ
cord-324859-0yuhb5dl	166	11	assessment	assessment	NN
cord-324859-0yuhb5dl	166	12	of	of	IN
cord-324859-0yuhb5dl	166	13	the	the	DT
cord-324859-0yuhb5dl	166	14	presence	presence	NN
cord-324859-0yuhb5dl	166	15	of	of	IN
cord-324859-0yuhb5dl	166	16	a	a	DT
cord-324859-0yuhb5dl	166	17	possible	possible	JJ
cord-324859-0yuhb5dl	166	18	publication	publication	NN
cord-324859-0yuhb5dl	166	19	bias	bias	NN
cord-324859-0yuhb5dl	166	20	among	among	IN
cord-324859-0yuhb5dl	166	21	studies	study	NNS
cord-324859-0yuhb5dl	166	22	of	of	IN
cord-324859-0yuhb5dl	166	23	each	each	DT
cord-324859-0yuhb5dl	166	24	outcome	outcome	NN
cord-324859-0yuhb5dl	166	25	(	(	-LRB-
cord-324859-0yuhb5dl	166	26	File	File	NNP
cord-324859-0yuhb5dl	166	27	S1	S1	NNP
cord-324859-0yuhb5dl	166	28	)	)	-RRB-
cord-324859-0yuhb5dl	166	29	.	.	.
cord-324859-0yuhb5dl	167	1	A	a	DT
cord-324859-0yuhb5dl	167	2	few	few	JJ
cord-324859-0yuhb5dl	167	3	plots	plot	NNS
cord-324859-0yuhb5dl	167	4	demonstrated	demonstrate	VBD
cord-324859-0yuhb5dl	167	5	some	some	DT
cord-324859-0yuhb5dl	167	6	asymmetry	asymmetry	NN
cord-324859-0yuhb5dl	167	7	which	which	WDT
cord-324859-0yuhb5dl	167	8	was	be	VBD
cord-324859-0yuhb5dl	167	9	further	further	RB
cord-324859-0yuhb5dl	167	10	statistically	statistically	RB
cord-324859-0yuhb5dl	167	11	assessed	assess	VBN
cord-324859-0yuhb5dl	167	12	using	use	VBG
cord-324859-0yuhb5dl	167	13	Egger	Egger	NNP
cord-324859-0yuhb5dl	167	14	's	's	POS
cord-324859-0yuhb5dl	167	15	test	test	NN
cord-324859-0yuhb5dl	167	16	in	in	IN
cord-324859-0yuhb5dl	167	17	Stata	Stata	NNP
cord-324859-0yuhb5dl	167	18	.	.	.
cord-324859-0yuhb5dl	168	1	There	there	EX
cord-324859-0yuhb5dl	168	2	was	be	VBD
cord-324859-0yuhb5dl	168	3	a	a	DT
cord-324859-0yuhb5dl	168	4	strong	strong	JJ
cord-324859-0yuhb5dl	168	5	evidence	evidence	NN
cord-324859-0yuhb5dl	168	6	to	to	TO
cord-324859-0yuhb5dl	168	7	suggest	suggest	VB
cord-324859-0yuhb5dl	168	8	the	the	DT
cord-324859-0yuhb5dl	168	9	possibility	possibility	NN
cord-324859-0yuhb5dl	168	10	of	of	IN
cord-324859-0yuhb5dl	168	11	a	a	DT
cord-324859-0yuhb5dl	168	12	publication	publication	NN
cord-324859-0yuhb5dl	168	13	bias	bias	NN
cord-324859-0yuhb5dl	168	14	among	among	IN
cord-324859-0yuhb5dl	168	15	studies	study	NNS
cord-324859-0yuhb5dl	168	16	for	for	IN
cord-324859-0yuhb5dl	168	17	the	the	DT
cord-324859-0yuhb5dl	168	18	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	168	19	outcome	outcome	NN
cord-324859-0yuhb5dl	168	20	(	(	-LRB-
cord-324859-0yuhb5dl	168	21	P	p	NN
cord-324859-0yuhb5dl	168	22	-	-	HYPH
cord-324859-0yuhb5dl	168	23	value	value	NN
cord-324859-0yuhb5dl	168	24	<	<	XX
cord-324859-0yuhb5dl	168	25	.001	.001	CD
cord-324859-0yuhb5dl	168	26	)	)	-RRB-
cord-324859-0yuhb5dl	168	27	,	,	,
cord-324859-0yuhb5dl	168	28	while	while	IN
cord-324859-0yuhb5dl	168	29	the	the	DT
cord-324859-0yuhb5dl	168	30	evidence	evidence	NN
cord-324859-0yuhb5dl	168	31	for	for	IN
cord-324859-0yuhb5dl	168	32	other	other	JJ
cord-324859-0yuhb5dl	168	33	outcomes	outcome	NNS
cord-324859-0yuhb5dl	168	34	was	be	VBD
cord-324859-0yuhb5dl	168	35	not	not	RB
cord-324859-0yuhb5dl	168	36	found	find	VBN
cord-324859-0yuhb5dl	168	37	to	to	TO
cord-324859-0yuhb5dl	168	38	be	be	VB
cord-324859-0yuhb5dl	168	39	significant	significant	JJ
cord-324859-0yuhb5dl	168	40	.	.	.
cord-324859-0yuhb5dl	169	1	It	-PRON-	PRP
cord-324859-0yuhb5dl	169	2	may	may	MD
cord-324859-0yuhb5dl	169	3	be	be	VB
cord-324859-0yuhb5dl	169	4	important	important	JJ
cord-324859-0yuhb5dl	169	5	to	to	TO
cord-324859-0yuhb5dl	169	6	note	note	VB
cord-324859-0yuhb5dl	169	7	that	that	IN
cord-324859-0yuhb5dl	169	8	given	give	VBN
cord-324859-0yuhb5dl	169	9	the	the	DT
cord-324859-0yuhb5dl	169	10	high	high	JJ
cord-324859-0yuhb5dl	169	11	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	169	12	among	among	IN
cord-324859-0yuhb5dl	169	13	studies	study	NNS
cord-324859-0yuhb5dl	169	14	for	for	IN
cord-324859-0yuhb5dl	169	15	a	a	DT
cord-324859-0yuhb5dl	169	16	majority	majority	NN
cord-324859-0yuhb5dl	169	17	of	of	IN
cord-324859-0yuhb5dl	169	18	the	the	DT
cord-324859-0yuhb5dl	169	19	outcomes	outcome	NNS
cord-324859-0yuhb5dl	169	20	,	,	,
cord-324859-0yuhb5dl	169	21	as	as	RB
cord-324859-0yuhb5dl	169	22	well	well	RB
cord-324859-0yuhb5dl	169	23	as	as	IN
cord-324859-0yuhb5dl	169	24	the	the	DT
cord-324859-0yuhb5dl	169	25	fact	fact	NN
cord-324859-0yuhb5dl	169	26	that	that	IN
cord-324859-0yuhb5dl	169	27	such	such	JJ
cord-324859-0yuhb5dl	169	28	bias	bias	NN
cord-324859-0yuhb5dl	169	29	detection	detection	NN
cord-324859-0yuhb5dl	169	30	tests	test	NNS
cord-324859-0yuhb5dl	169	31	are	be	VBP
cord-324859-0yuhb5dl	169	32	known	know	VBN
cord-324859-0yuhb5dl	169	33	to	to	TO
cord-324859-0yuhb5dl	169	34	be	be	VB
cord-324859-0yuhb5dl	169	35	underpowered	underpowere	VBN
cord-324859-0yuhb5dl	169	36	,	,	,
cord-324859-0yuhb5dl	169	37	these	these	DT
cord-324859-0yuhb5dl	169	38	observations	observation	NNS
cord-324859-0yuhb5dl	169	39	need	need	VBP
cord-324859-0yuhb5dl	169	40	to	to	TO
cord-324859-0yuhb5dl	169	41	be	be	VB
cord-324859-0yuhb5dl	169	42	interpreted	interpret	VBN
cord-324859-0yuhb5dl	169	43	with	with	IN
cord-324859-0yuhb5dl	169	44	caution	caution	NN
cord-324859-0yuhb5dl	169	45	.	.	.
cord-324859-0yuhb5dl	170	1	Based	base	VBN
cord-324859-0yuhb5dl	170	2	on	on	IN
cord-324859-0yuhb5dl	170	3	the	the	DT
cord-324859-0yuhb5dl	170	4	reviewed	review	VBN
cord-324859-0yuhb5dl	170	5	studies	study	NNS
cord-324859-0yuhb5dl	170	6	,	,	,
cord-324859-0yuhb5dl	170	7	we	-PRON-	PRP
cord-324859-0yuhb5dl	170	8	found	find	VBD
cord-324859-0yuhb5dl	170	9	that	that	IN
cord-324859-0yuhb5dl	170	10	patients	patient	NNS
cord-324859-0yuhb5dl	170	11	diagnosed	diagnose	VBN
cord-324859-0yuhb5dl	170	12	with	with	IN
cord-324859-0yuhb5dl	170	13	severe	severe	JJ
cord-324859-0yuhb5dl	170	14	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	170	15	had	have	VBD
cord-324859-0yuhb5dl	170	16	significantly	significantly	RB
cord-324859-0yuhb5dl	170	17	higher	high	JJR
cord-324859-0yuhb5dl	170	18	levels	level	NNS
cord-324859-0yuhb5dl	170	19	of	of	IN
cord-324859-0yuhb5dl	170	20	circulating	circulate	VBG
cord-324859-0yuhb5dl	170	21	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	170	22	,	,	,
cord-324859-0yuhb5dl	170	23	IL-8	IL-8	NNP
cord-324859-0yuhb5dl	170	24	,	,	,
cord-324859-0yuhb5dl	170	25	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	170	26	,	,	,
cord-324859-0yuhb5dl	170	27	IL-2R	IL-2R	NNP
cord-324859-0yuhb5dl	170	28	and	and	CC
cord-324859-0yuhb5dl	170	29	TNF	TNF	NNP
cord-324859-0yuhb5dl	170	30	-	-	HYPH
cord-324859-0yuhb5dl	170	31	alpha	alpha	NN
cord-324859-0yuhb5dl	170	32	,	,	,
cord-324859-0yuhb5dl	170	33	as	as	IN
cord-324859-0yuhb5dl	170	34	compared	compare	VBN
cord-324859-0yuhb5dl	170	35	to	to	IN
cord-324859-0yuhb5dl	170	36	the	the	DT
cord-324859-0yuhb5dl	170	37	patients	patient	NNS
cord-324859-0yuhb5dl	170	38	who	who	WP
cord-324859-0yuhb5dl	170	39	had	have	VBD
cord-324859-0yuhb5dl	170	40	a	a	DT
cord-324859-0yuhb5dl	170	41	mild	mild	NN
cord-324859-0yuhb5dl	170	42	-	-	HYPH
cord-324859-0yuhb5dl	170	43	to	to	IN
cord-324859-0yuhb5dl	170	44	-	-	HYPH
cord-324859-0yuhb5dl	170	45	moderate	moderate	JJ
cord-324859-0yuhb5dl	170	46	form	form	NN
cord-324859-0yuhb5dl	170	47	of	of	IN
cord-324859-0yuhb5dl	170	48	the	the	DT
cord-324859-0yuhb5dl	170	49	disease	disease	NN
cord-324859-0yuhb5dl	170	50	.	.	.
cord-324859-0yuhb5dl	171	1	Similarly	similarly	RB
cord-324859-0yuhb5dl	171	2	,	,	,
cord-324859-0yuhb5dl	171	3	in	in	IN
cord-324859-0yuhb5dl	171	4	the	the	DT
cord-324859-0yuhb5dl	171	5	pooled	pool	VBN
cord-324859-0yuhb5dl	171	6	analysis	analysis	NN
cord-324859-0yuhb5dl	171	7	,	,	,
cord-324859-0yuhb5dl	171	8	CD4	CD4	NNP
cord-324859-0yuhb5dl	171	9	+	+	CC
cord-324859-0yuhb5dl	171	10	T	t	NN
cord-324859-0yuhb5dl	171	11	cells	cell	NNS
cord-324859-0yuhb5dl	171	12	as	as	RB
cord-324859-0yuhb5dl	171	13	well	well	RB
cord-324859-0yuhb5dl	171	14	as	as	IN
cord-324859-0yuhb5dl	171	15	CD8	CD8	NNP
cord-324859-0yuhb5dl	171	16	+	+	CC
cord-324859-0yuhb5dl	171	17	T	T	NNP
cord-324859-0yuhb5dl	171	18	cells	cell	NNS
cord-324859-0yuhb5dl	171	19	were	be	VBD
cord-324859-0yuhb5dl	171	20	significantly	significantly	RB
cord-324859-0yuhb5dl	171	21	reduced	reduce	VBN
cord-324859-0yuhb5dl	171	22	in	in	IN
cord-324859-0yuhb5dl	171	23	severely	severely	RB
cord-324859-0yuhb5dl	171	24	ill	ill	JJ
cord-324859-0yuhb5dl	171	25	patients	patient	NNS
cord-324859-0yuhb5dl	171	26	as	as	IN
cord-324859-0yuhb5dl	171	27	compared	compare	VBN
cord-324859-0yuhb5dl	171	28	to	to	IN
cord-324859-0yuhb5dl	171	29	those	those	DT
cord-324859-0yuhb5dl	171	30	with	with	IN
cord-324859-0yuhb5dl	171	31	mild	mild	JJ
cord-324859-0yuhb5dl	171	32	-	-	HYPH
cord-324859-0yuhb5dl	171	33	tomoderate	tomoderate	JJ
cord-324859-0yuhb5dl	171	34	disease	disease	NN
cord-324859-0yuhb5dl	171	35	.	.	.
cord-324859-0yuhb5dl	172	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	172	2	findings	finding	NNS
cord-324859-0yuhb5dl	172	3	corroborate	corroborate	VBP
cord-324859-0yuhb5dl	172	4	with	with	IN
cord-324859-0yuhb5dl	172	5	the	the	DT
cord-324859-0yuhb5dl	172	6	current	current	JJ
cord-324859-0yuhb5dl	172	7	understanding	understanding	NN
cord-324859-0yuhb5dl	172	8	of	of	IN
cord-324859-0yuhb5dl	172	9	the	the	DT
cord-324859-0yuhb5dl	172	10	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	172	11	immunopathogenesis	immunopathogenesis	NN
cord-324859-0yuhb5dl	172	12	which	which	WDT
cord-324859-0yuhb5dl	172	13	is	be	VBZ
cord-324859-0yuhb5dl	172	14	largely	largely	RB
cord-324859-0yuhb5dl	172	15	based	base	VBN
cord-324859-0yuhb5dl	172	16	on	on	IN
cord-324859-0yuhb5dl	172	17	findings	finding	NNS
cord-324859-0yuhb5dl	172	18	from	from	IN
cord-324859-0yuhb5dl	172	19	studies	study	NNS
cord-324859-0yuhb5dl	172	20	on	on	IN
cord-324859-0yuhb5dl	172	21	SARS	SARS	NNP
cord-324859-0yuhb5dl	172	22	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	172	23	(	(	-LRB-
cord-324859-0yuhb5dl	172	24	SARS	SARS	NNP
cord-324859-0yuhb5dl	172	25	-	-	HYPH
cord-324859-0yuhb5dl	172	26	CoV	CoV	NNP
cord-324859-0yuhb5dl	172	27	)	)	-RRB-
cord-324859-0yuhb5dl	172	28	that	that	WDT
cord-324859-0yuhb5dl	172	29	bears	bear	VBZ
cord-324859-0yuhb5dl	172	30	nearly	nearly	RB
cord-324859-0yuhb5dl	172	31	80	80	CD
cord-324859-0yuhb5dl	172	32	%	%	NN
cord-324859-0yuhb5dl	172	33	nucleic	nucleic	JJ
cord-324859-0yuhb5dl	172	34	acid	acid	NN
cord-324859-0yuhb5dl	172	35	homology	homology	NN
cord-324859-0yuhb5dl	172	36	with	with	IN
cord-324859-0yuhb5dl	172	37	SARS	SARS	NNP
cord-324859-0yuhb5dl	172	38	-	-	HYPH
cord-324859-0yuhb5dl	172	39	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	172	40	.	.	.
cord-324859-0yuhb5dl	173	1	65	65	CD
cord-324859-0yuhb5dl	174	1	,	,	,
cord-324859-0yuhb5dl	174	2	66	66	CD
cord-324859-0yuhb5dl	175	1	Following	follow	VBG
cord-324859-0yuhb5dl	175	2	the	the	DT
cord-324859-0yuhb5dl	175	3	virus	virus	NN
cord-324859-0yuhb5dl	175	4	entry	entry	NN
cord-324859-0yuhb5dl	175	5	into	into	IN
cord-324859-0yuhb5dl	175	6	the	the	DT
cord-324859-0yuhb5dl	175	7	lung	lung	NN
cord-324859-0yuhb5dl	175	8	epithelial	epithelial	NN
cord-324859-0yuhb5dl	175	9	cells	cell	NNS
cord-324859-0yuhb5dl	175	10	,	,	,
cord-324859-0yuhb5dl	175	11	the	the	DT
cord-324859-0yuhb5dl	175	12	innate	innate	JJ
cord-324859-0yuhb5dl	175	13	immune	immune	JJ
cord-324859-0yuhb5dl	175	14	response	response	NN
cord-324859-0yuhb5dl	175	15	is	be	VBZ
cord-324859-0yuhb5dl	175	16	triggered	trigger	VBN
cord-324859-0yuhb5dl	175	17	leading	lead	VBG
cord-324859-0yuhb5dl	175	18	to	to	IN
cord-324859-0yuhb5dl	175	19	the	the	DT
cord-324859-0yuhb5dl	175	20	first	first	JJ
cord-324859-0yuhb5dl	175	21	wave	wave	NN
cord-324859-0yuhb5dl	175	22	of	of	IN
cord-324859-0yuhb5dl	175	23	hypercytokinaemia	hypercytokinaemia	NNP
cord-324859-0yuhb5dl	175	24	.	.	.
cord-324859-0yuhb5dl	176	1	The	the	DT
cord-324859-0yuhb5dl	176	2	delayed	delay	VBN
cord-324859-0yuhb5dl	176	3	type	type	NN
cord-324859-0yuhb5dl	177	1	I	-PRON-	PRP
cord-324859-0yuhb5dl	177	2	interferon	interferon	RB
cord-324859-0yuhb5dl	177	3	(	(	-LRB-
cord-324859-0yuhb5dl	177	4	IFN	IFN	NNP
cord-324859-0yuhb5dl	177	5	)	)	-RRB-
cord-324859-0yuhb5dl	177	6	response	response	NN
cord-324859-0yuhb5dl	177	7	in	in	IN
cord-324859-0yuhb5dl	177	8	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	177	9	infections	infection	NNS
cord-324859-0yuhb5dl	177	10	is	be	VBZ
cord-324859-0yuhb5dl	177	11	known	know	VBN
cord-324859-0yuhb5dl	177	12	to	to	TO
cord-324859-0yuhb5dl	177	13	be	be	VB
cord-324859-0yuhb5dl	177	14	associated	associate	VBN
cord-324859-0yuhb5dl	177	15	with	with	IN
cord-324859-0yuhb5dl	177	16	more	more	JJR
cord-324859-0yuhb5dl	177	17	severe	severe	JJ
cord-324859-0yuhb5dl	177	18	forms	form	NNS
cord-324859-0yuhb5dl	177	19	of	of	IN
cord-324859-0yuhb5dl	177	20	the	the	DT
cord-324859-0yuhb5dl	177	21	disease	disease	NN
cord-324859-0yuhb5dl	177	22	resulting	result	VBG
cord-324859-0yuhb5dl	177	23	in	in	IN
cord-324859-0yuhb5dl	177	24	rapid	rapid	JJ
cord-324859-0yuhb5dl	177	25	viral	viral	JJ
cord-324859-0yuhb5dl	177	26	multiplication	multiplication	NN
cord-324859-0yuhb5dl	177	27	and	and	CC
cord-324859-0yuhb5dl	177	28	paradoxical	paradoxical	JJ
cord-324859-0yuhb5dl	177	29	hyperinflammation	hyperinflammation	NN
cord-324859-0yuhb5dl	177	30	induced	induce	VBN
cord-324859-0yuhb5dl	177	31	by	by	IN
cord-324859-0yuhb5dl	177	32	type	type	NN
cord-324859-0yuhb5dl	177	33	I	-PRON-	PRP
cord-324859-0yuhb5dl	177	34	interferons	interferon	NNS
cord-324859-0yuhb5dl	177	35	.	.	.
cord-324859-0yuhb5dl	178	1	67	67	CD
cord-324859-0yuhb5dl	178	2	,	,	,
cord-324859-0yuhb5dl	178	3	68	68	CD
cord-324859-0yuhb5dl	178	4	Further	further	JJ
cord-324859-0yuhb5dl	178	5	activation	activation	NN
cord-324859-0yuhb5dl	178	6	of	of	IN
cord-324859-0yuhb5dl	178	7	the	the	DT
cord-324859-0yuhb5dl	178	8	type	type	NN
cord-324859-0yuhb5dl	178	9	I	-PRON-	PRP
cord-324859-0yuhb5dl	178	10	IFN	IFN	NNP
cord-324859-0yuhb5dl	178	11	signalling	signal	VBG
cord-324859-0yuhb5dl	178	12	pathways	pathway	NNS
cord-324859-0yuhb5dl	178	13	leads	lead	VBZ
cord-324859-0yuhb5dl	178	14	to	to	IN
cord-324859-0yuhb5dl	178	15	a	a	DT
cord-324859-0yuhb5dl	178	16	significant	significant	JJ
cord-324859-0yuhb5dl	178	17	influx	influx	NN
cord-324859-0yuhb5dl	178	18	of	of	IN
cord-324859-0yuhb5dl	178	19	neutrophils	neutrophil	NNS
cord-324859-0yuhb5dl	178	20	,	,	,
cord-324859-0yuhb5dl	178	21	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	178	22	monocytes	monocyte	NNS
cord-324859-0yuhb5dl	178	23	-	-	HYPH
cord-324859-0yuhb5dl	178	24	macrophages	macrophage	NNS
cord-324859-0yuhb5dl	178	25	,	,	,
cord-324859-0yuhb5dl	178	26	dendritic	dendritic	JJ
cord-324859-0yuhb5dl	178	27	cells	cell	NNS
cord-324859-0yuhb5dl	178	28	and	and	CC
cord-324859-0yuhb5dl	178	29	NK	NK	NNP
cord-324859-0yuhb5dl	178	30	cells	cell	NNS
cord-324859-0yuhb5dl	178	31	into	into	IN
cord-324859-0yuhb5dl	178	32	the	the	DT
cord-324859-0yuhb5dl	178	33	lungs	lung	NNS
cord-324859-0yuhb5dl	178	34	.	.	.
cord-324859-0yuhb5dl	179	1	These	these	DT
cord-324859-0yuhb5dl	179	2	infiltrating	infiltrate	VBG
cord-324859-0yuhb5dl	179	3	cells	cell	NNS
cord-324859-0yuhb5dl	179	4	are	be	VBP
cord-324859-0yuhb5dl	179	5	the	the	DT
cord-324859-0yuhb5dl	179	6	major	major	JJ
cord-324859-0yuhb5dl	179	7	source	source	NN
cord-324859-0yuhb5dl	179	8	of	of	IN
cord-324859-0yuhb5dl	179	9	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	179	10	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	179	11	that	that	WDT
cord-324859-0yuhb5dl	179	12	set	set	VBD
cord-324859-0yuhb5dl	179	13	off	off	RP
cord-324859-0yuhb5dl	179	14	the	the	DT
cord-324859-0yuhb5dl	179	15	second	second	JJ
cord-324859-0yuhb5dl	179	16	wave	wave	NN
cord-324859-0yuhb5dl	179	17	-	-	:
cord-324859-0yuhb5dl	179	18	the	the	DT
cord-324859-0yuhb5dl	179	19	dreaded	dreaded	JJ
cord-324859-0yuhb5dl	179	20	cytokine	cytokine	NN
cord-324859-0yuhb5dl	179	21	storm	storm	NN
cord-324859-0yuhb5dl	179	22	.	.	.
cord-324859-0yuhb5dl	180	1	69	69	CD
cord-324859-0yuhb5dl	181	1	A	a	DT
cord-324859-0yuhb5dl	181	2	characteristic	characteristic	JJ
cord-324859-0yuhb5dl	181	3	feature	feature	NN
cord-324859-0yuhb5dl	181	4	of	of	IN
cord-324859-0yuhb5dl	181	5	severe	severe	JJ
cord-324859-0yuhb5dl	181	6	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	181	7	is	be	VBZ
cord-324859-0yuhb5dl	181	8	lymphopenia	lymphopenia	NNP
cord-324859-0yuhb5dl	181	9	that	that	WDT
cord-324859-0yuhb5dl	181	10	has	have	VBZ
cord-324859-0yuhb5dl	181	11	been	be	VBN
cord-324859-0yuhb5dl	181	12	ascribed	ascribe	VBN
cord-324859-0yuhb5dl	181	13	to	to	IN
cord-324859-0yuhb5dl	181	14	multiple	multiple	JJ
cord-324859-0yuhb5dl	181	15	plausible	plausible	JJ
cord-324859-0yuhb5dl	181	16	mechanisms	mechanism	NNS
cord-324859-0yuhb5dl	181	17	including	include	VBG
cord-324859-0yuhb5dl	181	18	direct	direct	JJ
cord-324859-0yuhb5dl	181	19	viral	viral	JJ
cord-324859-0yuhb5dl	181	20	cytopathic	cytopathic	JJ
cord-324859-0yuhb5dl	181	21	effects	effect	NNS
cord-324859-0yuhb5dl	181	22	,	,	,
cord-324859-0yuhb5dl	181	23	inhibitory	inhibitory	JJ
cord-324859-0yuhb5dl	181	24	effects	effect	NNS
cord-324859-0yuhb5dl	181	25	of	of	IN
cord-324859-0yuhb5dl	181	26	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	181	27	including	include	VBG
cord-324859-0yuhb5dl	181	28	TNFalpha	TNFalpha	NNP
cord-324859-0yuhb5dl	181	29	,	,	,
cord-324859-0yuhb5dl	181	30	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	181	31	and	and	CC
cord-324859-0yuhb5dl	181	32	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	181	33	,	,	,
cord-324859-0yuhb5dl	181	34	and	and	CC
cord-324859-0yuhb5dl	181	35	immune	immune	JJ
cord-324859-0yuhb5dl	181	36	cell	cell	NN
cord-324859-0yuhb5dl	181	37	redistribution	redistribution	NN
cord-324859-0yuhb5dl	181	38	into	into	IN
cord-324859-0yuhb5dl	181	39	the	the	DT
cord-324859-0yuhb5dl	181	40	lungs	lung	NNS
cord-324859-0yuhb5dl	181	41	and	and	CC
cord-324859-0yuhb5dl	181	42	lymphoid	lymphoid	JJ
cord-324859-0yuhb5dl	181	43	organs	organ	NNS
cord-324859-0yuhb5dl	181	44	.	.	.
cord-324859-0yuhb5dl	182	1	[	[	-LRB-
cord-324859-0yuhb5dl	182	2	70	70	CD
cord-324859-0yuhb5dl	182	3	]	]	-RRB-
cord-324859-0yuhb5dl	182	4	[	[	-LRB-
cord-324859-0yuhb5dl	182	5	71	71	CD
cord-324859-0yuhb5dl	182	6	]	]	-RRB-
cord-324859-0yuhb5dl	182	7	[	[	-LRB-
cord-324859-0yuhb5dl	182	8	72	72	CD
cord-324859-0yuhb5dl	182	9	]	]	-RRB-
cord-324859-0yuhb5dl	183	1	Diminished	Diminished	NNP
cord-324859-0yuhb5dl	183	2	T	t	NN
cord-324859-0yuhb5dl	183	3	-	-	HYPH
cord-324859-0yuhb5dl	183	4	cell	cell	NN
cord-324859-0yuhb5dl	183	5	responses	response	NNS
cord-324859-0yuhb5dl	183	6	are	be	VBP
cord-324859-0yuhb5dl	183	7	known	know	VBN
cord-324859-0yuhb5dl	183	8	to	to	TO
cord-324859-0yuhb5dl	183	9	further	far	RBR
cord-324859-0yuhb5dl	183	10	retard	retard	VB
cord-324859-0yuhb5dl	183	11	viral	viral	JJ
cord-324859-0yuhb5dl	183	12	clearance	clearance	NN
cord-324859-0yuhb5dl	183	13	,	,	,
cord-324859-0yuhb5dl	183	14	thus	thus	RB
cord-324859-0yuhb5dl	183	15	leading	lead	VBG
cord-324859-0yuhb5dl	183	16	to	to	IN
cord-324859-0yuhb5dl	183	17	a	a	DT
cord-324859-0yuhb5dl	183	18	cytokine	cytokine	NN
cord-324859-0yuhb5dl	183	19	-	-	HYPH
cord-324859-0yuhb5dl	183	20	driven	drive	VBN
cord-324859-0yuhb5dl	183	21	vicious	vicious	JJ
cord-324859-0yuhb5dl	183	22	cycle	cycle	NN
cord-324859-0yuhb5dl	183	23	.	.	.
cord-324859-0yuhb5dl	184	1	The	the	DT
cord-324859-0yuhb5dl	184	2	hyperinflammatory	hyperinflammatory	JJ
cord-324859-0yuhb5dl	184	3	state	state	NN
cord-324859-0yuhb5dl	184	4	eventually	eventually	RB
cord-324859-0yuhb5dl	184	5	leads	lead	VBZ
cord-324859-0yuhb5dl	184	6	to	to	IN
cord-324859-0yuhb5dl	184	7	significant	significant	JJ
cord-324859-0yuhb5dl	184	8	damage	damage	NN
cord-324859-0yuhb5dl	184	9	to	to	IN
cord-324859-0yuhb5dl	184	10	the	the	DT
cord-324859-0yuhb5dl	184	11	lung	lung	NN
cord-324859-0yuhb5dl	184	12	microvasculature	microvasculature	NN
cord-324859-0yuhb5dl	184	13	and	and	CC
cord-324859-0yuhb5dl	184	14	alveolar	alveolar	NN
cord-324859-0yuhb5dl	184	15	epithelium	epithelium	NN
cord-324859-0yuhb5dl	184	16	causing	cause	VBG
cord-324859-0yuhb5dl	184	17	vascular	vascular	JJ
cord-324859-0yuhb5dl	184	18	leakage	leakage	NN
cord-324859-0yuhb5dl	184	19	and	and	CC
cord-324859-0yuhb5dl	184	20	alveolar	alveolar	NN
cord-324859-0yuhb5dl	184	21	oedema	oedema	NN
cord-324859-0yuhb5dl	184	22	resulting	result	VBG
cord-324859-0yuhb5dl	184	23	in	in	IN
cord-324859-0yuhb5dl	184	24	life	life	NN
cord-324859-0yuhb5dl	184	25	-	-	HYPH
cord-324859-0yuhb5dl	184	26	threatening	threaten	VBG
cord-324859-0yuhb5dl	184	27	acute	acute	JJ
cord-324859-0yuhb5dl	184	28	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	184	29	distress	distress	NN
cord-324859-0yuhb5dl	184	30	syndrome	syndrome	NN
cord-324859-0yuhb5dl	184	31	(	(	-LRB-
cord-324859-0yuhb5dl	184	32	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	184	33	)	)	-RRB-
cord-324859-0yuhb5dl	184	34	.	.	.
cord-324859-0yuhb5dl	185	1	These	these	DT
cord-324859-0yuhb5dl	185	2	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	185	3	and	and	CC
cord-324859-0yuhb5dl	185	4	chemokines	chemokine	NNS
cord-324859-0yuhb5dl	185	5	have	have	VBP
cord-324859-0yuhb5dl	185	6	also	also	RB
cord-324859-0yuhb5dl	185	7	been	be	VBN
cord-324859-0yuhb5dl	185	8	linked	link	VBN
cord-324859-0yuhb5dl	185	9	to	to	IN
cord-324859-0yuhb5dl	185	10	extrapulmonary	extrapulmonary	JJ
cord-324859-0yuhb5dl	185	11	complications	complication	NNS
cord-324859-0yuhb5dl	185	12	of	of	IN
cord-324859-0yuhb5dl	185	13	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	185	14	including	include	VBG
cord-324859-0yuhb5dl	185	15	multiple	multiple	JJ
cord-324859-0yuhb5dl	185	16	-	-	HYPH
cord-324859-0yuhb5dl	185	17	organ	organ	NN
cord-324859-0yuhb5dl	185	18	dysfunction	dysfunction	NN
cord-324859-0yuhb5dl	185	19	syndrome	syndrome	NN
cord-324859-0yuhb5dl	185	20	.	.	.
cord-324859-0yuhb5dl	186	1	73	73	CD
cord-324859-0yuhb5dl	187	1	these	these	DT
cord-324859-0yuhb5dl	187	2	proposed	propose	VBN
cord-324859-0yuhb5dl	187	3	mechanisms	mechanism	NNS
cord-324859-0yuhb5dl	187	4	,	,	,
cord-324859-0yuhb5dl	187	5	we	-PRON-	PRP
cord-324859-0yuhb5dl	187	6	found	find	VBD
cord-324859-0yuhb5dl	187	7	significantly	significantly	RB
cord-324859-0yuhb5dl	187	8	higher	high	JJR
cord-324859-0yuhb5dl	187	9	circulating	circulate	VBG
cord-324859-0yuhb5dl	187	10	levels	level	NNS
cord-324859-0yuhb5dl	187	11	of	of	IN
cord-324859-0yuhb5dl	187	12	pro	pro	JJ
cord-324859-0yuhb5dl	187	13	-	-	JJ
cord-324859-0yuhb5dl	187	14	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	187	15	markers	marker	NNS
cord-324859-0yuhb5dl	188	1	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	188	2	,	,	,
cord-324859-0yuhb5dl	188	3	IL-2R	IL-2R	NNP
cord-324859-0yuhb5dl	188	4	and	and	CC
cord-324859-0yuhb5dl	188	5	TNF	TNF	NNP
cord-324859-0yuhb5dl	188	6	-	-	HYPH
cord-324859-0yuhb5dl	188	7	alpha	alpha	NN
cord-324859-0yuhb5dl	188	8	among	among	IN
cord-324859-0yuhb5dl	188	9	patients	patient	NNS
cord-324859-0yuhb5dl	188	10	diagnosed	diagnose	VBN
cord-324859-0yuhb5dl	188	11	with	with	IN
cord-324859-0yuhb5dl	188	12	severe	severe	JJ
cord-324859-0yuhb5dl	188	13	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	189	1	as	as	IN
cord-324859-0yuhb5dl	189	2	compared	compare	VBN
cord-324859-0yuhb5dl	189	3	to	to	IN
cord-324859-0yuhb5dl	189	4	the	the	DT
cord-324859-0yuhb5dl	189	5	non	non	JJ
cord-324859-0yuhb5dl	189	6	-	-	JJ
cord-324859-0yuhb5dl	189	7	severe	severe	JJ
cord-324859-0yuhb5dl	189	8	cases	case	NNS
cord-324859-0yuhb5dl	189	9	.	.	.
cord-324859-0yuhb5dl	190	1	IL-8	IL-8	NNP
cord-324859-0yuhb5dl	190	2	,	,	,
cord-324859-0yuhb5dl	190	3	also	also	RB
cord-324859-0yuhb5dl	190	4	known	know	VBN
cord-324859-0yuhb5dl	190	5	as	as	IN
cord-324859-0yuhb5dl	190	6	CXCL8	CXCL8	NNP
cord-324859-0yuhb5dl	190	7	,	,	,
cord-324859-0yuhb5dl	190	8	is	be	VBZ
cord-324859-0yuhb5dl	190	9	a	a	DT
cord-324859-0yuhb5dl	190	10	key	key	JJ
cord-324859-0yuhb5dl	190	11	regulator	regulator	NN
cord-324859-0yuhb5dl	190	12	of	of	IN
cord-324859-0yuhb5dl	190	13	neutrophil	neutrophil	NN
cord-324859-0yuhb5dl	190	14	and	and	CC
cord-324859-0yuhb5dl	190	15	monocyte	monocyte	NN
cord-324859-0yuhb5dl	190	16	chemotaxis	chemotaxis	NN
cord-324859-0yuhb5dl	190	17	in	in	IN
cord-324859-0yuhb5dl	190	18	the	the	DT
cord-324859-0yuhb5dl	190	19	lungs	lung	NNS
cord-324859-0yuhb5dl	190	20	and	and	CC
cord-324859-0yuhb5dl	190	21	is	be	VBZ
cord-324859-0yuhb5dl	190	22	considered	consider	VBN
cord-324859-0yuhb5dl	190	23	to	to	TO
cord-324859-0yuhb5dl	190	24	be	be	VB
cord-324859-0yuhb5dl	190	25	a	a	DT
cord-324859-0yuhb5dl	190	26	prognostic	prognostic	JJ
cord-324859-0yuhb5dl	190	27	marker	marker	NN
cord-324859-0yuhb5dl	190	28	for	for	IN
cord-324859-0yuhb5dl	190	29	the	the	DT
cord-324859-0yuhb5dl	190	30	clinical	clinical	JJ
cord-324859-0yuhb5dl	190	31	course	course	NN
cord-324859-0yuhb5dl	190	32	of	of	IN
cord-324859-0yuhb5dl	190	33	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	190	34	.	.	.
cord-324859-0yuhb5dl	191	1	75	75	CD
cord-324859-0yuhb5dl	191	2	,	,	,
cord-324859-0yuhb5dl	191	3	76	76	CD
cord-324859-0yuhb5dl	192	1	In	in	IN
cord-324859-0yuhb5dl	192	2	patients	patient	NNS
cord-324859-0yuhb5dl	192	3	with	with	IN
cord-324859-0yuhb5dl	192	4	acute	acute	JJ
cord-324859-0yuhb5dl	192	5	lung	lung	NN
cord-324859-0yuhb5dl	192	6	injury	injury	NN
cord-324859-0yuhb5dl	192	7	,	,	,
cord-324859-0yuhb5dl	192	8	elevated	elevated	JJ
cord-324859-0yuhb5dl	192	9	plasma	plasma	NN
cord-324859-0yuhb5dl	192	10	IL-8	il-8	NN
cord-324859-0yuhb5dl	192	11	levels	level	NNS
cord-324859-0yuhb5dl	192	12	have	have	VBP
cord-324859-0yuhb5dl	192	13	been	be	VBN
cord-324859-0yuhb5dl	192	14	associated	associate	VBN
cord-324859-0yuhb5dl	192	15	with	with	IN
cord-324859-0yuhb5dl	192	16	an	an	DT
cord-324859-0yuhb5dl	192	17	increased	increase	VBN
cord-324859-0yuhb5dl	192	18	risk	risk	NN
cord-324859-0yuhb5dl	192	19	of	of	IN
cord-324859-0yuhb5dl	192	20	mortality	mortality	NN
cord-324859-0yuhb5dl	192	21	,	,	,
cord-324859-0yuhb5dl	192	22	as	as	RB
cord-324859-0yuhb5dl	192	23	well	well	RB
cord-324859-0yuhb5dl	192	24	as	as	IN
cord-324859-0yuhb5dl	192	25	reduced	reduce	VBN
cord-324859-0yuhb5dl	192	26	ventilator	ventilator	NN
cord-324859-0yuhb5dl	192	27	-	-	HYPH
cord-324859-0yuhb5dl	192	28	free	free	JJ
cord-324859-0yuhb5dl	192	29	and	and	CC
cord-324859-0yuhb5dl	192	30	organ	organ	NN
cord-324859-0yuhb5dl	192	31	failure	failure	NN
cord-324859-0yuhb5dl	192	32	-	-	HYPH
cord-324859-0yuhb5dl	192	33	free	free	JJ
cord-324859-0yuhb5dl	192	34	days	day	NNS
cord-324859-0yuhb5dl	192	35	.	.	.
cord-324859-0yuhb5dl	193	1	77	77	CD
cord-324859-0yuhb5dl	194	1	In	in	IN
cord-324859-0yuhb5dl	194	2	contrast	contrast	NN
cord-324859-0yuhb5dl	194	3	to	to	IN
cord-324859-0yuhb5dl	194	4	SARS	SARS	NNP
cord-324859-0yuhb5dl	194	5	,	,	,
cord-324859-0yuhb5dl	194	6	we	-PRON-	PRP
cord-324859-0yuhb5dl	194	7	found	find	VBD
cord-324859-0yuhb5dl	194	8	elevated	elevated	JJ
cord-324859-0yuhb5dl	194	9	levels	level	NNS
cord-324859-0yuhb5dl	194	10	of	of	IN
cord-324859-0yuhb5dl	194	11	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	194	12	,	,	,
cord-324859-0yuhb5dl	194	13	a	a	DT
cord-324859-0yuhb5dl	194	14	T	t	NN
cord-324859-0yuhb5dl	194	15	helper	helper	NN
cord-324859-0yuhb5dl	194	16	type	type	NN
cord-324859-0yuhb5dl	194	17	2	2	CD
cord-324859-0yuhb5dl	195	1	(	(	-LRB-
cord-324859-0yuhb5dl	195	2	Th2	th2	CD
cord-324859-0yuhb5dl	195	3	)	)	-RRB-
cord-324859-0yuhb5dl	195	4	cellsecreted	cellsecrete	VBN
cord-324859-0yuhb5dl	195	5	cytokine	cytokine	NN
cord-324859-0yuhb5dl	195	6	and	and	CC
cord-324859-0yuhb5dl	195	7	an	an	DT
cord-324859-0yuhb5dl	195	8	inhibitor	inhibitor	NN
cord-324859-0yuhb5dl	195	9	of	of	IN
cord-324859-0yuhb5dl	195	10	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	195	11	response	response	NN
cord-324859-0yuhb5dl	195	12	,	,	,
cord-324859-0yuhb5dl	195	13	in	in	IN
cord-324859-0yuhb5dl	195	14	severe	severe	JJ
cord-324859-0yuhb5dl	195	15	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	195	16	patients	patient	NNS
cord-324859-0yuhb5dl	195	17	as	as	IN
cord-324859-0yuhb5dl	195	18	compared	compare	VBN
cord-324859-0yuhb5dl	195	19	to	to	IN
cord-324859-0yuhb5dl	195	20	non	non	JJ
cord-324859-0yuhb5dl	195	21	-	-	JJ
cord-324859-0yuhb5dl	195	22	severe	severe	JJ
cord-324859-0yuhb5dl	195	23	cases	case	NNS
cord-324859-0yuhb5dl	195	24	.	.	.
cord-324859-0yuhb5dl	196	1	Higher	high	JJR
cord-324859-0yuhb5dl	196	2	levels	level	NNS
cord-324859-0yuhb5dl	196	3	of	of	IN
cord-324859-0yuhb5dl	196	4	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	196	5	have	have	VBP
cord-324859-0yuhb5dl	196	6	also	also	RB
cord-324859-0yuhb5dl	196	7	been	be	VBN
cord-324859-0yuhb5dl	196	8	associated	associate	VBN
cord-324859-0yuhb5dl	196	9	with	with	IN
cord-324859-0yuhb5dl	196	10	increased	increase	VBN
cord-324859-0yuhb5dl	196	11	expression	expression	NN
cord-324859-0yuhb5dl	196	12	of	of	IN
cord-324859-0yuhb5dl	196	13	T	t	NN
cord-324859-0yuhb5dl	196	14	-	-	HYPH
cord-324859-0yuhb5dl	196	15	cell	cell	NN
cord-324859-0yuhb5dl	196	16	exhaustion	exhaustion	NN
cord-324859-0yuhb5dl	196	17	markers	marker	NNS
cord-324859-0yuhb5dl	196	18	,	,	,
cord-324859-0yuhb5dl	196	19	PD-1	PD-1	NNP
cord-324859-0yuhb5dl	196	20	and	and	CC
cord-324859-0yuhb5dl	196	21	Tim-3	Tim-3	NNP
cord-324859-0yuhb5dl	196	22	,	,	,
cord-324859-0yuhb5dl	196	23	in	in	IN
cord-324859-0yuhb5dl	196	24	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	196	25	patients	patient	NNS
cord-324859-0yuhb5dl	196	26	and	and	CC
cord-324859-0yuhb5dl	196	27	their	-PRON-	PRP$
cord-324859-0yuhb5dl	196	28	consequently	consequently	RB
cord-324859-0yuhb5dl	196	29	impaired	impair	VBN
cord-324859-0yuhb5dl	196	30	ability	ability	NN
cord-324859-0yuhb5dl	196	31	to	to	TO
cord-324859-0yuhb5dl	196	32	clear	clear	VB
cord-324859-0yuhb5dl	196	33	viral	viral	JJ
cord-324859-0yuhb5dl	196	34	infections	infection	NNS
cord-324859-0yuhb5dl	196	35	especially	especially	RB
cord-324859-0yuhb5dl	196	36	in	in	IN
cord-324859-0yuhb5dl	196	37	severely	severely	RB
cord-324859-0yuhb5dl	196	38	affected	affect	VBN
cord-324859-0yuhb5dl	196	39	individuals	individual	NNS
cord-324859-0yuhb5dl	196	40	.	.	.
cord-324859-0yuhb5dl	197	1	78	78	CD
cord-324859-0yuhb5dl	198	1	The	the	DT
cord-324859-0yuhb5dl	198	2	difference	difference	NN
cord-324859-0yuhb5dl	198	3	in	in	IN
cord-324859-0yuhb5dl	198	4	levels	level	NNS
cord-324859-0yuhb5dl	198	5	of	of	IN
cord-324859-0yuhb5dl	198	6	TNF	tnf	NN
cord-324859-0yuhb5dl	198	7	-	-	HYPH
cord-324859-0yuhb5dl	198	8	alpha	alpha	NN
cord-324859-0yuhb5dl	198	9	though	though	IN
cord-324859-0yuhb5dl	198	10	significant	significant	JJ
cord-324859-0yuhb5dl	198	11	was	be	VBD
cord-324859-0yuhb5dl	198	12	not	not	RB
cord-324859-0yuhb5dl	198	13	pronounced	pronounce	VBN
cord-324859-0yuhb5dl	198	14	,	,	,
cord-324859-0yuhb5dl	198	15	which	which	WDT
cord-324859-0yuhb5dl	198	16	could	could	MD
cord-324859-0yuhb5dl	198	17	be	be	VB
cord-324859-0yuhb5dl	198	18	a	a	DT
cord-324859-0yuhb5dl	198	19	consequence	consequence	NN
cord-324859-0yuhb5dl	198	20	of	of	IN
cord-324859-0yuhb5dl	198	21	lesser	less	JJR
cord-324859-0yuhb5dl	198	22	number	number	NN
cord-324859-0yuhb5dl	198	23	of	of	IN
cord-324859-0yuhb5dl	198	24	studies	study	NNS
cord-324859-0yuhb5dl	198	25	reporting	report	VBG
cord-324859-0yuhb5dl	198	26	the	the	DT
cord-324859-0yuhb5dl	198	27	outcome	outcome	NN
cord-324859-0yuhb5dl	198	28	as	as	RB
cord-324859-0yuhb5dl	198	29	well	well	RB
cord-324859-0yuhb5dl	198	30	as	as	IN
cord-324859-0yuhb5dl	198	31	the	the	DT
cord-324859-0yuhb5dl	198	32	rather	rather	RB
cord-324859-0yuhb5dl	198	33	small	small	JJ
cord-324859-0yuhb5dl	198	34	sample	sample	NN
cord-324859-0yuhb5dl	198	35	sizes	size	NNS
cord-324859-0yuhb5dl	198	36	of	of	IN
cord-324859-0yuhb5dl	198	37	a	a	DT
cord-324859-0yuhb5dl	198	38	majority	majority	NN
cord-324859-0yuhb5dl	198	39	of	of	IN
cord-324859-0yuhb5dl	198	40	the	the	DT
cord-324859-0yuhb5dl	198	41	included	include	VBN
cord-324859-0yuhb5dl	198	42	studies	study	NNS
cord-324859-0yuhb5dl	198	43	.	.	.
cord-324859-0yuhb5dl	199	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	199	2	found	find	VBD
cord-324859-0yuhb5dl	199	3	a	a	DT
cord-324859-0yuhb5dl	199	4	significant	significant	JJ
cord-324859-0yuhb5dl	199	5	reduction	reduction	NN
cord-324859-0yuhb5dl	199	6	in	in	IN
cord-324859-0yuhb5dl	199	7	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	199	8	counts	count	NNS
cord-324859-0yuhb5dl	199	9	-	-	:
cord-324859-0yuhb5dl	199	10	both	both	DT
cord-324859-0yuhb5dl	199	11	CD4	CD4	NNP
cord-324859-0yuhb5dl	199	12	+	+	CC
cord-324859-0yuhb5dl	199	13	and	and	CC
cord-324859-0yuhb5dl	199	14	CD8	CD8	NNP
cord-324859-0yuhb5dl	199	15	+	+	CC
cord-324859-0yuhb5dl	199	16	in	in	IN
cord-324859-0yuhb5dl	199	17	patients	patient	NNS
cord-324859-0yuhb5dl	199	18	diagnosed	diagnose	VBN
cord-324859-0yuhb5dl	199	19	with	with	IN
cord-324859-0yuhb5dl	199	20	severe	severe	JJ
cord-324859-0yuhb5dl	199	21	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	199	22	.	.	.
cord-324859-0yuhb5dl	200	1	Similar	similar	JJ
cord-324859-0yuhb5dl	200	2	findings	finding	NNS
cord-324859-0yuhb5dl	200	3	have	have	VBP
cord-324859-0yuhb5dl	200	4	also	also	RB
cord-324859-0yuhb5dl	200	5	been	be	VBN
cord-324859-0yuhb5dl	200	6	reported	report	VBN
cord-324859-0yuhb5dl	200	7	for	for	IN
cord-324859-0yuhb5dl	200	8	SARS	SARS	NNP
cord-324859-0yuhb5dl	200	9	as	as	RB
cord-324859-0yuhb5dl	200	10	well	well	RB
cord-324859-0yuhb5dl	200	11	as	as	IN
cord-324859-0yuhb5dl	200	12	MERS	MERS	NNPS
cord-324859-0yuhb5dl	200	13	and	and	CC
cord-324859-0yuhb5dl	200	14	have	have	VBP
cord-324859-0yuhb5dl	200	15	been	be	VBN
cord-324859-0yuhb5dl	200	16	linked	link	VBN
cord-324859-0yuhb5dl	200	17	to	to	IN
cord-324859-0yuhb5dl	200	18	disease	disease	NN
cord-324859-0yuhb5dl	200	19	severity	severity	NN
cord-324859-0yuhb5dl	200	20	and	and	CC
cord-324859-0yuhb5dl	200	21	adverse	adverse	JJ
cord-324859-0yuhb5dl	200	22	outcomes	outcome	NNS
cord-324859-0yuhb5dl	200	23	in	in	IN
cord-324859-0yuhb5dl	200	24	these	these	DT
cord-324859-0yuhb5dl	200	25	patients	patient	NNS
cord-324859-0yuhb5dl	200	26	.	.	.
cord-324859-0yuhb5dl	201	1	[	[	-LRB-
cord-324859-0yuhb5dl	201	2	79	79	CD
cord-324859-0yuhb5dl	201	3	]	]	-RRB-
cord-324859-0yuhb5dl	201	4	[	[	-LRB-
cord-324859-0yuhb5dl	201	5	80	80	CD
cord-324859-0yuhb5dl	201	6	]	]	-RRB-
cord-324859-0yuhb5dl	202	1	[	[	-LRB-
cord-324859-0yuhb5dl	202	2	81	81	CD
cord-324859-0yuhb5dl	202	3	]	]	-RRB-
cord-324859-0yuhb5dl	203	1	[	[	-LRB-
cord-324859-0yuhb5dl	203	2	82	82	CD
cord-324859-0yuhb5dl	203	3	]	]	-RRB-
cord-324859-0yuhb5dl	204	1	[	[	-LRB-
cord-324859-0yuhb5dl	204	2	83	83	CD
cord-324859-0yuhb5dl	204	3	]	]	-RRB-
cord-324859-0yuhb5dl	205	1	In	in	IN
cord-324859-0yuhb5dl	205	2	follow	follow	NN
cord-324859-0yuhb5dl	205	3	-	-	HYPH
cord-324859-0yuhb5dl	205	4	up	up	NN
cord-324859-0yuhb5dl	205	5	studies	study	NNS
cord-324859-0yuhb5dl	205	6	in	in	IN
cord-324859-0yuhb5dl	205	7	patients	patient	NNS
cord-324859-0yuhb5dl	205	8	with	with	IN
cord-324859-0yuhb5dl	205	9	SARS	SARS	NNP
cord-324859-0yuhb5dl	205	10	,	,	,
cord-324859-0yuhb5dl	205	11	it	-PRON-	PRP
cord-324859-0yuhb5dl	205	12	was	be	VBD
cord-324859-0yuhb5dl	205	13	shown	show	VBN
cord-324859-0yuhb5dl	205	14	that	that	IN
cord-324859-0yuhb5dl	205	15	while	while	IN
cord-324859-0yuhb5dl	205	16	CD8	CD8	NNP
cord-324859-0yuhb5dl	205	17	+	+	CC
cord-324859-0yuhb5dl	205	18	T	T	NNP
cord-324859-0yuhb5dl	205	19	lymphocytes	lymphocyte	NNS
cord-324859-0yuhb5dl	205	20	return	return	VBP
cord-324859-0yuhb5dl	205	21	to	to	IN
cord-324859-0yuhb5dl	205	22	normal	normal	JJ
cord-324859-0yuhb5dl	205	23	levels	level	NNS
cord-324859-0yuhb5dl	205	24	in	in	IN
cord-324859-0yuhb5dl	205	25	2	2	CD
cord-324859-0yuhb5dl	205	26	-	-	SYM
cord-324859-0yuhb5dl	205	27	3	3	CD
cord-324859-0yuhb5dl	205	28	months	month	NNS
cord-324859-0yuhb5dl	205	29	,	,	,
cord-324859-0yuhb5dl	205	30	memory	memory	NN
cord-324859-0yuhb5dl	205	31	CD4	CD4	NNP
cord-324859-0yuhb5dl	205	32	+	+	CC
cord-324859-0yuhb5dl	205	33	T	t	NN
cord-324859-0yuhb5dl	205	34	cells	cell	NNS
cord-324859-0yuhb5dl	205	35	can	can	MD
cord-324859-0yuhb5dl	205	36	take	take	VB
cord-324859-0yuhb5dl	205	37	up	up	RP
cord-324859-0yuhb5dl	205	38	to	to	IN
cord-324859-0yuhb5dl	205	39	a	a	DT
cord-324859-0yuhb5dl	205	40	year	year	NN
cord-324859-0yuhb5dl	205	41	for	for	IN
cord-324859-0yuhb5dl	205	42	full	full	JJ
cord-324859-0yuhb5dl	205	43	recovery	recovery	NN
cord-324859-0yuhb5dl	205	44	.	.	.
cord-324859-0yuhb5dl	206	1	84	84	CD
cord-324859-0yuhb5dl	207	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	207	2	findings	finding	NNS
cord-324859-0yuhb5dl	207	3	can	can	MD
cord-324859-0yuhb5dl	207	4	have	have	VB
cord-324859-0yuhb5dl	207	5	important	important	JJ
cord-324859-0yuhb5dl	207	6	clinical	clinical	JJ
cord-324859-0yuhb5dl	207	7	implications	implication	NNS
cord-324859-0yuhb5dl	207	8	for	for	IN
cord-324859-0yuhb5dl	207	9	diagnostic	diagnostic	JJ
cord-324859-0yuhb5dl	207	10	as	as	RB
cord-324859-0yuhb5dl	207	11	well	well	RB
cord-324859-0yuhb5dl	207	12	as	as	IN
cord-324859-0yuhb5dl	207	13	therapeutic	therapeutic	JJ
cord-324859-0yuhb5dl	207	14	purposes	purpose	NNS
cord-324859-0yuhb5dl	207	15	of	of	IN
cord-324859-0yuhb5dl	207	16	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	207	17	management	management	NN
cord-324859-0yuhb5dl	207	18	.	.	.
cord-324859-0yuhb5dl	208	1	Currently	currently	RB
cord-324859-0yuhb5dl	208	2	,	,	,
cord-324859-0yuhb5dl	208	3	there	there	EX
cord-324859-0yuhb5dl	208	4	is	be	VBZ
cord-324859-0yuhb5dl	208	5	no	no	DT
cord-324859-0yuhb5dl	208	6	consensus	consensus	NN
cord-324859-0yuhb5dl	208	7	on	on	IN
cord-324859-0yuhb5dl	208	8	the	the	DT
cord-324859-0yuhb5dl	208	9	utility	utility	NN
cord-324859-0yuhb5dl	208	10	of	of	IN
cord-324859-0yuhb5dl	208	11	serial	serial	JJ
cord-324859-0yuhb5dl	208	12	immune	immune	JJ
cord-324859-0yuhb5dl	208	13	monitoring	monitoring	NN
cord-324859-0yuhb5dl	208	14	in	in	IN
cord-324859-0yuhb5dl	208	15	patients	patient	NNS
cord-324859-0yuhb5dl	208	16	with	with	IN
cord-324859-0yuhb5dl	208	17	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	208	18	.	.	.
cord-324859-0yuhb5dl	209	1	Based	base	VBN
cord-324859-0yuhb5dl	209	2	on	on	IN
cord-324859-0yuhb5dl	209	3	our	-PRON-	PRP$
cord-324859-0yuhb5dl	209	4	findings	finding	NNS
cord-324859-0yuhb5dl	209	5	,	,	,
cord-324859-0yuhb5dl	209	6	cytokine	cytokine	NN
cord-324859-0yuhb5dl	209	7	-	-	:
cord-324859-0yuhb5dl	209	8	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	209	9	,	,	,
cord-324859-0yuhb5dl	209	10	IL-8	IL-8	NNP
cord-324859-0yuhb5dl	209	11	,	,	,
cord-324859-0yuhb5dl	209	12	IL-10	IL-10	NNP
cord-324859-0yuhb5dl	209	13	,	,	,
cord-324859-0yuhb5dl	209	14	IL-2R	IL-2R	NNP
cord-324859-0yuhb5dl	209	15	and	and	CC
cord-324859-0yuhb5dl	209	16	TNF	TNF	NNP
cord-324859-0yuhb5dl	209	17	-	-	HYPH
cord-324859-0yuhb5dl	209	18	alphalevels	alphalevels	NNP
cord-324859-0yuhb5dl	209	19	can	can	MD
cord-324859-0yuhb5dl	209	20	serve	serve	VB
cord-324859-0yuhb5dl	209	21	as	as	IN
cord-324859-0yuhb5dl	209	22	potential	potential	JJ
cord-324859-0yuhb5dl	209	23	prognostic	prognostic	JJ
cord-324859-0yuhb5dl	209	24	biomarkers	biomarker	NNS
cord-324859-0yuhb5dl	209	25	for	for	IN
cord-324859-0yuhb5dl	209	26	risk	risk	NN
cord-324859-0yuhb5dl	209	27	stratification	stratification	NN
cord-324859-0yuhb5dl	209	28	of	of	IN
cord-324859-0yuhb5dl	209	29	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	209	30	patients	patient	NNS
cord-324859-0yuhb5dl	209	31	.	.	.
cord-324859-0yuhb5dl	210	1	An	an	DT
cord-324859-0yuhb5dl	210	2	important	important	JJ
cord-324859-0yuhb5dl	210	3	question	question	NN
cord-324859-0yuhb5dl	210	4	that	that	WDT
cord-324859-0yuhb5dl	210	5	is	be	VBZ
cord-324859-0yuhb5dl	210	6	yet	yet	RB
cord-324859-0yuhb5dl	210	7	to	to	TO
cord-324859-0yuhb5dl	210	8	be	be	VB
cord-324859-0yuhb5dl	210	9	answered	answer	VBN
cord-324859-0yuhb5dl	210	10	is	be	VBZ
cord-324859-0yuhb5dl	210	11	whether	whether	IN
cord-324859-0yuhb5dl	210	12	the	the	DT
cord-324859-0yuhb5dl	210	13	therapeutic	therapeutic	JJ
cord-324859-0yuhb5dl	210	14	blockade	blockade	NN
cord-324859-0yuhb5dl	210	15	of	of	IN
cord-324859-0yuhb5dl	210	16	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	210	17	is	be	VBZ
cord-324859-0yuhb5dl	210	18	considered	consider	VBN
cord-324859-0yuhb5dl	210	19	only	only	RB
cord-324859-0yuhb5dl	210	20	in	in	IN
cord-324859-0yuhb5dl	210	21	patients	patient	NNS
cord-324859-0yuhb5dl	210	22	with	with	IN
cord-324859-0yuhb5dl	210	23	elevated	elevated	JJ
cord-324859-0yuhb5dl	210	24	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	210	25	levels	level	NNS
cord-324859-0yuhb5dl	210	26	since	since	IN
cord-324859-0yuhb5dl	210	27	variability	variability	NN
cord-324859-0yuhb5dl	210	28	has	have	VBZ
cord-324859-0yuhb5dl	210	29	been	be	VBN
cord-324859-0yuhb5dl	210	30	noted	note	VBN
cord-324859-0yuhb5dl	210	31	in	in	IN
cord-324859-0yuhb5dl	210	32	individual	individual	JJ
cord-324859-0yuhb5dl	210	33	studies	study	NNS
cord-324859-0yuhb5dl	210	34	comparing	compare	VBG
cord-324859-0yuhb5dl	210	35	severe	severe	JJ
cord-324859-0yuhb5dl	210	36	and	and	CC
cord-324859-0yuhb5dl	210	37	non	non	JJ
cord-324859-0yuhb5dl	210	38	-	-	JJ
cord-324859-0yuhb5dl	210	39	severe	severe	JJ
cord-324859-0yuhb5dl	210	40	cases	case	NNS
cord-324859-0yuhb5dl	210	41	.	.	.
cord-324859-0yuhb5dl	211	1	For	for	IN
cord-324859-0yuhb5dl	211	2	this	this	DT
cord-324859-0yuhb5dl	211	3	,	,	,
cord-324859-0yuhb5dl	211	4	the	the	DT
cord-324859-0yuhb5dl	211	5	cut	cut	VB
cord-324859-0yuhb5dl	211	6	-	-	HYPH
cord-324859-0yuhb5dl	211	7	off	off	RP
cord-324859-0yuhb5dl	211	8	values	value	NNS
cord-324859-0yuhb5dl	211	9	for	for	IN
cord-324859-0yuhb5dl	211	10	initiation	initiation	NN
cord-324859-0yuhb5dl	211	11	of	of	IN
cord-324859-0yuhb5dl	211	12	therapy	therapy	NN
cord-324859-0yuhb5dl	211	13	will	will	MD
cord-324859-0yuhb5dl	211	14	need	need	VB
cord-324859-0yuhb5dl	211	15	to	to	TO
cord-324859-0yuhb5dl	211	16	be	be	VB
cord-324859-0yuhb5dl	211	17	defined	define	VBN
cord-324859-0yuhb5dl	211	18	based	base	VBN
cord-324859-0yuhb5dl	211	19	on	on	IN
cord-324859-0yuhb5dl	211	20	well	well	RB
cord-324859-0yuhb5dl	211	21	-	-	HYPH
cord-324859-0yuhb5dl	211	22	designed	design	VBN
cord-324859-0yuhb5dl	211	23	and	and	CC
cord-324859-0yuhb5dl	211	24	adequately	adequately	RB
cord-324859-0yuhb5dl	211	25	powered	powered	JJ
cord-324859-0yuhb5dl	211	26	prospective	prospective	JJ
cord-324859-0yuhb5dl	211	27	studies	study	NNS
cord-324859-0yuhb5dl	211	28	.	.	.
cord-324859-0yuhb5dl	212	1	Screening	screening	NN
cord-324859-0yuhb5dl	212	2	of	of	IN
cord-324859-0yuhb5dl	212	3	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	212	4	patients	patient	NNS
cord-324859-0yuhb5dl	212	5	for	for	IN
cord-324859-0yuhb5dl	212	6	hyperinflammatory	hyperinflammatory	NNP
cord-324859-0yuhb5dl	212	7	state	state	NN
cord-324859-0yuhb5dl	212	8	using	use	VBG
cord-324859-0yuhb5dl	212	9	laboratory	laboratory	NN
cord-324859-0yuhb5dl	212	10	trends	trend	NNS
cord-324859-0yuhb5dl	212	11	and	and	CC
cord-324859-0yuhb5dl	212	12	severity	severity	NN
cord-324859-0yuhb5dl	212	13	grading	grading	NN
cord-324859-0yuhb5dl	212	14	systems	system	NNS
cord-324859-0yuhb5dl	212	15	such	such	JJ
cord-324859-0yuhb5dl	212	16	as	as	IN
cord-324859-0yuhb5dl	212	17	HScore	HScore	NNP
cord-324859-0yuhb5dl	212	18	,	,	,
cord-324859-0yuhb5dl	212	19	devised	devise	VBN
cord-324859-0yuhb5dl	212	20	originally	originally	RB
cord-324859-0yuhb5dl	212	21	for	for	IN
cord-324859-0yuhb5dl	212	22	secondary	secondary	JJ
cord-324859-0yuhb5dl	212	23	haemophagocytic	haemophagocytic	JJ
cord-324859-0yuhb5dl	212	24	lymphohistiocytosis	lymphohistiocytosis	NNP
cord-324859-0yuhb5dl	212	25	(	(	-LRB-
cord-324859-0yuhb5dl	212	26	sHLH	sHLH	NNP
cord-324859-0yuhb5dl	212	27	)	)	-RRB-
cord-324859-0yuhb5dl	212	28	,	,	,
cord-324859-0yuhb5dl	212	29	can	can	MD
cord-324859-0yuhb5dl	212	30	be	be	VB
cord-324859-0yuhb5dl	212	31	useful	useful	JJ
cord-324859-0yuhb5dl	212	32	in	in	IN
cord-324859-0yuhb5dl	212	33	identifying	identify	VBG
cord-324859-0yuhb5dl	212	34	ideal	ideal	JJ
cord-324859-0yuhb5dl	212	35	candidates	candidate	NNS
cord-324859-0yuhb5dl	212	36	for	for	IN
cord-324859-0yuhb5dl	212	37	immunosuppressive	immunosuppressive	JJ
cord-324859-0yuhb5dl	212	38	therapies	therapy	NNS
cord-324859-0yuhb5dl	212	39	.	.	.
cord-324859-0yuhb5dl	213	1	85	85	CD
cord-324859-0yuhb5dl	213	2	Currently	currently	RB
cord-324859-0yuhb5dl	213	3	,	,	,
cord-324859-0yuhb5dl	213	4	there	there	EX
cord-324859-0yuhb5dl	213	5	is	be	VBZ
cord-324859-0yuhb5dl	213	6	significant	significant	JJ
cord-324859-0yuhb5dl	213	7	interest	interest	NN
cord-324859-0yuhb5dl	213	8	in	in	IN
cord-324859-0yuhb5dl	213	9	evaluating	evaluate	VBG
cord-324859-0yuhb5dl	213	10	the	the	DT
cord-324859-0yuhb5dl	213	11	efficacy	efficacy	NN
cord-324859-0yuhb5dl	213	12	and	and	CC
cord-324859-0yuhb5dl	213	13	safety	safety	NN
cord-324859-0yuhb5dl	213	14	of	of	IN
cord-324859-0yuhb5dl	213	15	tocilizumab	tocilizumab	NNP
cord-324859-0yuhb5dl	213	16	,	,	,
cord-324859-0yuhb5dl	213	17	a	a	DT
cord-324859-0yuhb5dl	213	18	humanized	humanize	VBN
cord-324859-0yuhb5dl	213	19	monoclonal	monoclonal	JJ
cord-324859-0yuhb5dl	213	20	antibody	antibody	NN
cord-324859-0yuhb5dl	213	21	against	against	IN
cord-324859-0yuhb5dl	213	22	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	213	23	,	,	,
cord-324859-0yuhb5dl	213	24	in	in	IN
cord-324859-0yuhb5dl	213	25	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	213	26	patients	patient	NNS
cord-324859-0yuhb5dl	213	27	as	as	IN
cord-324859-0yuhb5dl	213	28	evidenced	evidence	VBN
cord-324859-0yuhb5dl	213	29	by	by	IN
cord-324859-0yuhb5dl	213	30	more	more	JJR
cord-324859-0yuhb5dl	213	31	than	than	IN
cord-324859-0yuhb5dl	213	32	50	50	CD
cord-324859-0yuhb5dl	213	33	ongoing	ongoing	JJ
cord-324859-0yuhb5dl	213	34	clinical	clinical	JJ
cord-324859-0yuhb5dl	213	35	studies	study	NNS
cord-324859-0yuhb5dl	213	36	across	across	IN
cord-324859-0yuhb5dl	213	37	the	the	DT
cord-324859-0yuhb5dl	213	38	globe	globe	NN
cord-324859-0yuhb5dl	213	39	.	.	.
cord-324859-0yuhb5dl	214	1	86	86	CD
cord-324859-0yuhb5dl	215	1	The	the	DT
cord-324859-0yuhb5dl	215	2	drug	drug	NN
cord-324859-0yuhb5dl	215	3	is	be	VBZ
cord-324859-0yuhb5dl	215	4	currently	currently	RB
cord-324859-0yuhb5dl	215	5	approved	approve	VBN
cord-324859-0yuhb5dl	215	6	for	for	IN
cord-324859-0yuhb5dl	215	7	rheumatoid	rheumatoid	NN
cord-324859-0yuhb5dl	215	8	arthritis	arthritis	NN
cord-324859-0yuhb5dl	215	9	,	,	,
cord-324859-0yuhb5dl	215	10	giant	giant	JJ
cord-324859-0yuhb5dl	215	11	cell	cell	NN
cord-324859-0yuhb5dl	215	12	arteritis	arteritis	NN
cord-324859-0yuhb5dl	215	13	and	and	CC
cord-324859-0yuhb5dl	215	14	cytokine	cytokine	NN
cord-324859-0yuhb5dl	215	15	release	release	NN
cord-324859-0yuhb5dl	215	16	syndrome	syndrome	NN
cord-324859-0yuhb5dl	215	17	as	as	RB
cord-324859-0yuhb5dl	215	18	well	well	RB
cord-324859-0yuhb5dl	215	19	as	as	IN
cord-324859-0yuhb5dl	215	20	used	use	VBN
cord-324859-0yuhb5dl	215	21	off	off	IN
cord-324859-0yuhb5dl	215	22	-	-	HYPH
cord-324859-0yuhb5dl	215	23	label	label	NN
cord-324859-0yuhb5dl	215	24	for	for	IN
cord-324859-0yuhb5dl	215	25	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	215	26	as	as	IN
cord-324859-0yuhb5dl	215	27	an	an	DT
cord-324859-0yuhb5dl	215	28	investigational	investigational	JJ
cord-324859-0yuhb5dl	215	29	agent	agent	NN
cord-324859-0yuhb5dl	215	30	.	.	.
cord-324859-0yuhb5dl	216	1	However	however	RB
cord-324859-0yuhb5dl	216	2	,	,	,
cord-324859-0yuhb5dl	216	3	the	the	DT
cord-324859-0yuhb5dl	216	4	timing	timing	NN
cord-324859-0yuhb5dl	216	5	of	of	IN
cord-324859-0yuhb5dl	216	6	the	the	DT
cord-324859-0yuhb5dl	216	7	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	216	8	blocking	block	VBG
cord-324859-0yuhb5dl	216	9	therapy	therapy	NN
cord-324859-0yuhb5dl	216	10	in	in	IN
cord-324859-0yuhb5dl	216	11	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	216	12	patients	patient	NNS
cord-324859-0yuhb5dl	216	13	appears	appear	VBZ
cord-324859-0yuhb5dl	216	14	to	to	TO
cord-324859-0yuhb5dl	216	15	be	be	VB
cord-324859-0yuhb5dl	216	16	crucial	crucial	JJ
cord-324859-0yuhb5dl	216	17	since	since	IN
cord-324859-0yuhb5dl	216	18	preclinical	preclinical	JJ
cord-324859-0yuhb5dl	216	19	studies	study	NNS
cord-324859-0yuhb5dl	216	20	have	have	VBP
cord-324859-0yuhb5dl	216	21	demonstrated	demonstrate	VBN
cord-324859-0yuhb5dl	216	22	that	that	IN
cord-324859-0yuhb5dl	216	23	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	216	24	is	be	VBZ
cord-324859-0yuhb5dl	216	25	required	require	VBN
cord-324859-0yuhb5dl	216	26	for	for	IN
cord-324859-0yuhb5dl	216	27	viral	viral	JJ
cord-324859-0yuhb5dl	216	28	clearance	clearance	NN
cord-324859-0yuhb5dl	216	29	as	as	RB
cord-324859-0yuhb5dl	216	30	well	well	RB
cord-324859-0yuhb5dl	216	31	as	as	IN
cord-324859-0yuhb5dl	216	32	control	control	NN
cord-324859-0yuhb5dl	216	33	of	of	IN
cord-324859-0yuhb5dl	216	34	lung	lung	NN
cord-324859-0yuhb5dl	216	35	inflammation	inflammation	NN
cord-324859-0yuhb5dl	216	36	.	.	.
cord-324859-0yuhb5dl	217	1	87	87	CD
cord-324859-0yuhb5dl	218	1	On	on	IN
cord-324859-0yuhb5dl	218	2	the	the	DT
cord-324859-0yuhb5dl	218	3	contrary	contrary	JJ
cord-324859-0yuhb5dl	218	4	,	,	,
cord-324859-0yuhb5dl	218	5	high	high	JJ
cord-324859-0yuhb5dl	218	6	levels	level	NNS
cord-324859-0yuhb5dl	218	7	of	of	IN
cord-324859-0yuhb5dl	218	8	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	218	9	may	may	MD
cord-324859-0yuhb5dl	218	10	also	also	RB
cord-324859-0yuhb5dl	218	11	promote	promote	VB
cord-324859-0yuhb5dl	218	12	viral	viral	JJ
cord-324859-0yuhb5dl	218	13	persistence	persistence	NN
cord-324859-0yuhb5dl	218	14	through	through	IN
cord-324859-0yuhb5dl	218	15	suppression	suppression	NN
cord-324859-0yuhb5dl	218	16	of	of	IN
cord-324859-0yuhb5dl	218	17	T	t	NN
cord-324859-0yuhb5dl	218	18	-	-	HYPH
cord-324859-0yuhb5dl	218	19	cell	cell	NN
cord-324859-0yuhb5dl	218	20	cytolytic	cytolytic	JJ
cord-324859-0yuhb5dl	218	21	activity	activity	NN
cord-324859-0yuhb5dl	218	22	.	.	.
cord-324859-0yuhb5dl	219	1	88	88	CD
cord-324859-0yuhb5dl	219	2	,	,	,
cord-324859-0yuhb5dl	219	3	89	89	CD
cord-324859-0yuhb5dl	220	1	This	this	DT
cord-324859-0yuhb5dl	220	2	dilemma	dilemma	NN
cord-324859-0yuhb5dl	220	3	needs	need	VBZ
cord-324859-0yuhb5dl	220	4	to	to	TO
cord-324859-0yuhb5dl	220	5	be	be	VB
cord-324859-0yuhb5dl	220	6	resolved	resolve	VBN
cord-324859-0yuhb5dl	220	7	through	through	IN
cord-324859-0yuhb5dl	220	8	clinical	clinical	JJ
cord-324859-0yuhb5dl	220	9	trials	trial	NNS
cord-324859-0yuhb5dl	220	10	aimed	aim	VBN
cord-324859-0yuhb5dl	220	11	to	to	TO
cord-324859-0yuhb5dl	220	12	determine	determine	VB
cord-324859-0yuhb5dl	220	13	whether	whether	IN
cord-324859-0yuhb5dl	220	14	early	early	JJ
cord-324859-0yuhb5dl	220	15	IL-6R	IL-6R	NNP
cord-324859-0yuhb5dl	220	16	blockade	blockade	NN
cord-324859-0yuhb5dl	220	17	hampers	hamper	NNS
cord-324859-0yuhb5dl	220	18	viral	viral	JJ
cord-324859-0yuhb5dl	220	19	clearance	clearance	NN
cord-324859-0yuhb5dl	220	20	.	.	.
cord-324859-0yuhb5dl	221	1	Based	base	VBN
cord-324859-0yuhb5dl	221	2	on	on	IN
cord-324859-0yuhb5dl	221	3	the	the	DT
cord-324859-0yuhb5dl	221	4	available	available	JJ
cord-324859-0yuhb5dl	221	5	evidence	evidence	NN
cord-324859-0yuhb5dl	221	6	,	,	,
cord-324859-0yuhb5dl	221	7	management	management	NN
cord-324859-0yuhb5dl	221	8	of	of	IN
cord-324859-0yuhb5dl	221	9	early	early	JJ
cord-324859-0yuhb5dl	221	10	stages	stage	NNS
cord-324859-0yuhb5dl	221	11	of	of	IN
cord-324859-0yuhb5dl	221	12	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	221	13	should	should	MD
cord-324859-0yuhb5dl	221	14	focus	focus	VB
cord-324859-0yuhb5dl	221	15	on	on	IN
cord-324859-0yuhb5dl	221	16	antiviral	antiviral	JJ
cord-324859-0yuhb5dl	221	17	approaches	approach	NNS
cord-324859-0yuhb5dl	221	18	and/or	and/or	CC
cord-324859-0yuhb5dl	221	19	augmentation	augmentation	NN
cord-324859-0yuhb5dl	221	20	of	of	IN
cord-324859-0yuhb5dl	221	21	IFN	IFN	NNP
cord-324859-0yuhb5dl	221	22	type	type	NN
cord-324859-0yuhb5dl	221	23	I	-PRON-	PRP
cord-324859-0yuhb5dl	221	24	response	response	NN
cord-324859-0yuhb5dl	221	25	.	.	.
cord-324859-0yuhb5dl	222	1	Remdesivir	Remdesivir	NNP
cord-324859-0yuhb5dl	222	2	,	,	,
cord-324859-0yuhb5dl	222	3	an	an	DT
cord-324859-0yuhb5dl	222	4	antiviral	antiviral	JJ
cord-324859-0yuhb5dl	222	5	prodrug	prodrug	NN
cord-324859-0yuhb5dl	222	6	,	,	,
cord-324859-0yuhb5dl	222	7	has	have	VBZ
cord-324859-0yuhb5dl	222	8	recently	recently	RB
cord-324859-0yuhb5dl	222	9	shown	show	VBN
cord-324859-0yuhb5dl	222	10	some	some	DT
cord-324859-0yuhb5dl	222	11	benefit	benefit	NN
cord-324859-0yuhb5dl	222	12	in	in	IN
cord-324859-0yuhb5dl	222	13	patients	patient	NNS
cord-324859-0yuhb5dl	222	14	with	with	IN
cord-324859-0yuhb5dl	222	15	moderate	moderate	JJ
cord-324859-0yuhb5dl	222	16	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	222	17	,	,	,
cord-324859-0yuhb5dl	222	18	indicating	indicate	VBG
cord-324859-0yuhb5dl	222	19	that	that	IN
cord-324859-0yuhb5dl	222	20	targeting	target	VBG
cord-324859-0yuhb5dl	222	21	early	early	JJ
cord-324859-0yuhb5dl	222	22	stages	stage	NNS
cord-324859-0yuhb5dl	222	23	of	of	IN
cord-324859-0yuhb5dl	222	24	the	the	DT
cord-324859-0yuhb5dl	222	25	illness	illness	NN
cord-324859-0yuhb5dl	222	26	and	and	CC
cord-324859-0yuhb5dl	222	27	patients	patient	NNS
cord-324859-0yuhb5dl	222	28	with	with	IN
cord-324859-0yuhb5dl	222	29	moderate	moderate	JJ
cord-324859-0yuhb5dl	222	30	disease	disease	NN
cord-324859-0yuhb5dl	222	31	is	be	VBZ
cord-324859-0yuhb5dl	222	32	perhaps	perhaps	RB
cord-324859-0yuhb5dl	222	33	a	a	DT
cord-324859-0yuhb5dl	222	34	more	more	RBR
cord-324859-0yuhb5dl	222	35	rational	rational	JJ
cord-324859-0yuhb5dl	222	36	approach	approach	NN
cord-324859-0yuhb5dl	222	37	.	.	.
cord-324859-0yuhb5dl	223	1	90	90	CD
cord-324859-0yuhb5dl	223	2	Subsequently	subsequently	RB
cord-324859-0yuhb5dl	223	3	,	,	,
cord-324859-0yuhb5dl	223	4	in	in	IN
cord-324859-0yuhb5dl	223	5	more	more	RBR
cord-324859-0yuhb5dl	223	6	advanced	advanced	JJ
cord-324859-0yuhb5dl	223	7	stages	stage	NNS
cord-324859-0yuhb5dl	223	8	,	,	,
cord-324859-0yuhb5dl	223	9	use	use	NN
cord-324859-0yuhb5dl	223	10	of	of	IN
cord-324859-0yuhb5dl	223	11	immunomodulation	immunomodulation	NN
cord-324859-0yuhb5dl	223	12	strategies	strategy	NNS
cord-324859-0yuhb5dl	223	13	to	to	TO
cord-324859-0yuhb5dl	223	14	control	control	VB
cord-324859-0yuhb5dl	223	15	the	the	DT
cord-324859-0yuhb5dl	223	16	infection	infection	NN
cord-324859-0yuhb5dl	223	17	-	-	HYPH
cord-324859-0yuhb5dl	223	18	associated	associate	VBN
cord-324859-0yuhb5dl	223	19	hyperinflammation	hyperinflammation	NN
cord-324859-0yuhb5dl	223	20	could	could	MD
cord-324859-0yuhb5dl	223	21	be	be	VB
cord-324859-0yuhb5dl	223	22	critical	critical	JJ
cord-324859-0yuhb5dl	223	23	in	in	IN
cord-324859-0yuhb5dl	223	24	reducing	reduce	VBG
cord-324859-0yuhb5dl	223	25	COVID-19-linked	covid-19-linked	JJ
cord-324859-0yuhb5dl	223	26	mortality	mortality	NN
cord-324859-0yuhb5dl	223	27	.	.	.
cord-324859-0yuhb5dl	224	1	The	the	DT
cord-324859-0yuhb5dl	224	2	latter	latter	JJ
cord-324859-0yuhb5dl	224	3	is	be	VBZ
cord-324859-0yuhb5dl	224	4	also	also	RB
cord-324859-0yuhb5dl	224	5	supported	support	VBN
cord-324859-0yuhb5dl	224	6	by	by	IN
cord-324859-0yuhb5dl	224	7	the	the	DT
cord-324859-0yuhb5dl	224	8	findings	finding	NNS
cord-324859-0yuhb5dl	224	9	from	from	IN
cord-324859-0yuhb5dl	224	10	SARS	SARS	NNP
cord-324859-0yuhb5dl	224	11	patients	patient	NNS
cord-324859-0yuhb5dl	224	12	,	,	,
cord-324859-0yuhb5dl	224	13	where	where	WRB
cord-324859-0yuhb5dl	224	14	ARDS	ARDS	NNP
cord-324859-0yuhb5dl	224	15	occurs	occur	VBZ
cord-324859-0yuhb5dl	224	16	despite	despite	IN
cord-324859-0yuhb5dl	224	17	declining	decline	VBG
cord-324859-0yuhb5dl	224	18	viral	viral	JJ
cord-324859-0yuhb5dl	224	19	loads	load	NNS
cord-324859-0yuhb5dl	224	20	,	,	,
cord-324859-0yuhb5dl	224	21	suggesting	suggest	VBG
cord-324859-0yuhb5dl	224	22	the	the	DT
cord-324859-0yuhb5dl	224	23	role	role	NN
cord-324859-0yuhb5dl	224	24	of	of	IN
cord-324859-0yuhb5dl	224	25	hyperinflammation	hyperinflammation	NN
cord-324859-0yuhb5dl	224	26	rather	rather	RB
cord-324859-0yuhb5dl	224	27	than	than	IN
cord-324859-0yuhb5dl	224	28	pathogen	pathogen	NN
cord-324859-0yuhb5dl	224	29	virulence	virulence	NN
cord-324859-0yuhb5dl	224	30	in	in	IN
cord-324859-0yuhb5dl	224	31	determining	determine	VBG
cord-324859-0yuhb5dl	224	32	adverse	adverse	JJ
cord-324859-0yuhb5dl	224	33	patient	patient	JJ
cord-324859-0yuhb5dl	224	34	outcomes	outcome	NNS
cord-324859-0yuhb5dl	224	35	.	.	.
cord-324859-0yuhb5dl	225	1	91	91	CD
cord-324859-0yuhb5dl	226	1	The	the	DT
cord-324859-0yuhb5dl	226	2	recent	recent	JJ
cord-324859-0yuhb5dl	226	3	findings	finding	NNS
cord-324859-0yuhb5dl	226	4	from	from	IN
cord-324859-0yuhb5dl	226	5	the	the	DT
cord-324859-0yuhb5dl	226	6	RECOVERY	recovery	NN
cord-324859-0yuhb5dl	226	7	(	(	-LRB-
cord-324859-0yuhb5dl	226	8	Randomised	Randomised	NNP
cord-324859-0yuhb5dl	226	9	Evaluation	Evaluation	NNP
cord-324859-0yuhb5dl	226	10	of	of	IN
cord-324859-0yuhb5dl	226	11	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	226	12	thER	thER	NNP
cord-324859-0yuhb5dl	226	13	-	-	HYPH
cord-324859-0yuhb5dl	226	14	apY	apY	NNP
cord-324859-0yuhb5dl	226	15	)	)	-RRB-
cord-324859-0yuhb5dl	226	16	trial	trial	NN
cord-324859-0yuhb5dl	226	17	,	,	,
cord-324859-0yuhb5dl	226	18	where	where	WRB
cord-324859-0yuhb5dl	226	19	low	low	JJ
cord-324859-0yuhb5dl	226	20	-	-	HYPH
cord-324859-0yuhb5dl	226	21	dose	dose	NN
cord-324859-0yuhb5dl	226	22	dexamethasone	dexamethasone	NN
cord-324859-0yuhb5dl	226	23	reduced	reduce	VBN
cord-324859-0yuhb5dl	226	24	mortality	mortality	NN
cord-324859-0yuhb5dl	226	25	by	by	IN
cord-324859-0yuhb5dl	226	26	one	one	CD
cord-324859-0yuhb5dl	226	27	-	-	HYPH
cord-324859-0yuhb5dl	226	28	third	third	NN
cord-324859-0yuhb5dl	226	29	in	in	IN
cord-324859-0yuhb5dl	226	30	mechanically	mechanically	RB
cord-324859-0yuhb5dl	226	31	ventilated	ventilate	VBN
cord-324859-0yuhb5dl	226	32	and	and	CC
cord-324859-0yuhb5dl	226	33	one	one	CD
cord-324859-0yuhb5dl	226	34	-	-	HYPH
cord-324859-0yuhb5dl	226	35	fifth	fifth	NN
cord-324859-0yuhb5dl	226	36	in	in	IN
cord-324859-0yuhb5dl	226	37	oxygen	oxygen	NN
cord-324859-0yuhb5dl	226	38	-	-	HYPH
cord-324859-0yuhb5dl	226	39	requiring	require	VBG
cord-324859-0yuhb5dl	226	40	patients	patient	NNS
cord-324859-0yuhb5dl	226	41	,	,	,
cord-324859-0yuhb5dl	226	42	are	be	VBP
cord-324859-0yuhb5dl	226	43	in	in	IN
cord-324859-0yuhb5dl	226	44	consonance	consonance	NN
cord-324859-0yuhb5dl	226	45	with	with	IN
cord-324859-0yuhb5dl	226	46	this	this	DT
cord-324859-0yuhb5dl	226	47	approach	approach	NN
cord-324859-0yuhb5dl	226	48	.	.	.
cord-324859-0yuhb5dl	227	1	The	the	DT
cord-324859-0yuhb5dl	227	2	trial	trial	NN
cord-324859-0yuhb5dl	227	3	enrolled	enrol	VBD
cord-324859-0yuhb5dl	227	4	more	more	JJR
cord-324859-0yuhb5dl	227	5	than	than	IN
cord-324859-0yuhb5dl	227	6	6000	6000	CD
cord-324859-0yuhb5dl	227	7	patients	patient	NNS
cord-324859-0yuhb5dl	227	8	,	,	,
cord-324859-0yuhb5dl	227	9	and	and	CC
cord-324859-0yuhb5dl	227	10	evidently	evidently	RB
cord-324859-0yuhb5dl	227	11	,	,	,
cord-324859-0yuhb5dl	227	12	no	no	DT
cord-324859-0yuhb5dl	227	13	mortality	mortality	NN
cord-324859-0yuhb5dl	227	14	benefit	benefit	NN
cord-324859-0yuhb5dl	227	15	was	be	VBD
cord-324859-0yuhb5dl	227	16	observed	observe	VBN
cord-324859-0yuhb5dl	227	17	in	in	IN
cord-324859-0yuhb5dl	227	18	individuals	individual	NNS
cord-324859-0yuhb5dl	227	19	not	not	RB
cord-324859-0yuhb5dl	227	20	requiring	require	VBG
cord-324859-0yuhb5dl	227	21	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	227	22	support	support	NN
cord-324859-0yuhb5dl	227	23	at	at	IN
cord-324859-0yuhb5dl	227	24	randomization	randomization	NN
cord-324859-0yuhb5dl	227	25	.	.	.
cord-324859-0yuhb5dl	228	1	92	92	CD
cord-324859-0yuhb5dl	229	1	However	however	RB
cord-324859-0yuhb5dl	229	2	,	,	,
cord-324859-0yuhb5dl	229	3	our	-PRON-	PRP$
cord-324859-0yuhb5dl	229	4	review	review	NN
cord-324859-0yuhb5dl	229	5	findings	finding	NNS
cord-324859-0yuhb5dl	229	6	need	need	VBP
cord-324859-0yuhb5dl	229	7	to	to	TO
cord-324859-0yuhb5dl	229	8	be	be	VB
cord-324859-0yuhb5dl	229	9	interpreted	interpret	VBN
cord-324859-0yuhb5dl	229	10	with	with	IN
cord-324859-0yuhb5dl	229	11	caution	caution	NN
cord-324859-0yuhb5dl	229	12	,	,	,
cord-324859-0yuhb5dl	229	13	owing	owe	VBG
cord-324859-0yuhb5dl	229	14	to	to	IN
cord-324859-0yuhb5dl	229	15	the	the	DT
cord-324859-0yuhb5dl	229	16	high	high	JJ
cord-324859-0yuhb5dl	229	17	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	229	18	among	among	IN
cord-324859-0yuhb5dl	229	19	studies	study	NNS
cord-324859-0yuhb5dl	229	20	reporting	report	VBG
cord-324859-0yuhb5dl	229	21	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	229	22	markers	marker	NNS
cord-324859-0yuhb5dl	229	23	.	.	.
cord-324859-0yuhb5dl	230	1	Several	several	JJ
cord-324859-0yuhb5dl	230	2	factors	factor	NNS
cord-324859-0yuhb5dl	230	3	could	could	MD
cord-324859-0yuhb5dl	230	4	be	be	VB
cord-324859-0yuhb5dl	230	5	responsible	responsible	JJ
cord-324859-0yuhb5dl	230	6	for	for	IN
cord-324859-0yuhb5dl	230	7	this	this	DT
cord-324859-0yuhb5dl	230	8	variation	variation	NN
cord-324859-0yuhb5dl	230	9	in	in	IN
cord-324859-0yuhb5dl	230	10	effect	effect	NN
cord-324859-0yuhb5dl	230	11	estimates	estimate	NNS
cord-324859-0yuhb5dl	230	12	in	in	IN
cord-324859-0yuhb5dl	230	13	some	some	DT
cord-324859-0yuhb5dl	230	14	of	of	IN
cord-324859-0yuhb5dl	230	15	the	the	DT
cord-324859-0yuhb5dl	230	16	outcomes	outcome	NNS
cord-324859-0yuhb5dl	230	17	,	,	,
cord-324859-0yuhb5dl	230	18	like	like	IN
cord-324859-0yuhb5dl	230	19	variability	variability	NN
cord-324859-0yuhb5dl	230	20	in	in	IN
cord-324859-0yuhb5dl	230	21	sample	sample	NN
cord-324859-0yuhb5dl	230	22	sizes	size	NNS
cord-324859-0yuhb5dl	230	23	and	and	CC
cord-324859-0yuhb5dl	230	24	non	non	JJ
cord-324859-0yuhb5dl	230	25	-	-	JJ
cord-324859-0yuhb5dl	230	26	uniform	uniform	JJ
cord-324859-0yuhb5dl	230	27	distribution	distribution	NN
cord-324859-0yuhb5dl	230	28	of	of	IN
cord-324859-0yuhb5dl	230	29	patients	patient	NNS
cord-324859-0yuhb5dl	230	30	in	in	IN
cord-324859-0yuhb5dl	230	31	the	the	DT
cord-324859-0yuhb5dl	230	32	severe	severe	JJ
cord-324859-0yuhb5dl	230	33	and	and	CC
cord-324859-0yuhb5dl	230	34	non	non	JJ
cord-324859-0yuhb5dl	230	35	-	-	JJ
cord-324859-0yuhb5dl	230	36	severe	severe	JJ
cord-324859-0yuhb5dl	230	37	groups	group	NNS
cord-324859-0yuhb5dl	230	38	.	.	.
cord-324859-0yuhb5dl	231	1	Heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	231	2	might	may	MD
cord-324859-0yuhb5dl	231	3	also	also	RB
cord-324859-0yuhb5dl	231	4	be	be	VB
cord-324859-0yuhb5dl	231	5	a	a	DT
cord-324859-0yuhb5dl	231	6	consequence	consequence	NN
cord-324859-0yuhb5dl	231	7	of	of	IN
cord-324859-0yuhb5dl	231	8	weak	weak	JJ
cord-324859-0yuhb5dl	231	9	study	study	NN
cord-324859-0yuhb5dl	231	10	designs	design	NNS
cord-324859-0yuhb5dl	231	11	and	and	CC
cord-324859-0yuhb5dl	231	12	other	other	JJ
cord-324859-0yuhb5dl	231	13	methodological	methodological	JJ
cord-324859-0yuhb5dl	231	14	shortcomings	shortcoming	NNS
cord-324859-0yuhb5dl	231	15	,	,	,
cord-324859-0yuhb5dl	231	16	studies	study	NNS
cord-324859-0yuhb5dl	231	17	employing	employ	VBG
cord-324859-0yuhb5dl	231	18	varied	varied	JJ
cord-324859-0yuhb5dl	231	19	cut	cut	NN
cord-324859-0yuhb5dl	231	20	-	-	HYPH
cord-324859-0yuhb5dl	231	21	offs	off	NNS
cord-324859-0yuhb5dl	231	22	to	to	TO
cord-324859-0yuhb5dl	231	23	categorize	categorize	VB
cord-324859-0yuhb5dl	231	24	patients	patient	NNS
cord-324859-0yuhb5dl	231	25	into	into	IN
cord-324859-0yuhb5dl	231	26	disease	disease	NN
cord-324859-0yuhb5dl	231	27	severity	severity	NN
cord-324859-0yuhb5dl	231	28	groups	group	NNS
cord-324859-0yuhb5dl	231	29	and	and	CC
cord-324859-0yuhb5dl	231	30	differences	difference	NNS
cord-324859-0yuhb5dl	231	31	in	in	IN
cord-324859-0yuhb5dl	231	32	the	the	DT
cord-324859-0yuhb5dl	231	33	underlying	underlie	VBG
cord-324859-0yuhb5dl	231	34	comorbid	comorbid	NN
cord-324859-0yuhb5dl	231	35	conditions	condition	NNS
cord-324859-0yuhb5dl	231	36	,	,	,
cord-324859-0yuhb5dl	231	37	as	as	RB
cord-324859-0yuhb5dl	231	38	well	well	RB
cord-324859-0yuhb5dl	231	39	as	as	IN
cord-324859-0yuhb5dl	231	40	variability	variability	NN
cord-324859-0yuhb5dl	231	41	in	in	IN
cord-324859-0yuhb5dl	231	42	the	the	DT
cord-324859-0yuhb5dl	231	43	timing	timing	NN
cord-324859-0yuhb5dl	231	44	of	of	IN
cord-324859-0yuhb5dl	231	45	measurement	measurement	NN
cord-324859-0yuhb5dl	231	46	of	of	IN
cord-324859-0yuhb5dl	231	47	the	the	DT
cord-324859-0yuhb5dl	231	48	biomarkers	biomarker	NNS
cord-324859-0yuhb5dl	231	49	.	.	.
cord-324859-0yuhb5dl	232	1	However	however	RB
cord-324859-0yuhb5dl	232	2	,	,	,
cord-324859-0yuhb5dl	232	3	the	the	DT
cord-324859-0yuhb5dl	232	4	fact	fact	NN
cord-324859-0yuhb5dl	232	5	that	that	IN
cord-324859-0yuhb5dl	232	6	the	the	DT
cord-324859-0yuhb5dl	232	7	statistical	statistical	JJ
cord-324859-0yuhb5dl	232	8	test	test	NN
cord-324859-0yuhb5dl	232	9	for	for	IN
cord-324859-0yuhb5dl	232	10	assessment	assessment	NN
cord-324859-0yuhb5dl	232	11	of	of	IN
cord-324859-0yuhb5dl	232	12	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	232	13	is	be	VBZ
cord-324859-0yuhb5dl	232	14	largely	largely	RB
cord-324859-0yuhb5dl	232	15	underpowered	underpowered	JJ
cord-324859-0yuhb5dl	232	16	in	in	IN
cord-324859-0yuhb5dl	232	17	a	a	DT
cord-324859-0yuhb5dl	232	18	meta	meta	JJ
cord-324859-0yuhb5dl	232	19	-	-	HYPH
cord-324859-0yuhb5dl	232	20	analysis	analysis	NN
cord-324859-0yuhb5dl	232	21	22	22	CD
cord-324859-0yuhb5dl	232	22	wherein	wherein	WRB
cord-324859-0yuhb5dl	232	23	studies	study	NNS
cord-324859-0yuhb5dl	232	24	are	be	VBP
cord-324859-0yuhb5dl	232	25	either	either	CC
cord-324859-0yuhb5dl	232	26	very	very	RB
cord-324859-0yuhb5dl	232	27	few	few	JJ
cord-324859-0yuhb5dl	232	28	in	in	IN
cord-324859-0yuhb5dl	232	29	number	number	NN
cord-324859-0yuhb5dl	232	30	or	or	CC
cord-324859-0yuhb5dl	232	31	have	have	VB
cord-324859-0yuhb5dl	232	32	small	small	JJ
cord-324859-0yuhb5dl	232	33	sample	sample	NN
cord-324859-0yuhb5dl	232	34	sizes	size	NNS
cord-324859-0yuhb5dl	232	35	should	should	MD
cord-324859-0yuhb5dl	232	36	also	also	RB
cord-324859-0yuhb5dl	232	37	be	be	VB
cord-324859-0yuhb5dl	232	38	taken	take	VBN
cord-324859-0yuhb5dl	232	39	into	into	IN
cord-324859-0yuhb5dl	232	40	consideration	consideration	NN
cord-324859-0yuhb5dl	232	41	.	.	.
cord-324859-0yuhb5dl	233	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	233	2	undertook	undertake	VBD
cord-324859-0yuhb5dl	233	3	a	a	DT
cord-324859-0yuhb5dl	233	4	sensitivity	sensitivity	NN
cord-324859-0yuhb5dl	233	5	analysis	analysis	NN
cord-324859-0yuhb5dl	233	6	with	with	IN
cord-324859-0yuhb5dl	233	7	only	only	JJ
cord-324859-0yuhb5dl	233	8	studies	study	NNS
cord-324859-0yuhb5dl	233	9	that	that	WDT
cord-324859-0yuhb5dl	233	10	were	be	VBD
cord-324859-0yuhb5dl	233	11	peer	peer	NN
cord-324859-0yuhb5dl	233	12	-	-	HYPH
cord-324859-0yuhb5dl	233	13	reviewed	review	VBN
cord-324859-0yuhb5dl	233	14	and	and	CC
cord-324859-0yuhb5dl	233	15	published	publish	VBN
cord-324859-0yuhb5dl	233	16	,	,	,
cord-324859-0yuhb5dl	233	17	excluding	exclude	VBG
cord-324859-0yuhb5dl	233	18	the	the	DT
cord-324859-0yuhb5dl	233	19	preprints	preprint	NNS
cord-324859-0yuhb5dl	233	20	,	,	,
cord-324859-0yuhb5dl	233	21	and	and	CC
cord-324859-0yuhb5dl	233	22	found	find	VBD
cord-324859-0yuhb5dl	233	23	that	that	IN
cord-324859-0yuhb5dl	233	24	there	there	EX
cord-324859-0yuhb5dl	233	25	was	be	VBD
cord-324859-0yuhb5dl	233	26	no	no	DT
cord-324859-0yuhb5dl	233	27	major	major	JJ
cord-324859-0yuhb5dl	233	28	change	change	NN
cord-324859-0yuhb5dl	233	29	in	in	IN
cord-324859-0yuhb5dl	233	30	the	the	DT
cord-324859-0yuhb5dl	233	31	direction	direction	NN
cord-324859-0yuhb5dl	233	32	and	and	CC
cord-324859-0yuhb5dl	233	33	magnitude	magnitude	NN
cord-324859-0yuhb5dl	233	34	of	of	IN
cord-324859-0yuhb5dl	233	35	the	the	DT
cord-324859-0yuhb5dl	233	36	effects	effect	NNS
cord-324859-0yuhb5dl	233	37	.	.	.
cord-324859-0yuhb5dl	234	1	This	this	DT
cord-324859-0yuhb5dl	234	2	underscores	underscore	VBZ
cord-324859-0yuhb5dl	234	3	the	the	DT
cord-324859-0yuhb5dl	234	4	robustness	robustness	NN
cord-324859-0yuhb5dl	234	5	and	and	CC
cord-324859-0yuhb5dl	234	6	validity	validity	NN
cord-324859-0yuhb5dl	234	7	of	of	IN
cord-324859-0yuhb5dl	234	8	our	-PRON-	PRP$
cord-324859-0yuhb5dl	234	9	findings	finding	NNS
cord-324859-0yuhb5dl	234	10	.	.	.
cord-324859-0yuhb5dl	235	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	235	2	results	result	NNS
cord-324859-0yuhb5dl	235	3	for	for	IN
cord-324859-0yuhb5dl	235	4	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	235	5	are	be	VBP
cord-324859-0yuhb5dl	235	6	consistent	consistent	JJ
cord-324859-0yuhb5dl	235	7	with	with	IN
cord-324859-0yuhb5dl	235	8	the	the	DT
cord-324859-0yuhb5dl	235	9	other	other	JJ
cord-324859-0yuhb5dl	235	10	recently	recently	RB
cord-324859-0yuhb5dl	235	11	published	publish	VBN
cord-324859-0yuhb5dl	235	12	reviews	review	NNS
cord-324859-0yuhb5dl	235	13	comparing	compare	VBG
cord-324859-0yuhb5dl	235	14	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	235	15	levels	level	NNS
cord-324859-0yuhb5dl	235	16	between	between	IN
cord-324859-0yuhb5dl	235	17	severe	severe	JJ
cord-324859-0yuhb5dl	235	18	and	and	CC
cord-324859-0yuhb5dl	235	19	moderate	moderate	JJ
cord-324859-0yuhb5dl	235	20	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	235	21	patients	patient	NNS
cord-324859-0yuhb5dl	235	22	.	.	.
cord-324859-0yuhb5dl	236	1	[	[	-LRB-
cord-324859-0yuhb5dl	236	2	10	10	CD
cord-324859-0yuhb5dl	236	3	]	]	-RRB-
cord-324859-0yuhb5dl	236	4	[	[	-LRB-
cord-324859-0yuhb5dl	236	5	11	11	CD
cord-324859-0yuhb5dl	236	6	]	]	-RRB-
cord-324859-0yuhb5dl	236	7	[	[	-LRB-
cord-324859-0yuhb5dl	236	8	12	12	CD
cord-324859-0yuhb5dl	236	9	]	]	-RRB-
cord-324859-0yuhb5dl	237	1	Nonetheless	nonetheless	RB
cord-324859-0yuhb5dl	237	2	,	,	,
cord-324859-0yuhb5dl	237	3	there	there	EX
cord-324859-0yuhb5dl	237	4	is	be	VBZ
cord-324859-0yuhb5dl	237	5	a	a	DT
cord-324859-0yuhb5dl	237	6	need	need	NN
cord-324859-0yuhb5dl	237	7	for	for	IN
cord-324859-0yuhb5dl	237	8	further	further	JJ
cord-324859-0yuhb5dl	237	9	high	high	JJ
cord-324859-0yuhb5dl	237	10	-	-	HYPH
cord-324859-0yuhb5dl	237	11	quality	quality	NN
cord-324859-0yuhb5dl	237	12	prospective	prospective	JJ
cord-324859-0yuhb5dl	237	13	studies	study	NNS
cord-324859-0yuhb5dl	237	14	to	to	TO
cord-324859-0yuhb5dl	237	15	contribute	contribute	VB
cord-324859-0yuhb5dl	237	16	to	to	IN
cord-324859-0yuhb5dl	237	17	the	the	DT
cord-324859-0yuhb5dl	237	18	existing	exist	VBG
cord-324859-0yuhb5dl	237	19	knowledge	knowledge	NN
cord-324859-0yuhb5dl	237	20	,	,	,
cord-324859-0yuhb5dl	237	21	enabling	enable	VBG
cord-324859-0yuhb5dl	237	22	researchers	researcher	NNS
cord-324859-0yuhb5dl	237	23	to	to	TO
cord-324859-0yuhb5dl	237	24	better	better	RB
cord-324859-0yuhb5dl	237	25	understand	understand	VB
cord-324859-0yuhb5dl	237	26	the	the	DT
cord-324859-0yuhb5dl	237	27	immunopathology	immunopathology	NN
cord-324859-0yuhb5dl	237	28	of	of	IN
cord-324859-0yuhb5dl	237	29	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	237	30	.	.	.
cord-324859-0yuhb5dl	238	1	To	to	IN
cord-324859-0yuhb5dl	238	2	the	the	DT
cord-324859-0yuhb5dl	238	3	best	good	JJS
cord-324859-0yuhb5dl	238	4	of	of	IN
cord-324859-0yuhb5dl	238	5	our	-PRON-	PRP$
cord-324859-0yuhb5dl	238	6	knowledge	knowledge	NN
cord-324859-0yuhb5dl	238	7	,	,	,
cord-324859-0yuhb5dl	238	8	ours	-PRON-	PRP
cord-324859-0yuhb5dl	238	9	is	be	VBZ
cord-324859-0yuhb5dl	238	10	the	the	DT
cord-324859-0yuhb5dl	238	11	first	first	JJ
cord-324859-0yuhb5dl	238	12	systematic	systematic	JJ
cord-324859-0yuhb5dl	238	13	review	review	NN
cord-324859-0yuhb5dl	238	14	and	and	CC
cord-324859-0yuhb5dl	238	15	meta	meta	NNP
cord-324859-0yuhb5dl	238	16	-	-	HYPH
cord-324859-0yuhb5dl	238	17	analysis	analysis	NN
cord-324859-0yuhb5dl	238	18	to	to	TO
cord-324859-0yuhb5dl	238	19	provide	provide	VB
cord-324859-0yuhb5dl	238	20	a	a	DT
cord-324859-0yuhb5dl	238	21	detailed	detailed	JJ
cord-324859-0yuhb5dl	238	22	overview	overview	NN
cord-324859-0yuhb5dl	238	23	of	of	IN
cord-324859-0yuhb5dl	238	24	the	the	DT
cord-324859-0yuhb5dl	238	25	immunological	immunological	JJ
cord-324859-0yuhb5dl	238	26	and	and	CC
cord-324859-0yuhb5dl	238	27	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	238	28	response	response	NN
cord-324859-0yuhb5dl	238	29	in	in	IN
cord-324859-0yuhb5dl	238	30	severe	severe	JJ
cord-324859-0yuhb5dl	238	31	and	and	CC
cord-324859-0yuhb5dl	238	32	non	non	JJ
cord-324859-0yuhb5dl	238	33	-	-	JJ
cord-324859-0yuhb5dl	238	34	severe	severe	JJ
cord-324859-0yuhb5dl	238	35	patients	patient	NNS
cord-324859-0yuhb5dl	238	36	of	of	IN
cord-324859-0yuhb5dl	238	37	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	238	38	and	and	CC
cord-324859-0yuhb5dl	238	39	quantify	quantify	VB
cord-324859-0yuhb5dl	238	40	the	the	DT
cord-324859-0yuhb5dl	238	41	difference	difference	NN
cord-324859-0yuhb5dl	238	42	in	in	IN
cord-324859-0yuhb5dl	238	43	various	various	JJ
cord-324859-0yuhb5dl	238	44	outcomes	outcome	NNS
cord-324859-0yuhb5dl	238	45	between	between	IN
cord-324859-0yuhb5dl	238	46	the	the	DT
cord-324859-0yuhb5dl	238	47	two	two	CD
cord-324859-0yuhb5dl	238	48	groups	group	NNS
cord-324859-0yuhb5dl	238	49	studied	study	VBD
cord-324859-0yuhb5dl	238	50	.	.	.
cord-324859-0yuhb5dl	239	1	Secondly	secondly	RB
cord-324859-0yuhb5dl	239	2	,	,	,
cord-324859-0yuhb5dl	239	3	a	a	DT
cord-324859-0yuhb5dl	239	4	few	few	JJ
cord-324859-0yuhb5dl	239	5	previous	previous	JJ
cord-324859-0yuhb5dl	239	6	reviews	review	NNS
cord-324859-0yuhb5dl	239	7	have	have	VBP
cord-324859-0yuhb5dl	239	8	primarily	primarily	RB
cord-324859-0yuhb5dl	239	9	focused	focus	VBN
cord-324859-0yuhb5dl	239	10	on	on	IN
cord-324859-0yuhb5dl	239	11	the	the	DT
cord-324859-0yuhb5dl	239	12	comparison	comparison	NN
cord-324859-0yuhb5dl	239	13	of	of	IN
cord-324859-0yuhb5dl	239	14	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	239	15	levels	level	NNS
cord-324859-0yuhb5dl	239	16	between	between	IN
cord-324859-0yuhb5dl	239	17	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	239	18	patients	patient	NNS
cord-324859-0yuhb5dl	239	19	of	of	IN
cord-324859-0yuhb5dl	239	20	varying	vary	VBG
cord-324859-0yuhb5dl	239	21	disease	disease	NN
cord-324859-0yuhb5dl	239	22	severity	severity	NN
cord-324859-0yuhb5dl	239	23	,	,	,
cord-324859-0yuhb5dl	239	24	and	and	CC
cord-324859-0yuhb5dl	239	25	our	-PRON-	PRP$
cord-324859-0yuhb5dl	239	26	work	work	NN
cord-324859-0yuhb5dl	239	27	provides	provide	VBZ
cord-324859-0yuhb5dl	239	28	updated	update	VBN
cord-324859-0yuhb5dl	239	29	evidence	evidence	NN
cord-324859-0yuhb5dl	239	30	on	on	IN
cord-324859-0yuhb5dl	239	31	the	the	DT
cord-324859-0yuhb5dl	239	32	same	same	JJ
cord-324859-0yuhb5dl	239	33	,	,	,
cord-324859-0yuhb5dl	239	34	while	while	IN
cord-324859-0yuhb5dl	239	35	exploring	explore	VBG
cord-324859-0yuhb5dl	239	36	not	not	RB
cord-324859-0yuhb5dl	239	37	just	just	RB
cord-324859-0yuhb5dl	239	38	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	239	39	but	but	CC
cord-324859-0yuhb5dl	239	40	other	other	JJ
cord-324859-0yuhb5dl	239	41	markers	marker	NNS
cord-324859-0yuhb5dl	239	42	as	as	RB
cord-324859-0yuhb5dl	239	43	well	well	RB
cord-324859-0yuhb5dl	239	44	.	.	.
cord-324859-0yuhb5dl	240	1	Thirdly	thirdly	RB
cord-324859-0yuhb5dl	240	2	,	,	,
cord-324859-0yuhb5dl	240	3	considering	consider	VBG
cord-324859-0yuhb5dl	240	4	that	that	IN
cord-324859-0yuhb5dl	240	5	we	-PRON-	PRP
cord-324859-0yuhb5dl	240	6	have	have	VBP
cord-324859-0yuhb5dl	240	7	enormous	enormous	JJ
cord-324859-0yuhb5dl	240	8	literature	literature	NN
cord-324859-0yuhb5dl	240	9	being	be	VBG
cord-324859-0yuhb5dl	240	10	rapidly	rapidly	RB
cord-324859-0yuhb5dl	240	11	published	publish	VBN
cord-324859-0yuhb5dl	240	12	,	,	,
cord-324859-0yuhb5dl	240	13	we	-PRON-	PRP
cord-324859-0yuhb5dl	240	14	covered	cover	VBD
cord-324859-0yuhb5dl	240	15	7	7	CD
cord-324859-0yuhb5dl	240	16	distinct	distinct	JJ
cord-324859-0yuhb5dl	240	17	databases	database	NNS
cord-324859-0yuhb5dl	240	18	and	and	CC
cord-324859-0yuhb5dl	240	19	used	use	VBD
cord-324859-0yuhb5dl	240	20	a	a	DT
cord-324859-0yuhb5dl	240	21	sensitive	sensitive	JJ
cord-324859-0yuhb5dl	240	22	search	search	NN
cord-324859-0yuhb5dl	240	23	strategy	strategy	NN
cord-324859-0yuhb5dl	240	24	to	to	TO
cord-324859-0yuhb5dl	240	25	obtain	obtain	VB
cord-324859-0yuhb5dl	240	26	as	as	RB
cord-324859-0yuhb5dl	240	27	many	many	JJ
cord-324859-0yuhb5dl	240	28	relevant	relevant	JJ
cord-324859-0yuhb5dl	240	29	studies	study	NNS
cord-324859-0yuhb5dl	240	30	as	as	IN
cord-324859-0yuhb5dl	240	31	possible	possible	JJ
cord-324859-0yuhb5dl	240	32	.	.	.
cord-324859-0yuhb5dl	241	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	241	2	review	review	NN
cord-324859-0yuhb5dl	241	3	has	have	VBZ
cord-324859-0yuhb5dl	241	4	a	a	DT
cord-324859-0yuhb5dl	241	5	few	few	JJ
cord-324859-0yuhb5dl	241	6	limitations	limitation	NNS
cord-324859-0yuhb5dl	241	7	.	.	.
cord-324859-0yuhb5dl	242	1	Some	some	DT
cord-324859-0yuhb5dl	242	2	studies	study	NNS
cord-324859-0yuhb5dl	242	3	had	have	VBD
cord-324859-0yuhb5dl	242	4	not	not	RB
cord-324859-0yuhb5dl	242	5	provided	provide	VBN
cord-324859-0yuhb5dl	242	6	the	the	DT
cord-324859-0yuhb5dl	242	7	necessary	necessary	JJ
cord-324859-0yuhb5dl	242	8	information	information	NN
cord-324859-0yuhb5dl	242	9	on	on	IN
cord-324859-0yuhb5dl	242	10	their	-PRON-	PRP$
cord-324859-0yuhb5dl	242	11	methodological	methodological	JJ
cord-324859-0yuhb5dl	242	12	aspects	aspect	NNS
cord-324859-0yuhb5dl	242	13	which	which	WDT
cord-324859-0yuhb5dl	242	14	may	may	MD
cord-324859-0yuhb5dl	242	15	have	have	VB
cord-324859-0yuhb5dl	242	16	led	lead	VBN
cord-324859-0yuhb5dl	242	17	to	to	IN
cord-324859-0yuhb5dl	242	18	a	a	DT
cord-324859-0yuhb5dl	242	19	possible	possible	JJ
cord-324859-0yuhb5dl	242	20	underestimation	underestimation	NN
cord-324859-0yuhb5dl	242	21	of	of	IN
cord-324859-0yuhb5dl	242	22	their	-PRON-	PRP$
cord-324859-0yuhb5dl	242	23	quality	quality	NN
cord-324859-0yuhb5dl	242	24	.	.	.
cord-324859-0yuhb5dl	243	1	Also	also	RB
cord-324859-0yuhb5dl	243	2	,	,	,
cord-324859-0yuhb5dl	243	3	authors	author	NNS
cord-324859-0yuhb5dl	243	4	were	be	VBD
cord-324859-0yuhb5dl	243	5	contacted	contact	VBN
cord-324859-0yuhb5dl	243	6	regarding	regard	VBG
cord-324859-0yuhb5dl	243	7	a	a	DT
cord-324859-0yuhb5dl	243	8	possible	possible	JJ
cord-324859-0yuhb5dl	243	9	overlap	overlap	NN
cord-324859-0yuhb5dl	243	10	of	of	IN
cord-324859-0yuhb5dl	243	11	participants	participant	NNS
cord-324859-0yuhb5dl	243	12	in	in	IN
cord-324859-0yuhb5dl	243	13	some	some	DT
cord-324859-0yuhb5dl	243	14	studies	study	NNS
cord-324859-0yuhb5dl	243	15	conducted	conduct	VBN
cord-324859-0yuhb5dl	243	16	at	at	IN
cord-324859-0yuhb5dl	243	17	a	a	DT
cord-324859-0yuhb5dl	243	18	common	common	JJ
cord-324859-0yuhb5dl	243	19	hospital	hospital	NN
cord-324859-0yuhb5dl	243	20	,	,	,
cord-324859-0yuhb5dl	243	21	but	but	CC
cord-324859-0yuhb5dl	243	22	a	a	DT
cord-324859-0yuhb5dl	243	23	majority	majority	NN
cord-324859-0yuhb5dl	243	24	(	(	-LRB-
cord-324859-0yuhb5dl	243	25	95	95	CD
cord-324859-0yuhb5dl	243	26	%	%	NN
cord-324859-0yuhb5dl	243	27	)	)	-RRB-
cord-324859-0yuhb5dl	243	28	of	of	IN
cord-324859-0yuhb5dl	243	29	them	-PRON-	PRP
cord-324859-0yuhb5dl	243	30	did	do	VBD
cord-324859-0yuhb5dl	243	31	not	not	RB
cord-324859-0yuhb5dl	243	32	respond	respond	VB
cord-324859-0yuhb5dl	243	33	to	to	IN
cord-324859-0yuhb5dl	243	34	our	-PRON-	PRP$
cord-324859-0yuhb5dl	243	35	queries	query	NNS
cord-324859-0yuhb5dl	243	36	.	.	.
cord-324859-0yuhb5dl	244	1	In	in	IN
cord-324859-0yuhb5dl	244	2	addition	addition	NN
cord-324859-0yuhb5dl	244	3	,	,	,
cord-324859-0yuhb5dl	244	4	our	-PRON-	PRP$
cord-324859-0yuhb5dl	244	5	analyses	analysis	NNS
cord-324859-0yuhb5dl	244	6	of	of	IN
cord-324859-0yuhb5dl	244	7	immune	immune	JJ
cord-324859-0yuhb5dl	244	8	responses	response	NNS
cord-324859-0yuhb5dl	244	9	in	in	IN
cord-324859-0yuhb5dl	244	10	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	244	11	were	be	VBD
cord-324859-0yuhb5dl	244	12	limited	limit	VBN
cord-324859-0yuhb5dl	244	13	by	by	IN
cord-324859-0yuhb5dl	244	14	findings	finding	NNS
cord-324859-0yuhb5dl	244	15	reported	report	VBN
cord-324859-0yuhb5dl	244	16	by	by	IN
cord-324859-0yuhb5dl	244	17	individual	individual	JJ
cord-324859-0yuhb5dl	244	18	studies	study	NNS
cord-324859-0yuhb5dl	244	19	and	and	CC
cord-324859-0yuhb5dl	244	20	we	-PRON-	PRP
cord-324859-0yuhb5dl	244	21	could	could	MD
cord-324859-0yuhb5dl	244	22	not	not	RB
cord-324859-0yuhb5dl	244	23	evaluate	evaluate	VB
cord-324859-0yuhb5dl	244	24	the	the	DT
cord-324859-0yuhb5dl	244	25	entire	entire	JJ
cord-324859-0yuhb5dl	244	26	spectrum	spectrum	NN
cord-324859-0yuhb5dl	244	27	of	of	IN
cord-324859-0yuhb5dl	244	28	immune	immune	JJ
cord-324859-0yuhb5dl	244	29	-	-	HYPH
cord-324859-0yuhb5dl	244	30	active	active	JJ
cord-324859-0yuhb5dl	244	31	molecules	molecule	NNS
cord-324859-0yuhb5dl	244	32	involved	involve	VBN
cord-324859-0yuhb5dl	244	33	in	in	IN
cord-324859-0yuhb5dl	244	34	the	the	DT
cord-324859-0yuhb5dl	244	35	SARS	SARS	NNP
cord-324859-0yuhb5dl	244	36	-	-	HYPH
cord-324859-0yuhb5dl	244	37	CoV-2-driven	CoV-2-driven	VBN
cord-324859-0yuhb5dl	244	38	cytokine	cytokine	NN
cord-324859-0yuhb5dl	244	39	storm	storm	NN
cord-324859-0yuhb5dl	244	40	.	.	.
cord-324859-0yuhb5dl	245	1	Moreover	moreover	RB
cord-324859-0yuhb5dl	245	2	,	,	,
cord-324859-0yuhb5dl	245	3	all	all	PDT
cord-324859-0yuhb5dl	245	4	the	the	DT
cord-324859-0yuhb5dl	245	5	studies	study	NNS
cord-324859-0yuhb5dl	245	6	included	include	VBN
cord-324859-0yuhb5dl	245	7	in	in	IN
cord-324859-0yuhb5dl	245	8	the	the	DT
cord-324859-0yuhb5dl	245	9	meta	meta	NNP
cord-324859-0yuhb5dl	245	10	-	-	HYPH
cord-324859-0yuhb5dl	245	11	analysis	analysis	NN
cord-324859-0yuhb5dl	245	12	are	be	VBP
cord-324859-0yuhb5dl	245	13	from	from	IN
cord-324859-0yuhb5dl	245	14	China	China	NNP
cord-324859-0yuhb5dl	245	15	.	.	.
cord-324859-0yuhb5dl	246	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	246	2	literature	literature	NN
cord-324859-0yuhb5dl	246	3	search	search	NN
cord-324859-0yuhb5dl	246	4	was	be	VBD
cord-324859-0yuhb5dl	246	5	conducted	conduct	VBN
cord-324859-0yuhb5dl	246	6	during	during	IN
cord-324859-0yuhb5dl	246	7	the	the	DT
cord-324859-0yuhb5dl	246	8	initial	initial	JJ
cord-324859-0yuhb5dl	246	9	months	month	NNS
cord-324859-0yuhb5dl	246	10	of	of	IN
cord-324859-0yuhb5dl	246	11	the	the	DT
cord-324859-0yuhb5dl	246	12	pandemic	pandemic	NN
cord-324859-0yuhb5dl	246	13	,	,	,
cord-324859-0yuhb5dl	246	14	wherein	wherein	WRB
cord-324859-0yuhb5dl	246	15	most	most	JJS
cord-324859-0yuhb5dl	246	16	of	of	IN
cord-324859-0yuhb5dl	246	17	the	the	DT
cord-324859-0yuhb5dl	246	18	available	available	JJ
cord-324859-0yuhb5dl	246	19	data	datum	NNS
cord-324859-0yuhb5dl	246	20	was	be	VBD
cord-324859-0yuhb5dl	246	21	from	from	IN
cord-324859-0yuhb5dl	246	22	Chinese	chinese	JJ
cord-324859-0yuhb5dl	246	23	patients	patient	NNS
cord-324859-0yuhb5dl	246	24	.	.	.
cord-324859-0yuhb5dl	247	1	This	this	DT
cord-324859-0yuhb5dl	247	2	could	could	MD
cord-324859-0yuhb5dl	247	3	limit	limit	VB
cord-324859-0yuhb5dl	247	4	the	the	DT
cord-324859-0yuhb5dl	247	5	generalizability	generalizability	NN
cord-324859-0yuhb5dl	247	6	of	of	IN
cord-324859-0yuhb5dl	247	7	our	-PRON-	PRP$
cord-324859-0yuhb5dl	247	8	findings	finding	NNS
cord-324859-0yuhb5dl	247	9	to	to	IN
cord-324859-0yuhb5dl	247	10	some	some	DT
cord-324859-0yuhb5dl	247	11	extent	extent	NN
cord-324859-0yuhb5dl	247	12	.	.	.
cord-324859-0yuhb5dl	248	1	Since	since	IN
cord-324859-0yuhb5dl	248	2	levels	level	NNS
cord-324859-0yuhb5dl	248	3	of	of	IN
cord-324859-0yuhb5dl	248	4	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	248	5	markers	marker	NNS
cord-324859-0yuhb5dl	248	6	can	can	MD
cord-324859-0yuhb5dl	248	7	vary	vary	VB
cord-324859-0yuhb5dl	248	8	over	over	IN
cord-324859-0yuhb5dl	248	9	the	the	DT
cord-324859-0yuhb5dl	248	10	course	course	NN
cord-324859-0yuhb5dl	248	11	of	of	IN
cord-324859-0yuhb5dl	248	12	the	the	DT
cord-324859-0yuhb5dl	248	13	infection	infection	NN
cord-324859-0yuhb5dl	248	14	,	,	,
cord-324859-0yuhb5dl	248	15	the	the	DT
cord-324859-0yuhb5dl	248	16	timing	timing	NN
cord-324859-0yuhb5dl	248	17	of	of	IN
cord-324859-0yuhb5dl	248	18	laboratory	laboratory	NN
cord-324859-0yuhb5dl	248	19	assessments	assessment	NNS
cord-324859-0yuhb5dl	248	20	can	can	MD
cord-324859-0yuhb5dl	248	21	also	also	RB
cord-324859-0yuhb5dl	248	22	impact	impact	VB
cord-324859-0yuhb5dl	248	23	the	the	DT
cord-324859-0yuhb5dl	248	24	findings	finding	NNS
cord-324859-0yuhb5dl	248	25	.	.	.
cord-324859-0yuhb5dl	249	1	However	however	RB
cord-324859-0yuhb5dl	249	2	,	,	,
cord-324859-0yuhb5dl	249	3	the	the	DT
cord-324859-0yuhb5dl	249	4	median	median	JJ
cord-324859-0yuhb5dl	249	5	time	time	NN
cord-324859-0yuhb5dl	249	6	from	from	IN
cord-324859-0yuhb5dl	249	7	symptom	symptom	NN
cord-324859-0yuhb5dl	249	8	onset	onset	NN
cord-324859-0yuhb5dl	249	9	to	to	IN
cord-324859-0yuhb5dl	249	10	hospitalization	hospitalization	NN
cord-324859-0yuhb5dl	249	11	was	be	VBD
cord-324859-0yuhb5dl	249	12	reported	report	VBN
cord-324859-0yuhb5dl	249	13	by	by	IN
cord-324859-0yuhb5dl	249	14	nearly	nearly	RB
cord-324859-0yuhb5dl	249	15	one	one	CD
cord-324859-0yuhb5dl	249	16	-	-	HYPH
cord-324859-0yuhb5dl	249	17	third	third	NN
cord-324859-0yuhb5dl	249	18	of	of	IN
cord-324859-0yuhb5dl	249	19	the	the	DT
cord-324859-0yuhb5dl	249	20	studies	study	NNS
cord-324859-0yuhb5dl	249	21	and	and	CC
cord-324859-0yuhb5dl	249	22	it	-PRON-	PRP
cord-324859-0yuhb5dl	249	23	ranged	range	VBD
cord-324859-0yuhb5dl	249	24	from	from	IN
cord-324859-0yuhb5dl	249	25	7	7	CD
cord-324859-0yuhb5dl	249	26	-	-	SYM
cord-324859-0yuhb5dl	249	27	11	11	CD
cord-324859-0yuhb5dl	249	28	days	day	NNS
cord-324859-0yuhb5dl	249	29	.	.	.
cord-324859-0yuhb5dl	250	1	Lastly	lastly	RB
cord-324859-0yuhb5dl	250	2	,	,	,
cord-324859-0yuhb5dl	250	3	we	-PRON-	PRP
cord-324859-0yuhb5dl	250	4	could	could	MD
cord-324859-0yuhb5dl	250	5	not	not	RB
cord-324859-0yuhb5dl	250	6	include	include	VB
cord-324859-0yuhb5dl	250	7	non	non	JJ
cord-324859-0yuhb5dl	250	8	-	-	JJ
cord-324859-0yuhb5dl	250	9	English	english	JJ
cord-324859-0yuhb5dl	250	10	articles	article	NNS
cord-324859-0yuhb5dl	250	11	due	due	JJ
cord-324859-0yuhb5dl	250	12	to	to	IN
cord-324859-0yuhb5dl	250	13	unavailability	unavailability	NN
cord-324859-0yuhb5dl	250	14	of	of	IN
cord-324859-0yuhb5dl	250	15	appropriate	appropriate	JJ
cord-324859-0yuhb5dl	250	16	translators	translator	NNS
cord-324859-0yuhb5dl	250	17	.	.	.
cord-324859-0yuhb5dl	251	1	Our	-PRON-	PRP$
cord-324859-0yuhb5dl	251	2	findings	finding	NNS
cord-324859-0yuhb5dl	251	3	showed	show	VBD
cord-324859-0yuhb5dl	251	4	that	that	IN
cord-324859-0yuhb5dl	251	5	severe	severe	JJ
cord-324859-0yuhb5dl	251	6	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	251	7	was	be	VBD
cord-324859-0yuhb5dl	251	8	characterized	characterize	VBN
cord-324859-0yuhb5dl	251	9	by	by	IN
cord-324859-0yuhb5dl	251	10	elevated	elevated	JJ
cord-324859-0yuhb5dl	251	11	circulating	circulating	JJ
cord-324859-0yuhb5dl	251	12	levels	level	NNS
cord-324859-0yuhb5dl	251	13	of	of	IN
cord-324859-0yuhb5dl	251	14	pro	pro	JJ
cord-324859-0yuhb5dl	251	15	-	-	JJ
cord-324859-0yuhb5dl	251	16	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	251	17	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	251	18	and	and	CC
cord-324859-0yuhb5dl	251	19	lower	low	JJR
cord-324859-0yuhb5dl	251	20	levels	level	NNS
cord-324859-0yuhb5dl	251	21	of	of	IN
cord-324859-0yuhb5dl	251	22	T	t	NN
cord-324859-0yuhb5dl	251	23	lymphocytes	lymphocyte	NNS
cord-324859-0yuhb5dl	251	24	,	,	,
cord-324859-0yuhb5dl	251	25	when	when	WRB
cord-324859-0yuhb5dl	251	26	compared	compare	VBN
cord-324859-0yuhb5dl	251	27	to	to	IN
cord-324859-0yuhb5dl	251	28	patients	patient	NNS
cord-324859-0yuhb5dl	251	29	with	with	IN
cord-324859-0yuhb5dl	251	30	mild	mild	JJ
cord-324859-0yuhb5dl	251	31	-	-	HYPH
cord-324859-0yuhb5dl	251	32	to	to	IN
cord-324859-0yuhb5dl	251	33	-	-	HYPH
cord-324859-0yuhb5dl	251	34	moderate	moderate	JJ
cord-324859-0yuhb5dl	251	35	disease	disease	NN
cord-324859-0yuhb5dl	251	36	.	.	.
cord-324859-0yuhb5dl	252	1	However	however	RB
cord-324859-0yuhb5dl	252	2	,	,	,
cord-324859-0yuhb5dl	252	3	welldesigned	welldesigne	VBN
cord-324859-0yuhb5dl	252	4	and	and	CC
cord-324859-0yuhb5dl	252	5	adequately	adequately	RB
cord-324859-0yuhb5dl	252	6	powered	power	VBD
cord-324859-0yuhb5dl	252	7	prospective	prospective	JJ
cord-324859-0yuhb5dl	252	8	studies	study	NNS
cord-324859-0yuhb5dl	252	9	are	be	VBP
cord-324859-0yuhb5dl	252	10	warranted	warrant	VBN
cord-324859-0yuhb5dl	252	11	to	to	TO
cord-324859-0yuhb5dl	252	12	further	further	RB
cord-324859-0yuhb5dl	252	13	strengthen	strengthen	VB
cord-324859-0yuhb5dl	252	14	the	the	DT
cord-324859-0yuhb5dl	252	15	current	current	JJ
cord-324859-0yuhb5dl	252	16	evidence	evidence	NN
cord-324859-0yuhb5dl	252	17	base	base	NN
cord-324859-0yuhb5dl	252	18	.	.	.
cord-324859-0yuhb5dl	253	1	Prospective	prospective	JJ
cord-324859-0yuhb5dl	253	2	studies	study	NNS
cord-324859-0yuhb5dl	253	3	that	that	WDT
cord-324859-0yuhb5dl	253	4	follow	follow	VBP
cord-324859-0yuhb5dl	253	5	a	a	DT
cord-324859-0yuhb5dl	253	6	structured	structured	JJ
cord-324859-0yuhb5dl	253	7	approach	approach	NN
cord-324859-0yuhb5dl	253	8	towards	towards	IN
cord-324859-0yuhb5dl	253	9	intensive	intensive	JJ
cord-324859-0yuhb5dl	253	10	immune	immune	JJ
cord-324859-0yuhb5dl	253	11	monitoring	monitoring	NN
cord-324859-0yuhb5dl	253	12	along	along	IN
cord-324859-0yuhb5dl	253	13	with	with	IN
cord-324859-0yuhb5dl	253	14	daily	daily	JJ
cord-324859-0yuhb5dl	253	15	clinical	clinical	JJ
cord-324859-0yuhb5dl	253	16	evaluations	evaluation	NNS
cord-324859-0yuhb5dl	253	17	can	can	MD
cord-324859-0yuhb5dl	253	18	further	further	RB
cord-324859-0yuhb5dl	253	19	elucidate	elucidate	VB
cord-324859-0yuhb5dl	253	20	the	the	DT
cord-324859-0yuhb5dl	253	21	mechanisms	mechanism	NNS
cord-324859-0yuhb5dl	253	22	underlying	underlie	VBG
cord-324859-0yuhb5dl	253	23	COVID-19	covid-19	CD
cord-324859-0yuhb5dl	253	24	immunopathology	immunopathology	NN
cord-324859-0yuhb5dl	253	25	.	.	.
cord-324859-0yuhb5dl	254	1	Such	such	JJ
cord-324859-0yuhb5dl	254	2	data	datum	NNS
cord-324859-0yuhb5dl	254	3	will	will	MD
cord-324859-0yuhb5dl	254	4	be	be	VB
cord-324859-0yuhb5dl	254	5	crucial	crucial	JJ
cord-324859-0yuhb5dl	254	6	in	in	IN
cord-324859-0yuhb5dl	254	7	resolving	resolve	VBG
cord-324859-0yuhb5dl	254	8	the	the	DT
cord-324859-0yuhb5dl	254	9	clinical	clinical	JJ
cord-324859-0yuhb5dl	254	10	dilemmas	dilemma	NNS
cord-324859-0yuhb5dl	254	11	related	relate	VBN
cord-324859-0yuhb5dl	254	12	to	to	IN
cord-324859-0yuhb5dl	254	13	the	the	DT
cord-324859-0yuhb5dl	254	14	timing	timing	NN
cord-324859-0yuhb5dl	254	15	and	and	CC
cord-324859-0yuhb5dl	254	16	type	type	NN
cord-324859-0yuhb5dl	254	17	of	of	IN
cord-324859-0yuhb5dl	254	18	anti	anti	JJ
cord-324859-0yuhb5dl	254	19	-	-	JJ
cord-324859-0yuhb5dl	254	20	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	254	21	therapy	therapy	NN
cord-324859-0yuhb5dl	254	22	.	.	.
cord-324859-0yuhb5dl	255	1	Given	give	VBN
cord-324859-0yuhb5dl	255	2	the	the	DT
cord-324859-0yuhb5dl	255	3	urgency	urgency	NN
cord-324859-0yuhb5dl	255	4	of	of	IN
cord-324859-0yuhb5dl	255	5	generating	generate	VBG
cord-324859-0yuhb5dl	255	6	scientific	scientific	JJ
cord-324859-0yuhb5dl	255	7	data	datum	NNS
cord-324859-0yuhb5dl	255	8	to	to	TO
cord-324859-0yuhb5dl	255	9	help	help	VB
cord-324859-0yuhb5dl	255	10	understand	understand	VB
cord-324859-0yuhb5dl	255	11	the	the	DT
cord-324859-0yuhb5dl	255	12	disease	disease	NN
cord-324859-0yuhb5dl	255	13	and	and	CC
cord-324859-0yuhb5dl	255	14	its	-PRON-	PRP$
cord-324859-0yuhb5dl	255	15	shortterm	shortterm	JJ
cord-324859-0yuhb5dl	255	16	and	and	CC
cord-324859-0yuhb5dl	255	17	long	long	JJ
cord-324859-0yuhb5dl	255	18	-	-	HYPH
cord-324859-0yuhb5dl	255	19	term	term	NN
cord-324859-0yuhb5dl	255	20	implications	implication	NNS
cord-324859-0yuhb5dl	255	21	,	,	,
cord-324859-0yuhb5dl	255	22	it	-PRON-	PRP
cord-324859-0yuhb5dl	255	23	is	be	VBZ
cord-324859-0yuhb5dl	255	24	understandable	understandable	JJ
cord-324859-0yuhb5dl	255	25	that	that	IN
cord-324859-0yuhb5dl	255	26	efforts	effort	NNS
cord-324859-0yuhb5dl	255	27	are	be	VBP
cord-324859-0yuhb5dl	255	28	underway	underway	JJ
cord-324859-0yuhb5dl	255	29	to	to	TO
cord-324859-0yuhb5dl	255	30	make	make	VB
cord-324859-0yuhb5dl	255	31	research	research	NN
cord-324859-0yuhb5dl	255	32	publicly	publicly	RB
cord-324859-0yuhb5dl	255	33	available	available	JJ
cord-324859-0yuhb5dl	255	34	as	as	RB
cord-324859-0yuhb5dl	255	35	soon	soon	RB
cord-324859-0yuhb5dl	255	36	as	as	IN
cord-324859-0yuhb5dl	255	37	possible	possible	JJ
cord-324859-0yuhb5dl	255	38	.	.	.
cord-324859-0yuhb5dl	256	1	But	but	CC
cord-324859-0yuhb5dl	256	2	studies	study	NNS
cord-324859-0yuhb5dl	256	3	that	that	WDT
cord-324859-0yuhb5dl	256	4	are	be	VBP
cord-324859-0yuhb5dl	256	5	methodologically	methodologically	RB
cord-324859-0yuhb5dl	256	6	sound	sound	JJ
cord-324859-0yuhb5dl	256	7	and	and	CC
cord-324859-0yuhb5dl	256	8	involve	involve	VBP
cord-324859-0yuhb5dl	256	9	thorough	thorough	JJ
cord-324859-0yuhb5dl	256	10	reporting	reporting	NN
cord-324859-0yuhb5dl	256	11	of	of	IN
cord-324859-0yuhb5dl	256	12	essential	essential	JJ
cord-324859-0yuhb5dl	256	13	aspects	aspect	NNS
cord-324859-0yuhb5dl	256	14	are	be	VBP
cord-324859-0yuhb5dl	256	15	lacking	lack	VBG
cord-324859-0yuhb5dl	256	16	.	.	.
cord-324859-0yuhb5dl	257	1	We	-PRON-	PRP
cord-324859-0yuhb5dl	257	2	believe	believe	VBP
cord-324859-0yuhb5dl	257	3	the	the	DT
cord-324859-0yuhb5dl	257	4	several	several	JJ
cord-324859-0yuhb5dl	257	5	ongoing	ongoing	JJ
cord-324859-0yuhb5dl	257	6	studies	study	NNS
cord-324859-0yuhb5dl	257	7	evaluating	evaluate	VBG
cord-324859-0yuhb5dl	257	8	the	the	DT
cord-324859-0yuhb5dl	257	9	role	role	NN
cord-324859-0yuhb5dl	257	10	of	of	IN
cord-324859-0yuhb5dl	257	11	immunomodulation	immunomodulation	NN
cord-324859-0yuhb5dl	257	12	in	in	IN
cord-324859-0yuhb5dl	257	13	severe	severe	JJ
cord-324859-0yuhb5dl	257	14	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	257	15	patients	patient	NNS
cord-324859-0yuhb5dl	257	16	can	can	MD
cord-324859-0yuhb5dl	257	17	hopefully	hopefully	RB
cord-324859-0yuhb5dl	257	18	provide	provide	VB
cord-324859-0yuhb5dl	257	19	further	further	JJ
cord-324859-0yuhb5dl	257	20	clarity	clarity	NN
cord-324859-0yuhb5dl	257	21	,	,	,
cord-324859-0yuhb5dl	257	22	and	and	CC
cord-324859-0yuhb5dl	257	23	these	these	DT
cord-324859-0yuhb5dl	257	24	therapies	therapy	NNS
cord-324859-0yuhb5dl	257	25	may	may	MD
cord-324859-0yuhb5dl	257	26	prove	prove	VB
cord-324859-0yuhb5dl	257	27	instrumental	instrumental	JJ
cord-324859-0yuhb5dl	257	28	in	in	IN
cord-324859-0yuhb5dl	257	29	tackling	tackle	VBG
cord-324859-0yuhb5dl	257	30	hyperinflammation	hyperinflammation	NN
cord-324859-0yuhb5dl	257	31	to	to	TO
cord-324859-0yuhb5dl	257	32	improve	improve	VB
cord-324859-0yuhb5dl	257	33	patient	patient	JJ
cord-324859-0yuhb5dl	257	34	management	management	NN
cord-324859-0yuhb5dl	257	35	and	and	CC
cord-324859-0yuhb5dl	257	36	clinical	clinical	JJ
cord-324859-0yuhb5dl	257	37	outcomes	outcome	NNS
cord-324859-0yuhb5dl	257	38	.	.	.
cord-324859-0yuhb5dl	258	1	Coronavirus	Coronavirus	NNP
cord-324859-0yuhb5dl	258	2	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	259	1	(	(	-LRB-
cord-324859-0yuhb5dl	259	2	2019-nCoV	2019-ncov	LS
cord-324859-0yuhb5dl	259	3	)	)	-RRB-
cord-324859-0yuhb5dl	259	4	Dashboard	dashboard	NN
cord-324859-0yuhb5dl	259	5	by	by	IN
cord-324859-0yuhb5dl	259	6	the	the	DT
cord-324859-0yuhb5dl	259	7	CCSE	CCSE	NNP
cord-324859-0yuhb5dl	259	8	at	at	IN
cord-324859-0yuhb5dl	259	9	Johns	Johns	NNP
cord-324859-0yuhb5dl	259	10	Hopkins	Hopkins	NNP
cord-324859-0yuhb5dl	259	11	University	University	NNP
cord-324859-0yuhb5dl	259	12	Coronavirus	Coronavirus	NNP
cord-324859-0yuhb5dl	259	13	infections	infection	NNS
cord-324859-0yuhb5dl	259	14	and	and	CC
cord-324859-0yuhb5dl	259	15	immune	immune	JJ
cord-324859-0yuhb5dl	259	16	responses	response	NNS
cord-324859-0yuhb5dl	259	17	Coronavirus	Coronavirus	NNP
cord-324859-0yuhb5dl	259	18	is	be	VBZ
cord-324859-0yuhb5dl	259	19	the	the	DT
cord-324859-0yuhb5dl	259	20	trigger	trigger	NN
cord-324859-0yuhb5dl	259	21	,	,	,
cord-324859-0yuhb5dl	259	22	but	but	CC
cord-324859-0yuhb5dl	259	23	the	the	DT
cord-324859-0yuhb5dl	259	24	immune	immune	JJ
cord-324859-0yuhb5dl	259	25	response	response	NN
cord-324859-0yuhb5dl	259	26	is	be	VBZ
cord-324859-0yuhb5dl	259	27	deadly	deadly	JJ
cord-324859-0yuhb5dl	259	28	The	the	DT
cord-324859-0yuhb5dl	259	29	cytokine	cytokine	NN
cord-324859-0yuhb5dl	259	30	storm	storm	NN
cord-324859-0yuhb5dl	259	31	in	in	IN
cord-324859-0yuhb5dl	259	32	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	259	33	:	:	:
cord-324859-0yuhb5dl	259	34	an	an	DT
cord-324859-0yuhb5dl	259	35	overview	overview	NN
cord-324859-0yuhb5dl	259	36	of	of	IN
cord-324859-0yuhb5dl	259	37	the	the	DT
cord-324859-0yuhb5dl	259	38	involvement	involvement	NN
cord-324859-0yuhb5dl	259	39	of	of	IN
cord-324859-0yuhb5dl	259	40	the	the	DT
cord-324859-0yuhb5dl	259	41	chemokine	chemokine	NN
cord-324859-0yuhb5dl	259	42	/	/	SYM
cord-324859-0yuhb5dl	259	43	chemokine	chemokine	NN
cord-324859-0yuhb5dl	259	44	-	-	HYPH
cord-324859-0yuhb5dl	259	45	receptor	receptor	NN
cord-324859-0yuhb5dl	259	46	system	system	NN
cord-324859-0yuhb5dl	259	47	On	on	IN
cord-324859-0yuhb5dl	259	48	the	the	DT
cord-324859-0yuhb5dl	259	49	Alert	Alert	NNP
cord-324859-0yuhb5dl	259	50	for	for	IN
cord-324859-0yuhb5dl	259	51	Cytokine	Cytokine	NNP
cord-324859-0yuhb5dl	259	52	Storm	Storm	NNP
cord-324859-0yuhb5dl	259	53	:	:	:
cord-324859-0yuhb5dl	259	54	Immunopathology	immunopathology	NN
cord-324859-0yuhb5dl	259	55	in	in	IN
cord-324859-0yuhb5dl	259	56	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	259	57	.	.	.
cord-324859-0yuhb5dl	260	1	Arthritis	Arthritis	NNP
cord-324859-0yuhb5dl	260	2	Rheumatol	Rheumatol	NNP
cord-324859-0yuhb5dl	261	1	The	the	DT
cord-324859-0yuhb5dl	261	2	rheumatologist	rheumatologist	NN
cord-324859-0yuhb5dl	261	3	's	's	POS
cord-324859-0yuhb5dl	261	4	role	role	NN
cord-324859-0yuhb5dl	261	5	in	in	IN
cord-324859-0yuhb5dl	261	6	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	261	7	Clinical	clinical	JJ
cord-324859-0yuhb5dl	261	8	and	and	CC
cord-324859-0yuhb5dl	261	9	immunological	immunological	JJ
cord-324859-0yuhb5dl	261	10	features	feature	NNS
cord-324859-0yuhb5dl	261	11	of	of	IN
cord-324859-0yuhb5dl	261	12	severe	severe	JJ
cord-324859-0yuhb5dl	261	13	and	and	CC
cord-324859-0yuhb5dl	261	14	moderate	moderate	JJ
cord-324859-0yuhb5dl	261	15	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	261	16	disease	disease	NN
cord-324859-0yuhb5dl	261	17	2019	2019	CD
cord-324859-0yuhb5dl	262	1	The	the	DT
cord-324859-0yuhb5dl	262	2	potential	potential	JJ
cord-324859-0yuhb5dl	262	3	role	role	NN
cord-324859-0yuhb5dl	262	4	of	of	IN
cord-324859-0yuhb5dl	262	5	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	262	6	in	in	IN
cord-324859-0yuhb5dl	262	7	monitoring	monitor	VBG
cord-324859-0yuhb5dl	262	8	severe	severe	JJ
cord-324859-0yuhb5dl	262	9	case	case	NN
cord-324859-0yuhb5dl	262	10	of	of	IN
cord-324859-0yuhb5dl	262	11	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	262	12	disease	disease	NN
cord-324859-0yuhb5dl	262	13	2019	2019	CD
cord-324859-0yuhb5dl	262	14	A	a	DT
cord-324859-0yuhb5dl	262	15	glimpse	glimpse	NN
cord-324859-0yuhb5dl	262	16	into	into	IN
cord-324859-0yuhb5dl	262	17	the	the	DT
cord-324859-0yuhb5dl	262	18	eye	eye	NN
cord-324859-0yuhb5dl	262	19	of	of	IN
cord-324859-0yuhb5dl	262	20	the	the	DT
cord-324859-0yuhb5dl	262	21	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	262	22	cytokine	cytokine	NN
cord-324859-0yuhb5dl	262	23	storm	storm	NN
cord-324859-0yuhb5dl	262	24	Interleukin-6	Interleukin-6	NNP
cord-324859-0yuhb5dl	262	25	in	in	IN
cord-324859-0yuhb5dl	262	26	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	262	27	:	:	:
cord-324859-0yuhb5dl	262	28	a	a	DT
cord-324859-0yuhb5dl	262	29	systematic	systematic	JJ
cord-324859-0yuhb5dl	262	30	review	review	NN
cord-324859-0yuhb5dl	262	31	and	and	CC
cord-324859-0yuhb5dl	262	32	meta	meta	NNP
cord-324859-0yuhb5dl	262	33	-	-	HYPH
cord-324859-0yuhb5dl	262	34	analysis	analysis	NN
cord-324859-0yuhb5dl	262	35	.	.	.
cord-324859-0yuhb5dl	263	1	medRxiv	medRxiv	NNP
cord-324859-0yuhb5dl	263	2	Elevated	Elevated	NNP
cord-324859-0yuhb5dl	263	3	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	263	4	and	and	CC
cord-324859-0yuhb5dl	263	5	severe	severe	JJ
cord-324859-0yuhb5dl	263	6	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	263	7	:	:	:
cord-324859-0yuhb5dl	263	8	a	a	DT
cord-324859-0yuhb5dl	263	9	meta	meta	JJ
cord-324859-0yuhb5dl	263	10	-	-	HYPH
cord-324859-0yuhb5dl	263	11	analysis	analysis	NN
cord-324859-0yuhb5dl	263	12	Interleukin-6	Interleukin-6	NNP
cord-324859-0yuhb5dl	263	13	as	as	IN
cord-324859-0yuhb5dl	263	14	a	a	DT
cord-324859-0yuhb5dl	263	15	potential	potential	JJ
cord-324859-0yuhb5dl	263	16	biomarker	biomarker	NN
cord-324859-0yuhb5dl	263	17	of	of	IN
cord-324859-0yuhb5dl	263	18	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	263	19	progression	progression	NN
cord-324859-0yuhb5dl	263	20	Hematologic	Hematologic	NNP
cord-324859-0yuhb5dl	263	21	,	,	,
cord-324859-0yuhb5dl	263	22	biochemical	biochemical	JJ
cord-324859-0yuhb5dl	263	23	and	and	CC
cord-324859-0yuhb5dl	263	24	immune	immune	JJ
cord-324859-0yuhb5dl	263	25	biomarker	biomarker	NN
cord-324859-0yuhb5dl	263	26	abnormalities	abnormality	NNS
cord-324859-0yuhb5dl	263	27	associated	associate	VBN
cord-324859-0yuhb5dl	263	28	with	with	IN
cord-324859-0yuhb5dl	263	29	severe	severe	JJ
cord-324859-0yuhb5dl	263	30	illness	illness	NN
cord-324859-0yuhb5dl	263	31	and	and	CC
cord-324859-0yuhb5dl	263	32	mortality	mortality	NN
cord-324859-0yuhb5dl	263	33	in	in	IN
cord-324859-0yuhb5dl	263	34	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	263	35	disease	disease	NN
cord-324859-0yuhb5dl	263	36	2019	2019	CD
cord-324859-0yuhb5dl	263	37	(	(	-LRB-
cord-324859-0yuhb5dl	263	38	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	263	39	)	)	-RRB-
cord-324859-0yuhb5dl	263	40	:	:	:
cord-324859-0yuhb5dl	263	41	a	a	DT
cord-324859-0yuhb5dl	263	42	meta	meta	JJ
cord-324859-0yuhb5dl	263	43	-	-	HYPH
cord-324859-0yuhb5dl	263	44	analysis	analysis	NN
cord-324859-0yuhb5dl	263	45	Novel	Novel	NNP
cord-324859-0yuhb5dl	263	46	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	263	47	infection	infection	NN
cord-324859-0yuhb5dl	263	48	(	(	-LRB-
cord-324859-0yuhb5dl	263	49	COVID-19	covid-19	VB
cord-324859-0yuhb5dl	263	50	)	)	-RRB-
cord-324859-0yuhb5dl	263	51	in	in	IN
cord-324859-0yuhb5dl	263	52	humans	human	NNS
cord-324859-0yuhb5dl	263	53	:	:	:
cord-324859-0yuhb5dl	263	54	a	a	DT
cord-324859-0yuhb5dl	263	55	scoping	scoping	NN
cord-324859-0yuhb5dl	263	56	review	review	NN
cord-324859-0yuhb5dl	263	57	and	and	CC
cord-324859-0yuhb5dl	263	58	meta	meta	NNP
cord-324859-0yuhb5dl	263	59	-	-	HYPH
cord-324859-0yuhb5dl	263	60	analysis	analysis	NN
cord-324859-0yuhb5dl	263	61	Recor	Recor	NNP
cord-324859-0yuhb5dl	263	62	dID=183246	did=183246	JJ
cord-324859-0yuhb5dl	263	63	.	.	.
cord-324859-0yuhb5dl	264	1	Accessed	access	VBN
cord-324859-0yuhb5dl	264	2	The	the	DT
cord-324859-0yuhb5dl	264	3	PRISMA	PRISMA	NNP
cord-324859-0yuhb5dl	264	4	Group	Group	NNP
cord-324859-0yuhb5dl	264	5	.	.	.
cord-324859-0yuhb5dl	265	1	Preferred	preferred	JJ
cord-324859-0yuhb5dl	265	2	reporting	reporting	NN
cord-324859-0yuhb5dl	265	3	items	item	NNS
cord-324859-0yuhb5dl	265	4	for	for	IN
cord-324859-0yuhb5dl	265	5	systematic	systematic	JJ
cord-324859-0yuhb5dl	265	6	reviews	review	NNS
cord-324859-0yuhb5dl	265	7	and	and	CC
cord-324859-0yuhb5dl	265	8	meta	meta	NNP
cord-324859-0yuhb5dl	265	9	-	-	HYPH
cord-324859-0yuhb5dl	265	10	analyses	analysis	NNS
cord-324859-0yuhb5dl	265	11	:	:	:
cord-324859-0yuhb5dl	265	12	the	the	DT
cord-324859-0yuhb5dl	265	13	PRISMA	PRISMA	NNP
cord-324859-0yuhb5dl	265	14	Statement	Statement	NNP
cord-324859-0yuhb5dl	265	15	repor	repor	NNP
cord-324859-0yuhb5dl	265	16	ting	ting	NNP
cord-324859-0yuhb5dl	265	17	-	-	HYPH
cord-324859-0yuhb5dl	265	18	guide	guide	VB
cord-324859-0yuhb5dl	265	19	lines/	lines/	ADD
cord-324859-0yuhb5dl	265	20	meta	meta	NNP
cord-324859-0yuhb5dl	265	21	-	-	HYPH
cord-324859-0yuhb5dl	265	22	analy	analy	NNP
cord-324859-0yuhb5dl	265	23	sis	sis	NNP
cord-324859-0yuhb5dl	265	24	-	-	HYPH
cord-324859-0yuhb5dl	265	25	of	of	IN
cord-324859-0yuhb5dl	265	26	-	-	HYPH
cord-324859-0yuhb5dl	265	27	obser	obser	FW
cord-324859-0yuhb5dl	265	28	vatio	vatio	FW
cord-324859-0yuhb5dl	265	29	nal	nal	NNP
cord-324859-0yuhb5dl	265	30	-	-	HYPH
cord-324859-0yuhb5dl	265	31	studi	studi	NNP
cord-324859-0yuhb5dl	265	32	es	es	NNP
cord-324859-0yuhb5dl	265	33	-	-	HYPH
cord-324859-0yuhb5dl	265	34	in	in	IN
cord-324859-0yuhb5dl	265	35	-	-	HYPH
cord-324859-0yuhb5dl	265	36	epide	epide	NN
cord-324859-0yuhb5dl	265	37	miolo	miolo	NNP
cord-324859-0yuhb5dl	265	38	gy	gy	NNP
cord-324859-0yuhb5dl	265	39	-	-	HYPH
cord-324859-0yuhb5dl	265	40	a	a	DT
cord-324859-0yuhb5dl	265	41	-	-	HYPH
cord-324859-0yuhb5dl	265	42	propo	propo	NN
cord-324859-0yuhb5dl	265	43	sal	sal	NN
cord-324859-0yuhb5dl	265	44	-	-	HYPH
cord-324859-0yuhb5dl	265	45	for	for	IN
cord-324859-0yuhb5dl	265	46	-	-	HYPH
cord-324859-0yuhb5dl	265	47	repor	repor	NN
cord-324859-0yuhb5dl	265	48	ting	ting	NNP
cord-324859-0yuhb5dl	265	49	-	-	HYPH
cord-324859-0yuhb5dl	265	50	meta	meta	NNP
cord-324859-0yuhb5dl	265	51	-	-	HYPH
cord-324859-0yuhb5dl	265	52	analy	analy	NNP
cord-324859-0yuhb5dl	266	1	sis	sis	NN
cord-324859-0yuhb5dl	266	2	-	-	HYPH
cord-324859-0yuhb5dl	266	3	of	of	IN
cord-324859-0yuhb5dl	266	4	-	-	HYPH
cord-324859-0yuhb5dl	266	5	obser	obser	FW
cord-324859-0yuhb5dl	266	6	vatio	vatio	FW
cord-324859-0yuhb5dl	266	7	nal	nal	NNP
cord-324859-0yuhb5dl	266	8	-	-	HYPH
cord-324859-0yuhb5dl	266	9	studi	studi	NNP
cord-324859-0yuhb5dl	267	1	es	es	JJ
cord-324859-0yuhb5dl	267	2	-	-	HYPH
cord-324859-0yuhb5dl	267	3	in	in	IN
cord-324859-0yuhb5dl	267	4	-	-	HYPH
cord-324859-0yuhb5dl	267	5	epide	epide	NN
cord-324859-0yuhb5dl	267	6	miolo	miolo	NNP
cord-324859-0yuhb5dl	267	7	gy	gy	NNP
cord-324859-0yuhb5dl	267	8	-	-	HYPH
cord-324859-0yuhb5dl	267	9	moose	moose	NNP
cord-324859-0yuhb5dl	267	10	-group/	-group/	NNP
cord-324859-0yuhb5dl	268	1	Accessed	access	VBN
cord-324859-0yuhb5dl	268	2	Estimating	estimate	VBG
cord-324859-0yuhb5dl	268	3	the	the	DT
cord-324859-0yuhb5dl	268	4	sample	sample	NN
cord-324859-0yuhb5dl	268	5	mean	mean	NN
cord-324859-0yuhb5dl	268	6	and	and	CC
cord-324859-0yuhb5dl	268	7	standard	standard	JJ
cord-324859-0yuhb5dl	268	8	deviation	deviation	NN
cord-324859-0yuhb5dl	268	9	from	from	IN
cord-324859-0yuhb5dl	268	10	the	the	DT
cord-324859-0yuhb5dl	268	11	sample	sample	NN
cord-324859-0yuhb5dl	268	12	size	size	NN
cord-324859-0yuhb5dl	268	13	,	,	,
cord-324859-0yuhb5dl	268	14	median	median	NN
cord-324859-0yuhb5dl	268	15	,	,	,
cord-324859-0yuhb5dl	268	16	range	range	NN
cord-324859-0yuhb5dl	269	1	and/or	and/or	CC
cord-324859-0yuhb5dl	270	1	interquartile	interquartile	JJ
cord-324859-0yuhb5dl	270	2	range	range	VBP
cord-324859-0yuhb5dl	270	3	Meta	Meta	NNP
cord-324859-0yuhb5dl	270	4	-	-	HYPH
cord-324859-0yuhb5dl	270	5	analysis	analysis	NN
cord-324859-0yuhb5dl	270	6	in	in	IN
cord-324859-0yuhb5dl	270	7	clinical	clinical	JJ
cord-324859-0yuhb5dl	270	8	trials	trial	NNS
cord-324859-0yuhb5dl	271	1	Identifying	identify	VBG
cord-324859-0yuhb5dl	271	2	and	and	CC
cord-324859-0yuhb5dl	271	3	measuring	measure	VBG
cord-324859-0yuhb5dl	271	4	heterogeneity	heterogeneity	NN
cord-324859-0yuhb5dl	272	1	The	the	DT
cord-324859-0yuhb5dl	272	2	Newcastle	Newcastle	NNP
cord-324859-0yuhb5dl	272	3	-	-	HYPH
cord-324859-0yuhb5dl	272	4	Ottawa	Ottawa	NNP
cord-324859-0yuhb5dl	272	5	Scale	Scale	NNP
cord-324859-0yuhb5dl	272	6	for	for	IN
cord-324859-0yuhb5dl	272	7	assessing	assess	VBG
cord-324859-0yuhb5dl	272	8	the	the	DT
cord-324859-0yuhb5dl	272	9	quality	quality	NN
cord-324859-0yuhb5dl	272	10	of	of	IN
cord-324859-0yuhb5dl	272	11	non	non	JJ
cord-324859-0yuhb5dl	272	12	-	-	JJ
cord-324859-0yuhb5dl	272	13	randomized	randomized	JJ
cord-324859-0yuhb5dl	272	14	studies	study	NNS
cord-324859-0yuhb5dl	272	15	in	in	IN
cord-324859-0yuhb5dl	272	16	meta	meta	NNP
cord-324859-0yuhb5dl	272	17	-	-	HYPH
cord-324859-0yuhb5dl	272	18	analyses	analysis	NNS
cord-324859-0yuhb5dl	272	19	Bias	Bias	NNP
cord-324859-0yuhb5dl	272	20	in	in	IN
cord-324859-0yuhb5dl	272	21	meta	meta	NNP
cord-324859-0yuhb5dl	272	22	-	-	HYPH
cord-324859-0yuhb5dl	272	23	analysis	analysis	NN
cord-324859-0yuhb5dl	272	24	detected	detect	VBN
cord-324859-0yuhb5dl	272	25	by	by	IN
cord-324859-0yuhb5dl	272	26	a	a	DT
cord-324859-0yuhb5dl	272	27	simple	simple	JJ
cord-324859-0yuhb5dl	272	28	,	,	,
cord-324859-0yuhb5dl	272	29	graphical	graphical	JJ
cord-324859-0yuhb5dl	272	30	test	test	NN
cord-324859-0yuhb5dl	272	31	Epidemiological	epidemiological	JJ
cord-324859-0yuhb5dl	272	32	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	272	33	and	and	CC
cord-324859-0yuhb5dl	272	34	clinical	clinical	JJ
cord-324859-0yuhb5dl	272	35	features	feature	NNS
cord-324859-0yuhb5dl	272	36	of	of	IN
cord-324859-0yuhb5dl	272	37	32	32	CD
cord-324859-0yuhb5dl	272	38	critical	critical	JJ
cord-324859-0yuhb5dl	272	39	and	and	CC
cord-324859-0yuhb5dl	272	40	67	67	CD
cord-324859-0yuhb5dl	272	41	noncritical	noncritical	JJ
cord-324859-0yuhb5dl	272	42	cases	case	NNS
cord-324859-0yuhb5dl	272	43	of	of	IN
cord-324859-0yuhb5dl	272	44	COVID-19	covid-19	CD
cord-324859-0yuhb5dl	272	45	in	in	IN
cord-324859-0yuhb5dl	272	46	Chengdu	Chengdu	NNP
cord-324859-0yuhb5dl	272	47	Clinical	clinical	JJ
cord-324859-0yuhb5dl	272	48	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	272	49	and	and	CC
cord-324859-0yuhb5dl	272	50	prognosis	prognosis	NN
cord-324859-0yuhb5dl	272	51	in	in	IN
cord-324859-0yuhb5dl	272	52	cancer	cancer	NN
cord-324859-0yuhb5dl	272	53	patients	patient	NNS
cord-324859-0yuhb5dl	272	54	with	with	IN
cord-324859-0yuhb5dl	272	55	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	272	56	:	:	:
cord-324859-0yuhb5dl	272	57	a	a	DT
cord-324859-0yuhb5dl	272	58	single	single	JJ
cord-324859-0yuhb5dl	272	59	center	center	NN
cord-324859-0yuhb5dl	272	60	's	's	POS
cord-324859-0yuhb5dl	272	61	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	272	62	study	study	NN
cord-324859-0yuhb5dl	272	63	Epidemiological	epidemiological	JJ
cord-324859-0yuhb5dl	272	64	and	and	CC
cord-324859-0yuhb5dl	272	65	clinical	clinical	JJ
cord-324859-0yuhb5dl	272	66	features	feature	NNS
cord-324859-0yuhb5dl	272	67	of	of	IN
cord-324859-0yuhb5dl	272	68	125	125	CD
cord-324859-0yuhb5dl	272	69	hospitalized	hospitalize	VBN
cord-324859-0yuhb5dl	272	70	patients	patient	NNS
cord-324859-0yuhb5dl	272	71	with	with	IN
cord-324859-0yuhb5dl	272	72	COVID-19	covid-19	CD
cord-324859-0yuhb5dl	272	73	in	in	IN
cord-324859-0yuhb5dl	272	74	Clinical	clinical	JJ
cord-324859-0yuhb5dl	272	75	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	272	76	and	and	CC
cord-324859-0yuhb5dl	272	77	outcomes	outcome	NNS
cord-324859-0yuhb5dl	272	78	of	of	IN
cord-324859-0yuhb5dl	272	79	older	old	JJR
cord-324859-0yuhb5dl	272	80	patients	patient	NNS
cord-324859-0yuhb5dl	272	81	with	with	IN
cord-324859-0yuhb5dl	272	82	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	272	83	disease	disease	NN
cord-324859-0yuhb5dl	273	1	):	):	NNP
cord-324859-0yuhb5dl	274	1	a	a	DT
cord-324859-0yuhb5dl	274	2	single	single	RB
cord-324859-0yuhb5dl	274	3	-	-	HYPH
cord-324859-0yuhb5dl	274	4	centered	centered	JJ
cord-324859-0yuhb5dl	274	5	,	,	,
cord-324859-0yuhb5dl	274	6	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	274	7	study	study	NN
cord-324859-0yuhb5dl	274	8	Clinical	clinical	JJ
cord-324859-0yuhb5dl	274	9	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	274	10	of	of	IN
cord-324859-0yuhb5dl	274	11	113	113	CD
cord-324859-0yuhb5dl	274	12	deceased	deceased	JJ
cord-324859-0yuhb5dl	274	13	patients	patient	NNS
cord-324859-0yuhb5dl	274	14	with	with	IN
cord-324859-0yuhb5dl	274	15	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	274	16	disease	disease	NN
cord-324859-0yuhb5dl	274	17	2019	2019	CD
cord-324859-0yuhb5dl	274	18	:	:	:
cord-324859-0yuhb5dl	274	19	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	274	20	study	study	NN
cord-324859-0yuhb5dl	274	21	Clinical	clinical	JJ
cord-324859-0yuhb5dl	274	22	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	274	23	of	of	IN
cord-324859-0yuhb5dl	274	24	refractory	refractory	JJ
cord-324859-0yuhb5dl	274	25	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	274	26	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	274	27	in	in	IN
cord-324859-0yuhb5dl	274	28	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	274	29	,	,	,
cord-324859-0yuhb5dl	274	30	China	China	NNP
cord-324859-0yuhb5dl	274	31	Clinical	Clinical	NNP
cord-324859-0yuhb5dl	274	32	and	and	CC
cord-324859-0yuhb5dl	274	33	autoimmune	autoimmune	JJ
cord-324859-0yuhb5dl	274	34	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	274	35	of	of	IN
cord-324859-0yuhb5dl	274	36	severe	severe	JJ
cord-324859-0yuhb5dl	274	37	and	and	CC
cord-324859-0yuhb5dl	274	38	critical	critical	JJ
cord-324859-0yuhb5dl	274	39	cases	case	NNS
cord-324859-0yuhb5dl	274	40	of	of	IN
cord-324859-0yuhb5dl	274	41	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	274	42	Relationships	Relationships	NNPS
cord-324859-0yuhb5dl	274	43	among	among	IN
cord-324859-0yuhb5dl	274	44	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	274	45	subsets	subset	NNS
cord-324859-0yuhb5dl	274	46	,	,	,
cord-324859-0yuhb5dl	274	47	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	274	48	,	,	,
cord-324859-0yuhb5dl	274	49	and	and	CC
cord-324859-0yuhb5dl	274	50	the	the	DT
cord-324859-0yuhb5dl	274	51	pulmonary	pulmonary	JJ
cord-324859-0yuhb5dl	274	52	inflammation	inflammation	NN
cord-324859-0yuhb5dl	274	53	index	index	NN
cord-324859-0yuhb5dl	274	54	in	in	IN
cord-324859-0yuhb5dl	274	55	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	274	56	(	(	-LRB-
cord-324859-0yuhb5dl	274	57	COVID-19	covid-19	VB
cord-324859-0yuhb5dl	274	58	)	)	-RRB-
cord-324859-0yuhb5dl	274	59	infected	infect	VBN
cord-324859-0yuhb5dl	274	60	patients	patient	NNS
cord-324859-0yuhb5dl	274	61	Detectable	detectable	JJ
cord-324859-0yuhb5dl	274	62	serum	serum	NN
cord-324859-0yuhb5dl	274	63	severe	severe	JJ
cord-324859-0yuhb5dl	274	64	acute	acute	JJ
cord-324859-0yuhb5dl	274	65	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	274	66	syndrome	syndrome	NN
cord-324859-0yuhb5dl	274	67	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	274	68	2	2	CD
cord-324859-0yuhb5dl	274	69	viral	viral	JJ
cord-324859-0yuhb5dl	274	70	load	load	NN
cord-324859-0yuhb5dl	274	71	(	(	-LRB-
cord-324859-0yuhb5dl	274	72	RNAemia	RNAemia	NNP
cord-324859-0yuhb5dl	274	73	)	)	-RRB-
cord-324859-0yuhb5dl	274	74	is	be	VBZ
cord-324859-0yuhb5dl	274	75	closely	closely	RB
cord-324859-0yuhb5dl	274	76	correlated	correlate	VBN
cord-324859-0yuhb5dl	274	77	with	with	IN
cord-324859-0yuhb5dl	274	78	drastically	drastically	RB
cord-324859-0yuhb5dl	274	79	elevated	elevate	VBN
cord-324859-0yuhb5dl	274	80	interleukin	interleukin	NN
cord-324859-0yuhb5dl	274	81	6	6	CD
cord-324859-0yuhb5dl	274	82	level	level	NN
cord-324859-0yuhb5dl	274	83	in	in	IN
cord-324859-0yuhb5dl	274	84	critically	critically	RB
cord-324859-0yuhb5dl	274	85	ill	ill	JJ
cord-324859-0yuhb5dl	274	86	patients	patient	NNS
cord-324859-0yuhb5dl	274	87	with	with	IN
cord-324859-0yuhb5dl	274	88	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	274	89	disease	disease	NN
cord-324859-0yuhb5dl	274	90	2019	2019	CD
cord-324859-0yuhb5dl	274	91	Diagnostic	diagnostic	JJ
cord-324859-0yuhb5dl	274	92	utility	utility	NN
cord-324859-0yuhb5dl	274	93	of	of	IN
cord-324859-0yuhb5dl	274	94	clinical	clinical	JJ
cord-324859-0yuhb5dl	274	95	laboratory	laboratory	NN
cord-324859-0yuhb5dl	274	96	data	datum	NNS
cord-324859-0yuhb5dl	274	97	determinations	determination	NNS
cord-324859-0yuhb5dl	274	98	for	for	IN
cord-324859-0yuhb5dl	274	99	patients	patient	NNS
cord-324859-0yuhb5dl	274	100	with	with	IN
cord-324859-0yuhb5dl	274	101	the	the	DT
cord-324859-0yuhb5dl	274	102	severe	severe	JJ
cord-324859-0yuhb5dl	274	103	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	274	104	Clinical	clinical	JJ
cord-324859-0yuhb5dl	274	105	features	feature	NNS
cord-324859-0yuhb5dl	274	106	of	of	IN
cord-324859-0yuhb5dl	274	107	69	69	CD
cord-324859-0yuhb5dl	274	108	cases	case	NNS
cord-324859-0yuhb5dl	274	109	with	with	IN
cord-324859-0yuhb5dl	274	110	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	274	111	disease	disease	NN
cord-324859-0yuhb5dl	274	112	2019	2019	CD
cord-324859-0yuhb5dl	274	113	in	in	IN
cord-324859-0yuhb5dl	274	114	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	274	115	,	,	,
cord-324859-0yuhb5dl	274	116	China	China	NNP
cord-324859-0yuhb5dl	274	117	Dysregulation	Dysregulation	NNP
cord-324859-0yuhb5dl	274	118	of	of	IN
cord-324859-0yuhb5dl	274	119	immune	immune	JJ
cord-324859-0yuhb5dl	274	120	response	response	NN
cord-324859-0yuhb5dl	274	121	in	in	IN
cord-324859-0yuhb5dl	274	122	patients	patient	NNS
cord-324859-0yuhb5dl	274	123	with	with	IN
cord-324859-0yuhb5dl	274	124	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	274	125	2019	2019	CD
cord-324859-0yuhb5dl	274	126	(	(	-LRB-
cord-324859-0yuhb5dl	274	127	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	274	128	)	)	-RRB-
cord-324859-0yuhb5dl	274	129	in	in	IN
cord-324859-0yuhb5dl	274	130	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	274	131	,	,	,
cord-324859-0yuhb5dl	274	132	China	China	NNP
cord-324859-0yuhb5dl	274	133	Tocilizumab	Tocilizumab	NNP
cord-324859-0yuhb5dl	274	134	treatment	treatment	NN
cord-324859-0yuhb5dl	274	135	in	in	IN
cord-324859-0yuhb5dl	274	136	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	274	137	:	:	:
cord-324859-0yuhb5dl	274	138	a	a	DT
cord-324859-0yuhb5dl	274	139	single	single	JJ
cord-324859-0yuhb5dl	274	140	center	center	NN
cord-324859-0yuhb5dl	274	141	experience	experience	NN
cord-324859-0yuhb5dl	274	142	Coronavirus	Coronavirus	NNP
cord-324859-0yuhb5dl	274	143	disease	disease	NN
cord-324859-0yuhb5dl	274	144	2019	2019	CD
cord-324859-0yuhb5dl	274	145	in	in	IN
cord-324859-0yuhb5dl	274	146	elderly	elderly	JJ
cord-324859-0yuhb5dl	274	147	patients	patient	NNS
cord-324859-0yuhb5dl	274	148	:	:	:
cord-324859-0yuhb5dl	274	149	Characteristics	characteristic	NNS
cord-324859-0yuhb5dl	274	150	and	and	CC
cord-324859-0yuhb5dl	274	151	prognostic	prognostic	JJ
cord-324859-0yuhb5dl	274	152	factors	factor	NNS
cord-324859-0yuhb5dl	274	153	based	base	VBN
cord-324859-0yuhb5dl	274	154	on	on	IN
cord-324859-0yuhb5dl	274	155	4-week	4-week	CD
cord-324859-0yuhb5dl	274	156	follow	follow	NN
cord-324859-0yuhb5dl	274	157	-	-	HYPH
cord-324859-0yuhb5dl	274	158	up	up	RP
cord-324859-0yuhb5dl	274	159	Clinical	clinical	JJ
cord-324859-0yuhb5dl	274	160	predictors	predictor	NNS
cord-324859-0yuhb5dl	274	161	of	of	IN
cord-324859-0yuhb5dl	274	162	mortality	mortality	NN
cord-324859-0yuhb5dl	274	163	due	due	IN
cord-324859-0yuhb5dl	274	164	to	to	IN
cord-324859-0yuhb5dl	274	165	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	274	166	based	base	VBN
cord-324859-0yuhb5dl	274	167	on	on	IN
cord-324859-0yuhb5dl	274	168	an	an	DT
cord-324859-0yuhb5dl	274	169	analysis	analysis	NN
cord-324859-0yuhb5dl	274	170	of	of	IN
cord-324859-0yuhb5dl	274	171	data	datum	NNS
cord-324859-0yuhb5dl	274	172	of	of	IN
cord-324859-0yuhb5dl	274	173	150	150	CD
cord-324859-0yuhb5dl	274	174	patients	patient	NNS
cord-324859-0yuhb5dl	274	175	from	from	IN
cord-324859-0yuhb5dl	274	176	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	274	177	,	,	,
cord-324859-0yuhb5dl	274	178	China	China	NNP
cord-324859-0yuhb5dl	274	179	COVID-19	covid-19	VBP
cord-324859-0yuhb5dl	274	180	with	with	IN
cord-324859-0yuhb5dl	274	181	different	different	JJ
cord-324859-0yuhb5dl	274	182	severities	severity	NNS
cord-324859-0yuhb5dl	274	183	:	:	:
cord-324859-0yuhb5dl	274	184	a	a	DT
cord-324859-0yuhb5dl	274	185	multicenter	multicenter	JJ
cord-324859-0yuhb5dl	274	186	study	study	NN
cord-324859-0yuhb5dl	274	187	of	of	IN
cord-324859-0yuhb5dl	274	188	clinical	clinical	JJ
cord-324859-0yuhb5dl	274	189	features	feature	VBZ
cord-324859-0yuhb5dl	274	190	Risk	risk	NN
cord-324859-0yuhb5dl	274	191	factors	factor	NNS
cord-324859-0yuhb5dl	274	192	associated	associate	VBN
cord-324859-0yuhb5dl	274	193	with	with	IN
cord-324859-0yuhb5dl	274	194	disease	disease	NN
cord-324859-0yuhb5dl	274	195	progression	progression	NN
cord-324859-0yuhb5dl	274	196	in	in	IN
cord-324859-0yuhb5dl	274	197	a	a	DT
cord-324859-0yuhb5dl	274	198	cohort	cohort	NN
cord-324859-0yuhb5dl	274	199	of	of	IN
cord-324859-0yuhb5dl	274	200	patients	patient	NNS
cord-324859-0yuhb5dl	274	201	infected	infect	VBN
cord-324859-0yuhb5dl	274	202	with	with	IN
cord-324859-0yuhb5dl	274	203	the	the	DT
cord-324859-0yuhb5dl	274	204	2019	2019	CD
cord-324859-0yuhb5dl	274	205	novel	novel	NN
cord-324859-0yuhb5dl	274	206	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	275	1	The	the	DT
cord-324859-0yuhb5dl	275	2	correlation	correlation	NN
cord-324859-0yuhb5dl	275	3	between	between	IN
cord-324859-0yuhb5dl	275	4	viral	viral	JJ
cord-324859-0yuhb5dl	275	5	clearance	clearance	NN
cord-324859-0yuhb5dl	275	6	and	and	CC
cord-324859-0yuhb5dl	275	7	biochemical	biochemical	JJ
cord-324859-0yuhb5dl	275	8	outcomes	outcome	NNS
cord-324859-0yuhb5dl	275	9	of	of	IN
cord-324859-0yuhb5dl	275	10	94	94	CD
cord-324859-0yuhb5dl	275	11	COVID-19	covid-19	CD
cord-324859-0yuhb5dl	275	12	infected	infected	JJ
cord-324859-0yuhb5dl	275	13	discharged	discharge	VBN
cord-324859-0yuhb5dl	275	14	patients	patient	NNS
cord-324859-0yuhb5dl	275	15	Clinical	clinical	JJ
cord-324859-0yuhb5dl	275	16	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	275	17	of	of	IN
cord-324859-0yuhb5dl	275	18	SARS	SARS	NNP
cord-324859-0yuhb5dl	275	19	-	-	HYPH
cord-324859-0yuhb5dl	275	20	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	275	21	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	275	22	compared	compare	VBN
cord-324859-0yuhb5dl	275	23	to	to	IN
cord-324859-0yuhb5dl	275	24	controls	control	NNS
cord-324859-0yuhb5dl	275	25	in	in	IN
cord-324859-0yuhb5dl	275	26	Chinese	chinese	JJ
cord-324859-0yuhb5dl	275	27	Han	Han	NNP
cord-324859-0yuhb5dl	275	28	Population	Population	NNP
cord-324859-0yuhb5dl	275	29	.	.	.
cord-324859-0yuhb5dl	276	1	medRxiv	medRxiv	NFP
cord-324859-0yuhb5dl	276	2	Metabolic	metabolic	JJ
cord-324859-0yuhb5dl	276	3	disturbances	disturbance	NNS
cord-324859-0yuhb5dl	276	4	and	and	CC
cord-324859-0yuhb5dl	276	5	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	276	6	dysfunction	dysfunction	NN
cord-324859-0yuhb5dl	276	7	predict	predict	VBP
cord-324859-0yuhb5dl	276	8	severity	severity	NN
cord-324859-0yuhb5dl	276	9	of	of	IN
cord-324859-0yuhb5dl	276	10	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	276	11	disease	disease	NN
cord-324859-0yuhb5dl	276	12	2019	2019	CD
cord-324859-0yuhb5dl	276	13	(	(	-LRB-
cord-324859-0yuhb5dl	276	14	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	276	15	)	)	-RRB-
cord-324859-0yuhb5dl	276	16	:	:	:
cord-324859-0yuhb5dl	276	17	a	a	DT
cord-324859-0yuhb5dl	276	18	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	276	19	study	study	NN
cord-324859-0yuhb5dl	276	20	Potential	potential	JJ
cord-324859-0yuhb5dl	276	21	factors	factor	NNS
cord-324859-0yuhb5dl	276	22	for	for	IN
cord-324859-0yuhb5dl	276	23	prediction	prediction	NN
cord-324859-0yuhb5dl	276	24	of	of	IN
cord-324859-0yuhb5dl	276	25	disease	disease	NN
cord-324859-0yuhb5dl	276	26	severity	severity	NN
cord-324859-0yuhb5dl	276	27	of	of	IN
cord-324859-0yuhb5dl	276	28	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	276	29	patients	patient	NNS
cord-324859-0yuhb5dl	276	30	Epidemiological	epidemiological	JJ
cord-324859-0yuhb5dl	276	31	and	and	CC
cord-324859-0yuhb5dl	276	32	clinical	clinical	JJ
cord-324859-0yuhb5dl	276	33	features	feature	NNS
cord-324859-0yuhb5dl	276	34	of	of	IN
cord-324859-0yuhb5dl	276	35	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	276	36	patients	patient	NNS
cord-324859-0yuhb5dl	276	37	with	with	IN
cord-324859-0yuhb5dl	276	38	and	and	CC
cord-324859-0yuhb5dl	276	39	without	without	IN
cord-324859-0yuhb5dl	276	40	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	276	41	in	in	IN
cord-324859-0yuhb5dl	276	42	Beijing	Beijing	NNP
cord-324859-0yuhb5dl	276	43	,	,	,
cord-324859-0yuhb5dl	276	44	China	China	NNP
cord-324859-0yuhb5dl	276	45	.	.	.
cord-324859-0yuhb5dl	277	1	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	277	2	Dynamic	dynamic	JJ
cord-324859-0yuhb5dl	277	3	profile	profile	NN
cord-324859-0yuhb5dl	277	4	of	of	IN
cord-324859-0yuhb5dl	277	5	severe	severe	JJ
cord-324859-0yuhb5dl	277	6	or	or	CC
cord-324859-0yuhb5dl	277	7	critical	critical	JJ
cord-324859-0yuhb5dl	277	8	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	277	9	cases	case	NNS
cord-324859-0yuhb5dl	277	10	.	.	.
cord-324859-0yuhb5dl	278	1	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	278	2	Clinical	clinical	JJ
cord-324859-0yuhb5dl	278	3	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	278	4	of	of	IN
cord-324859-0yuhb5dl	278	5	51	51	CD
cord-324859-0yuhb5dl	278	6	patients	patient	NNS
cord-324859-0yuhb5dl	278	7	discharged	discharge	VBN
cord-324859-0yuhb5dl	278	8	from	from	IN
cord-324859-0yuhb5dl	278	9	hospital	hospital	NN
cord-324859-0yuhb5dl	278	10	with	with	IN
cord-324859-0yuhb5dl	278	11	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	278	12	in	in	IN
cord-324859-0yuhb5dl	278	13	Chongqing	Chongqing	NNP
cord-324859-0yuhb5dl	278	14	,	,	,
cord-324859-0yuhb5dl	278	15	China	China	NNP
cord-324859-0yuhb5dl	278	16	.	.	.
cord-324859-0yuhb5dl	279	1	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	279	2	COVID-19	covid-19	VBP
cord-324859-0yuhb5dl	279	3	in	in	IN
cord-324859-0yuhb5dl	279	4	a	a	DT
cord-324859-0yuhb5dl	279	5	designated	designate	VBN
cord-324859-0yuhb5dl	279	6	infectious	infectious	JJ
cord-324859-0yuhb5dl	279	7	diseases	disease	NNS
cord-324859-0yuhb5dl	279	8	hospital	hospital	NN
cord-324859-0yuhb5dl	279	9	outside	outside	IN
cord-324859-0yuhb5dl	279	10	Hubei	Hubei	NNP
cord-324859-0yuhb5dl	279	11	Province	Province	NNP
cord-324859-0yuhb5dl	279	12	,	,	,
cord-324859-0yuhb5dl	279	13	China	China	NNP
cord-324859-0yuhb5dl	279	14	.	.	.
cord-324859-0yuhb5dl	280	1	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	280	2	Virologic	Virologic	NNP
cord-324859-0yuhb5dl	280	3	and	and	CC
cord-324859-0yuhb5dl	280	4	clinical	clinical	JJ
cord-324859-0yuhb5dl	280	5	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	280	6	for	for	IN
cord-324859-0yuhb5dl	280	7	prognosis	prognosis	NN
cord-324859-0yuhb5dl	280	8	of	of	IN
cord-324859-0yuhb5dl	280	9	severe	severe	JJ
cord-324859-0yuhb5dl	280	10	COVID-19	covid-19	NN
cord-324859-0yuhb5dl	280	11	:	:	:
cord-324859-0yuhb5dl	280	12	a	a	DT
cord-324859-0yuhb5dl	280	13	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	280	14	observational	observational	JJ
cord-324859-0yuhb5dl	280	15	study	study	NN
cord-324859-0yuhb5dl	280	16	in	in	IN
cord-324859-0yuhb5dl	280	17	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	280	18	,	,	,
cord-324859-0yuhb5dl	280	19	China	China	NNP
cord-324859-0yuhb5dl	280	20	.	.	.
cord-324859-0yuhb5dl	281	1	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	281	2	Down	down	RB
cord-324859-0yuhb5dl	281	3	-	-	HYPH
cord-324859-0yuhb5dl	281	4	regulated	regulate	VBN
cord-324859-0yuhb5dl	281	5	gene	gene	NN
cord-324859-0yuhb5dl	281	6	expression	expression	NN
cord-324859-0yuhb5dl	281	7	spectrum	spectrum	NN
cord-324859-0yuhb5dl	281	8	and	and	CC
cord-324859-0yuhb5dl	281	9	immune	immune	JJ
cord-324859-0yuhb5dl	281	10	responses	response	NNS
cord-324859-0yuhb5dl	281	11	changed	change	VBD
cord-324859-0yuhb5dl	281	12	during	during	IN
cord-324859-0yuhb5dl	281	13	the	the	DT
cord-324859-0yuhb5dl	281	14	disease	disease	NN
cord-324859-0yuhb5dl	281	15	COVID-19	covid-19	CD
cord-324859-0yuhb5dl	281	16	patients	patient	NNS
cord-324859-0yuhb5dl	281	17	Longitudinal	longitudinal	JJ
cord-324859-0yuhb5dl	281	18	characteristics	characteristic	NNS
cord-324859-0yuhb5dl	281	19	of	of	IN
cord-324859-0yuhb5dl	281	20	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	281	21	responses	response	NNS
cord-324859-0yuhb5dl	281	22	and	and	CC
cord-324859-0yuhb5dl	281	23	cytokine	cytokine	NN
cord-324859-0yuhb5dl	281	24	profiles	profile	NNS
cord-324859-0yuhb5dl	281	25	in	in	IN
cord-324859-0yuhb5dl	281	26	the	the	DT
cord-324859-0yuhb5dl	281	27	peripheral	peripheral	JJ
cord-324859-0yuhb5dl	281	28	blood	blood	NN
cord-324859-0yuhb5dl	281	29	of	of	IN
cord-324859-0yuhb5dl	281	30	SARS	SARS	NNP
cord-324859-0yuhb5dl	281	31	-	-	HYPH
cord-324859-0yuhb5dl	281	32	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	281	33	infected	infect	VBD
cord-324859-0yuhb5dl	281	34	patients	patient	NNS
cord-324859-0yuhb5dl	281	35	Correlation	correlation	NN
cord-324859-0yuhb5dl	281	36	between	between	IN
cord-324859-0yuhb5dl	281	37	relative	relative	JJ
cord-324859-0yuhb5dl	281	38	nasopharyngeal	nasopharyngeal	JJ
cord-324859-0yuhb5dl	281	39	virus	virus	NN
cord-324859-0yuhb5dl	281	40	RNA	RNA	NNP
cord-324859-0yuhb5dl	281	41	load	load	NN
cord-324859-0yuhb5dl	281	42	and	and	CC
cord-324859-0yuhb5dl	281	43	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	281	44	count	count	NN
cord-324859-0yuhb5dl	281	45	disease	disease	NN
cord-324859-0yuhb5dl	281	46	severity	severity	NN
cord-324859-0yuhb5dl	281	47	in	in	IN
cord-324859-0yuhb5dl	281	48	patients	patient	NNS
cord-324859-0yuhb5dl	281	49	with	with	IN
cord-324859-0yuhb5dl	281	50	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	281	51	Retrospective	Retrospective	NNP
cord-324859-0yuhb5dl	281	52	analysis	analysis	NN
cord-324859-0yuhb5dl	281	53	of	of	IN
cord-324859-0yuhb5dl	281	54	laboratory	laboratory	NN
cord-324859-0yuhb5dl	281	55	testing	testing	NN
cord-324859-0yuhb5dl	281	56	in	in	IN
cord-324859-0yuhb5dl	281	57	54	54	CD
cord-324859-0yuhb5dl	281	58	patients	patient	NNS
cord-324859-0yuhb5dl	281	59	with	with	IN
cord-324859-0yuhb5dl	281	60	severe	severe	JJ
cord-324859-0yuhb5dl	281	61	-	-	HYPH
cord-324859-0yuhb5dl	281	62	or	or	CC
cord-324859-0yuhb5dl	281	63	critical	critical	JJ
cord-324859-0yuhb5dl	281	64	-	-	HYPH
cord-324859-0yuhb5dl	281	65	type	type	NN
cord-324859-0yuhb5dl	281	66	2019	2019	CD
cord-324859-0yuhb5dl	281	67	novel	novel	NN
cord-324859-0yuhb5dl	281	68	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	281	69	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	281	70	Suppressed	suppress	VBD
cord-324859-0yuhb5dl	281	71	T	T	NNP
cord-324859-0yuhb5dl	281	72	cell	cell	NN
cord-324859-0yuhb5dl	281	73	-	-	HYPH
cord-324859-0yuhb5dl	281	74	mediated	mediate	VBN
cord-324859-0yuhb5dl	281	75	immunity	immunity	NN
cord-324859-0yuhb5dl	281	76	in	in	IN
cord-324859-0yuhb5dl	281	77	patients	patient	NNS
cord-324859-0yuhb5dl	281	78	with	with	IN
cord-324859-0yuhb5dl	281	79	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	281	80	:	:	:
cord-324859-0yuhb5dl	281	81	a	a	DT
cord-324859-0yuhb5dl	281	82	clinical	clinical	JJ
cord-324859-0yuhb5dl	281	83	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	281	84	study	study	NN
cord-324859-0yuhb5dl	281	85	in	in	IN
cord-324859-0yuhb5dl	281	86	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	281	87	Risk	Risk	NNP
cord-324859-0yuhb5dl	281	88	-	-	HYPH
cord-324859-0yuhb5dl	281	89	adapted	adapt	VBN
cord-324859-0yuhb5dl	281	90	treatment	treatment	NN
cord-324859-0yuhb5dl	281	91	strategy	strategy	NN
cord-324859-0yuhb5dl	281	92	for	for	IN
cord-324859-0yuhb5dl	281	93	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	281	94	patients	patient	NNS
cord-324859-0yuhb5dl	281	95	Elevated	elevated	JJ
cord-324859-0yuhb5dl	281	96	exhaustion	exhaustion	NN
cord-324859-0yuhb5dl	281	97	levels	level	NNS
cord-324859-0yuhb5dl	281	98	and	and	CC
cord-324859-0yuhb5dl	281	99	reduced	reduce	VBN
cord-324859-0yuhb5dl	281	100	functional	functional	JJ
cord-324859-0yuhb5dl	281	101	diversity	diversity	NN
cord-324859-0yuhb5dl	281	102	of	of	IN
cord-324859-0yuhb5dl	281	103	T	t	NN
cord-324859-0yuhb5dl	281	104	cells	cell	NNS
cord-324859-0yuhb5dl	281	105	in	in	IN
cord-324859-0yuhb5dl	281	106	peripheral	peripheral	JJ
cord-324859-0yuhb5dl	281	107	blood	blood	NN
cord-324859-0yuhb5dl	281	108	may	may	MD
cord-324859-0yuhb5dl	281	109	predict	predict	VB
cord-324859-0yuhb5dl	281	110	severe	severe	JJ
cord-324859-0yuhb5dl	281	111	progression	progression	NN
cord-324859-0yuhb5dl	281	112	in	in	IN
cord-324859-0yuhb5dl	281	113	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	281	114	patients	patient	NNS
cord-324859-0yuhb5dl	281	115	Functional	functional	JJ
cord-324859-0yuhb5dl	281	116	exhaustion	exhaustion	NN
cord-324859-0yuhb5dl	281	117	of	of	IN
cord-324859-0yuhb5dl	281	118	antiviral	antiviral	JJ
cord-324859-0yuhb5dl	281	119	lymphocytes	lymphocyte	NNS
cord-324859-0yuhb5dl	281	120	in	in	IN
cord-324859-0yuhb5dl	281	121	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	281	122	patients	patient	NNS
cord-324859-0yuhb5dl	281	123	Risk	Risk	NNP
cord-324859-0yuhb5dl	281	124	factors	factor	NNS
cord-324859-0yuhb5dl	281	125	associated	associate	VBN
cord-324859-0yuhb5dl	281	126	with	with	IN
cord-324859-0yuhb5dl	281	127	acute	acute	JJ
cord-324859-0yuhb5dl	281	128	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	281	129	distress	distress	NN
cord-324859-0yuhb5dl	281	130	syndrome	syndrome	NN
cord-324859-0yuhb5dl	281	131	and	and	CC
cord-324859-0yuhb5dl	281	132	death	death	NN
cord-324859-0yuhb5dl	281	133	in	in	IN
cord-324859-0yuhb5dl	281	134	patients	patient	NNS
cord-324859-0yuhb5dl	281	135	with	with	IN
cord-324859-0yuhb5dl	281	136	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	281	137	disease	disease	NN
cord-324859-0yuhb5dl	281	138	2019	2019	CD
cord-324859-0yuhb5dl	281	139	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	281	140	in	in	IN
cord-324859-0yuhb5dl	281	141	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	281	142	,	,	,
cord-324859-0yuhb5dl	281	143	China	China	NNP
cord-324859-0yuhb5dl	281	144	Risk	risk	NN
cord-324859-0yuhb5dl	281	145	factors	factor	NNS
cord-324859-0yuhb5dl	281	146	for	for	IN
cord-324859-0yuhb5dl	281	147	severity	severity	NN
cord-324859-0yuhb5dl	281	148	and	and	CC
cord-324859-0yuhb5dl	281	149	mortality	mortality	NN
cord-324859-0yuhb5dl	281	150	in	in	IN
cord-324859-0yuhb5dl	281	151	adult	adult	NN
cord-324859-0yuhb5dl	281	152	COVID-19	covid-19	JJ
cord-324859-0yuhb5dl	281	153	inpatients	inpatient	NNS
cord-324859-0yuhb5dl	281	154	in	in	IN
cord-324859-0yuhb5dl	281	155	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	281	156	Clinical	Clinical	NNP
cord-324859-0yuhb5dl	281	157	course	course	NN
cord-324859-0yuhb5dl	281	158	and	and	CC
cord-324859-0yuhb5dl	281	159	risk	risk	NN
cord-324859-0yuhb5dl	281	160	factors	factor	NNS
cord-324859-0yuhb5dl	281	161	for	for	IN
cord-324859-0yuhb5dl	281	162	mortality	mortality	NN
cord-324859-0yuhb5dl	281	163	of	of	IN
cord-324859-0yuhb5dl	281	164	adult	adult	NN
cord-324859-0yuhb5dl	281	165	inpatients	inpatient	NNS
cord-324859-0yuhb5dl	281	166	with	with	IN
cord-324859-0yuhb5dl	281	167	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	281	168	in	in	IN
cord-324859-0yuhb5dl	281	169	Wuhan	Wuhan	NNP
cord-324859-0yuhb5dl	281	170	,	,	,
cord-324859-0yuhb5dl	281	171	China	China	NNP
cord-324859-0yuhb5dl	281	172	:	:	:
cord-324859-0yuhb5dl	281	173	a	a	DT
cord-324859-0yuhb5dl	281	174	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	281	175	cohort	cohort	NN
cord-324859-0yuhb5dl	281	176	study	study	NN
cord-324859-0yuhb5dl	282	1	Heart	heart	NN
cord-324859-0yuhb5dl	282	2	injury	injury	NN
cord-324859-0yuhb5dl	282	3	signs	sign	NNS
cord-324859-0yuhb5dl	282	4	are	be	VBP
cord-324859-0yuhb5dl	282	5	associated	associate	VBN
cord-324859-0yuhb5dl	282	6	with	with	IN
cord-324859-0yuhb5dl	282	7	higher	high	JJR
cord-324859-0yuhb5dl	282	8	and	and	CC
cord-324859-0yuhb5dl	282	9	earlier	early	JJR
cord-324859-0yuhb5dl	282	10	mortality	mortality	NN
cord-324859-0yuhb5dl	282	11	in	in	IN
cord-324859-0yuhb5dl	282	12	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	282	13	disease	disease	NN
cord-324859-0yuhb5dl	282	14	Prognostic	prognostic	JJ
cord-324859-0yuhb5dl	282	15	value	value	NN
cord-324859-0yuhb5dl	282	16	of	of	IN
cord-324859-0yuhb5dl	282	17	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	282	18	,	,	,
cord-324859-0yuhb5dl	282	19	C	C	NNP
cord-324859-0yuhb5dl	282	20	-	-	HYPH
cord-324859-0yuhb5dl	282	21	reactive	reactive	JJ
cord-324859-0yuhb5dl	282	22	protein	protein	NN
cord-324859-0yuhb5dl	282	23	,	,	,
cord-324859-0yuhb5dl	282	24	and	and	CC
cord-324859-0yuhb5dl	282	25	procalcitonin	procalcitonin	NNS
cord-324859-0yuhb5dl	282	26	in	in	IN
cord-324859-0yuhb5dl	282	27	patients	patient	NNS
cord-324859-0yuhb5dl	282	28	with	with	IN
cord-324859-0yuhb5dl	282	29	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	283	1	Can	Can	MD
cord-324859-0yuhb5dl	283	2	we	-PRON-	PRP
cord-324859-0yuhb5dl	283	3	use	use	VB
cord-324859-0yuhb5dl	283	4	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	283	5	(	(	-LRB-
cord-324859-0yuhb5dl	283	6	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	283	7	)	)	-RRB-
cord-324859-0yuhb5dl	283	8	blockade	blockade	NN
cord-324859-0yuhb5dl	283	9	for	for	IN
cord-324859-0yuhb5dl	283	10	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	283	11	disease	disease	NN
cord-324859-0yuhb5dl	283	12	2019	2019	CD
cord-324859-0yuhb5dl	283	13	(	(	-LRB-
cord-324859-0yuhb5dl	283	14	COVID-19)-induced	covid-19)-induce	VBN
cord-324859-0yuhb5dl	283	15	cytokine	cytokine	NN
cord-324859-0yuhb5dl	283	16	release	release	NN
cord-324859-0yuhb5dl	283	17	syndrome	syndrome	NN
cord-324859-0yuhb5dl	283	18	(	(	-LRB-
cord-324859-0yuhb5dl	283	19	CRS	CRS	NNP
cord-324859-0yuhb5dl	283	20	)	)	-RRB-
cord-324859-0yuhb5dl	283	21	?	?	.
cord-324859-0yuhb5dl	284	1	Genomic	genomic	JJ
cord-324859-0yuhb5dl	284	2	characterisation	characterisation	NN
cord-324859-0yuhb5dl	284	3	and	and	CC
cord-324859-0yuhb5dl	284	4	epidemiology	epidemiology	NN
cord-324859-0yuhb5dl	284	5	of	of	IN
cord-324859-0yuhb5dl	284	6	2019	2019	CD
cord-324859-0yuhb5dl	284	7	novel	novel	JJ
cord-324859-0yuhb5dl	284	8	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	284	9	:	:	:
cord-324859-0yuhb5dl	284	10	implications	implication	NNS
cord-324859-0yuhb5dl	284	11	for	for	IN
cord-324859-0yuhb5dl	284	12	virus	virus	NN
cord-324859-0yuhb5dl	284	13	origins	origin	NNS
cord-324859-0yuhb5dl	284	14	and	and	CC
cord-324859-0yuhb5dl	284	15	receptor	receptor	NN
cord-324859-0yuhb5dl	285	1	binding	bind	VBG
cord-324859-0yuhb5dl	285	2	Dysregulated	Dysregulated	NNP
cord-324859-0yuhb5dl	285	3	type	type	NN
cord-324859-0yuhb5dl	286	1	I	-PRON-	PRP
cord-324859-0yuhb5dl	286	2	interferon	interferon	VBD
cord-324859-0yuhb5dl	286	3	and	and	CC
cord-324859-0yuhb5dl	286	4	inflammatory	inflammatory	JJ
cord-324859-0yuhb5dl	286	5	monocyte	monocyte	JJ
cord-324859-0yuhb5dl	286	6	-	-	HYPH
cord-324859-0yuhb5dl	286	7	macrophage	macrophage	NN
cord-324859-0yuhb5dl	286	8	responses	response	NNS
cord-324859-0yuhb5dl	286	9	cause	cause	VBP
cord-324859-0yuhb5dl	286	10	lethal	lethal	JJ
cord-324859-0yuhb5dl	286	11	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	286	12	in	in	IN
cord-324859-0yuhb5dl	286	13	SARS	SARS	NNP
cord-324859-0yuhb5dl	286	14	-	-	HYPH
cord-324859-0yuhb5dl	286	15	CoV	CoV	NNP
cord-324859-0yuhb5dl	286	16	-	-	HYPH
cord-324859-0yuhb5dl	286	17	infected	infect	VBN
cord-324859-0yuhb5dl	286	18	mice	mouse	NNS
cord-324859-0yuhb5dl	286	19	Imbalanced	imbalanced	JJ
cord-324859-0yuhb5dl	286	20	host	host	NN
cord-324859-0yuhb5dl	286	21	response	response	NN
cord-324859-0yuhb5dl	286	22	to	to	IN
cord-324859-0yuhb5dl	286	23	SARS	SARS	NNP
cord-324859-0yuhb5dl	286	24	-	-	HYPH
cord-324859-0yuhb5dl	286	25	CoV-2	CoV-2	NNP
cord-324859-0yuhb5dl	286	26	drives	drive	VBZ
cord-324859-0yuhb5dl	286	27	development	development	NN
cord-324859-0yuhb5dl	286	28	of	of	IN
cord-324859-0yuhb5dl	286	29	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	287	1	Should	Should	MD
cord-324859-0yuhb5dl	287	2	we	-PRON-	PRP
cord-324859-0yuhb5dl	287	3	stimulate	stimulate	VB
cord-324859-0yuhb5dl	287	4	or	or	CC
cord-324859-0yuhb5dl	287	5	suppress	suppress	VB
cord-324859-0yuhb5dl	287	6	immune	immune	JJ
cord-324859-0yuhb5dl	287	7	responses	response	NNS
cord-324859-0yuhb5dl	287	8	in	in	IN
cord-324859-0yuhb5dl	287	9	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	287	10	?	?	.
cord-324859-0yuhb5dl	288	1	Cytokine	cytokine	NN
cord-324859-0yuhb5dl	288	2	and	and	CC
cord-324859-0yuhb5dl	288	3	anti	anti	JJ
cord-324859-0yuhb5dl	288	4	-	-	JJ
cord-324859-0yuhb5dl	288	5	cytokine	cytokine	JJ
cord-324859-0yuhb5dl	288	6	interventions	intervention	NNS
cord-324859-0yuhb5dl	288	7	Induction	Induction	NNP
cord-324859-0yuhb5dl	288	8	of	of	IN
cord-324859-0yuhb5dl	288	9	apoptosis	apoptosis	NN
cord-324859-0yuhb5dl	288	10	by	by	IN
cord-324859-0yuhb5dl	288	11	the	the	DT
cord-324859-0yuhb5dl	288	12	severe	severe	JJ
cord-324859-0yuhb5dl	288	13	acute	acute	JJ
cord-324859-0yuhb5dl	288	14	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	288	15	syndrome	syndrome	NN
cord-324859-0yuhb5dl	288	16	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	288	17	7a	7a	NN
cord-324859-0yuhb5dl	288	18	protein	protein	NN
cord-324859-0yuhb5dl	288	19	is	be	VBZ
cord-324859-0yuhb5dl	288	20	dependent	dependent	JJ
cord-324859-0yuhb5dl	288	21	on	on	IN
cord-324859-0yuhb5dl	288	22	its	-PRON-	PRP$
cord-324859-0yuhb5dl	288	23	interaction	interaction	NN
cord-324859-0yuhb5dl	288	24	with	with	IN
cord-324859-0yuhb5dl	288	25	the	the	DT
cord-324859-0yuhb5dl	288	26	Bcl	Bcl	NNP
cord-324859-0yuhb5dl	288	27	-	-	HYPH
cord-324859-0yuhb5dl	288	28	XL	XL	NNP
cord-324859-0yuhb5dl	288	29	protein	protein	NN
cord-324859-0yuhb5dl	288	30	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	288	31	,	,	,
cord-324859-0yuhb5dl	288	32	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	288	33	and	and	CC
cord-324859-0yuhb5dl	288	34	immunosuppression	immunosuppression	NN
cord-324859-0yuhb5dl	288	35	:	:	:
cord-324859-0yuhb5dl	289	1	what	what	WP
cord-324859-0yuhb5dl	289	2	can	can	MD
cord-324859-0yuhb5dl	289	3	we	-PRON-	PRP
cord-324859-0yuhb5dl	289	4	learn	learn	VB
cord-324859-0yuhb5dl	289	5	from	from	IN
cord-324859-0yuhb5dl	289	6	severe	severe	JJ
cord-324859-0yuhb5dl	289	7	acute	acute	JJ
cord-324859-0yuhb5dl	289	8	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	289	9	syndrome	syndrome	NN
cord-324859-0yuhb5dl	289	10	?	?	.
cord-324859-0yuhb5dl	290	1	Pathogenic	pathogenic	JJ
cord-324859-0yuhb5dl	290	2	human	human	JJ
cord-324859-0yuhb5dl	290	3	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	290	4	infections	infection	NNS
cord-324859-0yuhb5dl	290	5	:	:	:
cord-324859-0yuhb5dl	290	6	causes	cause	NNS
cord-324859-0yuhb5dl	290	7	and	and	CC
cord-324859-0yuhb5dl	290	8	consequences	consequence	NNS
cord-324859-0yuhb5dl	290	9	of	of	IN
cord-324859-0yuhb5dl	290	10	cytokine	cytokine	NN
cord-324859-0yuhb5dl	290	11	storm	storm	NN
cord-324859-0yuhb5dl	290	12	and	and	CC
cord-324859-0yuhb5dl	290	13	immunopathology	immunopathology	NN
cord-324859-0yuhb5dl	291	1	The	the	DT
cord-324859-0yuhb5dl	291	2	immunology	immunology	NN
cord-324859-0yuhb5dl	291	3	of	of	IN
cord-324859-0yuhb5dl	291	4	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	291	5	:	:	:
cord-324859-0yuhb5dl	291	6	is	be	VBZ
cord-324859-0yuhb5dl	291	7	immune	immune	JJ
cord-324859-0yuhb5dl	291	8	modulation	modulation	NN
cord-324859-0yuhb5dl	291	9	an	an	DT
cord-324859-0yuhb5dl	291	10	option	option	NN
cord-324859-0yuhb5dl	291	11	for	for	IN
cord-324859-0yuhb5dl	291	12	treatment	treatment	NN
cord-324859-0yuhb5dl	291	13	?	?	.
cord-324859-0yuhb5dl	292	1	Pathophysiological	pathophysiological	JJ
cord-324859-0yuhb5dl	292	2	roles	role	NNS
cord-324859-0yuhb5dl	292	3	of	of	IN
cord-324859-0yuhb5dl	292	4	interleukin-8	interleukin-8	NNP
cord-324859-0yuhb5dl	292	5	/	/	SYM
cord-324859-0yuhb5dl	292	6	CXCL8	cxcl8	NN
cord-324859-0yuhb5dl	292	7	in	in	IN
cord-324859-0yuhb5dl	292	8	pulmonary	pulmonary	JJ
cord-324859-0yuhb5dl	292	9	diseases	disease	NNS
cord-324859-0yuhb5dl	292	10	Biomarkers	Biomarkers	NNPS
cord-324859-0yuhb5dl	292	11	for	for	IN
cord-324859-0yuhb5dl	292	12	the	the	DT
cord-324859-0yuhb5dl	292	13	acute	acute	JJ
cord-324859-0yuhb5dl	292	14	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	292	15	distress	distress	NN
cord-324859-0yuhb5dl	292	16	syndrome	syndrome	NN
cord-324859-0yuhb5dl	292	17	:	:	:
cord-324859-0yuhb5dl	292	18	how	how	WRB
cord-324859-0yuhb5dl	292	19	to	to	TO
cord-324859-0yuhb5dl	292	20	make	make	VB
cord-324859-0yuhb5dl	292	21	the	the	DT
cord-324859-0yuhb5dl	292	22	diagnosis	diagnosis	NN
cord-324859-0yuhb5dl	292	23	more	more	RBR
cord-324859-0yuhb5dl	292	24	precise	precise	JJ
cord-324859-0yuhb5dl	292	25	Lower	lower	RBR
cord-324859-0yuhb5dl	292	26	tidal	tidal	JJ
cord-324859-0yuhb5dl	292	27	volume	volume	NN
cord-324859-0yuhb5dl	292	28	ventilation	ventilation	NN
cord-324859-0yuhb5dl	292	29	and	and	CC
cord-324859-0yuhb5dl	292	30	plasma	plasma	NN
cord-324859-0yuhb5dl	292	31	cytokine	cytokine	NN
cord-324859-0yuhb5dl	292	32	markers	marker	NNS
cord-324859-0yuhb5dl	292	33	of	of	IN
cord-324859-0yuhb5dl	292	34	inflammation	inflammation	NN
cord-324859-0yuhb5dl	292	35	in	in	IN
cord-324859-0yuhb5dl	292	36	patients	patient	NNS
cord-324859-0yuhb5dl	292	37	with	with	IN
cord-324859-0yuhb5dl	292	38	acute	acute	JJ
cord-324859-0yuhb5dl	292	39	lung	lung	NN
cord-324859-0yuhb5dl	292	40	injury	injury	NN
cord-324859-0yuhb5dl	292	41	Reduction	reduction	NN
cord-324859-0yuhb5dl	292	42	and	and	CC
cord-324859-0yuhb5dl	292	43	functional	functional	JJ
cord-324859-0yuhb5dl	292	44	exhaustion	exhaustion	NN
cord-324859-0yuhb5dl	292	45	of	of	IN
cord-324859-0yuhb5dl	292	46	T	t	NN
cord-324859-0yuhb5dl	292	47	cells	cell	NNS
cord-324859-0yuhb5dl	292	48	in	in	IN
cord-324859-0yuhb5dl	292	49	patients	patient	NNS
cord-324859-0yuhb5dl	292	50	T	T	NNP
cord-324859-0yuhb5dl	292	51	cell	cell	NN
cord-324859-0yuhb5dl	292	52	-	-	HYPH
cord-324859-0yuhb5dl	292	53	mediated	mediate	VBN
cord-324859-0yuhb5dl	292	54	immune	immune	JJ
cord-324859-0yuhb5dl	292	55	response	response	NN
cord-324859-0yuhb5dl	292	56	to	to	IN
cord-324859-0yuhb5dl	292	57	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	292	58	coronaviruses	coronaviruse	NNS
cord-324859-0yuhb5dl	293	1	Haematological	Haematological	NNP
cord-324859-0yuhb5dl	293	2	manifestations	manifestation	NNS
cord-324859-0yuhb5dl	293	3	in	in	IN
cord-324859-0yuhb5dl	293	4	patients	patient	NNS
cord-324859-0yuhb5dl	293	5	with	with	IN
cord-324859-0yuhb5dl	293	6	severe	severe	JJ
cord-324859-0yuhb5dl	293	7	acute	acute	JJ
cord-324859-0yuhb5dl	293	8	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	293	9	syndrome	syndrome	NN
cord-324859-0yuhb5dl	293	10	:	:	:
cord-324859-0yuhb5dl	294	1	retrospective	retrospective	JJ
cord-324859-0yuhb5dl	294	2	analysis	analysis	NNP
cord-324859-0yuhb5dl	295	1	Rapid	rapid	JJ
cord-324859-0yuhb5dl	295	2	loss	loss	NN
cord-324859-0yuhb5dl	295	3	of	of	IN
cord-324859-0yuhb5dl	295	4	both	both	DT
cord-324859-0yuhb5dl	295	5	CD4	CD4	NNP
cord-324859-0yuhb5dl	295	6	+	+	CC
cord-324859-0yuhb5dl	295	7	and	and	CC
cord-324859-0yuhb5dl	295	8	CD8	CD8	NNP
cord-324859-0yuhb5dl	295	9	+	+	CC
cord-324859-0yuhb5dl	295	10	T	T	NNP
cord-324859-0yuhb5dl	295	11	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	295	12	subsets	subset	NNS
cord-324859-0yuhb5dl	295	13	during	during	IN
cord-324859-0yuhb5dl	295	14	the	the	DT
cord-324859-0yuhb5dl	295	15	acute	acute	JJ
cord-324859-0yuhb5dl	295	16	phase	phase	NN
cord-324859-0yuhb5dl	295	17	of	of	IN
cord-324859-0yuhb5dl	295	18	severe	severe	JJ
cord-324859-0yuhb5dl	295	19	acute	acute	JJ
cord-324859-0yuhb5dl	295	20	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	295	21	syndrome	syndrome	NN
cord-324859-0yuhb5dl	296	1	Significant	significant	JJ
cord-324859-0yuhb5dl	296	2	changes	change	NNS
cord-324859-0yuhb5dl	296	3	of	of	IN
cord-324859-0yuhb5dl	296	4	peripheral	peripheral	JJ
cord-324859-0yuhb5dl	296	5	T	t	NN
cord-324859-0yuhb5dl	296	6	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	296	7	subsets	subset	NNS
cord-324859-0yuhb5dl	296	8	in	in	IN
cord-324859-0yuhb5dl	296	9	patients	patient	NNS
cord-324859-0yuhb5dl	296	10	with	with	IN
cord-324859-0yuhb5dl	296	11	severe	severe	JJ
cord-324859-0yuhb5dl	296	12	acute	acute	JJ
cord-324859-0yuhb5dl	296	13	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	296	14	syndrome	syndrome	NN
cord-324859-0yuhb5dl	296	15	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	296	16	,	,	,
cord-324859-0yuhb5dl	296	17	SARS	SARS	NNP
cord-324859-0yuhb5dl	296	18	and	and	CC
cord-324859-0yuhb5dl	296	19	MERS	MERS	NNP
cord-324859-0yuhb5dl	296	20	:	:	:
cord-324859-0yuhb5dl	296	21	are	be	VBP
cord-324859-0yuhb5dl	296	22	they	-PRON-	PRP
cord-324859-0yuhb5dl	296	23	closely	closely	RB
cord-324859-0yuhb5dl	296	24	related	relate	VBN
cord-324859-0yuhb5dl	296	25	?	?	.
cord-324859-0yuhb5dl	297	1	Dynamic	dynamic	JJ
cord-324859-0yuhb5dl	297	2	changes	change	NNS
cord-324859-0yuhb5dl	297	3	of	of	IN
cord-324859-0yuhb5dl	297	4	T	t	NN
cord-324859-0yuhb5dl	297	5	lymphocyte	lymphocyte	NN
cord-324859-0yuhb5dl	297	6	subsets	subset	NNS
cord-324859-0yuhb5dl	297	7	in	in	IN
cord-324859-0yuhb5dl	297	8	the	the	DT
cord-324859-0yuhb5dl	297	9	long	long	JJ
cord-324859-0yuhb5dl	297	10	-	-	HYPH
cord-324859-0yuhb5dl	297	11	term	term	NN
cord-324859-0yuhb5dl	297	12	follow	follow	NN
cord-324859-0yuhb5dl	297	13	-	-	HYPH
cord-324859-0yuhb5dl	297	14	up	up	NN
cord-324859-0yuhb5dl	297	15	of	of	IN
cord-324859-0yuhb5dl	297	16	severe	severe	JJ
cord-324859-0yuhb5dl	297	17	acute	acute	JJ
cord-324859-0yuhb5dl	297	18	respiratory	respiratory	JJ
cord-324859-0yuhb5dl	297	19	syndrome	syndrome	NN
cord-324859-0yuhb5dl	297	20	patients	patient	NNS
cord-324859-0yuhb5dl	297	21	COVID-19	covid-19	VBP
cord-324859-0yuhb5dl	297	22	:	:	:
cord-324859-0yuhb5dl	297	23	consider	consider	VB
cord-324859-0yuhb5dl	297	24	cytokine	cytokine	JJ
cord-324859-0yuhb5dl	297	25	storm	storm	NN
cord-324859-0yuhb5dl	297	26	syndromes	syndrome	NNS
cord-324859-0yuhb5dl	297	27	and	and	CC
cord-324859-0yuhb5dl	297	28	immunosuppression	immunosuppression	NN
cord-324859-0yuhb5dl	297	29	IL-6	IL-6	NNP
cord-324859-0yuhb5dl	297	30	in	in	IN
cord-324859-0yuhb5dl	297	31	Inflammation	inflammation	NN
cord-324859-0yuhb5dl	297	32	,	,	,
cord-324859-0yuhb5dl	297	33	Immunity	Immunity	NNP
cord-324859-0yuhb5dl	297	34	,	,	,
cord-324859-0yuhb5dl	297	35	and	and	CC
cord-324859-0yuhb5dl	297	36	Disease	Disease	NNP
cord-324859-0yuhb5dl	298	1	The	the	DT
cord-324859-0yuhb5dl	298	2	role	role	NN
cord-324859-0yuhb5dl	298	3	of	of	IN
cord-324859-0yuhb5dl	298	4	cytokines	cytokine	NNS
cord-324859-0yuhb5dl	298	5	including	include	VBG
cord-324859-0yuhb5dl	298	6	interleukin-6	interleukin-6	NNP
cord-324859-0yuhb5dl	298	7	in	in	IN
cord-324859-0yuhb5dl	298	8	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	298	9	induced	induce	VBN
cord-324859-0yuhb5dl	298	10	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	298	11	and	and	CC
cord-324859-0yuhb5dl	298	12	macrophage	macrophage	NN
cord-324859-0yuhb5dl	298	13	activation	activation	NN
cord-324859-0yuhb5dl	298	14	syndrome	syndrome	NN
cord-324859-0yuhb5dl	298	15	-	-	HYPH
cord-324859-0yuhb5dl	298	16	like	like	JJ
cord-324859-0yuhb5dl	298	17	disease	disease	NN
cord-324859-0yuhb5dl	299	1	The	the	DT
cord-324859-0yuhb5dl	299	2	role	role	NN
cord-324859-0yuhb5dl	299	3	of	of	IN
cord-324859-0yuhb5dl	299	4	interleukin	interleukin	NN
cord-324859-0yuhb5dl	299	5	6	6	CD
cord-324859-0yuhb5dl	299	6	during	during	IN
cord-324859-0yuhb5dl	299	7	viral	viral	JJ
cord-324859-0yuhb5dl	299	8	infections	infection	NNS
cord-324859-0yuhb5dl	299	9	Effect	Effect	NNP
cord-324859-0yuhb5dl	299	10	of	of	IN
cord-324859-0yuhb5dl	299	11	remdesivir	remdesivir	NNP
cord-324859-0yuhb5dl	299	12	vs	vs	IN
cord-324859-0yuhb5dl	299	13	standard	standard	JJ
cord-324859-0yuhb5dl	299	14	care	care	NN
cord-324859-0yuhb5dl	299	15	on	on	IN
cord-324859-0yuhb5dl	299	16	clinical	clinical	JJ
cord-324859-0yuhb5dl	299	17	status	status	NN
cord-324859-0yuhb5dl	299	18	at	at	IN
cord-324859-0yuhb5dl	299	19	11	11	CD
cord-324859-0yuhb5dl	299	20	days	day	NNS
cord-324859-0yuhb5dl	299	21	in	in	IN
cord-324859-0yuhb5dl	299	22	patients	patient	NNS
cord-324859-0yuhb5dl	299	23	with	with	IN
cord-324859-0yuhb5dl	299	24	moderate	moderate	JJ
cord-324859-0yuhb5dl	299	25	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	299	26	:	:	:
cord-324859-0yuhb5dl	299	27	a	a	DT
cord-324859-0yuhb5dl	299	28	randomized	randomized	JJ
cord-324859-0yuhb5dl	299	29	clinical	clinical	JJ
cord-324859-0yuhb5dl	299	30	trial	trial	NN
cord-324859-0yuhb5dl	299	31	Clinical	clinical	JJ
cord-324859-0yuhb5dl	299	32	progression	progression	NN
cord-324859-0yuhb5dl	299	33	and	and	CC
cord-324859-0yuhb5dl	299	34	viral	viral	JJ
cord-324859-0yuhb5dl	299	35	load	load	NN
cord-324859-0yuhb5dl	299	36	in	in	IN
cord-324859-0yuhb5dl	299	37	a	a	DT
cord-324859-0yuhb5dl	299	38	community	community	NN
cord-324859-0yuhb5dl	299	39	outbreak	outbreak	NN
cord-324859-0yuhb5dl	299	40	of	of	IN
cord-324859-0yuhb5dl	299	41	coronavirus	coronavirus	NN
cord-324859-0yuhb5dl	299	42	-	-	HYPH
cord-324859-0yuhb5dl	299	43	associated	associate	VBN
cord-324859-0yuhb5dl	299	44	SARS	SARS	NNP
cord-324859-0yuhb5dl	299	45	pneumonia	pneumonia	NN
cord-324859-0yuhb5dl	299	46	:	:	:
cord-324859-0yuhb5dl	299	47	a	a	DT
cord-324859-0yuhb5dl	299	48	prospective	prospective	JJ
cord-324859-0yuhb5dl	299	49	study	study	NN
cord-324859-0yuhb5dl	299	50	Effect	effect	NN
cord-324859-0yuhb5dl	299	51	of	of	IN
cord-324859-0yuhb5dl	299	52	dexamethasone	dexamethasone	NN
cord-324859-0yuhb5dl	299	53	in	in	IN
cord-324859-0yuhb5dl	299	54	hospitalized	hospitalize	VBN
cord-324859-0yuhb5dl	299	55	patients	patient	NNS
cord-324859-0yuhb5dl	299	56	with	with	IN
cord-324859-0yuhb5dl	299	57	COVID-19	COVID-19	NNP
cord-324859-0yuhb5dl	299	58	:	:	:
cord-324859-0yuhb5dl	299	59	preliminary	preliminary	JJ
cord-324859-0yuhb5dl	299	60	report	report	NN
cord-324859-0yuhb5dl	299	61	.	.	.
cord-324859-0yuhb5dl	300	1	medRxiv	medRxiv	NNS
cord-324859-0yuhb5dl	300	2	The	the	DT
cord-324859-0yuhb5dl	300	3	authors	author	NNS
cord-324859-0yuhb5dl	300	4	declare	declare	VBP
cord-324859-0yuhb5dl	300	5	that	that	IN
cord-324859-0yuhb5dl	300	6	they	-PRON-	PRP
cord-324859-0yuhb5dl	300	7	have	have	VBP
cord-324859-0yuhb5dl	300	8	no	no	DT
cord-324859-0yuhb5dl	300	9	competing	compete	VBG
cord-324859-0yuhb5dl	300	10	interests	interest	NNS
cord-324859-0yuhb5dl	300	11	.	.	.
cord-324859-0yuhb5dl	300	12	 	 	_SP